[
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991279",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "On the other hand , in a 52-week phase III trial involving 1,061 subjects , nintedanib was found to slow disease progression , but there was no statistically significant difference for the primary endpoint18 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the two replicate phase III INPULSIS\u00ae studies [2] , nintedanib was shown to slow disease progression in patients with IPF by reducing the annual rate of decline in forced vital capacity (FVC) [3] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib is in phase II or III clinical development for several cancer indications (clinicaltrials.gov identifier numbers: NCT00805194 , NCT00806819 and NCT01015118) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two phase III international , placebo-controlled , double-blind clinical studies with identical design (INPULSIS\u00ae-1 and INPULSIS\u00ae-2) investigated the efficacy and safety of nintedanib in patients with IPF [2 , 3] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Taken together , these results provide a strong rationale for the clinical efficacy of nintedanib in IPF , which has recently been demonstrated in two replicate international phase III clinical trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Phase III study results are currently available or awaited for motesanib and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27147901",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A phase III study of nintedanib/placebo plus best supportive care in patients with CRC refractory to standard therapies is ongoing (though not recruiting) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29736460",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Initial pirfenidone Phase III trial results were published in both 2010 and 2011 [13] , [14] , and additional publications of Phase III trials involving both pirfenidone [15] and nintedanib [16] were released in 2014 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Blocking SHP-1 via either PTP III or siRNA abolished nintedanib-mediated cell death (Figure 3b and c) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "We used a specific SHP-1 inhibitor (PTP III) as well as knocked down SHP-1 via transient transfection of SHP-1-targeted siRNAs to analyze the effect of nintedanib on TNBC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761724",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Predictive clinical markers of benefit for nintedanib , an angiokinase inhibitor , were evaluated using data from two large second-line NSCLC phase III trials (LUME-Lung 1 and LUME-Lung 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the clinical setting , a phase III clinical trial carried out in patients with advanced NSCLC reported that nintedanib combined with docetaxel significantly improved progression\u2010free survival compared to docetaxel alone in squamous populations , but did not prolong OS.11 The combination of nintedanib with platinum doublet (cisplatin plus gemcitabine) was also evaluated in a phase I/II study (NCT01346540) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24669297",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The results of the TOMORROW study were sufficiently compelling for two parallel phase III studies (NCT01335464 and NCT01335477) of nintedanib in IPF to be undertaken .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27730129",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The INPULSIS trials are replicate phase III randomised studies comparing the ef\ufb01cacy and safety of the tyrosine kinase inhibitor nintedanib (150 mg twice per day) with placebo in patients with IPF [60] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The INPULSIS\u00ae trials were two replicate , randomised , double-blind , phase III trials that compared the effects of nintedanib 150 mg twice daily with placebo over 52 weeks of treatment in patients with IPF [8] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Baseline characteristics were generally balanced between the nintedanib and placebo arms within the GAP stage I and GAP stage II/III subgroups (table 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In patients at GAP stage II/III , mean\u00b1sd duration of exposure to study medication was 10.1\u00b13.4 months and 10.4\u00b13.3 months in the nintedanib and placebo groups , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The study population comprised 500 patients at GAP stage I (nintedanib 304 , placebo 196) , 489 at GAP stage II (nintedanib 296 , placebo 193) , and 71 at GAP stage III (nintedanib 38 , placebo 33) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "in France , regulations did not permit the collection of data on race; \u00b6: n=299 for nintedanib and n=194 for placebo in GAP stage I subgroup; n=325 for nintedanib and n=224 for placebo in GAP stage II/III subgroup .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the analysis of the annual rate of decline in FVC in patients at GAP stage I , II and III at baseline , the effect of nintedanib was numerically greater in patients at GAP stage III (treatment-by-time-by-subgroup interaction p=0.10) (supplementary figure S1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The effect of nintedanib on time to first acute exacerbation across subgroups of patients at GAP stage I , II and III is presented in supplementary table S4 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In nintedanib-treated patients , the annual rate of decline in FVC was similar in patients at GAP stage I and GAP stage II/III at baseline (\u2212110.1 mL\u00b7year\u22121 and \u2212116.6 mL\u00b7year\u22121 , respectively) and in both subgroups was lower than in placebo-treated patients (\u2212218.5 mL\u00b7year\u22121 and \u2212227.6 mL\u00b7year\u22121 , respectively) (figure 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In patients at GAP stage II/III , the proportion of patients with one or more acute exacerbations was 7.8% in the nintedanib group and 9.3% in the placebo group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The treatment effect of nintedanib on change from baseline in SGRQ total score seemed to be more pronounced in patients at GAP stage II/III versus patients at GAP stage I at baseline .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib had a numerically greater effect on time to first acute exacerbation in patients at GAP stage I (HR 0.32 , 95% CI 0.11\u20130.93) than GAP stage II/III (HR 0.82 , 95% CI 0.46\u20131.47); however , the treatment-by-subgroup interaction was not significant (p=0.14; figure 3) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In patients at GAP stage I , patients who were treated with nintedanib were more likely to discontinue study drug prematurely than patients treated with placebo , with similar rates of discontinuation in nintedanib- and placebo-treated patients in the GAP stage II/III subgroups .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "This post hoc subgroup analysis of pooled data from the INPULSIS\u00ae trials suggested that nintedanib had a similar benefit on the rate of FVC decline across patient subgroups stratified by baseline GAP stage I versus II/III .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The difference in adjusted mean change from baseline in SGRQ total score at week 52 between nintedanib and placebo was \u22122.67 (95% CI \u22125.07\u2013\u22120.27) and 0.09 (95% CI \u22122.20\u20132.38) for patients at GAP stage II/III and GAP stage I , respectively (treatment-by-subgroup interaction p=0.06; figure 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The current post hoc analysis suggests a greater treatment effect of nintedanib on quality of life in patients at GAP stage II/III compared with GAP stage I. The reasons for the potential difference across GAP stages are unclear .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The overall proportion of patients who had at least one adverse event was similar in patients at GAP stage I and GAP stage II/III and in the nintedanib and placebo arms within each subgroup .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The treatment effect of nintedanib on reducing the annual rate of decline in FVC was consistent between patients at GAP stage I and GAP stage II/III at baseline (treatment-by-time-by-subgroup interaction p=0.92) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Similarly , there was a trend toward benefit of nintedanib on acute exacerbations of IPF in patients at GAP stage II/III compared with patients at GAP stage I. Additional studies are needed to evaluate whether nintedanib can improve quality of life or prevent acute exacerbations in specific patient subgroups .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "There was a numerically greater benefit of nintedanib on disease progression in patients at GAP stage III than GAP stage I or II; however , the small number of patients at GAP stage III limited the robustness of this analysis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "However , in patients at GAP stage I , the proportion of patients who prematurely discontinued study drug due to adverse events was nearly two-fold higher with nintedanib than with placebo , while premature discontinuations were similar with nintedanib and placebo in patients at GAP stage II/III .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044139",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In summary , this post hoc analysis suggested that nintedanib has similar benefit on the rate of FVC decline between patients at GAP stage I versus II/III , indicating that GAP stage is unlikely to be a helpful tool for cohort enrichment in similarly designed clinical trials of pharmacotherapies for IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30640710",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Pazopanib (an inhibitor of c-KIT , FGFR , PDGFR and VEGFR tyrosine kinases) and nintedanib (a small molecular inhibitor of PDFGR , FGFR and VEGFR) have both been evaluated in the phase III setting and showed outcomes similar to bevacizumab (117 , 118) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The pharmacokinetics of nintedanib were further characterised by two successive population pharmacokinetic (PopPK) analyses , the first based on combined pharmacokinetic data from NSCLC (n = 849) and IPF (n = 342) patients [49] and the second in IPF patients only (n = 933) [50] enrolled in the phase II and III trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In line with this , results from the PopPK analyses based on phase II and III data indicate that exposure to nintedanib was not influenced by mild (classified as creatinine clearance [CLCR] 60\u201390 mL/min) or moderate (CLCR 30\u201360 mL/min) renal impairment [49 , 50] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The trough concentration producing 80% of the Emax (EC80) on FVC decline was estimated to be 10\u201313 ng/mL , which was similar to the median trough concentration achieved with the therapeutic dose of nintedanib 150 mg twice daily (10 ng/mL) during the phase III trials (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Exposure\u2013response modelling of nintedanib in the treatment of patients with IPF was performed [69 , 70] using data from 1403 patients who participated in the phase II TOMORROW and the phase III INPULSIS trials [8 , 21] and received nintedanib doses of 50\u2013150 mg twice daily or placebo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib has been investigated in three international Phase II (TOMORROW) and Phase III clinical trials (INPULSIS\u00ae-1 and INPULSIS\u00ae-2) including almost 1,500 patients with IPF.30,84 These have been followed by open-label extension trials (NCT01170065 and INPULSIS\u00ae-ON) to provide a treatment option to all patients who completed the TOMORROW or INPULSIS\u00ae trials and to assess long-term safety and tolerability .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23818761",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Multiple-target receptor tyrosine kinase inhibitors , including nintedanib , have been developed to address this problem.12 Nintedanib has entered clinical trials for numerous malignancies , where it targets the neovascularization critical for tumor growth and metastasis.12\u201318 Phase III trials are ongoing in non-small-cell lung (LUME-Lung 1 and 2; NCT00805194 , and NCT 00806819 respectively) and ovarian cancer (LUME-Ovar1; NCT01015118) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "23818761",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Multiple-target receptor tyrosine kinase inhibitors , including nintedanib , have been developed to address this problem.12 Nintedanib has entered clinical trials for numerous malignancies , where it targets the neovascularization critical for tumor growth and metastasis.12\u201318 Phase III trials are ongoing in non-small-cell lung (LUME-Lung 1 and 2; NCT00805194 , and NCT 00806819 respectively) and ovarian cancer (LUME-Ovar1; NCT01015118) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23818761",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The results of the TOMORROW study were sufficiently positive for Boehringer Ingelheim to undertake two parallel Phase III registration studies of nintedanib in IPF (NCT01335464 and NCT01335477) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30249169",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Following the promising results of the TOMORROW study , two identical phase III studies were performed.11 The INPULSIS-1 and INPULSIS-2 were multicentre randomized double-blind placebo-controlled trials of nintedanib at a dose of 150 mg twice daily over a 52-week period .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27480166",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In a phase III study of docetaxel and nintedanib versus docetaxel , among patients with SCC lung (42%) , the addition of nintedanib was associated with a PFS of HR 0.77 (95% CI 0.62\u20130.96) , and an OS of HR 1.01 (95%CI 0.85\u20131.21 , p = 0.891) [Reck et al .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30533376",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the INPULSIS trials , international phase III clinical trials of IPF patients , nintedanib was shown to significantly reduce the annual rate of decline in FVC [3] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761806",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A phase III placebo-controlled randomized clinical trial for evaluation of nintedanib in SSc-ILD (SENSCIS) is being conducted at the time of the writing of this document .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28927084",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In a randomized phase III trial , maintenance treatment with 200 mg of nintedanib twice daily on days 2 to 21 of every 3 week cycle for up to 120 weeks was tested against placebo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "iii",
      "id": "P02461"
    },
    "sentence": "The results of the present study indicated that: i) Nintedanib is able to inhibit Pca cell proliferation and decrease the growth of xenografts; ii) resistance to nintedanib will develop during in vitro and vivo treatment; and iii) nintedanib induces Pca cell entosis via the upregulation of E-cadherin and ROCK1/2 through the PI3K/CDC42 signaling pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "iii",
      "id": "P02461"
    },
    "sentence": "The results of the present study indicated that: i) Nintedanib is able to inhibit Pca cell proliferation and decrease the growth of xenografts; ii) resistance to nintedanib will develop during in vitro and vivo treatment; and iii) nintedanib induces Pca cell entosis via the upregulation of E-cadherin and ROCK1/2 through the PI3K/CDC42 signaling pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27313464",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In a Phase III study of docetaxel with or without nintedanib , 42% had squamous cell subtype .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24971016",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In addition to bevacizumab , the VEGFR TKIs , pazopanib and nintedanib have shown significant activity in first-line Phase III trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26355897",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In this comprehensive analysis of 16,488 patients , 27 randomized Phase II and III trials using VEGFR-TKIs (sunitinib , sorafenib , pazopanib , axitinib , vandetanib , cediranib , ramucirumab , regorafenib , nintedanib , and motesanib) were included .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Another Phase III study (LUME-Lung 2) trial investigated the efficacy and safety of nintedanib (200 mg , bid on 2\u201321 days) in combination with standard pem-etrexed (500 mg/m2 on day 1) compared with pemetrexed alone (500 mg/m2 on day 1) in patients with advanced or recurrent nonsquamous NSCLC after relapse or failure of first-line chemotherapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Another placebo-controlled , Phase III trial of nintedanib plus docetaxel in patients with stage IIIB/IV or recurrent adenocarcinoma NSCLC after failure of first line chemotherapy is also ongoing (LUME-Columbus , NCT02231164) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The overall incidence of serious AEs was lower for the nintedanib group than for the bevacizumab group (37.6% vs 53.7%) (Table 2).76,77 A double-blind , randomized , Phase III study of nintedanib vs placebo in refractory CRC is currently ongoing (NCT02149108) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In addition , nintedanib has recently been approved for the treatment of idiopathic pulmonary fibrosis based on results from the replicate Phase III trials involving 1,066 patients from 24 countries.53 Nintedanib is thus the first targeted treatment for idiopathic pulmonary fibrosis , indicating the therapeutic potential of TKIs in non-malignant diseases .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In addition , nintedanib has recently been approved for the treatment of idiopathic pulmonary fibrosis based on results from the replicate Phase III trials involving 1,066 patients from 24 countries.53 Nintedanib is thus the first targeted treatment for idiopathic pulmonary fibrosis , indicating the therapeutic potential of TKIs in non-malignant diseases .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30455955",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib plus docetaxel was shown to be safe and effective for patients with advanced NSCLC previously treated with platinum\u2010based therapy by phase III trials and has been approved by the European Medicines Agency as a second\u2010line treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A randomized Phase III trial (LUME-Lung 2) was performed to evaluate nintedanib (200 mg twice daily) plus pemetrexed (500 mg/m2) in comparison with pemetrexed alone in white patients with advanced nonsquamous NSCLC after the failure of first-line therapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Another Phase III trial (LUME-Columbus) is currently in progress to investigate the efficacy and safety of combination treatment with nintedanib (200 mg twice daily) plus docetaxel (75 mg/m2) compared with placebo plus docetaxel (75 mg/m2) in individuals with advanced lung adenocarci-noma , including North American patients , after the failure of first-line chemotherapy (ClinicalTrials.gov identifier NCT02231164) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "At the time that the opportunity for Japanese patients to join the global LUME-Columbus Phase III trial was considered , the lack of tolerability of nintedanib at a dose of 200 mg twice daily in combination with docetaxel at 75 mg/m2 in patients with a BSA of <1.5 m2 had not been demonstrated in the Japanese Phase I trial .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A recent Phase III trial demonstrated that treatment with the combination of nintedanib and docetaxel resulted in a significant and clinically meaningful improvement in PFS and OS compared with docetaxel alone in predefined NSCLC patients with adenocarcinoma tumor histology .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29492843",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Further , EQ-5D estimates from phase III trials with nintedanib in IPF (INPULSIS\u00ae I and II) were available from an economic evaluation identified during the economic data search [25] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28039616",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "1Model structure Model structure The model used evidence from three randomised controlled trials (RCTs) for nintedanib: the phase II TOMORROW (To Improve Pulmonary Fibrosis with BIBF 1120) trial and two phase III INPULSIS trials (INPULSIS-1 and INPULSIS-2) [11 , 12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29943133",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two replicate , placebo-controlled phase III RCTs (INPULSIS-1 , INPULSIS-2) involving 1066 patients confirmed that nintedanib slows the rate of decline in FVC , indicating slower disease progression [9] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27805254",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A double-blind , randomized , phase III study of nintedanib vs. placebo in refractory colorectal cancer is currently ongoing (NCT02149108) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24381593",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Other investigational antiangiogenic agents , such as the triple angiokinase inhibitor BIBF1120 (also nintedanib; targets receptors for VEGF , fibroblast growth factor (FGF) , and platelet-derived growth factor (PDGF)) , have been studied in phase III maintenance therapy trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two randomized phase III trials (INPULSIS\u2122-1 and -2) showed that nintedanib reduced the decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) with a manageable side effect profile3\u20135 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26414070",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Some of these agents , including pazopanib , nintedanib , cediranib , and trebananib , have been evaluated in randomized Phase III clinical trials , and all have demonstrated a progression-free survival (PFS) benefit [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26950548",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Additionally , combination therapy of nintedanib with docetaxel has been reported to prolong the survival of stage III/IV NSCLC patients previously treated with a platinum-based therapy [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25329056",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "After screening , 20 phase II/III RCTs (7 for vandetanib , 2 for sunitinib , 3 for cediranib , 5 for sorafenib , 2 for motesanib , and 1 for nintedanib) involving a total of 10834 participants [14]\u2013[33] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30682083",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib is currently being investigated in a phase III trial in combination with paclitaxel and carboplatin for first line treatment of ovarian cancer [https://clinicaltrials.gov/show/NCT01015118] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A recent phase III clinical study showed that nintedanib prevented both the progression of restrictive pulmonary impairment and the acute exacerbation of idiopathic pulmonary fibrosis (IPF) , with good tolerability [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Additionally , a recent phase III clinical study for human IPF showed beneficial effects of nintedanib in improving forced vital capacity and reducing the incidence of acute exacerbations .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In contrast to dasatinib , the results from the phase III study and postmarketing surveillance revealed no evidence to warrant elevating the risk of pulmonary hypertension by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28234907",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In a recent Phase III study , nintedanib reduced the decline in lung function in patients with IPF [3] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27716819",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Overall , the toxicity profile of nintedanib observed in this study is consistent with previous large phase III studies of nintedanib as single-agent [21] or in combination with chemotherapy [20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31492155",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The Phase III INPULSIS and ASCEND trials showed that in subjects with mild or moderate FVC impairment at baseline , nintedanib and pirfenidone reduced the rate of decline in FVC by approximately 50% over 1 year of treatment [20 , 21] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30176872",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the two replicate Phase III INPULSIS\u00ae trials , nintedanib slowed disease progression in patients with IPF by reducing the rate of decline in forced vital capacity (FVC) by about 50% [22] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30971229",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In this analysis , we used data from the Phase III INPULSIS\u00ae trials of nintedanib in patients with IPF to investigate whether acute exacerbations reported as serious adverse events were associated with higher mortality than events reported as non-serious adverse events and to assess the effect of nintedanib on these events .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30971229",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Our analysis of data from the Phase III INPULSIS\u00ae trials of nintedanib in patients with IPF showed that acute exacerbations reported as serious adverse events were associated with higher mortality than events reported as non-serious adverse events .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23964926",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The effect of nintedanib on the progression of IPF and on AEx-IPF remains to be established and is being investigated in two ongoing 52-week Phase III trials (INPULSIS-1 and INPULSIS-2; NCT01335464 and NCT01335477) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The efficacy and safety of nintedanib as a treatment for IPF have been studied in the Phase II , 52-week , TOMORROW trial [10] and in the two replicate randomized , placebo-controlled , 52-week Phase III INPULSIS\u00ae trials [11 , 12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In this manuscript , we further characterize the safety and tolerability of nintedanib and describe how adverse events were reported and managed during these Phase III trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "We report collective safety data for nintedanib from the two Phase III INPULSIS\u00ae trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In two phase III clinical trials (INPULSIS 1 and 2) , treatment with nintedanib for one year led to reductions in the annual rate of decline in forced vital capacity versus placebo in patients with idiopathic pulmonary fibrosis (IPF) [9] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28881856",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The phase III LUME Columbus study (NCT02231164) was designed to compare the combination of nintedanib with docetaxel to docetaxel alone in NSCLC of adenocarcinoma histology after first-line chemotherapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib is currently in phase III clinical trials in ovarian and non-small cell lung cancer (NSCLC) , where it has been successful in combination with taxotere [6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27007053",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Recently , Vargatef (nintedanib , developed by Boehringer Ingelheim) was approved in the EU based on the results of a phase III study comparing Vargatef plus docetaxel to placebo plus docetaxel in patients with locally advanced/metastatic non-small-cell lung carcinoma (NSCLC) after first-line therapy in over 1,300 patients in 27 countries [95] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Here , we present the results of the phase III LUME-Colon 1 study that assessed the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29452346",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A phase III , randomised , double-blind , placebo-controlled trial evaluated the tyrosine kinase inhibitor nintedanib together with BSC versus placebo plus BSC in 768 patients previously treated with fluoropyrimidines , oxaliplatin , irinotecan and bevacizumab , and previous EGFR inhibitors in those with wild-type expression of KRAS/NRAS [26] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "COL3A1",
      "id": "P02461"
    },
    "sentence": "Selected quantitative assays (fold cell number , COL1A1 and COL3A1 expression) were used to compute IC50 values indicative of the antiproliferative and antifibrotic effects of nintedanib , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "COL3A1",
      "id": "P02461"
    },
    "sentence": "Likewise nintedanib dose-dependently reduced both COL3A1 and P4HA2 expression in control fibroblasts (Figure 1G and H) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23385789",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The trial was statistically powered to assess PFS at 36 weeks; this was 16% in patients receiving nintedanib and 5% on placebo (HR 0.65 , P=0.06) and the drug was taken forward to phase III in the first-line setting .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23385789",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Other larger phase III trials are also in progress , two in first-line treatment (pazopanib/placebo , NCT00866697 and nintedanib/placebo , AGO-OVAR-12 , NCT01015118) and one at first platinum-sensitive relapse (cediranib/placebo , ICON6 , NCT00532194) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29018526",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The protocol-defined HRCT criteria (table 1) will be based on those used in the INPULSIS studies , the phase III nintedanib trials in IPF.11 12 Patients meeting these protocol-defined criteria will be referred to as patients with UIP-like fibrotic patterns only; those not meeting the criteria will be referred to as patients with other HRCT fibrotic patterns .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29018526",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The PF-ILD study is an innovative phase III trial evaluating the antifibrotic agent nintedanib in patients with fibrosing ILD who , independent of their original clinical classification , exhibit a progressive fibrosing phenotype .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29862029",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The results of the two , replicate , placebo-controlled , Phase III INPULSIS trials showed that nintedanib slowed disease progression by significantly reducing the annual rate of decline in forced vital capacity (FVC).6 Change from baseline in SGRQ total score over 52 weeks was a key secondary endpoint in both trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two randomized phase III clinical trials have evaluated the efficacy of nintedanib in patients with advanced NSCLC , in the second-line setting (Table 3) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the large randomized multicenter phase III trial LUME-Lung1 , nintedanib in combination with docetaxel demonstrated clinically meaningful benefit in patients who progressed after a first-line chemotherapy [48] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The LUME-Lung 2 multicenter , randomized , double-blinded phase III trial investigated the efficacy and safety of nintedanib in combination with pemetrexed versus placebo plus pemetrexed in patients with locally advanced or metastatic non-squamous NSCLC with progression after chemotherapy [49] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29351242",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Despite the absence of significant benefit compared to other anti-agiogenesis drugs , Nintedanib was tested in a phase III study plus the best supportive care in comparison with placebo plus the best supportive care [79] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "This compound is now available clinically as Nintedanib and has been approved for the treatment of IPF based on the results of twin Phase III INPULSIS-1 and -2 trials [2] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib has recently been shown to ameliorate histological features of pulmonary arterial hypertension (PAH) and pulmonary fibrosis in pre-clinical models of SSc , which has encouraging implications for ongoing phase III clinical trials of nintedanib in SSc-associated ILD [136] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib has recently been shown to ameliorate histological features of pulmonary arterial hypertension (PAH) and pulmonary fibrosis in pre-clinical models of SSc , which has encouraging implications for ongoing phase III clinical trials of nintedanib in SSc-associated ILD [136] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28708103",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The randomized LUME-Colon 1 phase III trial was designed to evaluate the efficacy of nintedanib monotherapy in terms of PFS and OS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "24927147",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib showed promise in treating IPF patients in a phase II and III trial [144,145] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28779751",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib was approved by the United States Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis in October 2014 following successful phase III clinical trials [18] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27902583",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The Cochrane Central Register of Controlled Trials (CENTRAL) , PubMed (up to December 2015) , and Web of Science (up to December 2015) databases were searched for articles using \u201cVEGFR-TKIs,\u201d \u201cangiogenesis inhibitor,\u201d \u201csorafenib,\u201d \u201csunitinib,\u201d \u201cvandetanib,\u201d \u201caxitinib,\u201d \u201cpazopanib,\u201d \u201ccediranib,\u201d \u201cnintedanib,\u201d \u201cmotesanib,\u201d \u201cramucirumab,\u201d \u201cregorafenib,\u201d \u201canti-VEGFR agents,\u201d \u201cnon-small-cell lung cancer,\u201d \u201cprospective,\u201d \u201cphase II/III,\u201d \u201crandomized controlled trial,\u201d and \u201chumans. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A recent exception is nintedanib combined with docetaxel as a second-line therapy for advanced non-small cell lung carcinoma (NSCLC) patients , as reported in a phase III trial called LUME lung-1 [27] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24864163",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The randomized , double-blind , phase III AGO-OVAR12 trial investigated the efficacy of front-line nintedanib and CP versus nintedanib and placebo in patients with advanced ovarian cancer [51] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24864163",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Promising efficacy data have also been published for a number of emerging anti-angiogenic agents including trebananib , nintedanib and pazopanib , which are in phase III development for advanced ovarian cancer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In a pivotal randomized , double-blind phase III trial (LUME-Lung 1) , PFS was improved in the docetaxel plus nintedanib group in relative to placebo plus docetaxel (3.4 vs. 2.7 months , p = 0.0019) [63] , while the OS showed no discrepancy (10.1 months vs. 9.1 months , p = 0.2720) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "conducted a phase III trial , LUME-Lung 2 study , comparing the efficacy of nintedanib plus pemetrexed in patients with NSCLC exclusively [64] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28035951",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The efficacy of nintedanib in pulmonary fibrosis patients has been evaluated in two identical , randomized , double-blind , placebo-controlled , 52-week duration , phase III trials (INPULSIS-1 and INPULSIS-2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30082599",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Subsequently , the INPULSIS trials (INPULSIS-1 and 2) [127] , parallel phase III , multicentre RCTs , demonstrated a significant reduction in the rate of FVC decline over a 52-week period , in IPF patients receiving nintedanib compared to placebo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29895744",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "By 2014 , Nintedanib (III , Ofev\u00ae , Figure 1) , an orally available isatin-based triple-angiokinase inhibitor , was approved by the FDA for the management of idiopathic pulmonary fibrosis [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30103384",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "However , in a subsequent phase III trial (AGO-OVAR 12) nintedanib combined with platinum-based therapy did not induce a significant survival advantage after debulking surgery .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29973551",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib is another agent with IPF treatment efficacy reported in a phase III trial , but its label recommends discontinuation of its use in the perioperative period due to its potential to delay wound healing .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In Phase II and III trials , nintedanib was generally administered with food and current prescribing guidelines recommended that it should be taken with food [13] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the NSCLC Phase III trials , nintedanib 200 mg twice-daily or placebo was given in repeated 21 day treatment cycles in combination with single infusions of docetaxel 75 mg/m2 (LUME-Lung 1 trial [5]) or pemetrexed 500 mg/m2 (LUME-Lung 2 trial [6]) , administered on day 1 of each cycle .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In this regard , this analysis provides confirmation of the Phase I DDI trial findings using longer term nintedanib treatment in the Phase III trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29249039",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "LUME-OVAR 1 (AGO-OVAR 12/NCT01015118) was a randomized , double blind , phase III trial where nintedanib was added to standard first-line chemotherapy , followed by nintedanib maintenance for a maximum of 120 weeks , in patients with advanced epithelial ovarian cancer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The efficacy and safety of nintedanib combined with docetaxel was confirmed in the phase III LUME-Lung 1 trial , in which the median overall survival of patients with adenocarcinoma who received docetaxel 75 mg/m2 plus nintedanib 200 mg twice daily (bid) was significantly longer than that in patients who received docetaxel plus placebo [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "This investigation into an appropriate starting dose was initiated given the clinical benefits of nintedanib combination therapy previously observed in patients with lung adenocarcinoma in the global phase III LUME-Lung 1 trial [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Taking into consideration the small sample size , these findings indicate a clinical benefit of nintedanib plus docetaxel in Japanese patients with lung adenocarcinoma after platinum-based chemotherapy , and are consistent with results from the phase III LUME-Lung 1 trial [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29371589",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Further , two independent , multicenter , phase III studies assessed nintedanib combined with either docetaxel or pemetrexed in patients with advanced or recurrent NSCLC for whom first-line chemotherapy had failed .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "We observed that nintedanib at 0.4 \u03bcM reduced significantly the expression of COL1A1 (Collagen type I alpha 1 chain) , COL3A1 (collagen type III alpha 1 chain) , FN1 (Fibronectin 1) , CTGF (connective tissue growth factor) , PDGFA (platelet-derived growth factor A) , and TGFB1 (transforming growth factor beta 1) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "COL3A1",
      "id": "P02461"
    },
    "sentence": "We observed that nintedanib at 0.4 \u03bcM reduced significantly the expression of COL1A1 (Collagen type I alpha 1 chain) , COL3A1 (collagen type III alpha 1 chain) , FN1 (Fibronectin 1) , CTGF (connective tissue growth factor) , PDGFA (platelet-derived growth factor A) , and TGFB1 (transforming growth factor beta 1) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In contrast , collagen III was increased in mdx mice but it was not modified by nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "P \u2264 0.05 and **P \u2264 0.01 We quantified the collagen VI and collagen III content in heart sections of WT , mdx mice , and nintedanib-treated mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col3a1",
      "id": "P02461"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col3a1",
      "id": "P02461"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col3a1",
      "id": "P02461"
    },
    "sentence": "However , gene expression showed a significant decrease in the Col3a1 mRNA expression in nintedanib-treated mdx mice compared with non-treated mdx (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col3a1",
      "id": "P02461"
    },
    "sentence": "P < 0.05 , **P < 0.01 , ***P < 0.005 We confirmed the reduced expression of Col1a1 and Col3a1 by WB , with a significant decrease of collagen-1 in the tibialis anterior (p < 0.05) and a trend in the diaphragm (p = 0.08) of nintedanib-treated mdx mice compared with mdx mice (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24711160",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "As shown in Table 2 , two phase III trials have been initiated in NSCLC populations without exclusion of squamous cell histology , one of nintedanib plus docetaxel as second-line therapy in advanced or recurrent NSCLC (LUME-Lung 1 [NCT00805194]) and the other of cediranib in combination with first-line paclitaxel/carboplatin for advanced NSCLC (CAN-NCIC-BR29 [NCT00795340]) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557253",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The preclinical studies on nintedanib were not published before the drug was evaluated in a clinical IPF phase III trial , since the first preclinical study on pulmonary fibrosis was conducted in 2007 with BIBF1000 , a sibling molecule of nintedanib , that is , BIBF1120 (9) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557253",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In contrast , practically no preclinical data on nintedanib was published before it entered into clinical investigations resulting in positive results in phase II and III studies .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29109947",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Whereas the phase II trial of nintedanib identified a delay in time to the first investigator-reported AE in the nintedanib arm (122) , only one of the two INPULSIS phase III twin-trials showed a significant effect of nintedanib on AE-IPF (33) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "This review summarizes the clinical data emerging from phase I\u2013III clinical studies with nintedanib in NSCLC and in other tumors , focusing on the data that led to the recent approval by the European Medicines Agency as a second-line treatment in association with docetaxel in patients with advanced NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The LUME-Lung 1 was a large multicenter double-blind , placebo-controlled , phase III trial randomizing patients with NSCLC to second-line docetaxel plus placebo (n = 659) or docetaxel plus nintedanib (n = 655) (14) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "LUME-Lung 2 was a multicenter , randomized , double-blinded phase III study that investigated the efficacy and safety of nintedanib in combination with pemetrexed vs. placebo plus pemetrexed in patients with locally advanced or metastatic non-squamous NSCLC with relapse or failure after chemotherapy (15) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "LUME-Ovar 1 , also named AGO-OVAR 12 , is a phase III study testing association of first-line chemotherapy plus nintedanib or placebo in patients with advanced ovarian carcinoma (34) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "LUME-Meso is a randomized double-blind phase II/III study testing safety and efficacy of nintedanib in 537 naive patients with unresectable pleural mesothelioma (35) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two randomized phase III clinical trials have evaluated to date the efficacy of nintedanib in patients with advanced NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "LUME-Colon 1 is a double-blind randomized phase III study evaluating monotherapy with nintedanib and best supportive care (BSC) vs. placebo and BSC in patients with refractory advanced colorectal cancer pretreated with standard chemotherapies and biologic agents (36) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In neoadjuvant setting , a phase I study is evaluating the safety of nintedanib in combination with cisplatin and docetaxel before surgery in patients with stages I\u2013III NSCLC [http://ClinicalTrials.gov: NCT02225405] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In neoadjuvant setting , a phase I study is evaluating the safety of nintedanib in combination with cisplatin and docetaxel before surgery in patients with stage I\u2013III NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "From phase I to phase III clinical trials on nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Another phase III controlled randomized trial , LUME-Lung 2 (NCT00806819) evaluated the use of nintedanib in combination with pemetrexed (500 mg/m2) and compared with pemetrexed (500 mg/m2) plus placebo in patients with advanced , non-squamous NSCLC previously treated with chemotherapy (63) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Several clinical trials involving nintedanib are ongoing , including a phase III study (NCT02299141) , that will evaluate the effectiveness of nintedanib in molecularly selected NSCLC patients and investigate the potential role of some genes (VEGFR1-3 , PDGFR-A , PDGFR-B , and FGFR1-3) that might be involved in the regulation of mechanisms of acquired resistance to antiangiogenic agents .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26932377",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib works mainly by inhibiting angiogenesis so it may have implications for EMT-Type-III where angiogenesis is prominent and on the other hand Pirfenidone is more anti-fibrotic in action so may have implications for EMT-Type-II .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27905052",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Phase III data are currently available in front-line therapy on Bevacizumab , Pazopanib , and Nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29225786",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "We also look forward to seeing the results of many ongoing phase II and III clinical studies 79 which evaluate combinations of drugs already approved (pirfenidone and nintedanib) or new drugs that act against matrix deposition .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28184295",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two novel approaches\u2014the IL-6 receptor blocker tocilizumab and nintedanib\u2014are in phase III clinical trials , both of which are based on a rather robust rationale , and if all goes well , we may have new drugs for SSc soon .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27231556",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Phase III trials of nintedanib are also currently underway for non-small cell lung cancer and being planned for hepatocellular , renal , and colorectal cancers [12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27231556",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The potential effect of nintedanib nearly tripling PFS , when compared to the placebo , has warranted a 1,300 patient , phase III study of this drug in the LUME-Ovar 1 trial [14] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28396848",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the phase III LUME-lung 1 trial , nintedanib , an oral multiple TKI targeting FGFR1\u20133 , vascular endothelial growth factor receptor 1\u20133 , PDGFR \u03b1 and \u03b2 , RET , FLT3 , and Src family kinases , was investigated in combination with docetaxel after failure of first-line therapy versus placebo (37) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28424759",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The triple angiokinase inhibitor nintedanib is the only TKI agent that has shown significant results when tested in the phase III LUME-Lung1 study (Table 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26500886",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "So far , four of these anti-angiogenics (trebananib , pazopanib , nintedanib , and cediranib) were evaluated in phase III clinical trials (Table 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26500886",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the positive prospective , randomized phase III study (AGO-OVAR 12/LUME-Ovar 1) nintedanib 200 mg BID vs. placebo was taken parallel to chemotherapy with carboplatin AUC 5/6 and paclitaxel 175 mg/m2 followed by a maintenance phase for a maximum duration of 120 weeks (18) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27594913",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "AGO-OVAR 12 was a big phase III study recruiting 1366 chemo naive ovarian cancer patients , and randomizing them 2:1 to chemotherapy with nintedanib or placebo [12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26106328",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Recent phase III trial results showed that current drugs such as pirfenidone and nintedanib could only slow the progression of the disease (King et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29740320",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "However , two phase III trials have yielded positive outcomes so far , in the form of pirfenidone and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30618768",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Treatment emergent adverse events leading to discontinuation of nintedanib was 33% at 52-weeks , compared to 25.2% in INPULSIS-1 and 23.7% in INPULSIS-2 phase III clinical trials (Richeldi et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25127540",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "However , just recently both nintedanib and pirfenidone have been shown to slow disease progression in separate Phase III clinical trials and for the first time , two treatment alternatives might become available for IPF patients [8,9] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915874",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "In the Phase III INPULSIS trials , nintedanib reduced the risk of disease progression versus placebo in patients with IPF [17] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31238897",
    "tail": {
      "word": "iii",
      "id": "P02461"
    },
    "sentence": "All drugs have (i) been tested in clinical trials of GBM (nintedanib , paclitaxel , topotecan) , (ii) are currently in clinical trials of GBM (belinostat (NCT02137759) , sapanisertib (NCT02142803) , and selinexor (NCT01986348) , clinicaltrials.gov) or (iii) represent drugs within a class that are being investigated in GBM (carfilzomib; proteasome inhibitors , idasanutlin; mdm2 inhibitors , clinicaltrials.gov) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31238897",
    "tail": {
      "word": "iii",
      "id": "P02461"
    },
    "sentence": "All drugs have (i) been tested in clinical trials of GBM (nintedanib , paclitaxel , topotecan) , (ii) are currently in clinical trials of GBM (belinostat (NCT02137759) , sapanisertib (NCT02142803) , and selinexor (NCT01986348) , clinicaltrials.gov) or (iii) represent drugs within a class that are being investigated in GBM (carfilzomib; proteasome inhibitors , idasanutlin; mdm2 inhibitors , clinicaltrials.gov) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib has also shown significant efficacy in two Phase III trials of patients with idiopathic pulmonary fibrosis (IPF) , a progressive and severely debilitating lung disease (Richeldi et al , 2014) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Nintedanib (200 mg twice daily (bid)) in combination with chemotherapy has demonstrated significant efficacy in two Phase III studies of advanced non-small cell lung cancer (NSCLC; Hanna et al , 2013; Reck et al , 2014) and a Phase III study of advanced ovarian cancer (Du Bois et al , 2013) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The co-primary objective was to compare the efficacy and safety of nintedanib vs sunitinib ahead of potential Phase III clinical evaluation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26399408",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "During the last few years , tyrosine kinase receptor inhibitors such as nintedanib , developed and already used for the treatment of non-small cell lung carcinoma and other cancers , have been tested in phase II and III clinical trials for the treatment of IPF [48\u201352] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26399999",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Fourteen sites in China participated in the recent phase III international clinical study using nintedanib for the treatment of IPF [14] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29465476",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The efficacy and safety of nintedanib in patients with IPF were demonstrated in the Phase II TOMORROW trial and Phase III INPULSIS trials.23,24 The INPULSIS trials involved 1,066 patients with a diagnosis of IPF , FVC 50% or greater predicted and DLCO 30% to 79% predicted .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26640402",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "However other therapies such tyrosine kinase inhibitors as BIBF 1120 (Nintedanib) have been approved for application in patients with IPF in January 2015 based on results from the replicate Phase III INPULSIS trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30636861",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Information from two repeated Phase III clinical trials on IPF demonstrated that patients receiving nintedanib treatment showed successfully reduced disease progression and annual rates of decline in forced vital capacity relative to their placebo counterparts [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27623753",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The positive results of the pirfenidone 111 and nintedanib 112 phase III trials , demonstrating that agents targeting the different pathways that drive lung fibrosis can reduce the progression of IPF , provide excellent examples of why this understanding is important 113 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Recently , a large-scale randomized phase III study (INPULSIS 1 , INPULSIS 2) revealed that nintedanib inhibited the progression of IPF (4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26336412",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A multicenter , randomized , double-blinded , and placebo-controlled phase III clinical study (LUME-Lung 1) assessed the efficacy and safety of using nintedanib after failure of the first line of treatment for locally advanced or metastatic non-small-cell lung carcinoma (IIIb/IV according to the TNM classification) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25045437",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "This is a randomized , placebo-controlled phase III trial of standard carboplatin and paclitaxel with or without nintedanib , an oral inhibitor of VEGFR , PDGF receptor , and fibroblast growth factor receptor (FGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28382802",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The other remarkable targeted agents of which the results of phase III randomized trials were published in 2016 were cediranib , an oral antiangiogenic vascular endothelial growth factor receptor (VEGFR) 1\u20133 inhibitor , and nintedanib , an oral triple angiokinase inhibitor of VEGFR , platelet-derived growth factor receptor , and fibroblast growth factor receptor [3738] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28382802",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "A post-hoc analysis revealed that the significant difference of PFS between the nintedanib and placebo groups was found only in the non-high-risk subgroup , which was defined as the International Federation of Gynecology and Obstetrics (FIGO) stage III and postoperative residual tumor \u22641 cm , or FIGO stage II (median PFS 27.1 vs. 20.8 months , 95% CI=0.61\u20130.91) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23653825",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Additional phase III trials are in progress , including multi-targeted rTKIs (pazopanib and nintedanib) and an antibody directed against angiopoietin-2 (AMG-386) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26252298",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Among the included studies , there were nine phase III RCTs.6,7,13\u201319 Furthermore , nine agents (vandetanib , sunitinib , cediranib , nintedanib , sorafenib , motesanib , aflibercept , bevacizumab , and ramucirumab) with comparable data were identified .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Recent phase III studies demonstrated that nintedanib reduced the decline in forced vital capacity , resulting in decreased frequency of acute exacerbations in patients with IPF with tolerable adverse events (10,11) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "The LUME-Lung-1 phase III trial showed that nintedanib in combination with docetaxel is an effective second-line therapy for advanced NSCLC patients , especially for lung adenocarcinoma patients (12) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Although the effect of nintedanib monotherapy on NSCLC patients was limited , PFS was significantly improved in advanced NSCLC patients treated with nintedanib combined with docetaxel in the LUME-Lung-1 phase III study (12) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "This large-scale , Phase III clinical study demonstrated that nintedanib plus docetaxel significantly prolongs survival compared with docetaxel monotherapy for patients with advanced adenocarcinoma NSCLC who have failed first-line chemotherapy [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30854106",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Clinically , in a phase III clinical trial (LUME-Lung 1) , nintedanib , an oral multiple TKI targeting FGFR1-3 , was investigated in combination with docetaxel after failure of first-line therapy versus placebo in patients with advanced lung adenocarcinoma 9 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24648773",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Agents such as pazopanib , nintedanib , cediranib , and trebananib have been studied in randomized Phase III clinical trials and have demonstrated a PFS benefit.16\u201319 The improvement in PFS indicates a possible important role for the use of such drugs in the treatment of EOC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26578138",
    "tail": {
      "word": "III",
      "id": "P02461"
    },
    "sentence": "Two phase III trials of nintedanib in patients with IPF were conducted simultaneously , being designated INPULSIS-1 and INPULSIS-2. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29084964",
    "tail": {
      "word": "IGF1R",
      "id": "P08069"
    },
    "sentence": "For example , Hs 578T cells expressed high levels of PDGF receptor and were sensitive to nintedanib (and polyselective inhibitor of PDGF/VEGF/FGF receptors) , whereas MCF7 cells expressed IGF1R and were sensitive to the IGF1R inhibitors linsitinib and NVP-AEW541 (Supplementary Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28592821",
    "tail": {
      "word": "LAS",
      "id": "O43766"
    },
    "sentence": "Images were processed with the Leica software LAS X. To evaluate cytotoxic effects of nintedanib (Selleckchem , USA) , cells , used in the experiment , were seeded in 24-well plates at a cell number of 1 \u00d7 104/well .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "Tsk-1",
      "id": "Q9BXA7"
    },
    "sentence": "Nintedanib also showed anti-fibrotic effects in a dose-dependent manner in different animal models of SSc , including the bleomycin skin fibrosis model both in preventive and therapeutic applications , the chronic graft-versus-host disease model , and the Tsk-1 model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "PRs",
      "id": "P14193"
    },
    "sentence": "In the expansion phase , one CR and three PRs were observed in NSCLC patients treated with concomitant , continuous afatinib 30 mg QD plus nintedanib 150 mg BID (Table 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "PRs",
      "id": "P14193"
    },
    "sentence": "In the expansion phase , in patients treated with concomitant , continuous afatinib 30 mg QD plus nintedanib 150 mg BID , one CR and three PRs were observed in patients with NSCLC (with SD observed in 61% of patients); two patients with pancreatic adenocarcinoma achieved SD .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Angiogenin",
      "id": "P03950"
    },
    "sentence": "The results showed reduced protein levels of pro-angiogenic molecules such as FGF acidic , FGF basic and Endothelin , but increased levels of Amphiregulin , Interleukin 8 (IL-8) , and Angiogenin in Nintedanib-treated tumors , compared to controls , in Experiment 1 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Angiogenin",
      "id": "P03950"
    },
    "sentence": "Furthermore , after Nintedanib treatment , we observed decreased levels of Amphiregulin and Endoglin , which are oncogenic factors that stimulate cellular invasion and motility41 and found to be upregulated in the endothelia of newly formed vessels42; decreased Angiogenin levels were also observed in Nintedanib tumors43 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "aIt",
      "id": "Q8N695"
    },
    "sentence": "Data collected at screening unless otherwise stated aIt was not permitted to collect data on race in France bAt randomization c n = 624 for nintedanib 150 mg bid and n = 419 for placebo Baseline demographics and clinical characteristics in the INPULSIS\u00ae trials Based on patients who received \u22651 dose of study medication .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "aIt",
      "id": "Q8N695"
    },
    "sentence": "Data collected at screening unless otherwise stated aIt was not permitted to collect data on race in France bAt randomization c n = 624 for nintedanib 150 mg bid and n = 419 for placebo The mean (standard deviation [SD]) duration of exposure was 10.3 (3.4) months in the nintedanib group and 10.8 (2.8) months in the placebo group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31282197",
    "tail": {
      "word": "IL-10",
      "id": "P22301"
    },
    "sentence": "Recently , 2 drugs , pirfenidone and nintedanib , have been approved for the treatment of idiopathic pulmonary fibrosis.71 Pirfenidone has antifibrotic and anti-inflammatory activities via multiple targets such as TGF-\u03b2 , TNF , IL-10 , while nintedanib is an angiokinase inhibitor via VEGF receptor (VEGFR) , fibroblast growth factor receptor (FGFR), and PDGF receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "proton pump",
      "id": "P20648"
    },
    "sentence": "However , in clinical trials , coadministration with proton pump inhibitors or histamine H2 antagonists did not influence trough concentrations of nintedanib [19] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31427707",
    "tail": {
      "word": "proton pump",
      "id": "P20648"
    },
    "sentence": "There were no significant differences in patient characteristics , except for the concomitant treatment with proton pump inhibitor; therefore , combination treatment with a steroid and nintedanib may prevent nintedanib-associated diarrhea .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30176872",
    "tail": {
      "word": "proton pump",
      "id": "P20648"
    },
    "sentence": "Of the patients receiving anti-acid medication at baseline , 226 (93%) in the nintedanib group and 147 (91%) in the placebo group were receiving \u22651 proton pump inhibitor; 25 patients (10%) in the nintedanib group and 22 patients (14%) in the placebo group were receiving \u22651 histamine-2 receptor antagonist (Additional file 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29492843",
    "tail": {
      "word": "thiopurine S-methyltransferase",
      "id": "P51580"
    },
    "sentence": "The comparators included triple therapy (azathioprine , NAC and steroids) , a combination of triple therapy and a genotypic assay thiopurine S-methyltransferase (TPMT) , co-trimoxazole , sildenafil , pirfenidone , nintedanib and best supportive care .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29492843",
    "tail": {
      "word": "TPMT",
      "id": "P51580"
    },
    "sentence": "The comparators included triple therapy (azathioprine , NAC and steroids) , a combination of triple therapy and a genotypic assay thiopurine S-methyltransferase (TPMT) , co-trimoxazole , sildenafil , pirfenidone , nintedanib and best supportive care .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31452723",
    "tail": {
      "word": "tyrosine kinase receptor",
      "id": "P04629"
    },
    "sentence": "However , it is difficult to draw conclusions about the superiority of nintedanib in combination treatment based on tyrosine kinase receptor expression levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Here we use this animal model to characterize and compare the anti-cancer effect and modes of action of an established MTC drug , i.e. , Vandetanib , and that of two experimental TKI-based MTC treatments , Nintedanib alone and in combination with the HDAC inhibitor , Romidepsin , which has previously been co-administrated with TKIs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "For example , the second generation TKI , Nintedanib is a multi-kinase inhibitor that has been approved for the treatment of idiopathic pulmonary fibrosis [14] and is currently undergoing phase 2 clinical trials for MTC in Europe (ClinicalTrials.gov Identifier: NCT01788982) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "In our MTC animal model , Nintedanib arrested tumor growth across a 4-week treatment period compared to vehicle-treated controls (Figure 4A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "E) Proliferation assay of MTC cell lines treated with Nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Consistent with its anti-angiogenic effects , Nintedanib therapy also reduced phosphorylation of RET , VEGFR2 , and ERK1/2 in MTC tumors (Figure 4D). .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Thus Nintedanib has stronger anti-proliferative properties than Vandetanib in sporadic and RET-mutated familial cultured MTC cells and in our MTC mouse model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "As a second set of experiments , the effects of Nintedanib on RET-mutated familial MTC-derived TT cell growth was compared to that of Vandetanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Together these findings indicate that Vandetanib and Nintedanib use different mechanisms downstream of PI3K/AKT to stop MTC growth , although the two TKIs show several mechanistic similarities .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Phospho-Thr308 AKT was reduced in tumors from Vandetanib , Nintedanib , and Nintedanib + Romidepsin treated mice , but not in mice treated with Romidepsin alone in comparison with vehicle-treated MTC mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Our data suggests that the use of Nintedanib in combination with Romidepsin for MTC is unwarranted .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Given the role of Cdk5 in MTC proliferation [16] and in angiogenesis [37] , Cdk5 inhibitors might be considered as therapeutic drugs to be used alone or in combination with a TKI such as Nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Furthermore , Nintedanib , which blocks VEGFR2 , RET , ERK1,2 and PI3K/AKT/FOXO1 like Vandetanib , also inhibits PI3K/AKT/mTOR , but may still have limited long-term anti-tumor effects on MTC due to the development of resistance .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "The limited effects of Vandetanib and Nintedanib on sporadic MTC cell proliferation suggest that targeted therapies other than TKIs should be further explored .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29057215",
    "tail": {
      "word": "MTC",
      "id": "P04629"
    },
    "sentence": "Nintedanib (87) , anlotinib (88) , regorafenib (89) , and sulfatinib (90) all multikinase inhibitors are being investigated in several phase II studies for use in MTC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26399408",
    "tail": {
      "word": "tyrosine kinase receptor",
      "id": "P04629"
    },
    "sentence": "During the last few years , tyrosine kinase receptor inhibitors such as nintedanib , developed and already used for the treatment of non-small cell lung carcinoma and other cancers , have been tested in phase II and III clinical trials for the treatment of IPF [48\u201352] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26257929",
    "tail": {
      "word": "tyrosine kinase receptor",
      "id": "P04629"
    },
    "sentence": "Small molecules that inhibit the VEGF tyrosine kinase receptor more or less specifically are , vatalanib , cediranib , dovitinib , pazopanib , nintedanib and axitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557253",
    "tail": {
      "word": "CDK4",
      "id": "P11802"
    },
    "sentence": "Nintedanib , that is , BIBF1120 was discovered as a side product from large screening assays targeting the cyclin-dependent kinase (CDK4) kinase (10 , 11) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "CDK4",
      "id": "P11802"
    },
    "sentence": "Moreover , the expression of genes associated with cell proliferation , such as CDK1 , CDK4 , CCNA2 , and PLK1 , was significantly diminished in the lung-resident fibroblasts of IPF patients treated with nintedanib as compared to vehicle (Figure 7D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "CDK4",
      "id": "P11802"
    },
    "sentence": "D) Quantification of CDK1 , CDK4 , CCNA2 , and PLK1 gene transcripts by RT-PCR in the primary lung-resident fibroblasts isolated from human IPF lung cultures and treated with vehicle or nintedanib (1 \u03bcM) for 16 h (n = 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "FGF-2",
      "id": "P09038"
    },
    "sentence": "In IPF-HLF , PDGF-BB , FGF-2 and VEGF caused a significant pro-proliferative effect that was significantly reversed by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "basic fibroblast growth factor",
      "id": "P09038"
    },
    "sentence": "b) Nintedanib inhibits basic fibroblast growth factor (FGF) and PDGF-BB-stimulated motility of primary HLF from patients with idiopathic pulmonary fibrosis (IPF-HLF) and without IPF (N-HLF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "basic fibroblast growth factor",
      "id": "P09038"
    },
    "sentence": "b) Nintedanib inhibits basic fibroblast growth factor (FGF) and PDGF-BB-stimulated motility of primary HLF from patients with idiopathic pulmonary fibrosis (IPF-HLF) and without IPF (N-HLF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "FGF-2",
      "id": "P09038"
    },
    "sentence": "In a concentration-dependent manner , nintedanib induced apoptosis in HUVECs stimulated with VEGF or FGF-2 , in HUASMCs stimulated with PDGF-BB or FGF-2 , and in pericytes stimulated with PDGF-BB and FGF-2 [72] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26346347",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Pirfenidone exerts its antifibrotic effect through regulation of lung IFN-\u03b3 , bFGF , and TGF-\u03b21 levels during the development of BLM-induced pulmonary fibrosis in mice.78 Nintedanib and pirfenidone have different mechanisms of action so combination therapy with these two drugs could be effective .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "After incubation for 24 h , cells were treated with 50 ng/mL recombinant VEGF-C (PeproTech , Rocky Hill , NJ , USA) , PDGF-BB (PeproTech) , or bFGF (PeproTech) in the presence or absence of nintedanib at concentrations of 0.01 , 0.1 , and 1 \u03bcM. The control cells were treated with 0.1% DMSO .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Nintedanib prevents enhanced effects of cell proliferation , migration , and tube formation of HLECs stimulated by VEGF-C , PDGF-BB , and bFGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "FGF-2",
      "id": "P09038"
    },
    "sentence": "After trypsinization , HLECs were seeded on the gel at a density of 1\u00d7105 cells/well and incubated in the medium containing VEGF-C , FGF-2 , or PDGF-BB in the presence or absence of 0.1 \u03bcM nintedanib for 24 h. The control cells were treated with 0.1% DMSO .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Next , we investigated the effect of nintedanib on growth factor-induced migration of HLECs at a concentration of 0.1 \u03bcM. As expected , VEGF-C , PDGF-BB , and bFGF (50 ng/mL) significantly stimulated migration of HLECs from the upper chamber to the bottom of the filter (Figure 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Nintedanib inhibits lymphangiogenesis in vitro stimulated by growth factors , including VEGF-C , bFGF , and PDGF-BB .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29348469",
    "tail": {
      "word": "basic fibroblast growth factor",
      "id": "P09038"
    },
    "sentence": "Nintedanib blocks the activation of three tyrosine kinase receptors: the platelet-derived growth factor-\u03b2 (PDGF-\u03b2)-receptor , basic fibroblast growth factor and vascular endothelial growth factor11,12 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "HPASMCs were treated with multiple growth factors , specifically 5% fetal calf serum , PDGF-BB (30 ng/mL) , FGF2 (2 ng/mL) , epidermal growth factor (EGF) (0.5 ng/mL) , and insulin-like growth factor-1 (IGF-1) (0.5 \u03bcg/mL) with or without imatinib (3 \u03bcM) or nintedanib (0.3 \u03bcM) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "The proliferation of HPASMCs induced by multiple growth factors (PDGF-BB , FGF2 , EGF , and IGF) was significantly greater than that without stimulation in CCK-8 and BrdU assays , and nintedanib significantly inhibited this proliferation at 24 and 48 h after stimulation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Cells were pre-incubated for 30 minutes with nintedanib (400 nM) before different stimuli (recombinant human PDGF-BB [10 ng/ml] , recombinant human bFGF [10 ng/ml] , recombinant human VEGF [10 ng/ml]: R&D Systems; Abingdon , United Kingdom) were added for another 30 minutes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Cells were then exposed to different stimuli (recombinant human PDGF-BB [R&D Systems]; recombinant human bFGF [R&D Systems]; recombinant human VEGF [R&D Systems]) in the presence and absence of nintedanib (0.001 , 0.01 , 0.1 , 1 \u03bcM) for 48 hours before being manually counted (Neubauer hematocytometer) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Before stimulation with PDGF-BB , bFGF , or VEGF (all 10 ng/ml) for 30 minutes , cells were pre-incubated with nintedanib (400 nM) for 30 minutes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "As shown in Figure 2C , nintedanib significantly prevented the bFGF-induced pro-proliferative effect in IPF fibroblasts at concentrations of 0.01 , 0.1 , and 1 \u03bcM (p < 0.05; Figure 2C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Before stimulation with PDGF-BB , bFGF , or VEGF (all 10 ng/ml) for 30 minutes , cells were pre-incubated with nintedanib (400 nM) for 30 minutes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "In non-fibrotic fibroblasts , even the lowest concentration of nintedanib (0.001 \u03bcM) prevented the bFGF-induced proliferation (p < 0.05; Figure 2D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Primary human lung fibroblasts derived from IPF patients and from non-fibrotic lungs were pre-incubated for 30 minutes with increasing concentrations of nintedanib (0.001 , 0.01 , 0.1 , and 1 \u03bcM) , before adding PDGF-BB (10 ng/ml) , bFGF (10 ng/ml) , and VEGF (10 ng/ml) for 48 hours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "High levels of phosphorylated FGFR were found in unstimulated cells which could not be further enhanced by stimulation with bFGF , but a down-regulation was detected in the presence of nintedanib in IPF cells (Figure 1C).Figure 1 Effect of nintedanib on receptor expression and phosphorylation. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Primary human lung fibroblasts derived from IPF patients and from non-fibrotic lungs were pre-incubated for 30 minutes with increasing concentrations of nintedanib (0.001 , 0.01 , 0.1 , and 1 \u03bcM) , before adding PDGF-BB (10 ng/ml) , bFGF (10 ng/ml) , and VEGF (10 ng/ml) for 48 hours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "Based on the targets of nintedanib , FGF2 , PDGF-AA , PDGF-BB , VEGF-A , VEGF-B , VEGF-C , and TGF\u03b2-1 were examined in the different culture supernatants using ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "Nintedanib with the concentration of 30 nM or more also inhibited differentiation promoted by PDGF-BB and VEGF-A , but didn\u2019t inhibited differentiation promoted by FGF2 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "However , nintedanib could not inhibit the migration of fibrocytes stimulated by FGF2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "E. Expression/phosphorylation of FGFR1 and selected downstream signaling proteins in DMS114 and DMS114/NIN cells was analyzed by Western blot of total cell lysates of serum-starved cells , pre-incubated for 1h with the indicated concentration of nintedanib and stimulated for 15min with 20ng/ml FGF2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "With regard to FGFR1-downstream signaling in response to FGF2 , cotreatment with elacridar led to restoration of ERK and AKT phosphorylation inhibition by nintedanib in the DMS114/NIN subline (Figure 4B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGF2",
      "id": "P09038"
    },
    "sentence": "Serum-starved cells were treated with indicated concentrations of nintedanib or elacridar for 1h and stimulated with 10% FCS or 20ng/ml FGF2 for 15min .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28779751",
    "tail": {
      "word": "basic fibroblast growth factor",
      "id": "P09038"
    },
    "sentence": "Nintedanib is a multiple tyrosine kinase inhibitor that works on key angiogenesis pathways including platelet-derived growth factor (PDGF) , vascular endothelial growth factor (VEGF) , and basic fibroblast growth factor (FGF) [1] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "Using a scratch assay , we observed that nintedanib blocked cell migration promoted by PDGF-AA , bFGF , VEGF , and collagen tissue growth factor (CTGF) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "To study which growth factor signaling cascade targeted by nintedanib affects more prominently fibroblasts proliferation , we cultured human fibroblasts in the presence of recombinant PDGF-AA , recombinant human basic fibroblast growth factor (bFGF) , or recombinant human vascular endothelial growth factor (VEGF)-A , with or without nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "basic fibroblast growth factor",
      "id": "P09038"
    },
    "sentence": "To study which growth factor signaling cascade targeted by nintedanib affects more prominently fibroblasts proliferation , we cultured human fibroblasts in the presence of recombinant PDGF-AA , recombinant human basic fibroblast growth factor (bFGF) , or recombinant human vascular endothelial growth factor (VEGF)-A , with or without nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "We added to the medium 10 ng/ml PDGF-AA (R&D Systems , Minneapolis , MN) , 50 ng/ml VEGF-A (PeproTech , INC , Rocky Hill , NJ) or 10 ng/ml bFGF (PeproTech) with or without 0.4 \u00b5M nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29967964",
    "tail": {
      "word": "FGF-2",
      "id": "P09038"
    },
    "sentence": "The in vitro efficacy of nintedanib was explored in vascular endothelial growth factor (VEGF)- or fibroblast growth factor (FGF)-2-stimulated human umbilical vascular endothelial cells (HUVECs) , pericytes stimulated with platelet driven growth factor (PDGF) and FGF-2 , and TGF-\u03b2-induced primary culture of lung fibroblasts from IPF patients [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29967964",
    "tail": {
      "word": "bFGF",
      "id": "P09038"
    },
    "sentence": "This result stands in contrast to a previous report , where treatment of either VEGF- or bFGF-stimulated HUVECs with nintedanib resulted in inhibition of cell proliferation and apoptosis with EC50 values of less than 10 and 290 nM , respectively [6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib was shown to inhibit PDGFR phosphorylation and subsequent protein kinase B (Akt) and extracellular signal-regulated kinase (ERK)1/2 phosphorylation in lung tissue from mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib was shown to inhibit PDGFR phosphorylation and subsequent protein kinase B (Akt) and extracellular signal-regulated kinase (ERK)1/2 phosphorylation in lung tissue from mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib was originally designed as an anti-angiogenic drug targeting the receptor tyrosine kinases VEGFR , FGFR and PDGFR for the treatment of cancer [72] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an inhibitor of the receptor tyrosine kinases PDGFR-\u03b1/\u03b2 with half maximal inhibitory concentration (IC50) values of 59 and 65 nmol\u00b7L\u22121 , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The inhibitory activity of nintedanib on PDGFR phosphorylation was used to establish a pharmacokinetic/pharmacodynamic correlation for nintedanib in mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a multitargeted angiokinase inhibitor against many growth factor receptors , including PDGFR , FGFR , VEGFR,14 as well as the proto-oncogenes RET , FTL3 and Src,15 , 16 with anti-angiogenic activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Alternatively , nintedanib is a multitargeted angiokinase inhibitor against PDGFR , FGFR , VEGFR and non-receptor tyrosine kinases such as Src.15 Since PDGF\u03b2 has been reported to induce the JAK2\u2013STAT3 pathway by activating Src,36 nintedanib might inhibit JAK2 by directly inhibiting PDGF\u03b2 and Src .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26346347",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The antifibrotic effects of BIBF1000 \u2013 a compound similar to BIBF1120 \u2013 have been demonstrated in a BLM model in rats , and BIBF1000 weakly inhibited TGF-\u03b2 activity and subsequent \u03b1-SMA expression in lung fibroblasts in vitro.2 However , the kinase inhibitory profile of nintedanib suggests that PDGFR , FGFR , and VEGFR play important roles in lung fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Both VEGFR and PDGFR are also possible targets of nintedanib and may contribute to decreased ERK activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR , PDGFR , and FGFR.9 There is no previous study reporting the antitumor activity of nintedanib to LSCC with FGFR1 CNG .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR , PDGFR , and FGFR.9 There is no previous study reporting the antitumor activity of nintedanib to LSCC with FGFR1 CNG .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Interestingly , despite its inhibitory activity on PDGFR signaling , nintedanib did not affect the pericyte coverage of blood vessels resisting nintedanib treatment (Figures 2E and S2E) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30640710",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Pazopanib (an inhibitor of c-KIT , FGFR , PDGFR and VEGFR tyrosine kinases) and nintedanib (a small molecular inhibitor of PDFGR , FGFR and VEGFR) have both been evaluated in the phase III setting and showed outcomes similar to bevacizumab (117 , 118) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a potent , oral , small-molecule tyrosine kinase inhibitor (TKI) that blocks the kinase activity of a variety of receptors , including the receptor tyrosine kinases (RTKs) VEGFR 1\u20133; PDGFR-\u03b1 and -\u03b2; and FGFR 1\u20133 [14 , 15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib has been shown to inhibit the FGFR , PDGFR and VEGFR signalling cascades mediating lung fibroblast proliferation and migration [6 , 16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "In cell-free in vitro kinase assays , nintedanib showed nanomolar potency to inhibit all three VEGFR subtypes , PDGFR-\u03b1 and -\u03b2 and FGFR-1 , -2 and -3 [14] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The competitive binding of nintedanib to the ATP-binding pocket of the intracellular receptor kinase domain of VEGFR 1\u20133 , PDGFR-\u03b1 and -\u03b2 and FGFR 1\u20133 inhibits the tyrosine kinase activity of these receptors , thereby interfering with the cross-autophosphorylation of the receptor homodimers and blocking the signalling cascade [25] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , a triple angiokinase inhibitor of VEGFR , PDGFR , and FGFR , is one of these investigational targeted agents .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30611717",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is known to be an angiokinase inhibitor that antagonizes TGF-\u03b2R , FGFR , and PDGFR , whereas the mode of action (MOA) of pirfenidone remains elusive [32] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27340254",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "This strategy is also supported by the results of ramucirumab (a monoclonal antibody directed against VEGFR2) , and nintedanib (a TKI inhibiting VEGFR , PDGFR and FGFR) in the second-line setting [Garon et al .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "On the other hand , downregulation of both PDGFR subtypes in our experimental model might be the mechanistic link between nintedanib treatment and inhibition of SMC proliferation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Moreover , several cytokines exert a positive feedback and promote macrophage immigration , for example MCP-1,45 IL-646 or TNF\u03b1.47 Interestingly , there was a significantly reduced expression of PGDF , ligand for the PDGFR , and one of the most potent stimulators of SMC proliferation58 after treatment with nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that targets fibroblast growth factor receptor (FGFR) 1 , 2 , and 3; platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2; vascular endothelial growth factor receptor (VEGFR) 1 , 2 , and 3; and Src family tyrosine kinases Lck , Lyn , and Flt-3 [8] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "As mentioned above , nintedanib is a receptor tyrosine kinase inhibitor that targets FGFR 1 , 2 , and 3; PDGFR \u03b1 and \u03b2; and VEGFR 1 , 2 , and 3 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28138259",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , a potent , oral angiokinase inhibitor that targets the proangiogenic pathways mediated by VEGFR1\u20133 , FGF receptor (FGFR) 1\u20133 , and PDGFR-\u03b1 and \u03b2 , has demonstrated a survival benefit in combination with docetaxel vs docetaxel alone in previously treated lung adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24971016",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Several tyrosine kinase inhibitors (TKIs) under investigation in ovarian cancer target VEGF receptors as well as other proangiogenic molecules , eg , FGF: nintedanib , brivanib , dovitinib; PDGFR: cediranib , pazopanib; and c-Met: cabozantinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "This review summarizes the antitumor profile of nintedanib , a triple angiokinase inhibitor , which targets proangiogenic signaling of VEGFR , FGFR , and PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435296",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor of VEGFR , PDGFR , and FGFR , in addition to the Src and Abl tyrosine kinases .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30455955",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a small molecule receptor TKI of PDGFR \u03b1 and \u03b2 , FGFR1\u20103 , and VEGFR1\u20103 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30455955",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , a small molecule receptor tyrosine kinase inhibitor (TKI) of platelet\u2010derived growth factor receptor (PDGFR) , fibroblast growth factor receptor (FGFR) , and vascular endothelial growth factor receptor (VEGFR) , was approved as a treatment for idiopathic pulmonary fibrosis (IPF) in 2014 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28291245",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "BIBF1120 (or Nintedanib) is a triple tyrosine kinase or tyrosine kinase inhibitor that blocks key HSCs receptors e.g. FGFR , PDGFR and VEGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28291245",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "BIBF1120 (or Nintedanib) is a potent tyrosine inhibitor that blocks PDGFR , VEGFR and FGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31427707",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a triple receptor (PDGFR , VEGFR , and FGFR) tyrosine kinase inhibitor .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31427707",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a small-molecule tyrosine kinase and inhibits platelet-derived growth factor (PDGFR) , vascular endothelial growth factor (VEGFR) , and fibroblast growth factor receptors (FGFR)10\u201312 and was developed as an anti-cancer agent for patients with non-small cell lung cancer13,14 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29420662",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "However , the vast majority of them such as dovitinib , nintedanib , or ponatinib are neither highly specific nor selective and inhibit the kinase activity of several other receptors because of the high homology between the kinase domains of VEGFR , PDGFR , and FGFR [18] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30596712",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The successful findings reported for nintedanib highlight the importance of the PDGF/PDGFR axis as a therapeutic target for IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30596712",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "reported that nintedanib inactivated human lung fibroblasts through the inhibition of PDGFR-\u03b1 and -\u03b2 , and the IC50 of the nintedanib to inhibit the autophosphorylation of PDGFR-\u03b1 and -\u03b2 was 20-50-fold less than that of imatinib [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25244152",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Among these compounds are bevacizumab , targeting VEGF signaling [18]; sunitinib , targeting VEGF and PDGF; nintedanib targeting all three; and imatinib targeting just PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27716819",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF 1120) is a potent , oral , small-molecule tyrosine kinase inhibitor of VEGFR-1/-2/-3 , FGFR-1/-2/-3 and PDGFR-\u03b1/-\u03b2 signaling [6] , and has been recently approved for second line treatment of non-small cell lung cancer (NSCLC) of adenocarcinoma histology in combination with docetaxel .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "A significant inhibitory effect of nintedanib on phosphorylation of growth factor receptors by their specific ligands was observed for the PDGFR and the VEGFR in IPF cells (Figure 1C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib\u2019s targets include PDGFR , FGFR , and VEGFR [7] , which have been shown to be involved in lung fibrosis [4,6,14] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "This reduced sensitivity of IPF cells towards nintedanib might be explained by the higher PDGFR and FGFR expression in IPF cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "We hypothesize that the kinase inhibitor nintedanib inhibits c-Abl tyrosine kinase , similar to imatinib mesylate , a tyrosine kinase inhibitor specific for PDGFR as well as cAbl [35,38] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26138239",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Tyrosine kinase inhibitors such as Nintedanib , also known as BIBF1120 or Vargatef , block pathways that feed in to the MAPK pathway such as FGF , PDGFR and VEGF , which leads to reduced MAPK-signaling [37] and may be a mechanism by which this drug hinders disease progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "23964926",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an inhibitor of PDGFR , vascular endothelial growth factor receptor (VEGFR) , and fibroblast growth factor receptor (FGFR) [65] and this specificity of inhibition may be key to its effects on AEx-IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23964926",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "It is interesting that nintedanib may have an effect on AEx-IPF whereas the tyrosine kinase inhibitor imatinib , which inhibits the platelet-derived growth factor receptor (PDGFR) , did not [62] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "However , the roles of main targets , PDGFR , FGFR and VEGFR of nintedanib have not yet been analyzed in detail .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The incubation of MRC-5 cells with the culture supernatant of fibrocytes resulted in the phosphorylation of PDGFR , which was inhibited by nintedanib mainly at a concentration of 100 nM or more .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "However , the inhibitory effects of nintedanib were more potent on the phosphorylation of PDGFR compared to FGFR (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a potent tyrosine kinase inhibitor that targets FGFR , PDGFR , and VEGFR [7\u20139] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "In the present study , inhibitory effects were observed not only by nintedanib , but also by specific inhibitors for FGFR , PDGFR , and VEGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Furthermore , although the inhibitory effects of nintedanib on the phosphorylation of PDGFR were observed at approximately 10\u2013100 nM , the inhibition of FGFR phosphorylation required 100\u20131000 nM. These differences might be due to the two reason .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib and BGJ398 , the FGFR inhibitor , attenuated this proliferation at concentrations rather than 100 nM. Although imatinib , a PDGFR inhibitor , also suppressed the growth of fibroblasts , it required concentrations greater than 1 \u03bcM. The IC50 value of imatinib against PDGFR was reported to be in the range of 100 nM to 380 nM [25] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26156021",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that simultaneously blocks VEGFR , PDGFR and fibroblast growth factor receptors proangiogenic pathways [38] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30181810",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The multikinase inhibitor nintedanib , an anti-angiogenic inhibitor of VEGFR and PDGFR with anti-FGFR activity , in combination with chemotherapy has shown to be non inferior to bevacizumab-based regimen in metastatic colorectal cancer in a phase II clinical trial .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF 1120) is a small molecule tyrosine kinase inhibitor that inhibits several angiokinases including VEGFR1/Flt1 , VEGFR2/Flk1/KDR and VEGFR3/Flt4 as well as FGFR1 , FGFR2 , FGFR3 , PDGFR-alpha , PDGFR-beta and Flt3 [5] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29805748",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a multi-tyrosine kinase inhibitor targeting FGFR , PDGFR and VEGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a selective small-molecule inhibitor of FGFR , vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that has recently been approved for second-line treatment after chemotherapy failure in advanced lung adenocarcinoma [15 , 16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , a small-molecule FGFR/PDGFR/VEGFR TKI , demonstrated efficacy in clinical trials against lung cancer and is approved for second-line treatment of lung adenocarcinoma [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29515799",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor of VEGFR , FGFR , and PDGFR , which was involved in angiogenesis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (also known as BIBF 1120) competitively binds to the ATP-binding sites within the kinase domains of VEGFR receptors (VEGFR) 1\u20133 , PDGFR \u03b1/\u03b2 , and FGFR 1\u20134 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29659191",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "A second is a randomised phase II study of nintedanib (an oral tyrosine kinase inhibitor targeting VEGF receptors 1\u20133 , FGFR 1\u20133 , and PDGFR \u03b1 and \u03b2) compared to chemotherapy in patients with clear cell carcinoma of the ovary or endometrium , which will assess ARID1A mutational status retrospectively and correlate with outcome 27 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a novel triple angiokinase inhibitor targeting VEGFR1\u20133 , platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2 , fibroblast growth factor receptors (FGFR) 1\u20133 , and , in addition , is also an inhibitor of the Src family , RET , and FLT3 [46,47] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29351242",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an oral VEGFR-1/-2/-3 , FGFR-1/-2/-3 and PDGFR-\u03b1/\u03b2 inhibitor .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "24927147",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF 1120 , Boehringer Ingelheim) is a multitarget tyrosine kinase inhibitor that inhibits platelet derived growth factor receptor (PDGFR) , fibroblast growth factor receptor (FGFR) , and vascular endothelial growth factor receptor (VEGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27331812",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Considered as a multiple TKIs , nintedanib (BIBF1120) is a potent , oral , small-molecule agent , which can concurrently block PDGFR-\u03b1 and -\u03b2 , VEGFR1 , 2 and 3 , FGFR1 , 2 and 3 , Src and the PLT-3 family RTKs [121] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29670046",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Unfortunately , so far , small molecule tyrosine kinase inhibitors of VEGF , as well as FGF receptors (dovitinib used to inhibit VEGFR and FGFR; and nintedanib used to inhibit VEGFR , FGFR , and platelet-derived growth factor receptor (PDGFR)) were not effective in treating cancer patients after recurrence following anti-VEGF therapy [74,75] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29112159",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "In terms of clinical relevance of PDGFR signaling in IPF pathogenesis , one of the representative target receptors of nintedanib is PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866519",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Indeed , a recent phase 3 trial using nintedanib (an oral triple angiokinase inhibitor of VEGF receptor , PDGFR , and fibroblast growth factor receptor) , in addition to platinum based chemotherapy showed improved PFS for ovarian cancer (17.2 months vs 16.6 months; p = 0.024) [19] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27752291",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor of VEGFR , PDGFR , and fibroblast growth factor receptor .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23146151",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "BIBF 1120 (nintedanib) , an oxindole derivative is a triple kinase inhibitor with potent suppressing effects on VEGFR , PDGFR and bFGFR [9] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (Vargatef\u00ae) is a small-molecule tyrosine kinase inhibitor (TKI) targeting FGFR , vascular endothelial growth factor receptor (VEGFR) as well as platelet-derived growth factor receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a multiple angio-kinase inhibitor targeting VEGFR-1/2/3 , PDGFR-\u03b1/\u03b2 , and FGFR-1/2 [58] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "There was only partial inhibition of lung injury and fibrogenesis through Src knockout and pharmacologic inhibition with nintedanib suggested that there are other potential mechanisms , such as PDGFR , FGFR and VEGFR pathways contributing to MV\u2010induced EMT and pulmonary fibrosis (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Figure S2 Effects of nintedanib and Src heterozygous knockout on the mechanical ventilation\u2010induced PDGFR , FGFR , and VEGFR pathways .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27598213",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib also targets vascular endothelial growth factor receptor (VEGF) and platelet derived growth factor receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28035951",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , originally developed as an anticancer drug , is an orally administered inhibitor of multiple tyrosine kinases that targets vascular endothelial growth factor receptors (VEGFR) 1\u20133 , fibroblast growth factor receptors (FGFR) 1\u20133 , and platelet-derived growth factor receptors (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30841487",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The main molecular targets of nintedanib are the fibroblast growth factor receptor (FGFR) , the vascular endothelial growth factor receptor (VEGFR) , and the platelet-derived growth factor receptor (PDGFR) [10,11] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30841487",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "By competitively and reversibly blocking the receptor tyrosine kinases FGFR , VEGFR , and PDGFR , nintedanib inhibits fibroblasts proliferation , migration and transformation to myofibroblasts [12,13] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30841487",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Firstly , as nintedanib is known to interfere with VEGFR , FGFR , and PDGFR , and potentially also with TGF-\u03b2 signaling , its therapeutic effects will likely be observed when cells are stimulated with VEGF , FGF , PDGF , and/or TGF-\u03b2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30103384",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is another tyrosine kinase inhibitor for VEGFR-1-3 , FGFR 1-3 , PDGFR \u03b1 and \u03b2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31370258",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an indolinone and an angiokinase inhibitor able to interact with VEGFR-1 , -2 and -3 , PDGFR , FGFR and Src kinase family [79,80] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31108964",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "A phase II study of the multi-tyrosine kinase inhibitor , nintedanib , (including VEGFR- , FGFR and PDGFR-inhibition) as monotherapy in relapsed SCLC did not improve prognosis , see Table 3 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a kinase inhibitor targeting VEGFR (vascular endothelial growth factor receptor) 1 , 2 , and 3 , PDGFR (platelet-derived growth factor receptor) \u03b1 and \u03b2 , and FGFR (fibroblast growth factor receptor) 1 , 2 , and 3 [1\u20133] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26000013",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF1120) is an oral TKI of FGFR , VEGFR , PDGFR , FLT-3 , and lymphocyte-specific protein tyrosine kinase and significantly prolonged PFS in combination with docetaxel in patients with NSCLC [66] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27066487",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Indeed , nintedanib , a tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor , FGF receptor , and PDGFR , has recently gained approval around the world for treatment of IPF because of its effects on slowing the rate of decline of lung function (21) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30013972",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , previously known by its development code BIBF 1120 , is an intracellular inhibitor of the tyrosine kinases vascular endothelial growth factor receptor (VEGFR) 1-3 , fibroblast growth factor receptor (FGFR) 1-3 , and platelet-derived growth factor receptor (PDGFR) a and b (31) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28443282",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (Boehringer Ingelheim) , a multikinase inhibitor against VEGFR , PDGFR , and FGFR showed a survival benefit in subset analysis in patients with lung adenocarcinoma (53) and is now approved for routine use in the United Kingdom .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Several clinical trials involving nintedanib are ongoing , including a phase III study (NCT02299141) , that will evaluate the effectiveness of nintedanib in molecularly selected NSCLC patients and investigate the potential role of some genes (VEGFR1-3 , PDGFR-A , PDGFR-B , and FGFR1-3) that might be involved in the regulation of mechanisms of acquired resistance to antiangiogenic agents .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29868594",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a tyrosine-kinase inhibitor , targeting vascular endothelial growth factor receptor (VEGFR) , fibroblast growth factor receptor (FGFR) , and platelet derived growth factor receptor (PDGFR) (22).While the use of pirfenidone and nintedanib have been shown to slow the progression of IPF (26\u201328) , both compounds have significant side effects and neither is curative (28\u201330) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29868594",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a tyrosine-kinase inhibitor , targeting vascular endothelial growth factor receptor (VEGFR) , fibroblast growth factor receptor (FGFR) , and platelet derived growth factor receptor (PDGFR) (22).While the use of pirfenidone and nintedanib have been shown to slow the progression of IPF (26\u201328) , both compounds have significant side effects and neither is curative (28\u201330) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26691657",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib [36] (VEGFR 1-3 , FGFR 1-3 , PDGFR alpha/beta and RET TKI) added to docetaxel has demonstrated a significant OS benefit as compared with docetaxel alone in previously treated stage IV , PS 0-1 adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26691657",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib [36] (VEGFR 1-3 , FGFR 1-3 , PDGFR alpha/beta and RET TKI) added to docetaxel has demonstrated a significant OS benefit as compared with docetaxel alone in previously treated stage IV , PS 0-1 adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26691657",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib [36] (VEGFR 1-3 , FGFR 1-3 , PDGFR alpha/beta and RET TKI) added to docetaxel has demonstrated a significant OS benefit as compared with docetaxel alone in previously treated stage IV , PS 0-1 adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29560266",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "For example , trebananib (Ang2 inhibitor) and nintedanib (VEGFR/FGFR/PDGFR inhibitor) show clinical benefits for patients with advanced ovarian cancer when combined with chemotherapy ( Table 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28396848",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "In the phase III LUME-lung 1 trial , nintedanib , an oral multiple TKI targeting FGFR1\u20133 , vascular endothelial growth factor receptor 1\u20133 , PDGFR \u03b1 and \u03b2 , RET , FLT3 , and Src family kinases , was investigated in combination with docetaxel after failure of first-line therapy versus placebo (37) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557500",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "VEGF-targeted therapy is clearly an active approach in ovarian cancer (at least in combination with chemotherapy) and other anti-angiogenic agents have been investigated in this setting including pazopanib (6) , cedirinib (7) , nintedanib (8) , aflibercept (9) , trebananib (10) , sunitinib (11) , sorafenib (12) , and (PDGFR) imatinib (13) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26500886",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Based on significant benefit for lung cancer treatment and promising results from a phase II study in relapsed ovarian cancer (16 , 17) , another oral triple angiokinase inhibitor nintedanib (BIBF 1120) targeting VEGFR , PDGFR , and FGFR was studied for first-line therapy of ovarian cancer patients .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25538887",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (an inhibitor of VEGFR 1\u20133 , FGFR 1\u20134 , PDGFR , FLT-3 , and src) , is most advanced , with a positive randomized trial (LUME \u2013 Lung 1) in second line (docetaxel \u00b1 nintedanib) (21) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25538887",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (an inhibitor of VEGFR 1\u20133 , FGFR 1\u20134 , PDGFR , FLT-3 , and src) , is most advanced , with a positive randomized trial (LUME \u2013 Lung 1) in second line (docetaxel \u00b1 nintedanib) (21) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30483246",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a small molecule kinase inhibitor of platelet derived growth factor receptor (PDGFR) , vascular endothelial growth factor receptor (VEGFR) , and fibroblast growth factor receptor (FGFR) , which has been approved for the treatment of interstitial lung disease , and which can possibly be used for the treatment of (ILD in) SSc .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31221221",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "In 2014 , the European Medicines Agency (EMA) approved nintedanib , the first TKI targeting vascular endothelial growth factor receptor (VEGFR) , platelet-derived growth factor receptor (PDGFR) , and fibroblast growth factor receptor (FGFR) , for the treatment of advanced NSCLC in combination with docetaxel .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26913068",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a simultaneous inhibitor of VEGFR , PDGFR , and FGR , which shows antiangiogenic and antineoplasic inhibitory activity in lung cancer , impeding the growth of tumour cells [206] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31151284",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF 1120) is a recently developed orally available TKI of VEGFR 1\u20133 , FGFR , and PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31242658",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , a triple-angiokinase inhibitor , is a potent and selective inhibitor for tumor angiogenesis through the blocking of the tyrosine kinase activities of VEGFR1-3 , PDGFR-alpha and -beta , together with FGFR1-3 [100] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF 1120) is an indolinone derivative that binds to the ATP pockets of vascular endothelial growth-factor receptor (VEGFR) , platelet-derived growth-factor receptor (PDGFR) , and fibroblast growth-factor receptor (FGFR) , blocking their tyrosine- mediated kinase activity (Hilberg et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27881963",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Recently , an orally available TKI of VEGFR 1\u20133 , PDGFR and FGFR Nintedanib (BIBF 1120) has been developed .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26779535",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib , an orally administered inhibitor of multiple tyrosine kinases originally developed as an anticancer drug , is a small molecule that targets vascular endothelial growth factor receptors (VEGFR) 1\u20133 , fibroblast growth factor receptors (FGFR) 1\u20133 , and platelet-derived growth factor receptors (PDGFR) \u03b1 and \u03b2 [30] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "23936861",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib or BIBF 1120 (Boehringer Ingelheim; Ingelheim , Germany) is an oral small-molecule triple kinase inhibitor which inhibits VEGFR , PDGFR , and FGFRs and members of the Src family and flt-3 [83] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29967964",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a potent small molecule that inhibits the angiogenic receptor tyrosine kinases of fibroblast growth factor receptor (FGFR) , vascular endothelial growth factor receptor (VEGFR) , and platelet driven growth factor receptor (PDGFR) [6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "The strong antivascular effect seen with nintedanib may result from its potential to simultaneously inhibit multiple angiogenic and mitogenic signalling pathways (mediated by VEGFR , PDGFR , FGFR , RET and Flt3 [25]) , which may enable the drug to block compensatory angiogenic pathways that can be activated when anti-VEGF agents are used in isolation [3-12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Unlike other currently approved antiangiogenic therapies that inhibit signalling through VEGFR and/or PDGFR , nintedanib simultaneously inhibits three angiogenic signalling pathways .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an orally available triple angiokinase inhibitor that specifically inhibits VEGFR-1-3 , PDGFR-\u03b1/\u03b2 and fibroblast growth factor receptor (FGFR)-1-3 , as well as FLT-3 , RET and members of the Src family (Hilberg et al , 2008; Reck et al , 2014) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "As an inhibitor of VEGFR , PDGFR and FGFR angiogenic signalling pathways , nintedanib may have the potential to overcome acquired resistance seen with other antiangiogenic TKIs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor of VEGFR-1 , 2 and 3 , platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2 , and fibroblast growth factor receptor (FGFR) 1 , 2 and 3 (Hilberg et al , 2008) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26285805",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "For example , Nintedanib (Vargatef) is a small molecule multi-target TKI of FGFR , PDGFR and VEGFR used in the treatment of non-small-cell lung cancer [143] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a TKI with activity against the FGFR , VEGFR , and PDGFR families , as well as other targets [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30636861",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a well-known broad-spectrum tyrosine kinase inhibitor that targets multiple receptor kinases , such as PDGFR , VEGFR , FGFR , and Src family kinases , in a variety of tissue cells [20-22] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30636861",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Considering that the targets of nintedanib , such as PDGFR and FGFR , are also involved in the pathogenesis of intraocular fibrosis [25] , these findings in the abovementioned diseases may have direct implications for subconjunctival fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27871152",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Pirfenidone is an anti-fibrotic , anti-inflammatory and anti-oxidant molecule which inhibits TGF-\u03b2 induced collagen synthesis , whereas , nintedanib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR) , fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR) (8 , 9) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31282197",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Recently , 2 drugs , pirfenidone and nintedanib , have been approved for the treatment of idiopathic pulmonary fibrosis.71 Pirfenidone has antifibrotic and anti-inflammatory activities via multiple targets such as TGF-\u03b2 , TNF , IL-10 , while nintedanib is an angiokinase inhibitor via VEGF receptor (VEGFR) , fibroblast growth factor receptor (FGFR), and PDGF receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28210142",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Compared to other angiogenesis inhibitors , nintedanib has a different profile of targeting VEGFR , PDGFR , and FGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26257929",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a small molecule inhibiting VEGFRs 1 and 2 , FGFR and PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that acts on several receptor tyrosine kinases (PDGFR , FGFR , and VEGFR) (Hilberg et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26336412",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib acts on three types of cells: endothelial cells (VEGFR 1-3 , FGFR 1-3) , smooth muscle cells (FGFR 1-3 , PDGFR \u03b1 and \u03b2) , and pericytes (PDGFR \u03b1 and \u03b2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26336412",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF 1120) is an oral triokinase inhibitor , assessed in clinical studies , which inhibits the activity of vascular endothelial growth factor receptor 1-3 (VEGFR 1-3) , fibroblast growth factor receptor 1-3 (FGFR 1-3) , and platelet-derived growth factor \u03b1 and \u03b2 (PDGFR \u03b1 and \u03b2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib (BIBF1120) is a potent , oral angiokinase inhibitor that targets VEGFR-1-3 , PDGFR-\u03b1 and \u03b2 , and FGFR-1-3 signaling (9) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "This result suggested that activation of targets of nintedanib , FGFR , PDGFR and VEGFR kinases , does not affect the sensitivity of NSCLC cells to nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "First , RTK phosphorylation profiles including FGFR , PDGFR and VEGFR family kinases were investigated in the 5 nintedanib-sensitive and 5 nintedanib-resistant cell lines to clarify whether the kinases were associated with sensitivity to nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "These effects may be due to the multitargeted function of nintedanib , which inhibits FGFR as well as VEGFR and PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "PDGFR",
      "id": "P09619"
    },
    "sentence": "Nintedanib inhibits three major receptor classes involved in angiogenesis: VEGFR , FGFR and PDGFR [9,10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "CPT",
      "id": "Q56148"
    },
    "sentence": "One additional blood sample (7-mL BD Vacutainer CPT Tube) was obtained on day + 1 and again on day + 15 prior to the morning nintedanib dose and used to determine FGF23 levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28942086",
    "tail": {
      "word": "tyrosine kinase 3",
      "id": "P16591"
    },
    "sentence": "As an example , MCEMP1 (mast cell-expressed membrane protein 1) one of the outcome predictive genes when overexpressed , encodes a transmembrane protein isolated from human mast cells38 , known to work in concert with fibroblasts to aggravate pulmonary fibrosis39 or FLT3 (Fms-related tyrosine kinase 3) a strong Nintedanib-responsive tyrosine kinase with unknown roles in pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "endothelin-1",
      "id": "P05305"
    },
    "sentence": "The effect of nintedanib on endothelin-1 preconstricted pulmonary vessels was recently explored in precision-cut lung slices and isolated perfused lungs from mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25478169",
    "tail": {
      "word": "CRF",
      "id": "P06850"
    },
    "sentence": "In addition , in the postlaunch phase of nintedanib , the registry will optionally be extended and amended with an additional Case Report Form (CRF) module to serve the purpose to collect real-life data on treatment with nintedanib in the context of a postmarketing surveillance obligation if required .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "ERBB2",
      "id": "P04626"
    },
    "sentence": "ERBB2 is also a target gene of the FDA approved drug Nintedanib , which inhibits it .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26401847",
    "tail": {
      "word": "ErbB2",
      "id": "P04626"
    },
    "sentence": "In a preclinical study , the combination of nintedanib (a triple angiokinase inhibitor of VEGFRs , PDGFRs , and FGFRs) and afatinib (an irreversible pan-ErbB inhibitor of EGFR , ErbB2 , ErbB3 , and ErbB4) potently inhibited tumor growth in HT-29 xenograft model regardless of the Kirsten rat sarcoma viral oncogene homolog (KRAS) status [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29854313",
    "tail": {
      "word": "ERBB2",
      "id": "P04626"
    },
    "sentence": "On the other hand , at least 5 additional LC patients can be treated with targeted inhibitors such as crizotinib (MET) , nintedanib (FGFRs) , trastuzumab (ERBB2) or buparlisib (PI3KCA) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26566796",
    "tail": {
      "word": "HER2",
      "id": "P04626"
    },
    "sentence": "A phase II trial testing afatinib , a tyrosine kinase inhibitor (TKI) targeting EGFR and HER2 , alone and in combination with nintedanib , a multi-targeted anti-angiogenic TKI , in men with CRPC was recently reported [125] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28949289",
    "tail": {
      "word": "TSA",
      "id": "P32119"
    },
    "sentence": "A) Quantitative reverse transcriptase (qRT)-PCR was used to detect the expression levels of Shh in 14Fp cell line after trichostatin A (TSA) and nintedanib (NIN) treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30429477",
    "tail": {
      "word": "Fibroblast growth factor 1",
      "id": "P05230"
    },
    "sentence": "Fibroblast growth factor 1 (FGF1) is targetable indirectly through its receptors , FGFRs , with agents , including Nintedanib , Pazopanib , Ponatinib40 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30429477",
    "tail": {
      "word": "FGF1",
      "id": "P05230"
    },
    "sentence": "Fibroblast growth factor 1 (FGF1) is targetable indirectly through its receptors , FGFRs , with agents , including Nintedanib , Pazopanib , Ponatinib40 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "PP1",
      "id": "P50391"
    },
    "sentence": "On the other hand , inhibitors reported to target TGFBR , such as SB-431542 , RepSox , SB-525334 and PP1 , together with the multi-kinase inhibitors PD-161570 , PD-166285 , nintedanib , pazopanib and sorafenib revealed a significant correlation between their efficacy in blocking EMT and their inhibition of TGFBR1 or 2 (Figure 5C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "GGT",
      "id": "P19440"
    },
    "sentence": "Summary of nintedanib-related toxicities Abbreviations: AE adverse event , ALT alanine aminotransferase , AST aspartate aminotransferase , CTC Common Toxicity Criteria , GGT gamma-glutamyl transpeptidase .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "GGT",
      "id": "P19440"
    },
    "sentence": "Adverse events occurring markedly more frequently in patients receiving nintedanib vs sunitinib were diarrhoea , and increases in gamma-glutamyltransferase (GGT) , AST (any grade: 9.4% vs 0%) and ALT(7.8% vs 0%) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "GGT",
      "id": "P19440"
    },
    "sentence": "The rate of patients with AEs of increased GGT , ALT and AST liver enzymes was higher with nintedanib than with sunitinib , while AEs of increased lipases were higher with sunitinib than for nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib inhibits FGFR-1 , 2 , 3 and 4 with IC50 values of 69 , 37 , 108 and 610 nmol\u00b7L\u22121 , respectively , and VEGFR-1 , 2 and 3 with IC50 values of 34 , 21 and 13 nmol\u00b7L\u22121 , respectively [72] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "First , reduced F4/80+ cell infiltration might result from the inhibition of VEGF-A/VEGFR-1 pathway by nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Interestingly , VEGFR1 expression was increased in nintedanib-treated animals though no significance was reached (6777 \u03bcm2 \u00b1 1368 \u03bcm2 vs 3942 \u03bcm2 \u00b1 2574 \u03bcm2 (P = 0.17; Figure 5A)) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Although the expression of both PDGFR\u03b1 and PDGFR\u03b2 was clearly downregulated in nintedanib-treated grafts , the expression of FGFR1 , FGFR2 , and VEGFR2 was not influenced by nintedanib and interestingly the expression of the VEGFR1 was even elevated .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Reports concerning the existence of TKRs on DCs though are rare and can only be found for VEGFRs which are supposed to play a role in DC differentiation46 and the inhibition of T cell activation.47 One might therefore hypothesize that upregulated VEGFR1 after nintedanib treatment reduces DC ability to activate T cells .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30122949",
    "tail": {
      "word": "FLT",
      "id": "P17948"
    },
    "sentence": "The analysis of the time to occurrence of new lesions favored the nintedanib arm and in the second sensitivity analysis was significantly longer with nintedanib in the TSFLT <9 and PD-FLT populations (Table 3) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30122949",
    "tail": {
      "word": "FLT",
      "id": "P17948"
    },
    "sentence": "The treatment difference at 6 months was even more pronounced in patients with a poor prognosis (P<0.0001 for the TSFLT <9 adenocarcinoma population; P=0.0004 for the PD-FLT adenocarcinoma population) , as shown in Figure 1B and C. In all groups , nintedanib/docetaxel produced a significant reduction in tumor size over time compared with placebo/docetaxel .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDFGR-\u03b1 and PDFGR-\u03b2 , FGFR-1 , FGFR-2 , FGFR-3 , VEGFR-1 , VEGFR-2 , VEGFR-3 , and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "LTF is also known to stimulate cell migration and proliferation via VEGFA gene , whilst nintedanib targets the receptors for VEGFA , VEGFR1 and VEGFR2 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that is specific also for PDGFR\u03b1 and \u03b2 , FGFR1 , 2 , and 3 , and VEGFR1 , 2 , and 3 [6\u20138] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28708103",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib is a novel triple inhibitor targeting VEGFR-1 , -2 , and -3 , FGFR , and PDGF receptors in a balanced manner , and has been evaluated for the treatment of mCRC patients as both a single agent and in combinatorial regimens .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27331812",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Considered as a multiple TKIs , nintedanib (BIBF1120) is a potent , oral , small-molecule agent , which can concurrently block PDGFR-\u03b1 and -\u03b2 , VEGFR1 , 2 and 3 , FGFR1 , 2 and 3 , Src and the PLT-3 family RTKs [121] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "To confirm whether Nintedanib treatment (5 and 10 \u03bcM) could also affect the expression of VEGF receptors in human PCa cell lines , we analyzed the expression of both VEGFR-1 and R-2 in cell lysates .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Indeed , the results of the current study showed the Nintedanib antiangiogenic activity on reducing the VEGFR-1 levels in TRAMP mouse prostate , the main receptor involved in cell migration and proliferation [50] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30103384",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib is another tyrosine kinase inhibitor for VEGFR-1-3 , FGFR 1-3 , PDGFR \u03b1 and \u03b2 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31370258",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib is an indolinone and an angiokinase inhibitor able to interact with VEGFR-1 , -2 and -3 , PDGFR , FGFR and Src kinase family [79,80] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31443247",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Nintedanib , PDGFR\u03b1-\u03b2 , FGFR1-3 , VEGFR1-3 , FLT3 , Lck kinase , Lyn kinase , and Src kinase .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31093341",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Similarly a trial of nintedanib targeting VEGFR1-3 , PDGFR\u03b1/\u03b2 , and FGFR1-2 had a disease control rate of 75 % and a 6-month PFS >60 % , although it was not clear if disease progression was required prior to enrollment [39] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Several clinical trials involving nintedanib are ongoing , including a phase III study (NCT02299141) , that will evaluate the effectiveness of nintedanib in molecularly selected NSCLC patients and investigate the potential role of some genes (VEGFR1-3 , PDGFR-A , PDGFR-B , and FGFR1-3) that might be involved in the regulation of mechanisms of acquired resistance to antiangiogenic agents .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29270405",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "2014) EMA , but not FDA , approved the use of nintedanib , an oral multi-kinases inhibitor , targeting VEGFR1-3 , FRGFR1-3 , PDGFR\u03b1-\u03b2 , RET , FLT3 , and Src family kinases , combined with docetaxel for the second-line treatment of NSCLC (Lazzari et al. .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28943626",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Nintedanib which has activity VEGFR1-3 , FGFR1-3 and PDGFR\u03b1 and PDGFR\u03b2 has been approved for the treatment of non-small cell lung cancer and idiopathic pulmonary fibrosis [18] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29560266",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "76 established a mouse orthotopic model with a stable murine breast cancer cell line (Py2T) and developed an evasive resistance model with long-term treatment with nintedanib (potent inhibitor of fibroblast growth factor [FGF] receptor 1 [FGFR1] , 2 , and 3 , PDGF receptor \u03b1/\u03b2 , and VEGFR1 , 2 , and 3) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31242658",
    "tail": {
      "word": "VEGFR1",
      "id": "P17948"
    },
    "sentence": "Nintedanib , a triple-angiokinase inhibitor , is a potent and selective inhibitor for tumor angiogenesis through the blocking of the tyrosine kinase activities of VEGFR1-3 , PDGFR-alpha and -beta , together with FGFR1-3 [100] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib is an orally available triple angiokinase inhibitor that specifically inhibits VEGFR-1-3 , PDGFR-\u03b1/\u03b2 and fibroblast growth factor receptor (FGFR)-1-3 , as well as FLT-3 , RET and members of the Src family (Hilberg et al , 2008; Reck et al , 2014) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor of VEGFR-1 , 2 and 3 , platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2 , and fibroblast growth factor receptor (FGFR) 1 , 2 and 3 (Hilberg et al , 2008) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26336412",
    "tail": {
      "word": "vascular endothelial growth factor receptor 1",
      "id": "P17948"
    },
    "sentence": "Nintedanib (BIBF 1120) is an oral triokinase inhibitor , assessed in clinical studies , which inhibits the activity of vascular endothelial growth factor receptor 1-3 (VEGFR 1-3) , fibroblast growth factor receptor 1-3 (FGFR 1-3) , and platelet-derived growth factor \u03b1 and \u03b2 (PDGFR \u03b1 and \u03b2) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Nintedanib (BIBF1120) is a potent , oral angiokinase inhibitor that targets VEGFR-1-3 , PDGFR-\u03b1 and \u03b2 , and FGFR-1-3 signaling (9) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29103264",
    "tail": {
      "word": "VEGFR-1",
      "id": "P17948"
    },
    "sentence": "Sunitinib (SU11248) is an oral inhibitor of VEGFR-1 , -2 , -3 , PDG-FRs , KIT , FLT3 , RET , and CSF-1R [25] , while nintedanib (BIBF 1120) is an oral , triple angiokinase inhibitor , which acts simultaneously on 3 key receptor families involved in angiogenesis: VEGFRs , PDGFRs , and FGFRs [26] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "FMT",
      "id": "P23882"
    },
    "sentence": "Nintedanib (yellow molecules) interferes with fibroblast/myofibroblast proliferation , FMT and migration .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "FMT",
      "id": "P23882"
    },
    "sentence": "Nintedanib (yellow molecules) interferes with fibroblast/myofibroblast proliferation , FMT and migration .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Endoglin",
      "id": "P17813"
    },
    "sentence": "Furthermore , after Nintedanib treatment , we observed decreased levels of Amphiregulin and Endoglin , which are oncogenic factors that stimulate cellular invasion and motility41 and found to be upregulated in the endothelia of newly formed vessels42; decreased Angiogenin levels were also observed in Nintedanib tumors43 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Differences in PASP and FVC between baseline and assessment after 48 weeks were evaluated using a paired t-test in the nintedanib prospective study .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "In the nintedanib prospective study , pulmonary artery systolic pressure (PASP) measured using transthoracic echocardiography (TTE) and the results of pulmonary function test were evaluated at six periods (baseline , and 1 , 4 , 12 , 24 , and 48 weeks after starting nintedanib treatment) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "2Mean observed change from baseline in PASP and FVC in nintedanib prospective study .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "a The mean observed change from baseline in pulmonary artery systolic pressure (PASP) after starting nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "The value of the mean changes in PASP gradually increased and compared to baseline , PASP was significantly higher 48 weeks after nintedanib treatment (P = 0.001) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "A significant increase in the value of the mean PASP from baseline was observed 48 weeks after nintedanib in IPF patients with LTOT (P = 0.001) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "There was a significant increase in the value of the mean PASP 48 weeks after nintedanib relative to baseline in IPF patients with LTOT (P = 0.001) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "The value of the mean changes in PASP gradually increased and PASP was significantly higher at 48 weeks after nintedanib treatment than at baseline (P = 0.001) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "The values of the mean PASP changes 48 weeks after nintedanib treatment in IPF patients with (solid line) and without (dotted line) LTOT were 8.24 mmHg and 2.84 mmHg , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Two-sided P-values < 0.05 were considered significant Mean observed change from baseline in PASP and FVC in nintedanib prospective study .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Changes in the value of the mean PASP and FVC from baseline to 48 weeks after nintedanib treatment were assessed using a paired t-test .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "a The mean observed change from baseline in pulmonary artery systolic pressure (PASP) after starting nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "a The values of mean pulmonary artery systolic pressure (PASP) changes after nintedanib treatment in idiopathic pulmonary fibrosis (IPF) patients with (solid line) and without (dotted line) long-term oxygen treatment (LTOT) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "The value of the mean changes in PASP gradually increased and PASP was significantly higher at 48 weeks after nintedanib treatment than at baseline (P = 0.001) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "There was a significant increase in the value of the mean PASP 48 weeks after nintedanib relative to baseline in IPF patients with LTOT (P = 0.001) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "a The values of mean pulmonary artery systolic pressure (PASP) changes after nintedanib treatment in idiopathic pulmonary fibrosis (IPF) patients with (solid line) and without (dotted line) long-term oxygen treatment (LTOT) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Changes in the value of the mean PASP and FVC from baseline to 48 weeks after nintedanib treatment were assessed using a paired t-test .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Figure 4 shows the comparison of adjusted annual change in PASP between the nintedanib and no antifibrotic therapy groups in IPF patients with and without LTOT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Conversely , among IPF patients without LTOT , the adjusted annual change in PASP was significantly lower in the nintedanib group than in the no antifibrotic therapy group (0.26 mmHg vs 7.05 mmHg; P = 0.011) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Conversely , among IPF patients without LTOT , the adjusted annual change in PASP was significantly lower in the nintedanib group than in the no antifibrotic therapy group (0.26 mmHg vs 7.05 mmHg; P = 0.011) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Conversely , among IPF patients without LTOT , the adjusted annual change in PASP was significantly lower in the nintedanib group than in the no antifibrotic therapy group (0.26 mmHg vs 7.05 mmHg; P = 0.011) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Comparison of adjusted annual changes in pulmonary artery systolic pressure (PASP) between the nintedanib groups and no antifibrotic therapy groups in idiopathic pulmonary fibrosis (IPF) patients with long-term oxygen treatment (LTOT) (left) and without LTOT (right) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Additionally , our retrospective study demonstrated that adjusted annual change of PASP in IPF patients without LTOT treated with nintedanib was unchanged or decreased but adjusted annual change of PASP in IPF patients with LTOT treated with nintedanib was similar to that in patients without antifibrotic agents (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Our prospective study compared the effects of nintedanib in IPF patients with or without LTOT and showed that PASP at 48 weeks after starting nintedanib in IPF patients with LTOT was significantly increased , but not in IPF patients without LTOT (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "PASP",
      "id": "P15086"
    },
    "sentence": "Comparison of adjusted annual changes in pulmonary artery systolic pressure (PASP) between the nintedanib groups and no antifibrotic therapy groups in idiopathic pulmonary fibrosis (IPF) patients with long-term oxygen treatment (LTOT) (left) and without LTOT (right) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25784931",
    "tail": {
      "word": "Plk-1",
      "id": "P53350"
    },
    "sentence": "Volasertib (BI 6727) is a potent Plk-1 inhibitor which induces cell cycle arrest and apoptosis and was administered in combination with an angiokinase inhibitor Nintedanib (BIBF 1120) in a phase I dose-escalation study .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "PLK1",
      "id": "P53350"
    },
    "sentence": "Moreover , the expression of genes associated with cell proliferation , such as CDK1 , CDK4 , CCNA2 , and PLK1 , was significantly diminished in the lung-resident fibroblasts of IPF patients treated with nintedanib as compared to vehicle (Figure 7D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "PLK1",
      "id": "P53350"
    },
    "sentence": "D) Quantification of CDK1 , CDK4 , CCNA2 , and PLK1 gene transcripts by RT-PCR in the primary lung-resident fibroblasts isolated from human IPF lung cultures and treated with vehicle or nintedanib (1 \u03bcM) for 16 h (n = 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30186846",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) [2] or vascular endothelial growth factor (VEGF) [3] demonstrated survival improvement when combined with first-line platinum-based chemotherapy , while a small oral drug with anti-angiogenic properties , nintedanib [4] , had the same result in combination with docetaxel for salvage therapy in an adenocarcinoma sub-group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30186846",
    "tail": {
      "word": "epidermal growth factor receptor",
      "id": "P00533"
    },
    "sentence": "Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) [2] or vascular endothelial growth factor (VEGF) [3] demonstrated survival improvement when combined with first-line platinum-based chemotherapy , while a small oral drug with anti-angiogenic properties , nintedanib [4] , had the same result in combination with docetaxel for salvage therapy in an adenocarcinoma sub-group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27536143",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "In addition , other TAs are at varying stages of clinical development , such as anti-EGFR monoclonal antibodies (cetuximab and necitumumab) , immune modulator (thalidomide) , and small multikinase inhibitor targeting VEGF receptor/platelet-derived growth factor receptor/FLT-3/c-KIT (sorafenib , motesanib , nintedanib , and vandetanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31427707",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Recently , EGFR upregulation in IPF fibroblasts has been shown to be blocked by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26401847",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "In a preclinical study , the combination of nintedanib (a triple angiokinase inhibitor of VEGFRs , PDGFRs , and FGFRs) and afatinib (an irreversible pan-ErbB inhibitor of EGFR , ErbB2 , ErbB3 , and ErbB4) potently inhibited tumor growth in HT-29 xenograft model regardless of the Kirsten rat sarcoma viral oncogene homolog (KRAS) status [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26401847",
    "tail": {
      "word": "ErbB",
      "id": "P00533"
    },
    "sentence": "In a preclinical study , the combination of nintedanib (a triple angiokinase inhibitor of VEGFRs , PDGFRs , and FGFRs) and afatinib (an irreversible pan-ErbB inhibitor of EGFR , ErbB2 , ErbB3 , and ErbB4) potently inhibited tumor growth in HT-29 xenograft model regardless of the Kirsten rat sarcoma viral oncogene homolog (KRAS) status [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29452346",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "A phase III , randomised , double-blind , placebo-controlled trial evaluated the tyrosine kinase inhibitor nintedanib together with BSC versus placebo plus BSC in 768 patients previously treated with fluoropyrimidines , oxaliplatin , irinotecan and bevacizumab , and previous EGFR inhibitors in those with wild-type expression of KRAS/NRAS [26] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "All carcinoma cell lines were wild-type EGFR and KRAS (Blanco et al , 2009) to mimic critical genetic aspects of lung ADC patients that may be treated with nintedanib in the clinic (Bronte et al , 2016) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "The CM was used to stimulate the growth and invasion of a panel of ADC and SCC cell lines that were selected based on their EGFR and KRAS wild-type status to mimic key genetic features of those patients that may be treated with nintedanib (Bronte et al , 2016) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28367252",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Nintedanib , a triple kinase inhibitor , and ramucirumab , a monoclonal antibody against vascular EGFR , have also been approved in the combination with second-line chemotherapy with docetaxel .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26566796",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "A phase II trial testing afatinib , a tyrosine kinase inhibitor (TKI) targeting EGFR and HER2 , alone and in combination with nintedanib , a multi-targeted anti-angiogenic TKI , in men with CRPC was recently reported [125] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "A number of studies are evaluating the feasibility of the combination of nintedanib and other classes of drugs , including angiogenesis inhibitors such as bevacizumab , EGFR inhibitors such as afatinib , and immune checkpoint inhibitors such as pembrolizumab .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "For the nonsquamous , low PD-L1 expression EGFR mutation negative subgroups , ramucirumab plus docetaxel and nintedanib plus docetaxel provided the greatest benefit .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27378269",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "However , unlike any of the other tamoxifen-resistant clones , BT-474 Tam1 and Tam2 developed vulnerability to several EGFR/HER2-inhibitors (gefitinib , ibrutinib , neratinib , nintedanib; Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Taken together , these findings confirm the feasibility of dual EGFR/VEGFR blockade via concomitant , continuous afatinib plus nintedanib therapy in patients with advanced solid tumours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24643470",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Inhibition of EGFR phosphorylation was also shown for the afatinib/nintedanib combination in a colorectal cancer cell line (Poindessous et al .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Furthermore , we found that nintedanib inhibited EMT and reversed the resistance to EGFR-TKI with TGF-\u03b2-induced EMT through miR-200 family induction in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Therefore , we evaluated whether nintedanib overcomes EMT and the resistance to the EGFR-TKI gefitinib in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "These results suggest that nintedanib combined with EGFR-TKI might be a novel therapeutic strategy for NSCLC cells with EMT phenotype .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "These findings demonstrated a novel role of nintedanib as a potential therapeutic strategy for resistance to EGFR-TKI associated with TGF-\u03b21-induced EMT in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Further studies should be performed to clarify the effect of nintedanib on EMT and EGFR-TKI therapy in NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "Nintedanib combined with EGFR-TKI might be a new therapeutic strategy for NSCLC patients with acquired resistance to EGFR-TKI by EMT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29103264",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "It is probable that intracellular proliferation depends on PKs that are not influenced by non-EGFR TKs , as sunitinib and nintedanib are considered multi-targeted anti-angiogenic agents that act against VEGFRs , PDG-FRs and FGFRs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "EGFR",
      "id": "P00533"
    },
    "sentence": "In particular , agents that target the EGFR or the VEGFR , such as nintedanib , are associated with GI events in patients with NSCLC [7,39] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OATP",
      "id": "P46721"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "beta-actin",
      "id": "P60709"
    },
    "sentence": "A) Western blot analysis of HIF-1alpha , HIF-2alpha and beta-actin in DLD-1 and HT-29 cells after 24 hrs exposure to nintedanib (0,01 , 0,1 or 1 \u03bcM) or bevacizumab (250 \u03bcg/ml) under normoxia or hypoxia (1% O2). .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "protein kinase B",
      "id": "P31749"
    },
    "sentence": "Nintedanib was shown to inhibit PDGFR phosphorylation and subsequent protein kinase B (Akt) and extracellular signal-regulated kinase (ERK)1/2 phosphorylation in lung tissue from mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "protein kinase B",
      "id": "P31749"
    },
    "sentence": "Nintedanib was shown to inhibit PDGFR phosphorylation and subsequent protein kinase B (Akt) and extracellular signal-regulated kinase (ERK)1/2 phosphorylation in lung tissue from mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "Tyr",
      "id": "P14679"
    },
    "sentence": "Various PTPs have been reported to regulate the STAT3 pathway , including SHP-1,31 , 32 SHP-233 and PTEN.34 However , as shown in Supplementary Figure 4 , nintedanib treatment had no obvious effect on either PTEN or SHP-2 but suppressed the phosphorylation of JAK2 (Tyr1007/1008) and Src (Tyr 416) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "Nintedanib also reduced secreted tissue inhibitor of metalloproteinase (TIMP)-2 levels.71 However , the enzymatic activity and secretion of MMP-2 were significantly reduced at lower concentrations (approximately 1 and 100 nmol/L , respectively).71 Additionally , nintedanib is expected to have indirect activity on ECM secretion and deposition by reducing the number of fibroblasts/myofibroblasts in fibrotic lungs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "Nintedanib also reduced secreted tissue inhibitor of metalloproteinase (TIMP)-2 levels.71 However , the enzymatic activity and secretion of MMP-2 were significantly reduced at lower concentrations (approximately 1 and 100 nmol/L , respectively).71 Additionally , nintedanib is expected to have indirect activity on ECM secretion and deposition by reducing the number of fibroblasts/myofibroblasts in fibrotic lungs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "Similarly , in non-fibrotic control cells nintedanib caused a significant increase of pro-MMP-2 activity (p < 0.05; Figure 3B and D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "In IPF fibroblasts the activity of pro-MMP-2 was significantly induced by nintedanib (0.001 , 0.01 , 0.1 , 1 \u03bcM) , as demonstrated by gelatin zymography (p < 0.05; Figure 3A and C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "A , B) Representative gelatine-based zymograms of the effect of nintedanib on pro-MMP-2 enzymatic activity by IPF fibroblasts (A) and by control cells (B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "The effect of nintedanib on the secretion of MMP-2 and TIMP-2 by IPF fibroblasts (E , G) and control cells (F , H) was assessed by ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "A , B) Representative gelatine-based zymograms of the effect of nintedanib on pro-MMP-2 enzymatic activity by IPF fibroblasts (A) and by control cells (B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "The effect of nintedanib on the secretion of MMP-2 and TIMP-2 by IPF fibroblasts (E , G) and control cells (F , H) was assessed by ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "We found that nintedanib induced the activity and protein levels of MMP-2 , and reduced the levels of TIMP-2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27331812",
    "tail": {
      "word": "MMP-2",
      "id": "P08253"
    },
    "sentence": "In an animal model of pulmonary fibrosis , nintedanib was shown to induce pro-MMP-2 expression , inhibit matrix expression of protease tissue inhibitor-2 (TIMP-2) in lung fibroblasts [123] , reduce transdifferentiation of fibroblasts to myofibroblastsinduced by TGF-\u03b2 , and reduce collagen synthesis [124] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "LDH",
      "id": "P16115"
    },
    "sentence": "In the IPF analysis , serum lactate dehydrogenase (LDH) levels were identified as an additional factor significantly influencing nintedanib plasma concentrations .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "LDH",
      "id": "P16115"
    },
    "sentence": "Value of LDH in the medium with nintedanib and imatinib were normalized by that in the control medium without TKI .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "LDH",
      "id": "P16115"
    },
    "sentence": "We also performed LDH assay to assess the cell toxicity of nintedanib and imatinib as previously described [20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "LDH",
      "id": "P16115"
    },
    "sentence": "Values of LDH in the medium after treatment with imatinib and nintedanib were similar between all groups (Fig 2C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "LDH",
      "id": "P16115"
    },
    "sentence": "The LDH assay showed no difference even after treatment with nintedanib , suggesting no toxicity of nintedanib for HPASMCs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "LDH",
      "id": "P16115"
    },
    "sentence": "Additional covariates influencing BIBF 1202 exposure but not nintedanib exposure (i.e. , ECOG performance status and LDH) showed only small-to-moderate changes (< 30%) in BIBF 1202 exposure .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "To assess the generality of our findings , we analyzed microvessel densities and MCT4 expression in tumors of Rip1Tag2 transgenic mice that have been treated with nintedanib (Bill et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "Curiously , the co-expression of MCT4 with PGC1\u03b1 and COX IV was decreased and unchanged , respectively , in ST nintedanib-treated tumors , yet it was unchanged with PGC1\u03b1 and increased with COX IV comparing LT vehicle and nintedanib-treated tumors (Figures S4L , S4M , S4O , and S4P) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "Immunofluorescence staining for MCT1 and MCT4 demonstrated a diffuse baseline expression of MCT1 that remained unchanged during nintedanib treatment , whereas MCT4 was highly expressed in non-vascularized areas of LT nintedanib-treated tumors and to a lesser extent in ST-treated tumors (Figures 4A and S4B\u2013S4D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "To further assess the establishment of metabolic symbiosis in nintedanib therapy-resistant tumors , we assessed by immunofluorescence microscopy analysis the expression and localization of markers for hypoxia (pimonidazole) , glucose uptake (Glut1) , lactate export (MCT4) , mitochondrial biogenesis , and oxidative phosphorylation (PGC1\u03b1 and COX IV; LeBleu et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "The loss of MCT4 expression in shMCT4 cell lines significantly retarded tumor growth kinetics and final tumor weights under treatment with nintedanib as compared to shCtrl cells (Figures S5G\u2013S5I) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "The loss of MCT4 expression in these clones significantly repressed tumor growth as compared to wild-type cells under treatment , with nintedanib treatment leading to an additive effect in repressing tumor growth kinetics and final tumor weights (Figures 5E and 5F) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "Comparable to the Py2T breast cancer model , Rip1Tag2 mice also developed resistance to nintedanib therapy and did not display any revascularization in therapy-refractory tumors (Figure S4F) , and MCT4 expression was also only found in tumors after prolonged nintedanib treatment (Figure S4G) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "Instead , we observed an increase of MCT4 expression both at the protein and mRNA level in nintedanib-treated shMCT4 tumors (Figures S5K and S5L) , suggesting that cells with poor shRNA-mediated knockdown efficiency developed a selective growth advantage and elicited tumor recurrence .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "The results presented above beg the question whether , in Py2T tumor cells , hypoxia-induced glycolysis is directly affected by treatment with nintedanib and 3PO or the loss of MCT4 expression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "To determine any effects of therapeutic treatments on the rates of glycolysis and oxidative phosphorylation , the ratios between ECAR and OCR were determined in wild-type or MCT4 knockout Py2T cells cultured under normoxia or hypoxia and treated with solvent , nintedanib , or 3PO .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "Indeed , the expression of hypoxia-induced Glut1 correlated with the expression of hypoxia-induced MCT4 and with the hypoxia-marker pimonidazole in the hypoxic areas of nintedanib LT tumors (Figures 4C\u20134G , S4H , and S4I) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT4",
      "id": "O15427"
    },
    "sentence": "Accordingly , the genetic ablation of MCT4 expression in Py2T tumors treated with nintedanib show significantly delayed tumor growth .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27805254",
    "tail": {
      "word": "KRAS",
      "id": "P01116"
    },
    "sentence": "In the present study , the trifluridine and nintedanib monotherapies and the TFTD/nintedanib combination therapy indicated a similar anticancer activity in vitro and in vivo , irrespective of the KRAS status of the colorectal cancer cell lines (Figs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27805254",
    "tail": {
      "word": "KRAS",
      "id": "P01116"
    },
    "sentence": "TFTD has been shown to improve overall survival in a clinical setting regardless of KRAS tumor status that is consistent with these results (8,9) , Consequently , the combination therapy with TFTD and nintedanib may also be useful in the clinical treatment of colorectal tumors irrespective of the KRAS mutation status .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26401847",
    "tail": {
      "word": "KRAS",
      "id": "P01116"
    },
    "sentence": "In a preclinical study , the combination of nintedanib (a triple angiokinase inhibitor of VEGFRs , PDGFRs , and FGFRs) and afatinib (an irreversible pan-ErbB inhibitor of EGFR , ErbB2 , ErbB3 , and ErbB4) potently inhibited tumor growth in HT-29 xenograft model regardless of the Kirsten rat sarcoma viral oncogene homolog (KRAS) status [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29452346",
    "tail": {
      "word": "KRAS",
      "id": "P01116"
    },
    "sentence": "A phase III , randomised , double-blind , placebo-controlled trial evaluated the tyrosine kinase inhibitor nintedanib together with BSC versus placebo plus BSC in 768 patients previously treated with fluoropyrimidines , oxaliplatin , irinotecan and bevacizumab , and previous EGFR inhibitors in those with wild-type expression of KRAS/NRAS [26] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "KRAS",
      "id": "P01116"
    },
    "sentence": "All carcinoma cell lines were wild-type EGFR and KRAS (Blanco et al , 2009) to mimic critical genetic aspects of lung ADC patients that may be treated with nintedanib in the clinic (Bronte et al , 2016) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "KRAS",
      "id": "P01116"
    },
    "sentence": "The CM was used to stimulate the growth and invasion of a panel of ADC and SCC cell lines that were selected based on their EGFR and KRAS wild-type status to mimic key genetic features of those patients that may be treated with nintedanib (Bronte et al , 2016) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "IL-8",
      "id": "P10145"
    },
    "sentence": "The results showed reduced protein levels of pro-angiogenic molecules such as FGF acidic , FGF basic and Endothelin , but increased levels of Amphiregulin , Interleukin 8 (IL-8) , and Angiogenin in Nintedanib-treated tumors , compared to controls , in Experiment 1 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "CCND1",
      "id": "P24385"
    },
    "sentence": "In addition , cells treated with Nintedanib displayed downregulated genes involved in G1 phase transition such as ANAPC2 , CCND1 , CCNE1 , CDC25A , CDKN3 , E2F1 and SKP2 , besides MCM2 , MCM3 , MCM4 and MCM5 , responsible for DNA synthesis and replication (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31427707",
    "tail": {
      "word": "EGF",
      "id": "P01133"
    },
    "sentence": "The FGF pathway is reported to interplay with EGF signaling; thus , nintedanib causes the development of diarrhea through the inhibition of FGFR21 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "EGF",
      "id": "P01133"
    },
    "sentence": "HPASMCs were treated with multiple growth factors , specifically 5% fetal calf serum , PDGF-BB (30 ng/mL) , FGF2 (2 ng/mL) , epidermal growth factor (EGF) (0.5 ng/mL) , and insulin-like growth factor-1 (IGF-1) (0.5 \u03bcg/mL) with or without imatinib (3 \u03bcM) or nintedanib (0.3 \u03bcM) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "EGF",
      "id": "P01133"
    },
    "sentence": "The proliferation of HPASMCs induced by multiple growth factors (PDGF-BB , FGF2 , EGF , and IGF) was significantly greater than that without stimulation in CCK-8 and BrdU assays , and nintedanib significantly inhibited this proliferation at 24 and 48 h after stimulation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "RhoA",
      "id": "P61586"
    },
    "sentence": "Under a fluorescence microscope , positive expression of RhoA in nintedanib-resistant Pca cells was observed , which is a marker of entosis (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "RhoA",
      "id": "P61586"
    },
    "sentence": "Therefore , RhoA and ROCK1/2 expression was analyzed in Pca cells and it was observed that nintedanib treatment of 22RV1 and DU145 cells led to an increase in the expression of RhoA , ROCK1 and ROCK2 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31431179",
    "tail": {
      "word": "RhoA",
      "id": "P61586"
    },
    "sentence": "In previous work we found that drugs such as nintedanib and pirfenidone , which have been used to treat IPF [62,63] , elevate Rnd3 expression and thereby decrease RhoA activity [57] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "RhoA",
      "id": "P61586"
    },
    "sentence": "Treatment with pirfenidone and nintedanib impacts the RhoA signaling pathway in IPF cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "RhoA",
      "id": "P61586"
    },
    "sentence": "Our finding that nintedanib , a tyrosine kinase inhibitor , elevates Rnd3 expression and p190RhoGAP activity raises the possibility that this pathway may also be inhibited by other tyrosine kinases that elevate RhoA activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib might exert additional activity by directly blocking non-receptor kinases like Src and Lck (not illustrated) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib might exert additional activity by directly blocking non-receptor kinases like Src and Lck (not illustrated) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib also inhibits non-receptor tyrosine kinases of the Src family with IC50 values of 156 nmol\u00b7L\u22121 for Src , 16 nmol\u00b7L\u22121 for Lck and 195 nmol\u00b7L\u22121 for Lyn [72] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "LCK",
      "id": "P06239"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "tyrosine-protein kinase Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib also inhibits the proto-oncogene tyrosine-protein kinase Src (IC50=156 nmol/L) , lymphocyte-specific tyrosine-protein kinase Lck (IC50=16 nmol/L) , Lck/Yes novel tyrosine kinase Lyn (IC50=195 nmol/L) , and Fms-like tyrosine kinase 3 Flt-3 (IC50=26 nmol/L).51 Distinct functions that may impact the pathology of IPF have been described for specific tyrosine kinases .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib also inhibits the proto-oncogene tyrosine-protein kinase Src (IC50=156 nmol/L) , lymphocyte-specific tyrosine-protein kinase Lck (IC50=16 nmol/L) , Lck/Yes novel tyrosine kinase Lyn (IC50=195 nmol/L) , and Fms-like tyrosine kinase 3 Flt-3 (IC50=26 nmol/L).51 Distinct functions that may impact the pathology of IPF have been described for specific tyrosine kinases .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Besides , nintedanib also potently inhibits Lck , a downstream target of the T-cell receptor,18 which may reduce the chemokine for macrophage recruitment produced by effective T-cells .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that targets fibroblast growth factor receptor (FGFR) 1 , 2 , and 3; platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2; vascular endothelial growth factor receptor (VEGFR) 1 , 2 , and 3; and Src family tyrosine kinases Lck , Lyn , and Flt-3 [8] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib , is a TK inhibitor (TKI) that can inhibit FGFR1-3 , vascular endothelial growth factor (VEGFR)1-3 , platelet-derived growth factor receptor (PDGFR)\u03b1/\u03b2 , Src , Lck and Lyn , and a Phase II clinical trial has exhibited antitumor effects in patients with castration-resistant Pca (15) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "In addition , nintedanib inhibits Src family tyrosine kinases (Src , Lck , Lyn) , Flt-3 and RET (Hilberg et al , 2008; Wollin et al , 2014; Awasthi and Schwarz , 2015) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Moreover , previous studies have demonstrated that oral administration of 60 and 100 mg/kg of nintedanib is sufficient to inhibit FGFRs , VEGFRs , Lck , Src and Flt\u20103 in mice 21 , 40 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31443247",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib , PDGFR\u03b1-\u03b2 , FGFR1-3 , VEGFR1-3 , FLT3 , Lck kinase , Lyn kinase , and Src kinase .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28168189",
    "tail": {
      "word": "Lck",
      "id": "P06239"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor , hindering the vascular endothelial growth factor receptor (VEGFR1\u20133) , the FGFR1-3 , the platelet-derived growth factor receptors (PDGFR\u03b1/\u03b2) , fms-like tyrosine kinase 3 and members of the Src family (Src , Lyn , Lck) (63) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "caspase-1",
      "id": "P29466"
    },
    "sentence": "An I\u03baB kinase\u20132 (IKK-2) inhibitor was obtained from Calbiochem (La Jolla , CA) , a caspase-1 inhibitor (VX-765) and Erk signaling inhibitor (PD98059) were from InvivoGen (San Diego , CA) , a Jak-Stat3 signaling inhibitor (AG490) was from R&D Systems , and an RTK inhibitor (nintedanib) was from Chem Scene (Monmouth Junction , NJ) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30930781",
    "tail": {
      "word": "caspase-1",
      "id": "P29466"
    },
    "sentence": "The addition of y-VAD , caspase-1 inhibitor (A) , z-LEVD , caspase-4 inhibitor (B) , Pirfenidone (PIRF) (C) and Nintedanib (D) significantly reduced IL-1\u03b1 release after AIM2 activation by means of Poly dA:dT (dA:dT) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30930781",
    "tail": {
      "word": "caspase-1",
      "id": "P29466"
    },
    "sentence": "The addition of y-VAD , caspase-1 inhibitor (A) , z-LEVD , caspase-4 inhibitor (B) , monoclonal antibody against IL-1\u03b1 (C) , Nintedanib (E) , but not Pirfenidone (PIRF) (D) , significantly reduced TGF-\u03b2 release after AIM2 activation at 24 h post-treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27114711",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "In both trials , the patients within the nintedanib arm had a higher incidence of derangement of hepatic enzymes , more specifically a rise in aspartate aminotransferase , alanine aminotransferase , or both .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25767391",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "Levels of alanine aminotransferase , aspartate aminotransferase , or both that were three or more times the upper limit of the normal range occurred more frequently in the nintedanib groups than in the placebo groups (4.9% versus 0.5% in INPULSIS-1 and 5.2% versus 0.9% in INPULSIS-2 , respectively) , but were reversible and without clinically significant sequelae .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "We previously reported that 11 of 32 patients with IPF newly treated with nintedanib at a dose of 150 mg twice daily from September to December 2015 exhibited aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation with the Common Terminology Criteria for Adverse Events (CTCAE) grade \u226526 , 7 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "The most common reasons for nintedanib dose reduction were increased alanine aminotransferase (ALT) levels , increased aspartate aminotransferase (AST) levels and diarrhea .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "Summary of nintedanib-related toxicities Abbreviations: AE adverse event , ALT alanine aminotransferase , AST aspartate aminotransferase , CTC Common Toxicity Criteria , GGT gamma-glutamyl transpeptidase .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "Dose reductions in the nintedanib group were indicated for patients with diarrhoea grade 2 for >7 days despite optimal management; vomiting grade \u2a7e2; elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels grade \u2a7e2 together with elevated bilirubin levels grade >1; or any other AE grade 3/4 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "In the event of treatment-related Grade \u2a7e3 aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevations or Grade \u2a7e2 elevation in conjunction with Grade \u2a7e1 bilirubin elevation , treatment with nintedanib was interrupted until recovery to baseline .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28210142",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "G3 or worse adverse events that were more common in the docetaxel plus nintedanib arm than in the control arm were diarrhea , reversible increases in alanine aminotransferase , and reversible increases in aspartate aminotransferase .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "aspartate aminotransferase",
      "id": "P00509"
    },
    "sentence": "The AEs that occurred with nintedanib plus docetaxel more frequently than with placebo plus docetaxel were gastrointestinal (GI) events (diarrhea , nausea and vomiting) and elevations in liver enzymes (increases in alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels) [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "BCRP",
      "id": "Q9UNQ0"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "breast cancer resistance protein",
      "id": "Q9UNQ0"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643582",
    "tail": {
      "word": "BCRP",
      "id": "Q9UNQ0"
    },
    "sentence": "Since nintedanib is almost exclusively metabolized by phase II enzymes , this effect on AUC and Cmax is most likely due to P-gp induction.42 In general the use of strong P-gp or BCRP inhibitors or inducers is discouraged when MKIs are substrates for these transporters .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31452723",
    "tail": {
      "word": "ABCG2",
      "id": "Q9UNQ0"
    },
    "sentence": "Correlation analysis between ABC transporter expression levels and TKI response was based on the lowest concentrations of the TKI that induced significant cell count reduction (pazopanib: 1.25 \u00b5M , dovitinib: 6.25 \u00b5M , nintedanib: 6.25 \u00b5M) and the expression levels of ABCB1 , ABCC1 and ABCG2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "Nintedanib inhibits FGFR-1 , 2 , 3 and 4 with IC50 values of 69 , 37 , 108 and 610 nmol\u00b7L\u22121 , respectively , and VEGFR-1 , 2 and 3 with IC50 values of 34 , 21 and 13 nmol\u00b7L\u22121 , respectively [72] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26346347",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "The development of nintedanib began with the identification of a lead compound from a group of six-substituted indolinones via assessment of tumor angiogenesis inhibition , and this compound was shown to inhibit VEGFR-2.54 Derivatives of the lead compound were screened for triple angiokinase (eg , VEGFR-2 , FGFR-1 , and PDGFR\u03b1) inhibitory activity .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "In addition , we examined the effects of nintedanib on human LSCC cell lines harboring FGFR1 CNG .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Sensitivity of lung cancer cell lines positive for FGFR1 copy number gain (CNG) to nintedanib. .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "We examined the preclinical efficacy of nintedanib treatment on H520 and LK\u20102 LSCC cells harboring FGFR1 alterations .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "d) Effects of nintedanib on FGFR1 , ERK , and AKT phosphorylation in FGFR1 CNG\u2010positive lung squamous cell carcinoma cell lines .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "c) Effects of nintedanib on the proliferation of lung cancer cell lines according to FGFR1 copy number status .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "These results are consistent with previous findings.27 Nintedanib potently inhibited proliferation of all three cell lines positive for FGFR1 CNG with IC50 values of 0.76 \u00b1 0.04 , 0.55 \u00b1 0.24 , and 0.09 \u00b1 0.01 \u03bcM for H520 , H1581 , and LK\u20102 cells , respectively (Fig .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Inhibition of FGFR1 copy number gain\u2010positive lung squamous cell carcinoma tumor growth in vivo by nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "To determine whether the antitumor activity of nintedanib observed on FGFR1 CNG\u2010positive LSCC tumors was a direct result of FGFR1 signal inhibition , we characterized FGFR1 signaling in H520 and LK\u20102 xenografts .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Indeed , immunoblot analyses revealed that nintedanib inhibited the FGFR1 phosphorylation and its downstream molecule ERK in H520 tumors (Fig .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib had no effect on the phosphorylation of these various signaling molecules in cells negative for FGFR1 CNG (data not shown) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "a) Immunoblot analysis of the effects of nintedanib therapy on FGFR1 , ERK , and AKT phosphorylation in the H520 and LK\u20102 xenograft tumor model .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "These results suggest that nintedanib inhibits the proliferation of FGFR1 CNG\u2010positive lung cancer cells , at least in part , by blocking the FGFR1\u2013ERK signaling pathway .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Changes in tumor cell proliferation were similar to changes in p\u2010FGFR1 , suggesting that inhibition of FGFR1 phosphorylation by nintedanib may have contributed to suppress tumor growth .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Hence , our findings suggest that FGFR1 CNG\u2010positive LSCC showing increased FGFR1 signaling may be susceptible to therapy with multikinase inhibitors such as nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Fibroblast growth factor receptor 1 signaling has been implicated in a wide range of cellular processes , including proliferation.15 Therefore , we examined the influence of FGFR1 signal inhibition with nintedanib on cancer cell proliferation by Ki\u201067 expression (Fig .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "Fibroblast growth factor receptor 1",
      "id": "P11362"
    },
    "sentence": "Fibroblast growth factor receptor 1 signaling has been implicated in a wide range of cellular processes , including proliferation.15 Therefore , we examined the influence of FGFR1 signal inhibition with nintedanib on cancer cell proliferation by Ki\u201067 expression (Fig .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Notably , LK\u20102 cells showed high basal levels of FGFR1 phosphorylation in vitro and were effectively inhibited by nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "The difference in FGFR1 phosphorylation between the two tumor models could account for the difference in sensitivity to nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "We have also shown that nintedanib inhibited proliferation of the FGFR1 CNG\u2010positive LSCC cell lines H520 and LK\u20102 in vitro as well as the growth of tumors formed by these cells in vivo .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR , PDGFR , and FGFR.9 There is no previous study reporting the antitumor activity of nintedanib to LSCC with FGFR1 CNG .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR , PDGFR , and FGFR.9 There is no previous study reporting the antitumor activity of nintedanib to LSCC with FGFR1 CNG .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "In contrast , the IC50 values of nintedanib for lung cancer cells without FGFR1 CNG were approximately an order of magnitude larger (6.14 \u00b1 1.28 , 3.98 \u00b1 0.16 , and 5.37 \u00b1 2.38 \u03bcM for H1299 , A549 , and PC\u20109 cells , respectively) , indicating that nintedanib selectively inhibits the proliferation of cells positive for FGFR1 CNG .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "The association between the nintedanib and other FGFR gene alterations , other than FGFR1 CNG , remains unclear and should be clarified in future studies .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "In essence , our findings showed that inhibition of the FGFR1 signal pathway targets both cancer and vascular cells in tumors and provided preclinical evidence that supports the targeting of FGFR1 with nintedanib in LSCC tumors with FGFR1 alterations .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Together with our finding that nintedanib showed antitumor activity both in vitro and in vivo against LSCC cells positive for FGFR1 CNG , these results suggest that clinical investigation of nintedanib as a potential targeted therapy for recurrent LSCC positive for FGFR alteration is warranted .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "In cell-free in vitro kinase assays , nintedanib showed nanomolar potency to inhibit all three VEGFR subtypes , PDGFR-\u03b1 and -\u03b2 and FGFR-1 , -2 and -3 [14] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Although the expression of both PDGFR\u03b1 and PDGFR\u03b2 was clearly downregulated in nintedanib-treated grafts , the expression of FGFR1 , FGFR2 , and VEGFR2 was not influenced by nintedanib and interestingly the expression of the VEGFR1 was even elevated .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29297621",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "We found an overrepresentation of proteins in hAEC Exo that were involved in negatively regulating FGFR1 and FGFR2 , and PDGF\u2010mediated regulation of RAS through GAPs target pathways common to those targeted by nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib , is a TK inhibitor (TKI) that can inhibit FGFR1-3 , vascular endothelial growth factor (VEGFR)1-3 , platelet-derived growth factor receptor (PDGFR)\u03b1/\u03b2 , Src , Lck and Lyn , and a Phase II clinical trial has exhibited antitumor effects in patients with castration-resistant Pca (15) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26045670",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Amplification of FGFR1 can lead to poorer prognosis in early NSCLC,16 and several FGFR1 inhibitors have been demonstrated to suppress the growth of NSCLC cells overexpressing FGFR1 in NSCLC xenograft models.17,18 These inhibitors are mostly small-molecular inhibitors such as AZD4547 , ponatinib (AP24534) , and nintedanib (BIBF 1120) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28008744",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Agents targeted to FGFR1 , such as AZD4547 and nintedanib , have presented good safety and definite efficacy in this subtype of NSCLC.21 , 22 Along with developments in immunotherapy and targeted therapy for SQC , a great challenge faced is how to combine these two kinds of treatments to improve patient prognosis .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDFGR-\u03b1 and PDFGR-\u03b2 , FGFR-1 , FGFR-2 , FGFR-3 , VEGFR-1 , VEGFR-2 , VEGFR-3 , and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "The phosphorylation of FGFR1 and PDGF receptor-\u03b2 in PAs was significantly decreased by 2-week treatment with nintedanib [SuHx(5W) + Nin] (Fig 5A and 5B). .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "FGFR1 , 2 , and 3; PDGF receptor-\u03b1 and -\u03b2; and VEGF receptor-1 , -2 , and -3 are receptors that are targeted by nintedanib [36] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that is specific also for PDGFR\u03b1 and \u03b2 , FGFR1 , 2 , and 3 , and VEGFR1 , 2 , and 3 [6\u20138] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "24722523",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib is entering phase 2 studies in patients with FGFR1 amplified NSCLC (NCT01948141) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib (BIBF 1120) is a small molecule tyrosine kinase inhibitor that inhibits several angiokinases including VEGFR1/Flt1 , VEGFR2/Flk1/KDR and VEGFR3/Flt4 as well as FGFR1 , FGFR2 , FGFR3 , PDGFR-alpha , PDGFR-beta and Flt3 [5] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Sequencing of the kinase domain revealed no activating FGFR1 mutation in nintedanib-resistant DMS114/NIN cells (data not shown) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Preincubation of the cells with nintedanib for 1 hour completely blocked FGF2-mediated activation of FGFR1 signaling .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "However , the overall FGFR1 gene dose remained unaltered after nintedanib selection (aCGH analysis in Figure 2D) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "E. Expression/phosphorylation of FGFR1 and selected downstream signaling proteins in DMS114 and DMS114/NIN cells was analyzed by Western blot of total cell lysates of serum-starved cells , pre-incubated for 1h with the indicated concentration of nintedanib and stimulated for 15min with 20ng/ml FGF2 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Together , this suggests that , despite constant selection pressure of nintedanib , the FGFR1 signaling axis is still maintained or even upregulated as an oncogenic driver in the DMS114/NIN subline .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "B. The impact of the ABCB1 modulator elacridar on nintedanib-mediated inhibition of FGFR1 downstream target phosphorylation in DMS114 and DMS114/NIN cells was analyzed by Western blot .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30836705",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "Nintedanib was initially discovered as an inhibitor of angiogenesis-associated kinases including PDGFR\u03b1 , VEGFR and fibroblast growth factor receptor-1 (FGFR-1) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "A phase II study to examine the value of FGFR1 gene amplification as a predictor of nintedanib efficacy in patients with squamous cell NSCLC is currently ongoing (ClinicalTrials.gov: NCT01948141) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27331812",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Considered as a multiple TKIs , nintedanib (BIBF1120) is a potent , oral , small-molecule agent , which can concurrently block PDGFR-\u03b1 and -\u03b2 , VEGFR1 , 2 and 3 , FGFR1 , 2 and 3 , Src and the PLT-3 family RTKs [121] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23146151",
    "tail": {
      "word": "bFGFR",
      "id": "P11362"
    },
    "sentence": "BIBF 1120 (nintedanib) , an oxindole derivative is a triple kinase inhibitor with potent suppressing effects on VEGFR , PDGFR and bFGFR [9] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Based on this unique characteristic , nintedanib transport by ABCB1 was exemplarily dissected and inactivation by lysosomal trapping was identified to represent a novel resistance mechanism limiting nintedanib activity in FGFR1 amplification-driven lung cancer .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31000705",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "The FGFR1 over-expressing PC9-GR5 cells showed an IC50 of 2.3 \u00b5M for the FGFR1 inhibitor nintedanib; only 2\u201310 times lower than the rest of the panel .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31000705",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Western blotting showed that crizotinib at 2 \u00b5M effectively suppressed the phosphorylation of MET in PC9-GR1 , while BGB324 at the same concentration inhibited the activation of AXL in PC9-ER , and nintedanib the phosphorylation of FGFR substrate 2 (FRS2) , the main downstream effector of FGFR1 , in PC9-GR5 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31443247",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib , PDGFR\u03b1-\u03b2 , FGFR1-3 , VEGFR1-3 , FLT3 , Lck kinase , Lyn kinase , and Src kinase .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31093341",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Similarly a trial of nintedanib targeting VEGFR1-3 , PDGFR\u03b1/\u03b2 , and FGFR1-2 had a disease control rate of 75 % and a 6-month PFS >60 % , although it was not clear if disease progression was required prior to enrollment [39] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "A phase II study is ongoing to examine the value of FGFR1 gene amplification as a predictor of nintedanib efficacy in patients with squamous cell NSCLC [http://ClinicalTrials.gov: NCT01948141] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Several clinical trials involving nintedanib are ongoing , including a phase III study (NCT02299141) , that will evaluate the effectiveness of nintedanib in molecularly selected NSCLC patients and investigate the potential role of some genes (VEGFR1-3 , PDGFR-A , PDGFR-B , and FGFR1-3) that might be involved in the regulation of mechanisms of acquired resistance to antiangiogenic agents .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28168189",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor , hindering the vascular endothelial growth factor receptor (VEGFR1\u20133) , the FGFR1-3 , the platelet-derived growth factor receptors (PDGFR\u03b1/\u03b2) , fms-like tyrosine kinase 3 and members of the Src family (Src , Lyn , Lck) (63) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26603430",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "An example of this can be found in Table 2 in which the gene copy number of FGFR1 is being tested to predict patient response to the tyrosine kinase inhibitor nintedanib undergoing clinical evaluation for treatment of NSCLC with FGFR1 amplifications (Table 2) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28943626",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib which has activity VEGFR1-3 , FGFR1-3 and PDGFR\u03b1 and PDGFR\u03b2 has been approved for the treatment of non-small cell lung cancer and idiopathic pulmonary fibrosis [18] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29560266",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "76 established a mouse orthotopic model with a stable murine breast cancer cell line (Py2T) and developed an evasive resistance model with long-term treatment with nintedanib (potent inhibitor of fibroblast growth factor [FGF] receptor 1 [FGFR1] , 2 , and 3 , PDGF receptor \u03b1/\u03b2 , and VEGFR1 , 2 , and 3) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25505733",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "Nintedanib , a multi-targeted VEGF- and FGFR-1 receptor TKI demonstrated greater OS in a subgroup of adenocarcinoma patients when added to docetaxel versus chemotherapy alone (63) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31242658",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Nintedanib , a triple-angiokinase inhibitor , is a potent and selective inhibitor for tumor angiogenesis through the blocking of the tyrosine kinase activities of VEGFR1-3 , PDGFR-alpha and -beta , together with FGFR1-3 [100] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Preclinical studies have shown that nintedanib exerts an anti-fibrogenic effect by blocking FGFR1 in fibroblasts [16] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "As a multi-targeted inhibitor , nintedanib has been tested for its anti-cancer effects mostly as an antiangiogenic agent; however , its activity as an FGFR1 inhibitor in oncology remains unexplored .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Thus , developing the combination of nintedanib plus a hormonal agent as a treatment for FGFR1-amplified hormone receptor-positive breast cancer would be appealing , once a pharmacodynamic modulation of FGFR1 at a standard clinical dose has been demonstrated .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "2b) supports the FGFR1 inhibitory properties of nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "To our knowledge , there is no previous evidence for FGFR1 being modulated by nintedanib , when administered at standard doses .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "The combination of nintedanib (200 mg/bid) plus letrozole (2.5 mg/d) effectively inhibited both FGFR1 and aromatase in breast cancer patients , as evidenced by plasma FGF23 and 17-B-estradiol levels .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30285760",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "The gene-centric search result also provided information on three drugs (namely , AZD4547 , PD-173074 and nintedanib) that target both FGFR1 and FGFR3 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28433771",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "There are also FDA-approved drugs including ponatinib , nintedanib , pazopanib , and regorafenib , which are all multikinase inhibitors targeting FGFR1 with low specificity [19] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26336412",
    "tail": {
      "word": "fibroblast growth factor receptor 1",
      "id": "P11362"
    },
    "sentence": "Nintedanib (BIBF 1120) is an oral triokinase inhibitor , assessed in clinical studies , which inhibits the activity of vascular endothelial growth factor receptor 1-3 (VEGFR 1-3) , fibroblast growth factor receptor 1-3 (FGFR 1-3) , and platelet-derived growth factor \u03b1 and \u03b2 (PDGFR \u03b1 and \u03b2) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "FGFR-1",
      "id": "P11362"
    },
    "sentence": "Nintedanib (BIBF1120) is a potent , oral angiokinase inhibitor that targets VEGFR-1-3 , PDGFR-\u03b1 and \u03b2 , and FGFR-1-3 signaling (9) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30854106",
    "tail": {
      "word": "FGFR1",
      "id": "P11362"
    },
    "sentence": "Clinically , in a phase III clinical trial (LUME-Lung 1) , nintedanib , an oral multiple TKI targeting FGFR1-3 , was investigated in combination with docetaxel after failure of first-line therapy versus placebo in patients with advanced lung adenocarcinoma 9 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29805748",
    "tail": {
      "word": "LPA",
      "id": "P08519"
    },
    "sentence": "C) MDA-MB-231T cells were treated with nintedanib for 24 hours then plated in a Boyden chamber motility assay and allowed to migrate through a collagen coated membrane toward either 1% FBS or 5 \u03bcM LPA for 4 hours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib also inhibits non-receptor tyrosine kinases of the Src family with IC50 values of 156 nmol\u00b7L\u22121 for Src , 16 nmol\u00b7L\u22121 for Lck and 195 nmol\u00b7L\u22121 for Lyn [72] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28619847",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "D) Working model of the positive feedback signling loop triggered by the combination of nintedanib and MP07-66 , which counters the high level of cytosolic tyrosine phosphorylation , the crucial factor sustaining the oncogenic machinery in CLL cells , mediated by the aberrant form of HSP90-bound Lyn .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "LYN",
      "id": "P07948"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "tyrosine-protein kinase lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib also inhibits the proto-oncogene tyrosine-protein kinase Src (IC50=156 nmol/L) , lymphocyte-specific tyrosine-protein kinase Lck (IC50=16 nmol/L) , Lck/Yes novel tyrosine kinase Lyn (IC50=195 nmol/L) , and Fms-like tyrosine kinase 3 Flt-3 (IC50=26 nmol/L).51 Distinct functions that may impact the pathology of IPF have been described for specific tyrosine kinases .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that targets fibroblast growth factor receptor (FGFR) 1 , 2 , and 3; platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2; vascular endothelial growth factor receptor (VEGFR) 1 , 2 , and 3; and Src family tyrosine kinases Lck , Lyn , and Flt-3 [8] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib , is a TK inhibitor (TKI) that can inhibit FGFR1-3 , vascular endothelial growth factor (VEGFR)1-3 , platelet-derived growth factor receptor (PDGFR)\u03b1/\u03b2 , Src , Lck and Lyn , and a Phase II clinical trial has exhibited antitumor effects in patients with castration-resistant Pca (15) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "tyrosine-protein kinase lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30969999",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Due to the role of Lyn kinase in cancer , five Lyn inhibitors (Bosutinib , Ponatinib , Nintedanib , Dasatinib and Bafetinib) are used as therapeutics [26\u201332] , with additional inhibitors , such as Saracatinib , currently in clinical trials [33] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "In addition , nintedanib inhibits Src family tyrosine kinases (Src , Lck , Lyn) , Flt-3 and RET (Hilberg et al , 2008; Wollin et al , 2014; Awasthi and Schwarz , 2015) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31443247",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib , PDGFR\u03b1-\u03b2 , FGFR1-3 , VEGFR1-3 , FLT3 , Lck kinase , Lyn kinase , and Src kinase .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28168189",
    "tail": {
      "word": "Lyn",
      "id": "P07948"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor , hindering the vascular endothelial growth factor receptor (VEGFR1\u20133) , the FGFR1-3 , the platelet-derived growth factor receptors (PDGFR\u03b1/\u03b2) , fms-like tyrosine kinase 3 and members of the Src family (Src , Lyn , Lck) (63) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435296",
    "tail": {
      "word": "Abl",
      "id": "P00521"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor of VEGFR , PDGFR , and FGFR , in addition to the Src and Abl tyrosine kinases .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "Abl",
      "id": "P00521"
    },
    "sentence": "Protein analysis demonstrated an inhibitory effect of nintedanib (1 \u03bcM) on TGF-\u03b21-induced phosphorylation of the mitogen-activated protein (MAP) kinase ERK1/2 and the protein tyrosine kinase c-Abl (Figure 4D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "Abl",
      "id": "P00521"
    },
    "sentence": "It could be demonstrated that nintedanib inhibited TGF-\u03b21-induced phosphorylation of the MAP kinase ERK1/2 and of the protein tyrosine kinase c-Abl .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "Abl",
      "id": "P00521"
    },
    "sentence": "We hypothesize that the kinase inhibitor nintedanib inhibits c-Abl tyrosine kinase , similar to imatinib mesylate , a tyrosine kinase inhibitor specific for PDGFR as well as cAbl [35,38] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "Abl",
      "id": "P00521"
    },
    "sentence": "Based on our data we therefore suggest that the antagonistic effect of nintedanib on TGF-\u03b2-induced collagen secretion is \u2013 at least partly \u2013 due to the inhibition of c-Abl and/or ERK1/2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "ABL",
      "id": "P00521"
    },
    "sentence": "These data suggest that inhibition of TGF\u03b2-signaling contributes to the therapeutic efficacy of nintedanib in IPF patients , either indirectly through c-ABL and/or ERK , as hypothesized by the authors , or directly through TGFBR inhibition , as suggested by our findings .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OATP1B3",
      "id": "Q9NPD5"
    },
    "sentence": "In summary , in the clinical setting , nintedanib is unlikely to affect the pharmacokinetics of other drugs that are substrates of major drug-metabolising CYPs or uptake transporters , such as OATP1B1 , OATP1B3 , OAT1 , OAT3 or OCT2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OATP1B3",
      "id": "Q9NPD5"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "CIR",
      "id": "P17315"
    },
    "sentence": "Median PFS according to RECIST v1.0 by CIR was 5.3 months for nintedanib (95% CI , 3.0\u20135.5) vs. 3.9 months for sorafenib (95% CI , 2.8\u20137.4); HR = 1.35 (95% CI , 0.78\u20132.34; Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "CIR",
      "id": "P17315"
    },
    "sentence": "One patient on nintedanib had a PR of 16.0 months duration according to RECIST by CIR; two patients on sorafenib had a PR that lasted for 1.9 months and 2.9 months .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "CIR",
      "id": "P17315"
    },
    "sentence": "According to mRECIST by CIR , there were seven patients on nintedanib and six patients on sorafenib with a PR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "CIR",
      "id": "P17315"
    },
    "sentence": "The best percentage change from baseline in target lesions by CIR for nintedanib and sorafenib are shown in supplementary Figure S3A and Figure S3B , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "CIR",
      "id": "P17315"
    },
    "sentence": "The median TTP according to RECIST v1.0 by CIR was 5.5 months (95% CI , 3.0\u20135.6) in the nintedanib group vs. 4.6 months (95% CI , 2.8\u20137.4) in the sorafenib group; HR = 1.44 (95% CI , 0.81\u20132.57) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "proto-oncogene tyrosine-protein kinase src",
      "id": "P12931"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "proto-oncogene tyrosine-protein kinase Src",
      "id": "P12931"
    },
    "sentence": "Nintedanib also inhibits the proto-oncogene tyrosine-protein kinase Src (IC50=156 nmol/L) , lymphocyte-specific tyrosine-protein kinase Lck (IC50=16 nmol/L) , Lck/Yes novel tyrosine kinase Lyn (IC50=195 nmol/L) , and Fms-like tyrosine kinase 3 Flt-3 (IC50=26 nmol/L).51 Distinct functions that may impact the pathology of IPF have been described for specific tyrosine kinases .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "We analyzed the effect of nintedanib alone or when combined with paclitaxel and/or PD-L1 antibody , in both the primary tumor and the advanced metastatic treatment settings for breast cancer models , with the exception of LM2\u20134 xenograft models where PD-L1 antibody therapy was not undertaken .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "We first analyzed the effect of nintedanib , paclitaxel , a PD-L1 antibody and the various combinations on primary tumor growth .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "By using these syngeneic models , we were also able to evaluate nintedanib , paclitaxel and their combination with a PD-L1 antibody as a potential strategy to enhance overall antitumor efficacy of these drugs , considering also recent evidence suggesting the potential benefit of immunotherapy in TNBC patients [61\u201363] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "c-f) Effect of nintedanib , paclitaxel , anti-PD-L1 and the drug combinations on c) Vascularity; d) Proliferation; e) CD8+ tumor infiltrating cells; and f) Level of Necrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "However , only the combination of PD-L1 antibody with nintedanib induced tumor regression that persisted until day 43 after cell implantation , when tumor growth resumed (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Tumors in mice treated with nintedanib were less vascularized than tumors in the control group , reaching statistical significance when the TKI was administered in combination with paclitaxel and/or the PD-L1 antibody (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "c-f) Effect of nintedanib , paclitaxel , anti-PD-L1 and the drug combinations on c) Vascularity; d) Proliferation; e) CD8+ tumor infiltrating cells; and f) Level of Necrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Log-rank (Mantel Cox) test Nintedanib plus paclitaxel and PD-L1 antibody increased median survival in the advanced metastatic EMT-6/CDDP model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "In general , mice treated with paclitaxel , alone or when combined with either nintedanib or the PD-L1 antibody , showed decreased survival outcomes compared to the control group , the exception being those mice treated with the triple combination .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "In this case , the only relevant , significant improvement was observed when paclitaxel was added to the nintedanib plus anti-PD-L1 combination (ie .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Log-rank (Mantel Cox) test We observed that nintedanib alone or when combined with PD-L1 antibody did not show any benefit when used to treat advanced metastatic disease in the EMT-6/CDDP cell line (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Subsequently , to analyze the impact of nintedanib , paclitaxel , PD-L1 therapy and the combinations on advanced metastatic disease in immunocompetent mice , we followed similar procedures to that described for MDA-MB-231/LM2\u20134 , ie .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "6Toxicity of nintedanib , paclitaxel , PD-L1 antibody and the combinations in the EMT-6 and EMT-6/CDDP models .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "n = 6 (a) , n = 9\u201312 (b) , n = 8 (c) Toxicity of nintedanib , paclitaxel , PD-L1 antibody and the combinations in the EMT-6 and EMT-6/CDDP models .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Despite mice with EMT-6 primary tumors showing more toxicity in response to PD-L1 treatment than EMT-6/CDDP tumor-bearing mice , the antitumor effects induced were better after 5 doses of PD-L1 antibody when combined with nintedanib or paclitaxel .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Perhaps the most important finding of this study is the potential value of the triple drug combination (using nintedanib , paclitaxel and a PD-L1 antibody) in treating overt metastatic TNBC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Our results also highlight the potential of combining anti-PD-L1 therapy with nintedanib or paclitaxel to improve the overall antitumor efficacy of these drugs in TNBC , as well as the importance of utilizing preclinical models that involve treatment of not only primary tumors but also advanced metastatic disease .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "These therapy breaks in some mice receiving paclitaxel (alone or combined with nintedanib or PD-L1 antibody) may have influenced the tumor burden; and this together with the general health status of mice likely contributed to the effects observed on survival .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "However , adding paclitaxel to nintedanib plus PD-L1 antibody (ie .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "However , when adding nintedanib to paclitaxel (and to its combination with the PD-L1 antibody) such a trend disappeared (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "However , only nintedanib plus PD-L1 antibody treatment reached statistical significance in the EMT-6/CDDP model , compared to the control group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "On the other hand , the benefit of nintedanib combined with the PD-L1 antibody when treating EMT-6/CDDP primary tumors (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "nintedanib or paclitaxel , plus PD-L1 antibody) seems to be influenced by the aggressiveness of tumor cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "We therefore decided to evaluate whether combining the nintedanib and paclitaxel doublet with a PD-L1 immune checkpoint antibody could improve overall anti-tumor activity in the syngeneic immunocompetent EMT-6 and EMT-6/CDDP mouse tumor models .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "We observed that nintedanib and paclitaxel improved the antitumor effect of PD-L1 antibody (and/or possibly vice versa) when administered in combination , compared to the control group , whether treating either primary EMT-6 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "The reason why nintedanib or paclitaxel combined with the PD-L1 antibody showed efficacy when treating primary tumors , whereas only the triple combination caused prolonged median survival in the advanced metastatic setting using EMT-6/CDDP , is unknown .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Thus , in the advanced metastatic setting , contributions of the immunomodulatory roles of both nintedanib and paclitaxel to PD-L1 therapy seem necessary to increase median survival (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "This suggests that , presumably , the improved antitumor effect of PD-L1 antibody when combined with nintedanib may be related to an immunomodulatory effect of the TKI ameliorating the VEGF-mediated intra-tumoral immunosuppressive microenvironment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "Only nintedanib combined with the PD-L1 antibody showed a significant antitumor effect compared to the control group until day 27 (the time when all the mice in control group had reached endpoint) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "For the nonsquamous , low PD-L1 expression EGFR mutation negative subgroups , ramucirumab plus docetaxel and nintedanib plus docetaxel provided the greatest benefit .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "If the efficacy of these regimens had not been allowed to vary by histology , then the efficacy found for nintedanib would have been poorer than the results presented from this study for the nonsquamous subgroup for OS , and also we may not have seen a significant result for nivolumab in the squamous PD-L1 expression population .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29448944",
    "tail": {
      "word": "PD-L1",
      "id": "Q9NZQ7"
    },
    "sentence": "In patients with non-squamous histology , nintedanib or ramucirumab plus docetaxel , nivolumab , atezolizumab , and pembrolizumab (in patients with programmed death ligand-1 (PD-L1) > 1%) prolonged overall survival compared to docetaxel single agent [3 , 4 , 6\u20138] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "CD4",
      "id": "P01730"
    },
    "sentence": "Grafts of untreated control allografts and nintedanib-treated allografts retrieved 30 days after transplantation were immunohistological stained with specific markers for CD4+ T cells (CD4; A); DCs (CD205; B) and macrophages (F4/80; C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "CD4",
      "id": "P01730"
    },
    "sentence": "Of the several distinct subtypes of T cells especially CD4+ T cells are associated with the promotion of CAV and subsequent neointima formation.30,31,48,49 Our results show reduced CD4+ presence in grafts of nintedanib-treated animals , which is possibly associated with reduced stimulation by DCs as a cause of their decreased numbers as mentioned above .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "P4HA2",
      "id": "O15460"
    },
    "sentence": "Likewise nintedanib dose-dependently reduced both COL3A1 and P4HA2 expression in control fibroblasts (Figure 1G and H) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "P4HA2",
      "id": "O15460"
    },
    "sentence": "Likewise nintedanib elicited a larger downregulation of P4HA2 expression in ADC-TAFs than in SCC-TAFs , which is an essential enzyme for the intracellular stability of the procollagen triple helix that is required for its effective secretion (Chen and Raghunath , 2009; Schwarz , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "ROCK1",
      "id": "Q13464"
    },
    "sentence": "Therefore , RhoA and ROCK1/2 expression was analyzed in Pca cells and it was observed that nintedanib treatment of 22RV1 and DU145 cells led to an increase in the expression of RhoA , ROCK1 and ROCK2 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761724",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Despite failing the futility analysis , subsequent analysis of centrally reviewed PFS , the primary study endpoint , demonstrated a statistically significant improvement in the nintedanib\u2013pemetrexed arm (median , 4.4 vs 3.6 months , respectively; HR 0.83 (95% CI 0.70\u20130.99); p=0.0435),13 indicating benefit from treatment with nintedanib\u2013pemetrexed .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761724",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The HR-by-treatment interaction plot of TSFLT based on investigator-assessed PFS showed that patient benefit from nintedanib treatment was higher with shorter TSFLT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761724",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "A) Centrally assessed PFS (primary analysis) in patients treated with nintedanib\u2013pemetrexed in LUME-Lung 2 , (B) centrally assessed PFS (primary analysis) and (C) final OS in patients treated with nintedanib\u2013docetaxel in LUME-Lung 1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761724",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "This clinical marker defined that patients with shorter TSFLT who have a poorer prognosis derive a greater PFS and OS benefit from nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25556615",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "CP: carboplatin AUC 5 mg/mL per minute and paclitaxel 175 mg/m2 every 3 weeks; Pl: placebo; B: bevacizumab; Bm: bevacizumab maintenance; PFS: progression-free survival; N: nintedanib; Paz m: pazopanib maintenance .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26096019",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "AGO\u2010OVAR12 is another phase 3 study of antiangiogenic therapy evaluating nintedanib as front\u2010line therapy for women with advanced OC.60 The nintedanib arm exhibited a mild improvement in PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27480166",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In a phase III study of docetaxel and nintedanib versus docetaxel , among patients with SCC lung (42%) , the addition of nintedanib was associated with a PFS of HR 0.77 (95% CI 0.62\u20130.96) , and an OS of HR 1.01 (95%CI 0.85\u20131.21 , p = 0.891) [Reck et al .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30108437",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Similarly , nintedanib , an oral triple angiokinase inhibitor , was also reported to significantly improve both progression-free survival (PFS) and OS in NSCLC patients (LUME-Lung 1 trial) (Reck et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28408617",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "This approval was based on results of the LUME\u2010Lung 1 trial , which demonstrated a significant improvement in PFS (primary endpoint) with nintedanib in patients with advanced NSCLC of all histologies [63] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28927084",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Besides bevacizumab and pazopanib , a third anti-angiogenic drug , nintedanib , has been demonstrated to improve PFS in ovarian cancer patients .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28927084",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median PFS was significantly longer in the nintedanib group , although the absolute difference was small (17.2 vs. 16.6 months) (9) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28138259",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nintedanib exhibited only limited activity and showed the following results: ORR 5% , median PFS 1.0 month , and OS 9.8 months with grade 3 hepatic enzyme elevation occurring at 23%.42 VEGF is critical to the angiogenic process , and its circulating levels could be a further prognostic marker in SCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27313464",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In the squamous cell subtype , the addition of nintedanib was associated with a progression-free survival (PFS) of HR 0.77 (95% CI 0.62\u20130.96) and an OS of HR 1.01 (95% CI 0.85\u20131.21 , P=0.891) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "This analysis showed that median PFS was significantly improved in the pemetrexed plus nintedanib group compared with pemetrexed alone (4.4 vs 3.6 months , HR 0.83 , P=0.0435) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The PFS rates at 36 weeks were 16.3% and 5% in the nintedanib and placebo groups , respectively (HR 0.65 , 95% CI: 0.42\u20131.02 , P=0.06) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "This study demonstrated a significant improvement in median PFS in the nintedanib plus chemotherapy group compared with placebo/chemotherapy alone (17.3 vs 16.6 months , HR 0.84 , 95% CI: 0.72\u20130.98 , P=0.0239) (Table 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "No significant difference in median PFS was observed between nintedanib and sunitinib treated groups (8.44 vs 8.38 months , HR 1.16 , 95% CI: 0.71\u20131.89 , P=0.56) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In a subgroup analysis , a more pronounced PFS benefit was observed with nintedanib compared with the placebo arm in patients with <1 cm postsurgical residual tumor deposits (27.1 vs 20.8 months , HR 0.75 , 95% CI: 0.61\u20130.92 , P=0.005) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The final analysis of this study demonstrated that the median PFS was 10.5 months in the nintedanib group (95% CI: 9.4\u201312.4) and 15.4 months in the bevacizumab group (95% CI: 9.6\u201318.9) , which contrasted with a median PFS at the time of the interim analysis (nintedanib: 10.6 months , bevacizumab: 9.2 months) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The primary endpoint of this study was the kaplan-meier (KM) estimate of PFS at 9 months , which was 62.1% for the nintedanib regimen and 70.2% for the bevacizumab regimen; a numerical difference in PFS between treatments was \u22128.1% (95% CI: \u221227.8 to 11.5) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "A recent Phase III trial demonstrated that treatment with the combination of nintedanib and docetaxel resulted in a significant and clinically meaningful improvement in PFS and OS compared with docetaxel alone in predefined NSCLC patients with adenocarcinoma tumor histology .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26414070",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Some of these agents , including pazopanib , nintedanib , cediranib , and trebananib , have been evaluated in randomized Phase III clinical trials , and all have demonstrated a progression-free survival (PFS) benefit [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25329056",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "According to the current results , regimens containing sorafenib , sunitinib , cediranib , vandetanib , motesanib or nintedanib had substantial improvements for ORR and PFS outcomes , when compared with regimens free of these agents .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26402447",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Trial by Bois [12] showed that maintenance therapy using pazopanib can improve progression-free survival (PFS) for 5 to 6 months , and Ledermann [13] reported that maintenance therapy using nintedanib also improved PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28881856",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The independent centrally reviewed PFS was 4.4 months for nintedanib-pemetrexed versus 3.6 months for placebo-pemetrexed .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28881856",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Specifically , patients in the nintedanib and docetaxel arm exhibited improved PFS compared to patients in the docetaxel arm .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26156021",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "TT: treatment time; Cedi: cediranib; Plac: Placebo; Mote: motesanib; Nint: nintedanib; Pazo: pazopanib; Sora: sorafenib; Suni: sunitinib; Vand: vandetanib; GC: gemcitabine + carboplatin; DC: docetaxel + carboplatin; Doc: docetaxel; GP gemcitabine + cisplatin; Erlo: erlotinib; PC: paclitaxel + carboplatin; DDP:cisplatin; Pem: pemetrexed; Gefi: gefitinib; NA: not available; M: maintenance therapy; PFS: progression-free survival; OS: overall survival .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26789111",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In the LUME-Lung 1 randomized phase 3 trial , the addition of nintedanib to chemotherapy in the second line increased PFS with 0.7 months (HR 0.79 , P = .002) , but did not increase OS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29515799",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Although the median PFS (6.9 weeks) and OS (21.9 weeks) had no significant difference in nintedanib treatment , it was well tolerated and warrants further exploration [40] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29515799",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The PFS was 2.7 months and 3.4 months in the docetaxel plus the placebo group and the docetaxel plus nintedanib group , respectively , indicating the patients benefit from the nintedanib group (p = 0.0019) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In patients with metastatic CRC refractory to standard therapies , nintedanib did not increase OS and was associated with a modest but statistically significant increase in PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "It was assumed that nintedanib would increase median PFS by 2.7 weeks to 10.7 weeks versus 8 weeks with placebo (HR 0.75) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Key messagesIn patients with metastatic CRC refractory to standard therapies , nintedanib did not increase OS and was associated with a modest but statistically significant increase in PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The effect of nintedanib on PFS was consistent in most prespecified subgroup analyses (Figure 3B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Although not a co-primary end point , median PFS by investigator review was 2.6 months (95% CI 2.0\u20132.7) with nintedanib versus 1.4 months (95% CI 1.4\u20131.4) with placebo (HR 0.57; 95% CI 0.49\u20130.67; P < 0.0001; supplementary Figure S1 , available at Annals of Oncology online) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "This study of nintedanib versus placebo in patients with refractory metastatic CRC did not meet the co-primary end point; there was no improvement in OS , and there was a statistically significant , but modest , improvement in PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "However , this remains speculative at this stage; as shown in Figure 3B , the effect of nintedanib on PFS was consistent in most subgroups .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Results demonstrated that nintedanib did not improve OS and provided a statistically significant but modest increase in PFS in heavily pretreated patients with metastatic CRC that was refractory to all currently approved standard therapies .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "A possible interpretation of these PFS data is that there is a subgroup of patients that did benefit from nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29452346",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median OS was similar for nintedanib and placebo , but median PFS was longer in the nintedanib group (Table 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23385789",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The trial was statistically powered to assess PFS at 36 weeks; this was 16% in patients receiving nintedanib and 5% on placebo (HR 0.65 , P=0.06) and the drug was taken forward to phase III in the first-line setting .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30836705",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Moreover , it has been observed that adding nintedanib to traditional chemotherapy for the patients with non-small cell lung cancer (NSCLC) was able to improve the clinical outcomes in terms of longer OS and higher progression-free survival (PFS) [4,22] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The addition of nintedanib to docetaxel significantly improved PFS in the overall population (median 3.4 months versus 2.7 months; HR 0.79 , 95% CI: 0.68\u20130.92 , p = 0.0019) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Intention to treat (ITT) analysis showed that treatment with nintedanib plus pemetrexed significantly prolonged PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months; HR 0.83 , 95% CI: 0.7\u20130.99 , p = 0.04) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The primary endpoint was centrally reviewed PFS; secondary endpoints were OS , investigator-assessed PFS , ORR , safety , and QoL. Patients were randomized in a 1:1 ratio to nintedanib 200 mg b.i.d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28230776",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The TKI nintedanib has also been shown to be comparable with the PFS obtained with sunitinib and demonstrated a significantly lower frequency of hypertension (3.1% compared to 15.6%) [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28708103",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The randomized LUME-Colon 1 phase III trial was designed to evaluate the efficacy of nintedanib monotherapy in terms of PFS and OS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29088109",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Based on the positive PFS results of this study , a second phase Ib study testing the safety and pharmacology of nivolumab in combination with nintedanib is going to be initiated soon (Available online: https://clinicaltrials.gov/ , accessed on 29 October 2017) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866519",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Additionally , a recent phase II trial for platinum-resistant ovarian cancer patients has identified a group of patients with increased PFS after treatment with nintedanib [20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866519",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Indeed , a recent phase 3 trial using nintedanib (an oral triple angiokinase inhibitor of VEGF receptor , PDGFR , and fibroblast growth factor receptor) , in addition to platinum based chemotherapy showed improved PFS for ovarian cancer (17.2 months vs 16.6 months; p = 0.024) [19] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27752291",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median PFS was significantly longer in the nintedanib group than in the placebo group (17.2 months vs. 16.6 months , p = 0.024) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27752291",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nintedanib in combination with carboplatin and paclitaxel significantly increased PFS for women with advanced EOC , but is associated with more gastrointestinal adverse events [8] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27573659",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Further , this trial was not placebo controlled and has been criticized.15 The AGO-OVAR 12 trial randomized a large number of patients (N = 1,366) to nintedanib , another angiogenesis inhibitor , or placebo in combination with chemotherapy.14 OS data are not available but PFS was significantly better with nintedanib versus placebo (HR , 0.84; P = .024) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24864163",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median PFS was significantly longer in the nintedanib plus CP group (17.3 months) than in the nintedanib plus placebo group (16.6 months) (HR 0.84; 95% CI: 0.72\u20130.98; p = 0.0239) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24864163",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The triple angiokinase inhibitor , nintedanib (BIBF 1120) , showed a promising PFS benefit in a randomized , placebo-controlled phase II study in 83 women with recurrent ovarian cancer who had responded to chemotherapy , but who were at high risk of further early recurrence (Table 3) [50] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Interestingly , analysis in patients with adenocarcinoma histology showed a prolonged PFS (HR = 0.77 , p = 0.0193) and OS (HR = 0.83 , p = 0.0359) in the docetaxel plus nintedanib group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In a pivotal randomized , double-blind phase III trial (LUME-Lung 1) , PFS was improved in the docetaxel plus nintedanib group in relative to placebo plus docetaxel (3.4 vs. 2.7 months , p = 0.0019) [63] , while the OS showed no discrepancy (10.1 months vs. 9.1 months , p = 0.2720) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Although the clinical trial was stopped prematurely , a PFS advantage was observed in the nintedanib plus pemetrexed group in the subsequent analysis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27330807",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "b Overall survival for patients in complete remission after second-line therapy; CR2 The treatment of EOC has been filled with approaches that have resulted largely in PFS benefit in the biologic era with front-line maintenance +/\u2212concurrent anti-VEGF therapies (bevacizumab , pazopanib , nintedanib [15\u201318]) but not median overall survival (OS) benefit to date .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30545054",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Based on Nintedanib\u2019s activity to inhibit angiogenesis and block the fibroblast growth factor receptor (FGFR) pathway , this oral drug demonstrated PFS and OS of 11 months and 27.6 months , respectively [99] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30103384",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "PFS at 36-weeks was 5.0% vs. 16.3% in placebo and nintedanib treated patients [91] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30103384",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The median PFS was 17.2 vs. 16.6 months for patients treated with nintedanib and placebo , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30103384",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "A post-hoc analysis showed that nintedanib and platinum-based therapy combination improved PFS in non-high-risk patients [92] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31443247",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nintedanib , a triple angiogenesis inhibitor , was shown to slightly prolong median PFS to 3.71 months in advanced DTC , compared to 2.86 months in the placebo arm , in a recent phase II trial [45] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29249039",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nintedanib in combination with carboplatin and paclitaxel is an active first-line treatment that significantly increases PFS for women with advanced ovarian cancer , but is associated with more gastrointestinal adverse events .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31093341",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Similarly a trial of nintedanib targeting VEGFR1-3 , PDGFR\u03b1/\u03b2 , and FGFR1-2 had a disease control rate of 75 % and a 6-month PFS >60 % , although it was not clear if disease progression was required prior to enrollment [39] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26000013",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nintedanib (BIBF1120) is an oral TKI of FGFR , VEGFR , PDGFR , FLT-3 , and lymphocyte-specific protein tyrosine kinase and significantly prolonged PFS in combination with docetaxel in patients with NSCLC [66] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "PFS at 9 months , the primary objective , was 43.1 vs. 45.2% (p = 0.85) for nintedanib vs. sunitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median PFS was significantly longer with nintedanib than placebo (17.2 months [95% CI: 16.6\u201319.9] vs. 16.6 months [13.9\u201319.1]; HR: 0.84 [95% CI: 0.72\u20130.98]; p = 0.024) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In this trial , the addition of nintedanib to docetaxel significantly improved PFS in the total study population (median 3.4 months [95% CI: 2.9\u20133.9] vs. 2.7 months [2.6\u20132.8]; hazard ratio (HR): 0.79 [95% CI: 0.68\u20130.92] , p = 0.0019) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Moreover , nintedanib plus docetaxel improved PFS and disease control in the total study population .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "These results were partially confirmed by the LUME-Lung 2 trial that , despite early closure , showed that nintedanib plus pemetrexed resulted in a significant prolongation of PFS and disease control rate , while no difference in OS was seen between the arms , probably due to the final low power of the study .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Also , the subset of patients with adenocarcinoma and poor prognosis had a median PFS of 4.2 months in the docetaxel plus nintedanib group versus 1.6 months in the docetaxel plus placebo group (HR 0.67; 95% CI 0.43\u20131.04 , p = 0.0725) (56) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "They estimated a probability of 70% for nintedanib plus docetaxel being the best second-line treatment with regard to OS and PFS (59) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Additionally , the association between plasma levels of VEGF , FGF , and PDGF was evaluated , both baseline and after treatment with nintedanib plus docetaxel , as well as disease control rate , PFS , and OS , among 38 patients with NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The nintedanib arm had a significant better PFS (median PFS 4.4 versus 3.6 months compared with placebo; HR 0.83; 95% CI 0.70\u20130.99; p = 0.0435); however , this difference was not translated into an OS benefit (12.2 versus 12.7 months; HR 1.03; 95% CI 0.85\u20131.24; p = 0.7921) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The significant improvement in PFS in the overall population and the subgroup of patients with adenocarcinoma observed with the addition of nintedanib to cytotoxic drug therapy represents an attractive second-line treatment option .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29270405",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Moreover , phase II LUME-Meso trial suggested an improvement of PFS of malignant pleural mesothelioma treated with nintedanib in combination with standard treatments (Scagliotti et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27231556",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Eighty-three women were enrolled and following the treatment cycle , the PFS was 16.3% for nintedanib patients and 5% for placebo patients .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27231556",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The potential effect of nintedanib nearly tripling PFS , when compared to the placebo , has warranted a 1,300 patient , phase III study of this drug in the LUME-Ovar 1 trial [14] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28424759",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The LUME-Lung 2 study , examining a pemetrexed/nintedanib combination in the second-line setting , also demonstrated a modest but significant PFS improvement in comparison with pemetrexed monotherapy (PFS: 4.4 vs. 3.6 months; HR , 0.83 , 95% CI , 0.70\u20130.99; p = 0.0435) but failed to demonstrate a survival benefit (Table 1) (50) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26500886",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "While pazopanib and nintedanib could already demonstrate to significantly improve PFS of ovarian cancer patients within first-line therapy of two positive trials , the results of a third first-line study investigating trebananib are pending .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27594913",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The authors ultimately conclude that , \u201cNintedanib in combination with carboplatin and paclitaxel significantly increases progression-free survival (PFS)\u201d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27594913",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Also , the PFS rate in both the arms was dramatically low compared to the rates assumed during sample size calculation , ( 70% in nintedanib and 50% in placebo groups ) , and the median PFS was indistinguishable between arms .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27594913",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In fact , the median PFS in nintedanib was 17.2 months vs 16.6 months in placebo arm- a mere 0.6 months benefit .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27881963",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In patients with metastatic relapsed non-small cell lung cancer (NSCLC) and poor prognosis , who had failed first-line chemotherapy , eligible for phase II study (NCT00805194) shown remarkably benefit in median PFS and OS , by nintedanib-based therapy (Tai et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "23936861",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Single-agent treatment of nintedanib (BIBF 1120) in advanced NCSLC was well tolerated , with median PFS of 6.9 weeks and median overall survival (OS) of 21.9 weeks [84] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31077164",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Other targeted therapies with VEGFR antibodies (aflibercept , ramucirumab) and tyrosine kinase inhibitors with selectivity for VEGFRs (sorafenib , sunitinib , nintedanib , cediranib , motesanib , pazopanib , axitinib , vandetanib) showed responses and improved PFS but no survival advantages in patients with advanced NSCLC [4] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Although further studies are clearly needed , the similarity of the TTP/PFS data and patient populations between the regorafenib trials and the present subanalysis implies that nintedanib may be potentially active in the salvage setting .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In the phase II trial , 9-month PFS was shown to be 63% (95% CI: 50\u201375%) in the nintedanib plus mFOLFOX6 arm versus 69% (95% CI: 53\u201386%) in the bevacizumab plus mFOLFOX6 arm , while median PFS was 10.6 months (95% CI: 9.4\u201312.3 for nintedanib/mFOLFOX6 and 9.1\u2013not reached for bevacizumab/mFOLFOX6) in both arms .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nivolumab showed significant superiority over docetaxel plus ramucirumab and docetaxel plus nintedanib (P < 0.05) for OS and PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "There were inconsistencies between the results for OS and PFS for nintedanib , nivolumab , and S-1 plus bevacizumab , which makes it difficult to be certain of the relative effectiveness of these interventions .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "This was the case for docetaxel plus nintedanib for PFS of both nonsquamous and squamous tumor subtypes , for docetaxel plus nintedanib for the random-effects NMA for PFS of the nonsquamous tumor subtype , and for docetaxel plus ramucirumab for the random-effects NMA for PFS .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30987609",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The efficacy of docetaxel plus nintedanib and nivolumab were allowed to vary by histology in this study , although the actual trial results for these interventions had not shown there was a significant association with histology (e.g. , for nintedanib plus docetaxel: OS , P = 0.1194; PFS , P = 0.4700 , as stated by Reck et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The primary efficacy endpoint of PFS at 9 months was 43.1% for patients treated with nintedanib and 45.2% for sunitinib , derived from KM estimates (P=0.85 for the intergroup comparison) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median PFS for patients with liver metastases at baseline was 8.4 months with nintedanib and 5.6 months with sunitinib (HR , 0.43; 95% CI: 0.17\u20131.05; P=0.06) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Post hoc sub-analysis revealed PFS at 9 months for patients with liver or bone metastases at baseline to be 29.0% and 43.9% , respectively , with nintedanib and 14.3% and 25.0% with sunitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "With 60 patients in the nintedanib group , an additional 30 patients in the sunitinib group provided a high probability of recording any numerically positive treatment effect on the primary efficacy endpoint (i.e. , a greater proportion of patients with estimated 9-month PFS with nintedanib versus sunitinib) of \u223c70% , although this was not derived from hypothesis testing .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In the current exploratory study , treatment with nintedanib provided an investigator-assessed 9-month PFS and median PFS and OS similar to sunitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Median PFS according to RECIST v1.0 by CIR was 5.3 months for nintedanib (95% CI , 3.0\u20135.5) vs. 3.9 months for sorafenib (95% CI , 2.8\u20137.4); HR = 1.35 (95% CI , 0.78\u20132.34; Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "OS , overall survival; PFS , progression-free survival; TTP , time to progression Median OS was 11.9 months (95% CI , 9.2\u201316.7) in the nintedanib group vs. 11.4 months (95% CI , 6.5\u201317.0) in the sorafenib group; HR = 0.88 (95% CI , 0.52\u20131.47; Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31275535",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "As in nintedanib trials the 6 minute walk test was not considered , PFS OR available was estimated considering only confirmed \u226510% absolute decline in percent predicted FVC as a criterion to define the progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31275535",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "OR vs BSC for PFS and OS) and a scenario where ORs that were not statistically significant were set to 1 (exacerbation , diarrhoea and serious cardiac event for pirfenidone; progression , overall mortality , serious cardiac event and discontinuation for nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31275535",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "In scenario 2 , estimating nintedanib PFS and OS survival curves using BSC curves , instead of pirfenidone curves , led to reduced cost savings (-\u20ac3,837) and incremental QALYs (0.61); however , pirfenidone continued dominating nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28744168",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The study did meet its primary endpoint and median PFS was significantly improved in the nintedanib group; 3.4 m (95% CI: 2.9\u20133.9) vs 2.7 m (2.6\u20132.8); HR: 0.79 , 95% CI: 0.68\u20130.92 , P=0.0019 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28210142",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The combination of docetaxel and nintedanib significantly improved the primary end point of PFS , with an absolute gain of 0.7 months (median 3.4 versus 2.7 months , HR 0.79; P=0.0019) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28210142",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "No significant pharmacological interactions between chemotherapy and nintedanib were found.50 A Phase II trial evaluated two different twice daily dosages of nintedanib (150 mg [n=36] or 250 mg [n=37] as a single agent in 73 pretreated NSCLC patients with an ECOG performance status (PS) of 0\u20132.51 The trial reported median PFS of 6.9 weeks and OS of 21.9 weeks .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26336412",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "The primary endpoint of the examination was progression-free survival; its prolongation was demonstrated in the patients receiving nintedanib independently of the histological subtype of the neoplasm (PFS: 3.4 months [95% CI: 2.9-3.9] vs. 2.7 months [95% CI: 2.6-2.8] , p = 0.0019) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30069193",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "PFS amounted to 3.4 months in the nintedanib group and 2.7 months among patients who did not receive this agent [39 , 40] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27775259",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Nintedanib group (n=911) had a significantly longer PFS than placebo group (17.2 months [95% CI , 16.6 to 19.9] vs. 16.6 months [95% CI , 13.9 to 19.1]; HR , 0.84; 95% CI , 0.72 to 0.98; p=0.024) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25045437",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "After 752 observed events , the nintedanib arm exhibited a longer PFS than the placebo arm (median 17.3 months vs. 16.6 months; HR , 0.84; 95% CI , 0.72 to 0.98; p=0.024) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28382802",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "A post-hoc analysis revealed that the significant difference of PFS between the nintedanib and placebo groups was found only in the non-high-risk subgroup , which was defined as the International Federation of Gynecology and Obstetrics (FIGO) stage III and postoperative residual tumor \u22641 cm , or FIGO stage II (median PFS 27.1 vs. 20.8 months , 95% CI=0.61\u20130.91) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28382802",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "For nintedanib , median PFS benefit of the nintedanib addition to standard carboplatin and paclitaxel compared with placebo group was found in AGO-OVAR 12 study of 1,366 patients who underwent upfront surgery and standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (17.2 vs. 16.6 months , HR=0.84; 95% CI=0.72\u20130.98; p=0.024) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Although the effect of nintedanib monotherapy on NSCLC patients was limited , PFS was significantly improved in advanced NSCLC patients treated with nintedanib combined with docetaxel in the LUME-Lung-1 phase III study (12) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24648773",
    "tail": {
      "word": "PFS",
      "id": "P0AF12"
    },
    "sentence": "Agents such as pazopanib , nintedanib , cediranib , and trebananib have been studied in randomized Phase III clinical trials and have demonstrated a PFS benefit.16\u201319 The improvement in PFS indicates a possible important role for the use of such drugs in the treatment of EOC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "ret proto-oncogene",
      "id": "O43519"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044096",
    "tail": {
      "word": "NNTB",
      "id": "P0C188"
    },
    "sentence": "NNTH-NNTB indicated that nintedanib was better than pirfenidone in every outcome apart from acute exacerbations and FVC decline where there was no difference .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044096",
    "tail": {
      "word": "NNTB",
      "id": "P0C188"
    },
    "sentence": "The difference in the occurrence of dropouts indicates a slight clinical advantage of pirfenidone when it comes to safety , and this may be of interest when choosing an appropriate long-term solution for IPF , while the NNTB/NNTH results favor nintedanib as a treatment option .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib is a multitargeted angiokinase inhibitor against many growth factor receptors , including PDGFR , FGFR , VEGFR,14 as well as the proto-oncogenes RET , FTL3 and Src,15 , 16 with anti-angiogenic activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "Ret",
      "id": "P07949"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "ret",
      "id": "P07949"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30093982",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Other multi-target kinase inhibitors have also been tested in RET-rearrangement NSCLC , including sunitinib,23 sorafenib,24 alectinib,25 nintedanib , ponatinib and regorafenib.26 Data on these agents are generally limited to case reports .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31369645",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "For example , most VEGFR TKIs also target PDGFRs , and others have sensitivities to FGFRs (nintedanib , regorafenib) , TIE receptors (regorafenib) , c-KIT (dovitinib , pazopanib) , RET (sorafenib) , CSF-1R (linifanib) , among others [8] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28540330",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Other multi-kinase inhibitors with potential RET activity include sunitinib , sorafenib , alectinib , nintedanib , and ponatinib; however , it is unclear if these drugs are likely to achieve improved responses compared to cabozantinib , vandetanib , and lenvatinib [8] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib antagonizes RET and VEGF receptors and blocks endothelial cell proliferation and tumor growth in mouse models of pancreatic and lung cancers [15 , 20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Consistent with its anti-angiogenic effects , Nintedanib therapy also reduced phosphorylation of RET , VEGFR2 , and ERK1/2 in MTC tumors (Figure 4D). .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Thus Nintedanib has stronger anti-proliferative properties than Vandetanib in sporadic and RET-mutated familial cultured MTC cells and in our MTC mouse model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "As a second set of experiments , the effects of Nintedanib on RET-mutated familial MTC-derived TT cell growth was compared to that of Vandetanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Vandetanib and Nintedanib antagonize RET signaling , block tumor development but exhibit different anti-proliferative effects on tumor cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Romidepsin had no effect on phosphorylation of RET , VEGFR2 , or ERK1/2 while Nintedanib alone or in combination with Romidepsin lowered these signals , consistent with the previous results (Figure 5D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "These observations suggest that the mode of action of Vandetanib and Nintedanib are not identical and mediated not only via RET-dependent but also via RET-independent signaling pathways .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Furthermore , Nintedanib , which blocks VEGFR2 , RET , ERK1,2 and PI3K/AKT/FOXO1 like Vandetanib , also inhibits PI3K/AKT/mTOR , but may still have limited long-term anti-tumor effects on MTC due to the development of resistance .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "It would also be of interest to determine if the recently developed and very specific RET inhibitors , BLU-667 and LOXO-292 [4] exhibit improved anti-angiogenic and antiproliferative properties compared to Vandetanib and Nintedanib in vivo and in cell culture conditions .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "In addition , nintedanib inhibits Src family tyrosine kinases (Src , Lck , Lyn) , Flt-3 and RET (Hilberg et al , 2008; Wollin et al , 2014; Awasthi and Schwarz , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib is a novel triple angiokinase inhibitor targeting VEGFR1\u20133 , platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2 , fibroblast growth factor receptors (FGFR) 1\u20133 , and , in addition , is also an inhibitor of the Src family , RET , and FLT3 [46,47] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that targets VEGFRs , platelet-derived growth factor receptors and fibroblast growth factor receptors (FGFRs) -the three key pathways involved in angiogenesis- , and to a lesser extent , RET , Flt3 and Src [28] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29249039",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib (BIBF1120) is a next generation , potent triple angiokinase inhibitor of VEGFR1/2/3 , FGFR1/2/3 and PDGFR\u03b1/\u03b2 , with lesser activity against RET , Flt-3 and Src .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "In addition , nintedanib inhibits receptor kinases of RET , Flt3 , and the Src family [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib is a TKI targeting VEGFR1\u20133 , platelet-derived growth factor receptor \u03b1 (alpha) and \u03b2 (beta) , and fibroblast growth factor receptors (FGFR) 1\u20133 and , in addition , it also inhibits the Src family , RET , and FLT3 (5 , 6) (Figure 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29270405",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "2014) EMA , but not FDA , approved the use of nintedanib , an oral multi-kinases inhibitor , targeting VEGFR1-3 , FRGFR1-3 , PDGFR\u03b1-\u03b2 , RET , FLT3 , and Src family kinases , combined with docetaxel for the second-line treatment of NSCLC (Lazzari et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28943630",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor of VEGF , FGF and PDGF signaling , with lower levels of activity against RET , Flt-3 and Src .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26691657",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib [36] (VEGFR 1-3 , FGFR 1-3 , PDGFR alpha/beta and RET TKI) added to docetaxel has demonstrated a significant OS benefit as compared with docetaxel alone in previously treated stage IV , PS 0-1 adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26691657",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib [36] (VEGFR 1-3 , FGFR 1-3 , PDGFR alpha/beta and RET TKI) added to docetaxel has demonstrated a significant OS benefit as compared with docetaxel alone in previously treated stage IV , PS 0-1 adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26691657",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib [36] (VEGFR 1-3 , FGFR 1-3 , PDGFR alpha/beta and RET TKI) added to docetaxel has demonstrated a significant OS benefit as compared with docetaxel alone in previously treated stage IV , PS 0-1 adenocarcinoma .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28396848",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "In the phase III LUME-lung 1 trial , nintedanib , an oral multiple TKI targeting FGFR1\u20133 , vascular endothelial growth factor receptor 1\u20133 , PDGFR \u03b1 and \u03b2 , RET , FLT3 , and Src family kinases , was investigated in combination with docetaxel after failure of first-line therapy versus placebo (37) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "The strong antivascular effect seen with nintedanib may result from its potential to simultaneously inhibit multiple angiogenic and mitogenic signalling pathways (mediated by VEGFR , PDGFR , FGFR , RET and Flt3 [25]) , which may enable the drug to block compensatory angiogenic pathways that can be activated when anti-VEGF agents are used in isolation [3-12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Nintedanib is an orally available triple angiokinase inhibitor that specifically inhibits VEGFR-1-3 , PDGFR-\u03b1/\u03b2 and fibroblast growth factor receptor (FGFR)-1-3 , as well as FLT-3 , RET and members of the Src family (Hilberg et al , 2008; Reck et al , 2014) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29103264",
    "tail": {
      "word": "RET",
      "id": "P07949"
    },
    "sentence": "Sunitinib (SU11248) is an oral inhibitor of VEGFR-1 , -2 , -3 , PDG-FRs , KIT , FLT3 , RET , and CSF-1R [25] , while nintedanib (BIBF 1120) is an oral , triple angiokinase inhibitor , which acts simultaneously on 3 key receptor families involved in angiogenesis: VEGFRs , PDGFRs , and FGFRs [26] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28619847",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "At the molecular level , nintedanib induced caspase-dependent apoptosis , as witnessed by the cleavage of caspase-3 and PARP (Figure 4B , right-hand panel , lane 4) , the latter event being negligible when silencing SHP-1 , irrespective of the presence of nintedanib (lanes 6 and 8) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "In vitro studies showed that treatment with nintedanib induced proliferation arrest and apoptosis in endothelial cells , smooth muscle cells , and pericytes , cell types involved in angiogenesis , through the inhibition of both AKT and mitogen-activated protein kinases signaling pathways , resulting in an overexpression of the apoptosis marker cleaved caspase-3 (43) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "We observed a significant increase in cleaved caspase-3 activity and , hence , more apoptotic cells (green) in lung-resident myofibroblasts treated with nintedanib compared to vehicle alone (Figures 1A,B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "To determine the effect of nintedanib on apoptosis , lung-resident myofibroblasts isolated from the fibrotic lungs of TGF\u03b1 mice were treated with vehicle or nintedanib , and cleaved caspase-3 activity was measured .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "B) Immunostaining of lung sections from vehicle- or nintedanib-treated TGF\u03b1 mice using active caspase-3 Ab .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "C) Quantification of percent active caspase-3+ cells in subpleural regions from vehicle- or nintedanib-treated groups (n = 4/group; 5 representative images per animal). .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "caspase-3",
      "id": "P42574"
    },
    "sentence": "We then performed active caspase-3 immunostaining in paraffin lung sections and found significantly increased active caspase-3-positive cells in the fibrotic lesions from the nintedanib-treated mice (Figures 6B,C) , which also expressed significantly fewer ECM gene transcripts , such as collagen 1\u03b1 and fibronectin1 (Figure 6D) , than the vehicle-treated TGF\u03b1 mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "PTP",
      "id": "Q7MUW6"
    },
    "sentence": "Blocking SHP-1 via either PTP III or siRNA abolished nintedanib-mediated cell death (Figure 3b and c) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "PTP",
      "id": "Q7MUW6"
    },
    "sentence": "We used a specific SHP-1 inhibitor (PTP III) as well as knocked down SHP-1 via transient transfection of SHP-1-targeted siRNAs to analyze the effect of nintedanib on TNBC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "PTP",
      "id": "Q7MUW6"
    },
    "sentence": "Previous studies have indicated that the autoinhibitory structure of the N-SH2 and PTP domains is the major regulator of SHP-1 activity.3 , 5 , 26 Therefore , we used two mutant SHP-1 constructs to mimic the open-form structure of SHP-1 and examine the effect of nintedanib on SHP-1 autoinhibition .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28619847",
    "tail": {
      "word": "PTP",
      "id": "Q7MUW6"
    },
    "sentence": "C) Tyrosine phosphatase activity of SHP-1 immunoprecipitated in the absence (Ip1-SHP-1) and presence (Ip2-SHP-1) of serine/threonine phosphatase inhibitors from the cytosol of CLL cells of 15 patients as determined in vitro in the presence of increasing concentrations of nintedanib supplemented without (solid circles) or with 25 \u03bcM PTP I-I (open circles) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26401847",
    "tail": {
      "word": "ErbB4",
      "id": "Q15303"
    },
    "sentence": "In a preclinical study , the combination of nintedanib (a triple angiokinase inhibitor of VEGFRs , PDGFRs , and FGFRs) and afatinib (an irreversible pan-ErbB inhibitor of EGFR , ErbB2 , ErbB3 , and ErbB4) potently inhibited tumor growth in HT-29 xenograft model regardless of the Kirsten rat sarcoma viral oncogene homolog (KRAS) status [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "SRMS",
      "id": "Q9H3Y6"
    },
    "sentence": "1A. Phosphorylation of ROR1 and SRMS was significantly increased in nintedanib-resistant cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "And end-of-treatment (EOT) visit was scheduled 28 days after the last nintedanib dose The primary study endpoint was the change in FGF23 levels (pg/mL) from baseline to day + 15 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "One additional blood sample (7-mL BD Vacutainer CPT Tube) was obtained on day + 1 and again on day + 15 prior to the morning nintedanib dose and used to determine FGF23 levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "The sample size for the expansion cohort portion was determined by estimating the expected change in FGF23 levels after 14 days of treatment with nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "However , a dose-response effect was observed between nintedanib exposure and FGF23 levels (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "In the first case , if non-tolerable toxicity is observed , one dose reduction (to 200 mg/bid of nintedanib plus 2.5 mg of letrozole) should be attempted , and FGF23 patient\u2019s level should be re-determined 2 weeks later .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "However , this problem can be solved by nintedanib dose reductions \u201con demand,\u201d and other methods for solving this problem can be guided by making serial FGF23 determinations , given the direct correlation between nintedanib exposure and FGF23 levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "FGF23",
      "id": "Q7Z4T2"
    },
    "sentence": "The combination of nintedanib (200 mg/bid) plus letrozole (2.5 mg/d) effectively inhibited both FGFR1 and aromatase in breast cancer patients , as evidenced by plasma FGF23 and 17-B-estradiol levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "ITGA5",
      "id": "P08648"
    },
    "sentence": "The effects of E-cadherin induction seen in nintedanib in combination with siRNAs against CD99L2 , EMP3 , ITGA5 , VIM resulted from the BIBF1120 effect on the down-regulation of SYDE1 and ZEB1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "ITGA5",
      "id": "P08648"
    },
    "sentence": "The induction of SYDE1 or ZEB1 downstream of nintedanib might explain why silencing the mesenchymal genes such as CD99L2 , EMP3 , ITGA5 , and VIM alone did not lead to any significant up-regulation of E-cadherin .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "CDKN1",
      "id": "P38936"
    },
    "sentence": "Furthermore , Nintedanib exposure upregulated the cyclin-dependent kinase inhibitors such as CDKN1 and 2 that act like negative regulators of cell cycle progression alongside growth arrest and DNA damage-inducible 45 (GADD45) , a tumor suppressor known to play a role in mediating the anti-cancer activity of several chemotherapeutic drugs29,30 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28875146",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "The effects of pirfenidone and nintedanib on serum KL-6 and other biomarkers and their implications should be addressed in future studies .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "pem",
      "id": "P15941"
    },
    "sentence": "Another Phase III study (LUME-Lung 2) trial investigated the efficacy and safety of nintedanib (200 mg , bid on 2\u201321 days) in combination with standard pem-etrexed (500 mg/m2 on day 1) compared with pemetrexed alone (500 mg/m2 on day 1) in patients with advanced or recurrent nonsquamous NSCLC after relapse or failure of first-line chemotherapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28039616",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "In 2015 , the EMA approved nintedanib (OFEV\u00ae; Boehringer Ingelheim , Ingelheim , Germany) for this indication .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29943133",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "Only two drugs are currently licensed to treat IPF: pirfenidone (Esbriet , Roche) was approved by the European Medicines Agency (EMA) in 2011 and the US FDA in 2014 , and nintedanib (OFEV , Boehringer Ingelheim) was approved by the EMA in 2015 and the FDA in 2014 [5\u20137] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29946182",
    "tail": {
      "word": "PEM",
      "id": "P15941"
    },
    "sentence": "Afli: aflibercept; Atezo: atezolizumab; Ninte: nintedanib; DOCE: docetaxel; PEM: pemetrexed; Nivo: nivolumab; Pemb: pembrolizumab; Ramu: ramucirumab; Sun: sunitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29946182",
    "tail": {
      "word": "PEM",
      "id": "P15941"
    },
    "sentence": "Afli: aflibercept; Atezo: atezolizumab; Ninte: nintedanib; DOCE: docetaxel; PEM: pemetrexed; Nivo: nivolumab; Pemb: pembrolizumab; Ramu: ramucirumab; Sun: sunitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28881856",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "Based on data from the LUME-lung 1 trial , nintedanib is the only antiangiogenic drug that has been approved by the EMA in combination with docetaxel as a second-line treatment for metastatic NSCLC with adenocarcinoma histology after first-line chemotherapy failure .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26156021",
    "tail": {
      "word": "Pem",
      "id": "P15941"
    },
    "sentence": "TT: treatment time; Cedi: cediranib; Plac: Placebo; Mote: motesanib; Nint: nintedanib; Pazo: pazopanib; Sora: sorafenib; Suni: sunitinib; Vand: vandetanib; GC: gemcitabine + carboplatin; DC: docetaxel + carboplatin; Doc: docetaxel; GP gemcitabine + cisplatin; Erlo: erlotinib; PC: paclitaxel + carboplatin; DDP:cisplatin; Pem: pemetrexed; Gefi: gefitinib; NA: not available; M: maintenance therapy; PFS: progression-free survival; OS: overall survival .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29189700",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "In 2015 , the EMA approved also the nintedanib , a tyrosine kinase inhibitor (5) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26173796",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "Nintedanib , a tyrosine kinase inhibitor , has since been approved for IPF by the FDA [7] and the EMA [8] (in 2014 and 2015 , respectively) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31108995",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "Recently , it has been reported that nintedanib , but not pirfenidone , presented with remarkable improvement of the FVC together with decreased KL-6 value in a patient with IPF [14] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28173708",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "By 2015 , Nintedanib II has been approved by the European medicines agency (EMA) in Europe , as a second-line treatment in combination with docetaxel of locally advanced , metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma20 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28353114",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "Our data indicate that serum KL-6 levels are markedly increased in IPF as compared to healthy subjects but we did not find reduced KL-6 levels in the patients treated by pirfenidone or nintedanib [20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "In the same year , nintedanib combined with docetaxel therapy was approved for non-squamous non-small cell lung cancer (NSCLC) patients as a second-line treatment by the European Medicines Agency (EMA) but not by the FDA [62] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30208899",
    "tail": {
      "word": "PEM",
      "id": "P15941"
    },
    "sentence": "intravenous , NIN nintedanib , NIVO nivolumab , NR not reported , NSCLC non-small cell lung cancer , NSQ non-squamous , NTS not treatment-specific , OSC optimal standard care , OSI osimertinib , PD progressive disease , PEM pemetrexed , PEMB pembrolizumab , PF progression-free , PLA placebo , PR partial response , PSS progression-status-specific , q.d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30208899",
    "tail": {
      "word": "PEM",
      "id": "P15941"
    },
    "sentence": "intravenous , NIN nintedanib , NIVO nivolumab , NR not reported , NSCLC non-small cell lung cancer , NSQ non-squamous , NTS not treatment-specific , OSC optimal standard care , OSI osimertinib , PD progressive disease , PEM pemetrexed , PEMB pembrolizumab , PF progression-free , PLA placebo , PR partial response , PSS progression-status-specific , q.d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29270405",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "2014) EMA , but not FDA , approved the use of nintedanib , an oral multi-kinases inhibitor , targeting VEGFR1-3 , FRGFR1-3 , PDGFR\u03b1-\u03b2 , RET , FLT3 , and Src family kinases , combined with docetaxel for the second-line treatment of NSCLC (Lazzari et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31221221",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "In 2014 , the European Medicines Agency (EMA) approved nintedanib , the first TKI targeting vascular endothelial growth factor receptor (VEGFR) , platelet-derived growth factor receptor (PDGFR) , and fibroblast growth factor receptor (FGFR) , for the treatment of advanced NSCLC in combination with docetaxel .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26762154",
    "tail": {
      "word": "EMA",
      "id": "P15941"
    },
    "sentence": "The US Food and Drug Administration simultaneously approved pirfenidone and a tyrosine kinase inhibitor , nintedanib , for the treatment of patients with IPF in the USA , in October 2014 [17\u201320]; the EMA subsequently approved nintedanib in January 2015 [21] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438923",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "The re-escalated dosage of PSL improved his pneumonitis , and the serum levels of KL-6 decreased , and then nintedanib was started as additional therapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438923",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "The re-escalated dosage of PSL improved his pneumonitis , and the serum levels of KL-6 decreased , and then nintedanib was started as additional therapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438923",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "A re-escalated dosage of PSL improved his pneumonitis , and his serum levels of KL-6 decreased , following which nintedanib was started as additional therapy for the IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31023244",
    "tail": {
      "word": "PEM",
      "id": "P15941"
    },
    "sentence": "The drugs meeting these criteria were Docetaxel (DOC) , Pemetrexed (PEM) , Ramucirumab plus docetaxel (RAM + DOC) , Erlotinib (ERL) , Nintedanib plus docetaxel (NIN + DOC) , Afatinib (AFA) , Nivolumab (NIVO) , and Pembrolizumab (PEMBRO) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "The serum KL-6 level decreased while the levels of BNP and TRPG increased after nintedanib administration .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "Nintedanib was safely continued without severe side effects , and after the initiation of nintedanib administration , his CT findings and FVC stabilized , and the serum KL-6 level declined; however , his dyspnea on exertion worsened [modified medical research council (mMRC) dyspnea scale 3 \u2192 4] (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "Nintedanib was safely continued without severe side effects , and after the initiation of nintedanib administration , his CT findings and FVC stabilized , and the serum KL-6 level declined; however , his dyspnea on exertion worsened [modified medical research council (mMRC) dyspnea scale 3 \u2192 4] (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "Although his HRCT findings and FVC were stable , and the KL-6 level was improving with the administration of nintedanib , his pulmonary artery pressure worsened after starting nintedanib , suggesting that the worsening of his PH was not due to the progression of IPF but rather due to nintedanib administration .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568147",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "Even though the KL-6 concentration increased to 680 IU/mL when tested 2 months after the initiation of treatment with nintedanib , the concentrations gradually decreased and were normalized after 8 months .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568147",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "In the present case , the positive effects of nintedanib were clearly demonstrated by clinical parameters , including the FVC , HRCT findings , and serum KL-6 concentration .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568147",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "In this patient , the FVC gradually improved by 11.7% , and the KL-6 concentration decreased to normal levels with continued nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568147",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "The FVC , the findings of CT images , and serum concentrations of KL-6 may be useful for assessing the efficacy of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568147",
    "tail": {
      "word": "KL-6",
      "id": "P15941"
    },
    "sentence": "In the present patient , a transient decline in the FVC and an elevation of the serum concentrations of KL-6 were observed 2 months after the initiation of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "WEE1",
      "id": "P30291"
    },
    "sentence": "Treatment of PC3 cells with Nintedanib also led to a downregulation of genes responsible for DNA synthesis and replication such as MCM2 , MCM4 , MCM5 and WEE1 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "Antagonism of ETAR by tezosentan also led to a significant re-sensitization of DMS114/NIN cells towards nintedanib , while having only a minor effect in the parental cell line (Figure 8B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "B. Impact of ETAR blockade on viability of nintedanib-treated DMS114 and DMS114/NIN cells was measured by MTT assay .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "ETAR blockade by tezosentan abolished phosphorylation of both PKC isotypes and NF\u03baB p65 in the nintedanib-resistant subline (Figure 8A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "In summary , this suggests that transcriptional upregulation of ABCB1 in DMS114/NIN cells upon selection for nintedanib resistance is induced at least in part by an ETAR-mediated activation of the PKC-NF\u03baB signaling pathway (summarized in Figure 8F) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "Interestingly , nintedanib-selected sublines of NCI-H1703 and NCI-H520 cells , both lacking ABCB1 overexpression , also exhibited low and unaltered ETAR and ET-1 expression levels as compared to their parental cell lines (Figure 7E and 7F) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "Hence , antagonism of ETAR by tezosentan led to decreased levels of ABCB1 protein accompanied by decreased PKC and NF\u03baB phosphorylation and , importantly , to a significant re-sensitization of DMS114/NIN cells towards nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "One might hypothesize that ETAR-mediated ABCB1 activation is a consequence of the specific nintedanib target profile including major players in endothelial cell physiology like FGFR and VEGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ETAR",
      "id": "P9WMC1"
    },
    "sentence": "Moreover , combination approaches with ETAR antagonists or a switch to non-ABCB1 substrate FGFR inhibitors represent innovative strategies to manage nintedanib resistance in lung cancer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29952109",
    "tail": {
      "word": "PDE4",
      "id": "Q4ZHU6"
    },
    "sentence": "PDE4 inhibitors including piclamilast , roflumilast , and a novel agent (Compound 1) were tested and the efficacy of PDE4 inhibition was compared to pirfenidone and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29952109",
    "tail": {
      "word": "PDE4",
      "id": "Q4ZHU6"
    },
    "sentence": "We found that both prophylactic and therapeutic administration of PDE4 inhibitors including the novel agent Compound 1 significantly reduced lung fibrosis following type II AEC injury with an efficacy comparable to pirfenidone and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29952109",
    "tail": {
      "word": "PDE4",
      "id": "Q4ZHU6"
    },
    "sentence": "After establishing a therapeutic benefit of roflumilast and Compound 1 in reducing type II AEC\u2010injury\u2010induced fibrosis , we next compared the efficacy of PDE4 inhibition to treatment with the two FDA\u2010approved drugs for IPF (pirfenidone and nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29952109",
    "tail": {
      "word": "PDE4",
      "id": "Q4ZHU6"
    },
    "sentence": "Although roflumilast is known to show a body weight lowering effect in the clinical setting , treatment with the tested PDE4 inhibitors has a beneficial effect on weight loss in our fibrosis model compared to nintedanib and , less so , pirfenidone .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "RAF",
      "id": "P04049"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "FMS",
      "id": "P07333"
    },
    "sentence": "Nintedanib also inhibits FMS-like tyrosine kinase-3 (Flt-3) with an IC50 of 26 nmol\u00b7L\u22121 [72] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "Fms",
      "id": "P07333"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "Fms",
      "id": "P07333"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31369645",
    "tail": {
      "word": "CSF-1R",
      "id": "P07333"
    },
    "sentence": "For example , most VEGFR TKIs also target PDGFRs , and others have sensitivities to FGFRs (nintedanib , regorafenib) , TIE receptors (regorafenib) , c-KIT (dovitinib , pazopanib) , RET (sorafenib) , CSF-1R (linifanib) , among others [8] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28942086",
    "tail": {
      "word": "Fms",
      "id": "P07333"
    },
    "sentence": "As an example , MCEMP1 (mast cell-expressed membrane protein 1) one of the outcome predictive genes when overexpressed , encodes a transmembrane protein isolated from human mast cells38 , known to work in concert with fibroblasts to aggravate pulmonary fibrosis39 or FLT3 (Fms-related tyrosine kinase 3) a strong Nintedanib-responsive tyrosine kinase with unknown roles in pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29103264",
    "tail": {
      "word": "CSF-1R",
      "id": "P07333"
    },
    "sentence": "Sunitinib (SU11248) is an oral inhibitor of VEGFR-1 , -2 , -3 , PDG-FRs , KIT , FLT3 , RET , and CSF-1R [25] , while nintedanib (BIBF 1120) is an oral , triple angiokinase inhibitor , which acts simultaneously on 3 key receptor families involved in angiogenesis: VEGFRs , PDGFRs , and FGFRs [26] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "IL-6",
      "id": "P05231"
    },
    "sentence": "Similar high values could be found after nintedanib treatment (eg , TNF\u03b1 , IL-6 , INF\u03b3 and MCP-1) , which confirms that rather M1 macrophages with their typical inflammatory mediators are the important subpopulation in our transplant model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29943133",
    "tail": {
      "word": "IL-6",
      "id": "P05231"
    },
    "sentence": "Nintedanib has also demonstrated to have anti-inflammatory activities by reducing inflammatory mediators IL-1\u03b2 and IL-6 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28184295",
    "tail": {
      "word": "IL-6",
      "id": "P05231"
    },
    "sentence": "Two novel approaches\u2014the IL-6 receptor blocker tocilizumab and nintedanib\u2014are in phase III clinical trials , both of which are based on a rather robust rationale , and if all goes well , we may have new drugs for SSc soon .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "DIC",
      "id": "Q9UBX3"
    },
    "sentence": "Cell-free nintedanib fluorescence properties were determined by imaging of the drug in its crystalline form , afterwards dissolved to 1 mM in DMSO and recrystallized after DMSO evaporation in the DIC , FITC and DAPI channels at 40\u00d7 magnification .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "DIC",
      "id": "Q9UBX3"
    },
    "sentence": "After 24 h , cells were treated with 10 \u03bcM nintedanib and intracellular drug accumulation was imaged at the indicated time-points on a live cell microscope (Visitron Systems , Puchheim , Germany) using a 40\u00d7 oil immersion DIC objective and VisiView\u00ae software .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "DIC",
      "id": "Q9UBX3"
    },
    "sentence": "Cell-free nintedanib fluorescence properties in crystalline form or dissolved in DMSO were analyzed by fluorescence microscopy using DIC , FITC and DAPI channels. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "DIC",
      "id": "Q9UBX3"
    },
    "sentence": "Cell-free nintedanib fluorescence properties in crystalline form or dissolved in DMSO were analyzed by fluorescence microscopy using DIC , FITC and DAPI channels. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29802256",
    "tail": {
      "word": "EDA",
      "id": "P0A955"
    },
    "sentence": "Nintedanib at 3 \u00b5M moderately reduced pro-collagen expression but did not reduce the expression of \u03b1-SMA and EDA Fn (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29802256",
    "tail": {
      "word": "EDA",
      "id": "P0A955"
    },
    "sentence": "In contrast , Nintedanib inhibited the stress fiber assembly but not fluorescence intensity of \u03b1-SMA at all concentrations , and only high Nintedanib concentration (3 \u00b5M) inhibited pro-collagen and EDA Fn expressions (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "UDP",
      "id": "P0A1F6"
    },
    "sentence": "Further in vitro data indicated that nintedanib , at clinically relevant concentrations , did not inhibit glucuronidation by uridine 5\u2032-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase , UGT) 1A1 (UGT1A1) in human liver microsomes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643582",
    "tail": {
      "word": "UDP",
      "id": "P0A1F6"
    },
    "sentence": "For some MKIs , like nintedanib , phase II metabolism through UDP-glycosyltransferases (UGTs) , glutathione S-transferases and sulfotransferases (SULTs) is dominant in their metabolism.6,64,65 Inhibition or induction of these phase I and II enzymes by co-administered medication may lead to either (severe) toxicity or loss of effective MKI therapy , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27551531",
    "tail": {
      "word": "EpI",
      "id": "P10646"
    },
    "sentence": "This is consistent with the findings that CUDC-101 prevents in vitro and in vivo aggressiveness via suppressing EMT.20,21 We previously reported that a triple angiokinase inhibitor , Nintedanib , could restore E-cadherin expression.9 Therefore , the class of angiogenesis inhibitors was also subjected to the Phase 1 EpI screen .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Nintedanib significantly inhibited tumor growth in a TNBC-bearing animal model via the SHP-1/p-STAT3 pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "We also examined the effects of nintedanib on STAT3 phosphorylation in the cytoplasm and nucleus .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "These results suggested that STAT3 inhibition may be the major mechanism of nintedanib-induced apoptosis in TNBC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "As shown in Supplementary Figure 3 , nintedanib treatment had no obvious effect on total STAT3 levels but significantly decreased the phosphorylation of STAT3 in both the cytoplasm and nucleus .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "To further validate the role of STAT3 , we transiently transfected MDA-MB-231 cells with a STAT3 overexpression vector to determine the molecular changes induced by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Moreover , nintedanib induced considerable time-dependent apoptosis and reduction of p-STAT3 levels (Figure 2b) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "The results showed that nintedanib inhibited the expression levels of activated STAT3 (p-STAT3) and its downstream pro-proliferative molecules Mcl-1 , cyclin D1 and survivin at the indicated doses (Figure 2a) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "According to previous studies , SHP-1 serves as a crucial negative regulator in STAT3 signaling;25 thus , we determined whether SHP-1 is involved in nintedanib-induced STAT3 suppression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Ectopic expression of STAT3 increased p-STAT3 protein levels and decreased nintedanib-mediated apoptosis , suggesting that activated STAT3 signaling counteracts the anti-tumor activity of nintedanib (Figure 3a) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Therefore , nintedanib potentiates SHP-1 activity by relieving its autoinhibitory conformation to suppress p-STAT3 levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "TNBC cells transduced with \u0394N1 and D61A mutant SHP-1-expressing vectors were insensitive to nintedanib-mediated STAT3 inhibition (Figure 3e) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Moreover , we investigated whether nintedanib-mediated inhibition of tumor growth in MDA-MB-231 cells was dependent on the SHP-1/p-STAT3 pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Cell lysates treated with nintedanib were prepared and analyzed by western blot as previously reported.18 Antibodies targeting p-JAK2 (Tyr1007/1008) , JAK2 , p-SRC (Tyr416) , SRC , p-STAT3 (Tyr705) , STAT3 , survivin , poly (ADP-ribose) polymerase (PARP) and cleaved caspase 3 were purchased from Cell Signaling (Danvers , MA , USA) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Taken together , these data indicate that nintedanib inhibits TNBC tumor growth via SHP-1/p-STAT3 signaling .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "As STAT3 is a direct substrate of PTPRD , we also analyzed the expression of PTPRD in TNBC cells with nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "The data showed that p-STAT3 protein levels were reduced (Figure 4d) , whereas cleaved PARP levels (Figure 4d) and SHP-1 activity were increased (Figure 4e) in the tumor samples from mice treated with nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Our findings that nintedanib regulates the STAT3 pathway provide a rationale for its use to treat TNBC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "We found that nintedanib was effective in blocking STAT3 activation , thus leading to the suppression of numerous proteins involved in cancer survival and proliferation (Figure 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Therefore , the SHP-1/p-STAT3 pathway could be a crucial target for predicting the response to nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Blocking SHP-1 diminished the nintedanib-inhibited STAT3 effect , which provided further evidence that SHP-1 is the key modulator in nintedanib-mediated STAT3 inhibition (Figure 3) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Here we found evidence that STAT3 inhibition is linked to nintedanib-induced SHP-1 activation in both in vitro experiments and a preclinical TNBC xenograft tumor model (Figures 3d and 4e) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "In conclusion , we demonstrated that nintedanib activated SHP-1 by directly relieving the autoinhibition of SHP-1 and significantly inducing TNBC cell apoptosis via SHP-1-dependent p-STAT3 inhibition (Figure 6) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "We also found that nintedanib did not further increase SHP-1 activity in cells expressing SHP-1 mutant clones and that these cells were insensitive to nintedanib-mediated p-STAT3 inhibition (Figure 3) , suggesting that nintedanib restrains STAT3 activation by regulating SHP-1 autoinhibition .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "However , future studies to elucidate the mechanism by which nintedanib inhibits p-STAT3 signaling via the disruption of SHP-1 autoinhibition may lead to further progress in a new targeted therapy for TNBC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Various PTPs have been reported to regulate the STAT3 pathway , including SHP-1,31 , 32 SHP-233 and PTEN.34 However , as shown in Supplementary Figure 4 , nintedanib treatment had no obvious effect on either PTEN or SHP-2 but suppressed the phosphorylation of JAK2 (Tyr1007/1008) and Src (Tyr 416) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "Our findings provide a greater understanding of the molecular mechanism of nintedanib-driven regulation and identify the SHP-1/p-STAT3 pathway as a predictor of the nintedanib response , which can maximize the clinical benefits for TNBC treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "Stat3",
      "id": "P40763"
    },
    "sentence": "We therefore examined whether NLR and nintedanib might affect the phosphorylation of Erk1/2 , Stat3 , or Akt in RPE cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "Stat3",
      "id": "P40763"
    },
    "sentence": "Immunoblot analysis revealed that NLR induced the phosphorylation of Erk1/2 and Stat3 in a manner sensitive to inhibition by nintedanib (Fig 5A and 5B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "Stat3",
      "id": "P40763"
    },
    "sentence": "An I\u03baB kinase\u20132 (IKK-2) inhibitor was obtained from Calbiochem (La Jolla , CA) , a caspase-1 inhibitor (VX-765) and Erk signaling inhibitor (PD98059) were from InvivoGen (San Diego , CA) , a Jak-Stat3 signaling inhibitor (AG490) was from R&D Systems , and an RTK inhibitor (nintedanib) was from Chem Scene (Monmouth Junction , NJ) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "Stat3",
      "id": "P40763"
    },
    "sentence": "We found that NLR induced the phosphorylation of Erk1/2 and Stat3 in RPE cells and that these effects were inhibited by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "Stat3",
      "id": "P40763"
    },
    "sentence": "Serum-deprived cells were exposed to nintedanib (10 \u03bcM) for 1 h before incubation for 24 h in the additional absence or presence of NLR , after which cell lysates were collected for immunoblot analysis of total and phosphorylated (p-) forms of Erk1/2 (A) , Stat3 (B) , and Akt (C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31370258",
    "tail": {
      "word": "STAT3",
      "id": "P40763"
    },
    "sentence": "In addition , nintedanib potentially regulates the Src homology region 2 domain-containing phosphatase-1 (SHP-1) autoinhibition causing an increase in signal transducer and activator of transcription 3 (STAT3) dephosphorylation through a kinase-independent mechanism , in xenograft HCC tumor mouse models [80] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31370258",
    "tail": {
      "word": "signal transducer and activator of transcription 3",
      "id": "P40763"
    },
    "sentence": "In addition , nintedanib potentially regulates the Src homology region 2 domain-containing phosphatase-1 (SHP-1) autoinhibition causing an increase in signal transducer and activator of transcription 3 (STAT3) dephosphorylation through a kinase-independent mechanism , in xenograft HCC tumor mouse models [80] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31278260",
    "tail": {
      "word": "PPARg",
      "id": "P37231"
    },
    "sentence": "Quantitative real-time PCR analysis showed that neither nintedanib nor pirfenidone enhanced the expression of the lipogenic markers PLIN2 and PPARg (Supplementary Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29675024",
    "tail": {
      "word": "cmk",
      "id": "Q83LD8"
    },
    "sentence": "PBMCs were treated with the following substances: LPS 0.1 \u00b5g/ml , ATP 0.5 mM , Ac-Y-VAD-cmk (y-VAD) 1 \u00b5g/ml , glybenclamide (Gly) 1 \u00b5M , MDL28170 (MDL) 10 \u00b5M , Poly dA:dT (dA:dT) 1 \u00b5g/ml , z-IETD-fmk (IE) 0.5 \u00b5g/ml , nintedanib (10 nM) , and pirfenidone (0.1 \u00b5g/ml) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30930781",
    "tail": {
      "word": "cmk",
      "id": "Q83LD8"
    },
    "sentence": "PBMCs were treated with the following substances: LPS 0.1 \u03bcg/ml , ATP 0.5 mM , Poly (dA:dT) (dA:dT) 1 \u03bcg/ml , Ac-Y-VAD-cmk (y-VAD) 1 \u03bcg/ml , Z-LEVD-FMK (z-LEVD) 10 \u03bcM , Pirfenidone (PIRF) (0.1 \u03bcg/ml) Nintedanib (10 nM) , monoclonal antibody anti-IL-1\u03b1 (\u03b1-IL-1\u03b1) (1 ng/ml) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "Col1a1",
      "id": "P02452"
    },
    "sentence": "Nintedanib significantly downregulated mRNA levels of Fn1 and Col1a1 at 1 \u03bcM (\u2212 0.94 \u00b1 0.25 and \u2212 1.51 \u00b1 0.99 , respectively; log fold change compared to control) , while Pirfenidone significantly downregulated Col1a1 at 2.5 mM (\u2212 1.36 \u00b1 1.39 and \u2212 1.95 \u00b1 1.07 , respectively; log fold change compared to control) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "COL1A1",
      "id": "P02452"
    },
    "sentence": "Selected quantitative assays (fold cell number , COL1A1 and COL3A1 expression) were used to compute IC50 values indicative of the antiproliferative and antifibrotic effects of nintedanib , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "COL1A1",
      "id": "P02452"
    },
    "sentence": "Remarkably nintedanib even reduced COL1A1 and \u03b1-SMA in control fibroblasts pre-activated with TGF-\u03b21 for 3 days (Figure 1I and J) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "COL1A1",
      "id": "P02452"
    },
    "sentence": "Nintedanib downregulated the marked induction of both COL1A1 and \u03b1-SMA upon concomitant stimulation with TGF-\u03b21 in a dose-dependent fashion (Figure 1E and F) , whereas DMSO vehicle did not (Supplementary Figure S1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31278260",
    "tail": {
      "word": "COL1A1",
      "id": "P02452"
    },
    "sentence": "Nintedanib and pirfenidone did , however , lead to a 1.9- and 2.3-fold downregulation of COL1A1 , respectively (Supplementary Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31278260",
    "tail": {
      "word": "COL1A1",
      "id": "P02452"
    },
    "sentence": "Finally , whole-mount staining followed by confocal imaging and 3D reconstruction of IPF-derived PCLS (cultured for 5 days in the presence or absence of nintedanib or pirfenidone) revealed a slight decrease in COL1A1 deposition without an evident change in the abundance of LipidTOX+ cells (Supplementary Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "COL1A1",
      "id": "P02452"
    },
    "sentence": "We observed that nintedanib at 0.4 \u03bcM reduced significantly the expression of COL1A1 (Collagen type I alpha 1 chain) , COL3A1 (collagen type III alpha 1 chain) , FN1 (Fibronectin 1) , CTGF (connective tissue growth factor) , PDGFA (platelet-derived growth factor A) , and TGFB1 (transforming growth factor beta 1) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col1a1",
      "id": "P02452"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col1a1",
      "id": "P02452"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Col1a1",
      "id": "P02452"
    },
    "sentence": "P < 0.05 , **P < 0.01 , ***P < 0.005 We confirmed the reduced expression of Col1a1 and Col3a1 by WB , with a significant decrease of collagen-1 in the tibialis anterior (p < 0.05) and a trend in the diaphragm (p = 0.08) of nintedanib-treated mdx mice compared with mdx mice (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "cytochrome P450",
      "id": "Q83WG3"
    },
    "sentence": "CYP cytochrome P450 , UGT uridine diphosphate glucuronosyltransferase Nintedanib is dosed as a soft gelatine capsule .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "cytochrome P450",
      "id": "Q83WG3"
    },
    "sentence": "CYP cytochrome P450 , UGT uridine diphosphate glucuronosyltransferase Metabolism and excretion of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "cytochrome P450",
      "id": "Q83WG3"
    },
    "sentence": "Nintedanib has a low potential for drug\u2013drug interactions via cytochrome P450 but coadministration of drugs that are potent inhibitors or inducers of P-glycoprotein should be undertaken with care .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26273193",
    "tail": {
      "word": "cytochrome P450",
      "id": "Q83WG3"
    },
    "sentence": "The ability of KBP-7018 and nintedanib to inhibit the major human cytochrome P450 isozymes , including 1A2 , 2C9 , 2C19 , 2D6 , and 3A4 , was compared (Table 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "cytochrome P450",
      "id": "Q83WG3"
    },
    "sentence": "Thus , metabolism of nintedanib is predominantly cytochrome P450 enzyme independent , which facilitates the combination of nintedanib with cytotoxic chemotherapies , such as docetaxel , that are metabolized via cytochrome P450 enzymes (10) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "cytochrome P450",
      "id": "Q83WG3"
    },
    "sentence": "Peak plasma concentrations of nintedanib are reached 2\u20134 h after oral administration and have a terminal half-life of 10\u201315 h. Also , it is metabolized largely via hydrolytic cleavage by esterases; cytochrome P450 pathways have a minor role in the metabolism of the MATKI .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29516254",
    "tail": {
      "word": "STS",
      "id": "P08842"
    },
    "sentence": "Currently , a randomized EORTC phase II study ANITA comparing the oral angiogenesis inhibitor nintedanib with ifosfamide in second line is recruiting patients with advanced and metastatic STS , including SS (NCT02808247) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31523388",
    "tail": {
      "word": "BCL2",
      "id": "P10415"
    },
    "sentence": "The most potent partners for CDK inhibitors in multiple myeloma are the HDAC inhibitors CUDC101 and CUDC907 , the MEK1/2 inhibitor trametinib , the NOTCH inhibitor PF-03084014 , the BCL2 inhibitors GX15-070 and ABT-263 , the IDH1/2 inhibitor AGI-5180 , the FLT3 and JAK2 inhibitor SB1317 and also the FGFR-targeting inhibitors XL999 and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31238897",
    "tail": {
      "word": "mdm2",
      "id": "Q00987"
    },
    "sentence": "All drugs have (i) been tested in clinical trials of GBM (nintedanib , paclitaxel , topotecan) , (ii) are currently in clinical trials of GBM (belinostat (NCT02137759) , sapanisertib (NCT02142803) , and selinexor (NCT01986348) , clinicaltrials.gov) or (iii) represent drugs within a class that are being investigated in GBM (carfilzomib; proteasome inhibitors , idasanutlin; mdm2 inhibitors , clinicaltrials.gov) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31238897",
    "tail": {
      "word": "mdm2",
      "id": "Q00987"
    },
    "sentence": "All drugs have (i) been tested in clinical trials of GBM (nintedanib , paclitaxel , topotecan) , (ii) are currently in clinical trials of GBM (belinostat (NCT02137759) , sapanisertib (NCT02142803) , and selinexor (NCT01986348) , clinicaltrials.gov) or (iii) represent drugs within a class that are being investigated in GBM (carfilzomib; proteasome inhibitors , idasanutlin; mdm2 inhibitors , clinicaltrials.gov) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28942086",
    "tail": {
      "word": "membrane protein",
      "id": "Q9K597"
    },
    "sentence": "As an example , MCEMP1 (mast cell-expressed membrane protein 1) one of the outcome predictive genes when overexpressed , encodes a transmembrane protein isolated from human mast cells38 , known to work in concert with fibroblasts to aggravate pulmonary fibrosis39 or FLT3 (Fms-related tyrosine kinase 3) a strong Nintedanib-responsive tyrosine kinase with unknown roles in pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "TNF",
      "id": "P01375"
    },
    "sentence": "After stimulation with TGF-\u03b22 , TNF-\u03b1 , and IL-1\u03b2 , the morphology of HPMVECs changed from a cobblestone to spindle-shaped morphology , and nintedanib tended to prevent its change. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28877715",
    "tail": {
      "word": "TNF",
      "id": "P01375"
    },
    "sentence": "In the years 2011\u20132015 , the anti-fibrotic drug pirfenidone (inhibitor of TGF-\u03b2 , TNF \u03b1 and of PDGF) and the triple kinase inhibitor nintedanib (inhibitor of PDGF , VEGF , and FGF) have both been approved for treatment of Idiopathic Pulmonary Fibrosis (IPF) in the European Union as well as in the United States .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31282197",
    "tail": {
      "word": "TNF",
      "id": "P01375"
    },
    "sentence": "Recently , 2 drugs , pirfenidone and nintedanib , have been approved for the treatment of idiopathic pulmonary fibrosis.71 Pirfenidone has antifibrotic and anti-inflammatory activities via multiple targets such as TGF-\u03b2 , TNF , IL-10 , while nintedanib is an angiokinase inhibitor via VEGF receptor (VEGFR) , fibroblast growth factor receptor (FGFR), and PDGF receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31464219",
    "tail": {
      "word": "tumor necrosis factor",
      "id": "P01375"
    },
    "sentence": "Pirfenidone inhibits transforming growth factor-beta and tumor necrosis factor-alpha.[12] The ASCEND and the CAPACITY trials established that the drug reduced the risk of disease progression and 1-year mortality by ~50%.[34] Nintedanib , on the other hand , is a tyrosine kinase inhibitor .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "AXL",
      "id": "P30530"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31000705",
    "tail": {
      "word": "AXL",
      "id": "P30530"
    },
    "sentence": "Western blotting showed that crizotinib at 2 \u00b5M effectively suppressed the phosphorylation of MET in PC9-GR1 , while BGB324 at the same concentration inhibited the activation of AXL in PC9-ER , and nintedanib the phosphorylation of FGFR substrate 2 (FRS2) , the main downstream effector of FGFR1 , in PC9-GR5 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30545054",
    "tail": {
      "word": "somatostatin",
      "id": "P61278"
    },
    "sentence": "in a phase II study was nintedanib , involving 30 patients with advanced stage metastatic carcinoids on a stable dose of somatostatin analogue .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26853940",
    "tail": {
      "word": "AAK1",
      "id": "Q2M2I8"
    },
    "sentence": "An interesting hit was nintedanib , a tyrosine kinase inhibitor in development for the treatment of idiopathic pulmonary fibrosis , which has a 10-fold higher affinity for BIKE than AAK1 (Figures 3C and 3D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26853940",
    "tail": {
      "word": "AAK1",
      "id": "Q2M2I8"
    },
    "sentence": "It is highly probable that this is the mechanism of the observed selective inhibition of BIKE over AAK1 by nintedanib , although further crystal structures would be required to confirm our proposed binding mode .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27114711",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "In both trials , the patients within the nintedanib arm had a higher incidence of derangement of hepatic enzymes , more specifically a rise in aspartate aminotransferase , alanine aminotransferase , or both .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25767391",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "Levels of alanine aminotransferase , aspartate aminotransferase , or both that were three or more times the upper limit of the normal range occurred more frequently in the nintedanib groups than in the placebo groups (4.9% versus 0.5% in INPULSIS-1 and 5.2% versus 0.9% in INPULSIS-2 , respectively) , but were reversible and without clinically significant sequelae .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "We previously reported that 11 of 32 patients with IPF newly treated with nintedanib at a dose of 150 mg twice daily from September to December 2015 exhibited aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation with the Common Terminology Criteria for Adverse Events (CTCAE) grade \u226526 , 7 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "The most common reasons for nintedanib dose reduction were increased alanine aminotransferase (ALT) levels , increased aspartate aminotransferase (AST) levels and diarrhea .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "Summary of nintedanib-related toxicities Abbreviations: AE adverse event , ALT alanine aminotransferase , AST aspartate aminotransferase , CTC Common Toxicity Criteria , GGT gamma-glutamyl transpeptidase .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "Dose reductions in the nintedanib group were indicated for patients with diarrhoea grade 2 for >7 days despite optimal management; vomiting grade \u2a7e2; elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels grade \u2a7e2 together with elevated bilirubin levels grade >1; or any other AE grade 3/4 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "In the event of treatment-related Grade \u2a7e3 aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevations or Grade \u2a7e2 elevation in conjunction with Grade \u2a7e1 bilirubin elevation , treatment with nintedanib was interrupted until recovery to baseline .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28210142",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "G3 or worse adverse events that were more common in the docetaxel plus nintedanib arm than in the control arm were diarrhea , reversible increases in alanine aminotransferase , and reversible increases in aspartate aminotransferase .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "aminotransferase",
      "id": "Q75WK2"
    },
    "sentence": "The AEs that occurred with nintedanib plus docetaxel more frequently than with placebo plus docetaxel were gastrointestinal (GI) events (diarrhea , nausea and vomiting) and elevations in liver enzymes (increases in alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels) [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27521738",
    "tail": {
      "word": "cHP",
      "id": "Q99653"
    },
    "sentence": "No strong recommendations can be made regarding the use of nintedanib or pirfenidone in cHP or fibrotic CTD-ILD until the safety and efficacy of these agents are formally evaluated in such populations .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27521738",
    "tail": {
      "word": "cHP",
      "id": "Q99653"
    },
    "sentence": "The role of nintedanib and pirfenidone in cHP requires further study before either agent can be recommended for use .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "CHP",
      "id": "Q99653"
    },
    "sentence": "However , the abnormal radiographic lesions started from the basal lungs , and our patient conditions improved without isolation from possible antigens during nintedanib treatment , which are not compatible with CHP .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "CHP",
      "id": "Q99653"
    },
    "sentence": "Although our patient diagnosis remains undetermined , as described in the above discussion , nintedanib might attenuate acute lung injury in patients with AE-ILD , including IPF and CHP .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29755982",
    "tail": {
      "word": "CHP",
      "id": "Q99653"
    },
    "sentence": "Anti-fibrotic medications , including pirfenidone and nintedanib , are effective at slowing lung function decline in patients with IPF (12\u201314) , but their effectiveness in CHP is unknown .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26578138",
    "tail": {
      "word": "CHP",
      "id": "Q99653"
    },
    "sentence": "36 ) It is of note that , at present , there is evidence that pirfenidone and nintedanib are effective in treating IPF , but there is no evidence that they are effective in treating other fibrosing interstitial lung diseases , such as CHP and collagen vascular disease-associated pulmonary impairment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "Nintedanib inhibited the p\u2010FGFR1 and its downstream signaling molecule ERK in a concentration\u2010dependent manner in H520 and LK\u20102 cells (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "d) Effects of nintedanib on FGFR1 , ERK , and AKT phosphorylation in FGFR1 CNG\u2010positive lung squamous cell carcinoma cell lines .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "Both VEGFR and PDGFR are also possible targets of nintedanib and may contribute to decreased ERK activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "Indeed , immunoblot analyses revealed that nintedanib inhibited the FGFR1 phosphorylation and its downstream molecule ERK in H520 tumors (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27581340",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "a) Immunoblot analysis of the effects of nintedanib therapy on FGFR1 , ERK , and AKT phosphorylation in the H520 and LK\u20102 xenograft tumor model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30481203",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "Nintedanib is a receptor tyrosine kinase inhibitor of platelet-derived growth factor receptor (PDGFR)- , vascular endothelial growth factor receptor (VEGFR)- and fibroblast growth factor receptor (FGFR) signaling , which have been shown to critically regulate myofibroblast transformation and collagen production under fibrotic conditions , through subsequent signaling via the ERK , MAPK and the PI3K/Akt pathways [22\u201324] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "Erk",
      "id": "P29323"
    },
    "sentence": "An I\u03baB kinase\u20132 (IKK-2) inhibitor was obtained from Calbiochem (La Jolla , CA) , a caspase-1 inhibitor (VX-765) and Erk signaling inhibitor (PD98059) were from InvivoGen (San Diego , CA) , a Jak-Stat3 signaling inhibitor (AG490) was from R&D Systems , and an RTK inhibitor (nintedanib) was from Chem Scene (Monmouth Junction , NJ) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "These data suggest that inhibition of TGF\u03b2-signaling contributes to the therapeutic efficacy of nintedanib in IPF patients , either indirectly through c-ABL and/or ERK , as hypothesized by the authors , or directly through TGFBR inhibition , as suggested by our findings .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ERK",
      "id": "P29323"
    },
    "sentence": "With regard to FGFR1-downstream signaling in response to FGF2 , cotreatment with elacridar led to restoration of ERK and AKT phosphorylation inhibition by nintedanib in the DMS114/NIN subline (Figure 4B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "SHP-2",
      "id": "Q06124"
    },
    "sentence": "Various PTPs have been reported to regulate the STAT3 pathway , including SHP-1,31 , 32 SHP-233 and PTEN.34 However , as shown in Supplementary Figure 4 , nintedanib treatment had no obvious effect on either PTEN or SHP-2 but suppressed the phosphorylation of JAK2 (Tyr1007/1008) and Src (Tyr 416) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30208899",
    "tail": {
      "word": "OSC",
      "id": "Q04782"
    },
    "sentence": "intravenous , NIN nintedanib , NIVO nivolumab , NR not reported , NSCLC non-small cell lung cancer , NSQ non-squamous , NTS not treatment-specific , OSC optimal standard care , OSI osimertinib , PD progressive disease , PEM pemetrexed , PEMB pembrolizumab , PF progression-free , PLA placebo , PR partial response , PSS progression-status-specific , q.d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30208899",
    "tail": {
      "word": "OSC",
      "id": "Q04782"
    },
    "sentence": "intravenous , NIN nintedanib , NIVO nivolumab , NR not reported , NSCLC non-small cell lung cancer , NSQ non-squamous , NTS not treatment-specific , OSC optimal standard care , OSI osimertinib , PD progressive disease , PEM pemetrexed , PEMB pembrolizumab , PF progression-free , PLA placebo , PR partial response , PSS progression-status-specific , q.d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27144281",
    "tail": {
      "word": "MAP3K19",
      "id": "Q56UN5"
    },
    "sentence": "As the current standard of care drugs , pirfenidone and nintedanib have a large side effect profile , the specificity of Compound A coupled with the restricted pattern of expression of MAP3K19 suggest that it may not have these downsides in patients (Figs 1\u20134 , S1 Fig) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991279",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The two Food and Drug Administration (FDA)-approved pharmacological targets for treatment of IPF are TGF-\u03b2 (pirfenidone) and PDGF/VEGF/FGF (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In IPF-HLF , PDGF-BB , FGF-2 and VEGF caused a significant pro-proliferative effect that was significantly reversed by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In a concentration-dependent manner , nintedanib induced apoptosis in HUVECs stimulated with VEGF or FGF-2 , in HUASMCs stimulated with PDGF-BB or FGF-2 , and in pericytes stimulated with PDGF-BB and FGF-2 [72] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib inhibited the proliferation of VEGF-stimulated HUVECs , PDGF-BB-stimulated HUASMCs and PDGF-BB-stimulated bovine retinal pericytes with IC50 values of 9 , 69 and 79 nmol\u00b7L\u22121 , respectively [72] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The polypharmacology of nintedanib on the receptors for FGF , PDGF and VEGF , and on non-receptor kinases like Src results in a broad inhibitory activity on the downstream signalling cascades of fibroblasts and myofibroblasts and , potentially also on cells involved in angiogenesis in the lung (fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib acts primarily , but not exclusively , downstream of PDGF , FGF and VEGF , all of which are major growth factors in the pathogenesis of IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29435365",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The incidence of AEs associated with VEGF inhibition was generally low; bleeding events and hypertension were slightly higher with nintedanib than with placebo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25556615",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF 1120) is an intracellular inhibitor that targets multiple receptor tyrosine kinases , including the VEGF , fibroblast growth factor (FGF) , and platelet-derived growth factor (PDGF) receptors[55] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26919617",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Multitargeted kinase inhibitors include a RAF/vascular endothelial growth factor receptor\u20102 (VEGFR\u20102)/PDGFR\u2010\u03b2 inhibitor (sorafenib) , a VEGFR2/PDGFR\u2010\u03b2/KIT/FLT\u20103 inhibitor (sunitinib) , a VEGFR/KIT/PDGFR inhibitor (pazopanib) , a RET/VEGFR2/EGFR inhibitor (vandetanib) , a VEGF/PDGF inhibitor (axitinib) , a VEGFR/RET/KIT/PDGFR/RAF inhibitor (regorafenib) , a MET/RET/VEGFR/KIT/FLT\u20103/TIE\u20102/TRKB/AXL inhibitor (cabozantinib) , and a VEGFR/FGFR/PDGFR/SRC/LCK/LYN/FLT\u20103 inhibitor (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30186846",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) [2] or vascular endothelial growth factor (VEGF) [3] demonstrated survival improvement when combined with first-line platinum-based chemotherapy , while a small oral drug with anti-angiogenic properties , nintedanib [4] , had the same result in combination with docetaxel for salvage therapy in an adenocarcinoma sub-group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28717640",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Pirfenidone (an anti-fibrotic and anti-inflammatory medication) and nintedanib (an oxindole derivative that inhibits signalling from platelet-derived growth factor (PDGF) receptor , vascular endothelial growth factor (VEGF) receptor and fibroblast growth factor (FGF) receptor) have been shown to slow the decline in forced vital capacity [1] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "After incubation for 24 h , cells were treated with 50 ng/mL recombinant VEGF-C (PeproTech , Rocky Hill , NJ , USA) , PDGF-BB (PeproTech) , or bFGF (PeproTech) in the presence or absence of nintedanib at concentrations of 0.01 , 0.1 , and 1 \u03bcM. The control cells were treated with 0.1% DMSO .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib prevents enhanced effects of cell proliferation , migration , and tube formation of HLECs stimulated by VEGF-C , PDGF-BB , and bFGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "After trypsinization , HLECs were seeded on the gel at a density of 1\u00d7105 cells/well and incubated in the medium containing VEGF-C , FGF-2 , or PDGF-BB in the presence or absence of 0.1 \u03bcM nintedanib for 24 h. The control cells were treated with 0.1% DMSO .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Next , we investigated the effect of nintedanib on growth factor-induced migration of HLECs at a concentration of 0.1 \u03bcM. As expected , VEGF-C , PDGF-BB , and bFGF (50 ng/mL) significantly stimulated migration of HLECs from the upper chamber to the bottom of the filter (Figure 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib prevents enhanced effects of cell proliferation , migration , and tube formation of HLECs stimulated by VEGF-C , PDGF-BB , and bFGF.Both topical and systemic applications of nintedanib inhibit suture-induced hemangiogenesis and lymphangiogenesis in the murine cornea .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib prevents enhanced effects of cell proliferation , migration , and tube formation of HLECs stimulated by VEGF-C , PDGF-BB , and bFGF.Both topical and systemic applications of nintedanib inhibit suture-induced hemangiogenesis and lymphangiogenesis in the murine cornea .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF-A",
      "id": "P15692"
    },
    "sentence": "First , reduced F4/80+ cell infiltration might result from the inhibition of VEGF-A/VEGFR-1 pathway by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Infiltrating macrophages represent a major source of prolymph/angiogenic factors , such as VEGF-A , VEGF-C , and VEGF-D , leading to an immune amplification.5 Nintedanib might also abrogate the effects of these prolymph/angiogenic factors secreted by macrophages in addition to its impact on inflammatory cell recruitment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF-A",
      "id": "P15692"
    },
    "sentence": "Infiltrating macrophages represent a major source of prolymph/angiogenic factors , such as VEGF-A , VEGF-C , and VEGF-D , leading to an immune amplification.5 Nintedanib might also abrogate the effects of these prolymph/angiogenic factors secreted by macrophages in addition to its impact on inflammatory cell recruitment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28435226",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib inhibits lymphangiogenesis in vitro stimulated by growth factors , including VEGF-C , bFGF , and PDGF-BB .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30841023",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Ramucirumab , a monoclonal antibody to VEGF receptor 2 , and nintedanib , a multiple kinase inhibitor , are another angiogenesis inhibitors with proven survival benefit in the second or later line setting in lung cancer treatment4546 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28138259",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib exhibited only limited activity and showed the following results: ORR 5% , median PFS 1.0 month , and OS 9.8 months with grade 3 hepatic enzyme elevation occurring at 23%.42 VEGF is critical to the angiogenic process , and its circulating levels could be a further prognostic marker in SCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24971016",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Several tyrosine kinase inhibitors (TKIs) under investigation in ovarian cancer target VEGF receptors as well as other proangiogenic molecules , eg , FGF: nintedanib , brivanib , dovitinib; PDGFR: cediranib , pazopanib; and c-Met: cabozantinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27536143",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In addition , other TAs are at varying stages of clinical development , such as anti-EGFR monoclonal antibodies (cetuximab and necitumumab) , immune modulator (thalidomide) , and small multikinase inhibitor targeting VEGF receptor/platelet-derived growth factor receptor/FLT-3/c-KIT (sorafenib , motesanib , nintedanib , and vandetanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In vitro studies demonstrated that nintedanib treatment inhibited the proliferation of VEGF-stimulated human umbilical vein endothelial cells and human skin microvascular endothelial cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "By simultaneous targeting of VEGF , FGF , and PDGF signaling , nintedanib may offer a better approach for the treatment of several solid tumors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27382307",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Until now , three anti-VEGF agents , including bevacizumab , ramucirumab , and nintedanib , have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced NSCLC,6\u20139 and it is anticipated that the use of these agents in cancer patients would be increased in the near future .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27382307",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The search included the following terms: \u201canti-VEGF agents\u201d , \u201cVEGFR-TKIs\u201d , \u201cbevacizumab\u201d , \u201caflibercept\u201d , \u201csorafenib\u201d , \u201csunitinib\u201d , \u201cvandetanib\u201d , \u201cpazopanib\u201d , \u201caxitinib\u201d , \u201cmotesanib\u201d , \u201cramucirumab\u201d , \u201ccediranib\u201d , \u201cregorafenib\u201d , \u201ccabozantinib\u201d , \u201cbrivanib\u201d , \u201ctivozanib\u201d , \u201cnintedanib\u201d , \u201cangiogenesis inhibitors\u201d , \u201cnon-small-cell lung cancer\u201d , and \u201crandomized clinical trial\u201d .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28852519",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multi\u2010target receptor tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) , platelet\u2010derived growth factor (PDGF) , and fibroblast growth factor (FGF) , targeting several molecular pathways involved in the pathogenesis of IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30455955",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Therefore , concurrent use of ramucirumab and nintedanib in our case probably increased gastrointestinal perforation risk by inhibiting VEGF signal more strongly than monotherapy with ramucirumab or nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28096998",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "We herein report a case of acute exacerbation of IPF which was treated with nintedanib , an intracellular inhibitor of tyrosine kinases including the receptors for the fibroblast growth factor (FGF) , platelet\u2010derived growth factor (PDGF) , and vascular endothelial growth factor (VEGF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29564136",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that blocks receptors for platelet\u2010derived growth factor (PDGF) , vascular endothelial growth factor (VEGF) , and fibroblast growth factor (FGF) 9 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29564136",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The PDGF , VEGF , and FGF blockade induced by nintedanib 9 have the theoretical potential to increase perioperative bleeding risk , impair postoperative wound healing , and/or cause bronchial anastomotic complications after lung transplantation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29564136",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The PDGF , VEGF , and FGF blockade induced by nintedanib 9 is associated with a theoretical possibility of increased perioperative bleeding risk , impaired postoperative wound healing , and/or bronchial anastomotic complications , and this remains a topic of debate .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF 1120) is a potent , oral , and broadly active small-molecule tyrosine kinase inhibitor with median inhibitory concentrations in the low nanomolar range: 13\u201334 nmol/L for VEGF receptors 1\u20133; 59 nmol/L and 65 nmol/L for platelet-derived growth factor receptors \u03b1 and \u03b2 , respectively; 37\u2013108 nmol/L for fibroblast growth factor receptors 1\u20133; and 26 nmol/L for Flt3 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29209108",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Furthermore , curcumin and nintedanib attenuated angiogenesis in liver fibrosis via inhibiting VEGF expression in HSCs rather than LSECs[13,56] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29893938",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a small-molecule tyrosine kinase inhibitor acting on the PDGF , fibroblast growth factor and VEGF receptors (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29943133",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a specific tyrosine kinase inhibitor , also targeting PDGF , FGF and VEGF receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27805254",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib and bevacizumab inhibit angiogenesis by the competitive inhibition/antagonism of VEGF and the modulation of the tumor vasculature .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24381593",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Other investigational antiangiogenic agents , such as the triple angiokinase inhibitor BIBF1120 (also nintedanib; targets receptors for VEGF , fibroblast growth factor (FGF) , and platelet-derived growth factor (PDGF)) , have been studied in phase III maintenance therapy trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28440314",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib , a novel and approved tyrosine kinase inhibitor for IPF , robustly inhibits VEGF receptor , PDGF receptor and FGF receptor with resultant modification of IPF fibroblast biology and improved patients outcomes34041 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29348469",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In line with this , the tyrosine kinase inhibitor nintedanib targeting the PDGF , VEGF and FGF signaling cascades induced an anti-fibrotic effect and counteracted TGF-\u00df induced ECM secretion in IPF8 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28592821",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "To investigate whether the migration of endothelial cells into microtissues can be blocked , two anti-angiogenic agents , the triple angiokinase inhibitor nintedanib (Selleckchem , USA) and the monoclonal anti-VEGF antibody bevacizumab (Roche , Germany) , were applied to the system .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29321510",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The mechanism of action of pirfenidone is poorly understood , while nintedanib is an inhibitor of PDGF/VEGF/FGF receptor tyrosine kinases6,7 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "VEGFA",
      "id": "P15692"
    },
    "sentence": "LTF is also known to stimulate cell migration and proliferation via VEGFA gene , whilst nintedanib targets the receptors for VEGFA , VEGFR1 and VEGFR2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Interestingly , there was no significant difference in VEGF expression by Nintedanib compared to their respective vehicle controls in both studies (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26950548",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a small molecule tyrosine kinase inhibitor that blocks all FGF , PGDF , and VEGF receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26950548",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In conclusion , the results of this study demonstrate that VEGF-C is a critical regulator of tumor lymphangiogenesis in NSCLC and show that nintedanib inhibits tumor lymphangiogenesis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26950548",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Although we show that nintedanib has anti-lymphangiogenic activity , this compound was previously reported to not inhibit tumor lymphangiogenesis in a transgenic mouse model of pancreatic neuroendocrine tumor (PNET) that was genetically engineered to overexpress VEGF-C [32] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a triple tyrosine kinase inhibitor (TKI) of PDGF , FGF , and vascular endothelial growth factor (VEGF) receptors [15] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a TKI for PDGF , FGF , and VEGF receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "FGFR1 , 2 , and 3; PDGF receptor-\u03b1 and -\u03b2; and VEGF receptor-1 , -2 , and -3 are receptors that are targeted by nintedanib [36] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Blockade of VEGF signaling by nintedanib may disrupt the maintenance of endothelial cell characteristics , because VEGF signaling generally plays an endothelial protective role [39] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25244152",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Among these compounds are bevacizumab , targeting VEGF signaling [18]; sunitinib , targeting VEGF and PDGF; nintedanib targeting all three; and imatinib targeting just PDGFR .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27716819",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In the present study , treatment with nintedanib and LDAC was associated with a decrease of sVEGFR-2 serum concentrations , whereas blood levels of VEGF did not change significantly .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27716819",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Although the mechanisms responsible for the decrease of circulating VEGF receptors upon small molecule inhibition are not fully understood , our results are entirely in line with previous observations made with nintedanib in solid tumors [31] and with other kinase inhibitors targeting VEGFR-2 such as cediranib [32] or AG-01736 [33] in AML .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The NLR-induced secretion of VEGF from RPE cells as measured with an ELISA was inhibited by nintedanib in a concentration-dependent manner (Fig 2) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "To investigate whether RTK signaling might contribute to NLR-induced VEGF secretion from RPE cells , we examined the effect of a multiple RTK inhibitor (nintedanib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib binds to the intracellular tyrosine kinase domain of VEGF receptors 1 to 3 , fibroblast growth factor receptors 1 to 3 , and platelet-derived growth factor receptors \u03b1 and \u03b2 [30 , 31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "We therefore examined the effect of nintedanib , a multiple RTK inhibitor , on NLR-induced VEGF secretion from RPE cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "VEGF receptors are among the RTKs targeted by nintedanib , and their inhibition may therefore also contribute to the effect of nintedanib on CNV in this model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Expression of VEGF was confirmed in an area largely overlapping with that of CNV under both control and nintedanib conditions , but it was too discontinuous for area measurement (Fig 7A). .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "A) Choroidal flat-mount preparations from mice at 7 days after photocoagulation and intravitreous injection of 100 \u03bcM nintedanib or vehicle (control) were subjected to fluorescence staining with isolectin B4 and antibodies to VEGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "We did find that NLR increased the expression of paxillin in RPE cells and that this effect was attenuated by nintedanib , suggesting that focal adhesion signaling is triggered downstream of RTK activation and may contribute to the up-regulation of VEGF secretion .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "We found that nintedanib suppressed the development of neovascularization and VEGF expression in the laser-induced CNV model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "We found that nintedanib inhibited the NLR-induced secretion of VEGF from RPE cells in a concentration-dependent manner , consistent with the notion that this effect of NLR is mediated by RTK signaling .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Serum-deprived cells were incubated first for 1 h with various concentrations of nintedanib and then for 24 h in the additional absence or presence of NLR , after which culture supernatants were collected for measurement of VEGF with an ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31386668",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Although we detected VEGF expression by immunostaining in an area largely overlapping with that of CNV under both control and nintedanib conditions , the staining was too discontinuous for area measurement .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Cells were pre-incubated for 30 minutes with nintedanib (400 nM) before different stimuli (recombinant human PDGF-BB [10 ng/ml] , recombinant human bFGF [10 ng/ml] , recombinant human VEGF [10 ng/ml]: R&D Systems; Abingdon , United Kingdom) were added for another 30 minutes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Cells were then exposed to different stimuli (recombinant human PDGF-BB [R&D Systems]; recombinant human bFGF [R&D Systems]; recombinant human VEGF [R&D Systems]) in the presence and absence of nintedanib (0.001 , 0.01 , 0.1 , 1 \u03bcM) for 48 hours before being manually counted (Neubauer hematocytometer) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Before stimulation with PDGF-BB , bFGF , or VEGF (all 10 ng/ml) for 30 minutes , cells were pre-incubated with nintedanib (400 nM) for 30 minutes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Before stimulation with PDGF-BB , bFGF , or VEGF (all 10 ng/ml) for 30 minutes , cells were pre-incubated with nintedanib (400 nM) for 30 minutes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Primary human lung fibroblasts derived from IPF patients and from non-fibrotic lungs were pre-incubated for 30 minutes with increasing concentrations of nintedanib (0.001 , 0.01 , 0.1 , and 1 \u03bcM) , before adding PDGF-BB (10 ng/ml) , bFGF (10 ng/ml) , and VEGF (10 ng/ml) for 48 hours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF 1120) is an orally available indolinone derivate that competitively binds to the ATP-binding sites within the kinase domains of VEGF receptor (VEGFR)1 , VEGFR2 , VEGFR3 , FGF receptor (FGFR)1 , FGFR3 , and PDGF receptor (PDGFR)\u03b1 and PDGFR\u03b2 [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Primary human lung fibroblasts derived from IPF patients and from non-fibrotic lungs were pre-incubated for 30 minutes with increasing concentrations of nintedanib (0.001 , 0.01 , 0.1 , and 1 \u03bcM) , before adding PDGF-BB (10 ng/ml) , bFGF (10 ng/ml) , and VEGF (10 ng/ml) for 48 hours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "To further investigate nintedanib\u2019s anti-fibrotic potential , we determined the drug\u2019s effect on PDGF- , FGF- , and VEGF-induced collagen secretion .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In accordance with previous data [7] , nintedanib inhibited the PDGF- , FGF- , and VEGF-induced fibroblast proliferation in a concentration dependent manner in IPF as well as in non-fibrotic control cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26138239",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Tyrosine kinase inhibitors such as Nintedanib , also known as BIBF1120 or Vargatef , block pathways that feed in to the MAPK pathway such as FGF , PDGFR and VEGF , which leads to reduced MAPK-signaling [37] and may be a mechanism by which this drug hinders disease progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29471816",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multiple inhibitor of tyrosine kinase receptors implicated in lung fibrosis pathogenesis , including PDGF receptors \u03b1 and \u03b2 , VEGF receptors 1 , 2 and 3 , and FGF receptors 1 , 2 and 3 [91] , which was shown to prevent the development of lung fibrosis in the bleomycin murine model [92] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26846335",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Previously it has been shown that nintedanib can induce simultaneous inhibition of several targets , i.e. platelet derived growth factor (PDGF) , vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an intracellular inhibitor of tyrosine kinases , including the receptors for the fibroblast growth factor (FGF) , platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) [8 , 9] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In addition to diarrhea , adverse events associated with inhibition of VEGF or VEGFR include arterial hypertension , gastrointestinal perforations , thromboembolism and bleeding [19 , 20] and therefore these are potential risks of nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29409529",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib , a multi-tyrosine kinase inhibitor , ameliorates IPF progression and symptoms by blocking the tyrosine kinases coupled to platelet-derived growth factor (PDGF) , fibroblast growth factor (FGF) , and vascular endothelial growth factor (VEGF) receptors [5 , 6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF-1120) is a multi-tyrosine kinase inhibitor and is known to inhibit the receptor kinases of platelet-derived growth factor (PDGF) , fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) , which are all thought to play an important role in the pathogenesis of IPF [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Based on the targets of nintedanib , FGF2 , PDGF-AA , PDGF-BB , VEGF-A , VEGF-B , VEGF-C , and TGF\u03b2-1 were examined in the different culture supernatants using ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "VEGF-A",
      "id": "P15692"
    },
    "sentence": "Based on the targets of nintedanib , FGF2 , PDGF-AA , PDGF-BB , VEGF-A , VEGF-B , VEGF-C , and TGF\u03b2-1 were examined in the different culture supernatants using ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "VEGF-A",
      "id": "P15692"
    },
    "sentence": "Nintedanib with the concentration of 30 nM or more also inhibited differentiation promoted by PDGF-BB and VEGF-A , but didn\u2019t inhibited differentiation promoted by FGF2 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30237884",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an intracellular inhibitor of tyrosine kinases that targets the fibroblast growth factor (FGF) receptor , vascular endothelial growth factor (VEGF) receptor , and platelet\u2010derived growth factor (PDGF) receptor 2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30237884",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib inhibits tumour angiogenesis by blocking VEGF receptors 1\u20133 , FGF receptors 1\u20133 , and PDGF receptors \u03b1 and \u03b2 5 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29279415",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a small molecule that inhibits the activity of tyrosine kinase receptors , such as vascular endothelial growth factor (VEGF) receptor , PDGF receptor , and FGF receptor (Wollin et al .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28881856",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multitargeting antiangiogenic TKI that blocks the VEGF , PDGF and FGF signaling pathways .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Since bevacizumab and nintedanib both interfere with VEGF signaling , tissue extracts were prepared from untreated DLD-1 and HT-29 tumors and the concentration of human VEGF was determined by ELISA analysis (Figure 1B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "These findings likely reflect a direct inhibitory effect of nintedanib on the tumor cell-associated VEGF receptors , consistent with the potent angiokinase inhibitory activity of this compound .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Furthermore , for HT-29 tumors , bevacizumab treatment was associated with much stronger activation of autocrine VEGF signaling than was the case for nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "B) Induction of VEGF mRNA in DLD-1 (grey columns) and HT-29 (black columns) cells following 24 hrs exposure to nintedanib (0,01 , 0,1 or 1\u03bcM) or bevacizumab (250 \u03bcg/ml) under normoxia or hypoxia .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In clear contrast , for hypoxic HT-29 cells , nintedanib-exposure was accompanied by a dose-dependent increase in mRNA VEGF expression that reached ~2,4 times the levels of the untreated controls , whereas bevacizumab increased mRNA VEGF expression ~1.8-fold .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Interestingly , for HT-29 tumors , treatment with bevacizumab was accompanied by much higher activation of autocrine VEGF signaling than nintedanib , thereby identifying a key difference between the two agents .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The downregulation is unlikely to rely on VEGF-signaling alone , but likely involves other nintedanib targets like FGFR (fibroblast growth factor receptor) and PDGF (platelet-derived growth factor receptor receptor) family members [5] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "If the increased survival of HT-29 cells under hypoxia depends on their potent kinase activity including autocrine VEGF-signaling , we would predict that nintedanib should be more cytotoxic under hypoxic conditions than under normoxia .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib targets VEGF , FGF , and PDGF receptors [15] , and blocks angiogenesis , the process by which new blood vessels form within tumors , and does not exhibit the common adverse events associated TKI .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib antagonizes RET and VEGF receptors and blocks endothelial cell proliferation and tumor growth in mouse models of pancreatic and lung cancers [15 , 20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26170616",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (Vargatef\u00ae; Boehringer Ingelheim Ltd , Ingelheim , Germany) is a triple angiokinase inhibitor (https://youtu.be/0gDnGFumAXE) that simultaneously inhibits signaling pathways activated by VEGF , fibroblast growth factor (FGF) , and platelet-derived growth factor (PDGF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29659191",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "A second is a randomised phase II study of nintedanib (an oral tyrosine kinase inhibitor targeting VEGF receptors 1\u20133 , FGFR 1\u20133 , and PDGFR \u03b1 and \u03b2) compared to chemotherapy in patients with clear cell carcinoma of the ovary or endometrium , which will assess ARID1A mutational status retrospectively and correlate with outcome 27 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30445777",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multi-kinase inhibitor that targets VEGF receptors , PDGF receptors , and fibroblast growth factor receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30704051",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In contrast , the VEGF , FGF , and PDGF receptor inhibitor , nintedanib , has been approved for IPF treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Over the last decade there has been growing interest in the role of Vascular Endothelial Growth Factor (VEGF) in the pathogenesis of ILD , with the development of nintedanib for the treatment of IPF , a novel triple tyrosine kinase inhibitor of VEGF , fibroblast derived growth factor (FGF) and platelet derived growth factor (PDGF) receptors [2] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Best supportive care for these patients includes consideration of pharmacological options such as pirfenidone [92] and the triple tyrosine kinase inhibitor (VEGF , FGF and PDGF) nintedanib [2] , which attempt to slow disease progression with both pharmacological and non-pharmacological interventions to palliate symptoms .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29670046",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Unfortunately , so far , small molecule tyrosine kinase inhibitors of VEGF , as well as FGF receptors (dovitinib used to inhibit VEGFR and FGFR; and nintedanib used to inhibit VEGFR , FGFR , and platelet-derived growth factor receptor (PDGFR)) were not effective in treating cancer patients after recurrence following anti-VEGF therapy [74,75] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866519",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Indeed , a recent phase 3 trial using nintedanib (an oral triple angiokinase inhibitor of VEGF receptor , PDGFR , and fibroblast growth factor receptor) , in addition to platinum based chemotherapy showed improved PFS for ovarian cancer (17.2 months vs 16.6 months; p = 0.024) [19] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28779751",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multiple tyrosine kinase inhibitor that works on key angiogenesis pathways including platelet-derived growth factor (PDGF) , vascular endothelial growth factor (VEGF) , and basic fibroblast growth factor (FGF) [1] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28779751",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Unlike pirfenidone , whose mechanism of action is not fully elucidated , nintedanib is a potent multikinase inhibitor that blocks VEGF receptors among others .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25944985",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a triple angiokinase intracellular inhibitor of multiple tyrosine kinases including the fibroblast growth factor (FGF) , vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors [6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29455659",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "VEGFR-2 blocking antibodies , such as ramucirumab , antibody-like decoy traps that bind both VEGF and placental growth factor , as aflibercept and several TKIs acting as specific inhibitors or pan-kinase inhibitors that also target VEGFR , namely sunitinib , sorafenib , pazopanib , axitinib , regorafenib , nintedanib , cabozantinib and vatalanib [41\u201343] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28353114",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Of interest , VEGF is targeted by nintedanib used as a specific IPF therapy [57] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Currently Nintedanib (BIBF 1120) , a selective FGF and VEGF receptor inhibitor , is being evaluated in clinical trials for its safety and efficacy against PCa treatment [13] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Also , the Nintedanib treatment groups showed a significant decrease in prostatic epithelial VEGF immunoreactivity in the TN12 and TN16 groups (Figs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "To confirm whether Nintedanib treatment (5 and 10 \u03bcM) could also affect the expression of VEGF receptors in human PCa cell lines , we analyzed the expression of both VEGFR-1 and R-2 in cell lysates .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Currently , a new class of triple VEGF , PDGF and FGF signaling inhibitors , known as Nintedanib , is being evaluated .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Notably , in all Nintedanib treatment groups there was a decrease in tissue neovascularization , as observed by decreased microvessel density and VEGF immunoreactivity , a crucial molecule for tumor angiogenesis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "This suggests that , presumably , the improved antitumor effect of PD-L1 antibody when combined with nintedanib may be related to an immunomodulatory effect of the TKI ameliorating the VEGF-mediated intra-tumoral immunosuppressive microenvironment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24864163",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "PubMed/Medline and Embase databases were searched from 1 January 2002 to 8 November 2013 , using the terms: AEE788; aflibercept; AMG 386; angiogenesis inhibitors; anti-VEGF; bevacizumab; BIBF 1120; cediranib; imatinib; nintedanib; pazopanib; perifosine; sorafenib; sunitinib; trebananib; vascular endothelial growth factor; VEGF-receptor AND ovarian cancer OR fallopian tube cancer OR primary peritoneal cancer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an intracellular inhibitor of tyrosine kinases that targets platelet\u2010derived growth factor (PDGF) receptors \u03b1/\u03b2 , fibroblast growth factor (FGF) receptors 1\u20133 , vascular endothelial growth factor (VEGF) receptors 1\u20133 , TGF\u2010\u03b2 , c\u2010Abelson and Src family kinases .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib , an indolinone derivative originally designed as an anti\u2010angiogenic drug , targets the intracellular ATP binding pockets of PDGF , FGF and VEGF receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27598213",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib also targets vascular endothelial growth factor receptor (VEGF) and platelet derived growth factor receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30841487",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Firstly , as nintedanib is known to interfere with VEGFR , FGFR , and PDGFR , and potentially also with TGF-\u03b2 signaling , its therapeutic effects will likely be observed when cells are stimulated with VEGF , FGF , PDGF , and/or TGF-\u03b2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27618114",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib , which inhibits the VEGF receptor-2 (VEGFR-2) , was shown to specifically reverse VEGF-induced proliferation in human primary lung fibroblasts from IPF patients [23,24] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30082599",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib , a tyrosine kinase inhibitor initially developed as an anti-tumour agent [123] , was noted to have activity against fibroblasts through inhibition of vascular endothelial growth factor (VEGF) and other profibrotic mediators such as platelet-derived growth factor (PDGF) , fibroblast growth factor (FGF) , and transforming growth factor (TGF)-\u03b2 [124,125] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27330807",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "b Overall survival for patients in complete remission after second-line therapy; CR2 The treatment of EOC has been filled with approaches that have resulted largely in PFS benefit in the biologic era with front-line maintenance +/\u2212concurrent anti-VEGF therapies (bevacizumab , pazopanib , nintedanib [15\u201318]) but not median overall survival (OS) benefit to date .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28186126",
    "tail": {
      "word": "VEGFA",
      "id": "P15692"
    },
    "sentence": "The response pattern to regorafenib43 correlated strongly with nintedanib targeting VEGFR , but only weakly with Avastin , a monoclonal antibody inhibiting human VEGFA (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29084964",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "For example , Hs 578T cells expressed high levels of PDGF receptor and were sensitive to nintedanib (and polyselective inhibitor of PDGF/VEGF/FGF receptors) , whereas MCF7 cells expressed IGF1R and were sensitive to the IGF1R inhibitors linsitinib and NVP-AEW541 (Supplementary Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30021993",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The other new group of drugs inhibit the vascular endothelial growth factor (VEGF) pathway , including small molecule inhibitors (nintedanib) and antibodies (bevacuzumab and ramicurimab) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31370258",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In xenograft tumor mouse models , nintedanib showed an inhibiting activity of VEGF-dependent cell proliferation [79] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29794999",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The combination of VEGF inhibitor nintedanib with paclitaxel chemotherapy may provide an alternative therapy regimen for patients with BRAFWT metastatic melanoma (NIPAWILMA , NCT02308553) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an oral , triple angiokinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1\u20133 , fibroblast growth factor receptors 1\u20133 , and platelet-derived growth factor receptors \u03b1/\u03b2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28786378",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The proposed 10 times margin represents clear separation of VEGF-R inhibitors with and without significant increase in hypertension with the only exception of nintedanib. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28786378",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The proposed 10 times margin represents clear separation of VEGF-R inhibitors with and without significant increase in hypertension with the only exception of nintedanib. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31160550",
    "tail": {
      "word": "VEGFA",
      "id": "P15692"
    },
    "sentence": "So , in order to further verify the function of VEGFA in the formation of the skeletal muscle organoid , we utilized small molecular drug inhibitor (Nintedanib , s1010) of VEGFA receptors to block the receptors of VEGFA and found that not only the great divergence of organoid diameters (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Using a scratch assay , we observed that nintedanib blocked cell migration promoted by PDGF-AA , bFGF , VEGF , and collagen tissue growth factor (CTGF) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "VEGF-A",
      "id": "P15692"
    },
    "sentence": "In addition , we did not find differences in the differentiation index of myoblasts cultured in a medium containing PDGF-AA , b-FGF , or VEGF-A with or without nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "As nintedanib blocks the VEGF receptor , we also analyzed muscle vascularization .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "VEGF-A",
      "id": "P15692"
    },
    "sentence": "We added to the medium 10 ng/ml PDGF-AA (R&D Systems , Minneapolis , MN) , 50 ng/ml VEGF-A (PeproTech , INC , Rocky Hill , NJ) or 10 ng/ml bFGF (PeproTech) with or without 0.4 \u00b5M nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31221962",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib inhibits receptors related to the pathogenesis of PF , such as the platelet-derived growth factor (PDGF) receptor , fibroblast growth factor (FGF) receptor , and VEGF receptor , and decelerates the decrease in forced vital capacity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a new triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by VEGF receptors , platelet-derived growth factor (PDGF) receptors , and fibroblast growth factor (FGF) receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (Vargatef\u00ae; BIBF 1120) is a novel , potent , oral , triple angiokinase inhibitor that targets VEGF receptors 1 to 3 , PDGF receptors alpha and beta , and FGF receptors 1 to 3 (41\u201343) , as well as members of the Src family and FLT-3 (43) (Figure 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Intracellularly , the inhibitory effect of nintedanib was found to be markedly sustained , with inhibition of VEGF receptor activation for at least 32 h after being treated for 1 h with nintedanib , suggesting slow receptor dissociation kinetics and sustained inhibition (43) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Additionally , the association between plasma levels of VEGF , FGF , and PDGF was evaluated , both baseline and after treatment with nintedanib plus docetaxel , as well as disease control rate , PFS , and OS , among 38 patients with NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28943630",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor of VEGF , FGF and PDGF signaling , with lower levels of activity against RET , Flt-3 and Src .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28184295",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Although nintedanib acts downstream of receptors for pro-fibrotic cytokines , including the vascular endothelial growth factor (VEGF) , fibroblast growth factor (FGF) , and platelet-derived growth factor (PDGF) receptors , this drug could also influence inflammatory cytokine signaling 44 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27231556",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that simultaneously blocks the VEGF , platelet-derived , and fibroblast growth factor receptors [11] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25505733",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Although multiple agents targeting VEGF and VEGF receptors have been studied in lung cancer , only bevacizumab and more recently nintedanib have improved survival in advanced non-squamous NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557500",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "VEGF-targeted therapy is clearly an active approach in ovarian cancer (at least in combination with chemotherapy) and other anti-angiogenic agents have been investigated in this setting including pazopanib (6) , cedirinib (7) , nintedanib (8) , aflibercept (9) , trebananib (10) , sunitinib (11) , sorafenib (12) , and (PDGFR) imatinib (13) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28424759",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "These agents bind VEGFR-2 directly (e.g. , ramucirumab) , act as VEGF inhibitors (e.g. , aflibercept) , or block intracellular downstream signal transduction by the inhibition of the tyrosine kinases of VEGF receptors (e.g. , sorafenib and nintedanib) (6\u20138) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26500886",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In addition , several multikinase inhibitors were developed to interfere with the VEGF receptors and multiple intracellular pathways in addition to the VEGF cascade (e.g. , FGF and PDGF) , which could be implemented by the introduction of pazopanib , nintedanib , cediranib , sunitinib as well as sorafenib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28105074",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Similar multitargeted approaches were taken up by Prof Eric Van Cutsem (University of Leuven , Belgium) in the LUME trial utilising nintedanib against FGF VEGF , PDGF in colon cancer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27110282",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF 1120) is a triple angiokinase inhibitor that impedes angiogenesis at multiple levels by targeting VEGF , FGF , and PDGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26106328",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Pirfenidone works through downregulation of growth factor and procollagen I and II production and nintedanib is a small molecule tyrosine kinase inhibitor that blocks receptors for VEGF , PDGF , and FGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30042678",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that inhibits the ATP binding site of a host of tyrosine kinase receptors , including those for PDGF , FGF and VEGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29854780",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "One of the tyrosine kinase inhibitors , nintedanib , affects receptor signaling of VEGF , PDGF , and FGF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29967964",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "However , in the present study , HUVECs were stimulated with both VEGF and FGF (which were present in the fully supplemented EGM-2 media) , so they were expected to be more durable against the toxic effect of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28877715",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In the years 2011\u20132015 , the anti-fibrotic drug pirfenidone (inhibitor of TGF-\u03b2 , TNF \u03b1 and of PDGF) and the triple kinase inhibitor nintedanib (inhibitor of PDGF , VEGF , and FGF) have both been approved for treatment of Idiopathic Pulmonary Fibrosis (IPF) in the European Union as well as in the United States .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26940352",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multi-target receptor tyrosine kinase inhibitor that inhibits vascular endothelial growth factor (VEGF) , platelet-derived growth factor (PDGF) , and fibroblast growth factor (FGF) [1] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27863518",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib , by inhibition of VEGF and PDGF , may in theory also result in an increased peri-operative bleeding risk .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27863518",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor , which blocks receptors for platelet-derived growth factor (PDGF) , fibroblast growth factor (FGF) , and vascular endothelial growth factor (VEGF) , thus inhibiting downstream signaling in (myo-)fibroblasts [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Therefore , it is speculated that nintedanib , which inhibits the VEGF receptor , may adversely affect PH in IPF patients exposed to chronic hypoxia .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF 1120) is an inhibitor of receptor tyrosine kinases , including vascular endothelial growth factor (VEGF) receptor , fibroblast growth factor (FGF) receptor , platelet-derived growth factor (PDGF) receptor , and non-receptor tyrosine kinases of the Src family [4] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In this report , VEGF-induced proliferation of control MVECs obtained from control patients was reduced by nintedanib , and nintedanib inhibited VEGF-stimulated phosphorylation of ERK1/2 in a dose dependent manner [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30940113",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Treatment of VEGF receptor inhibition , such as with nintedanib , is beneficial for patients with IPF [23] , and adsorptive removal of circulating VEGF by polymyxin B haemoperfusion improves pulmonary oxygenation in AE-IPF [24] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30940113",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Interestingly , a prospective , randomized controlled study is currently ongoing in Japan for patients with NSCLC and IPF to evaluate the efficacy and safety of chemotherapy with or without nintedanib , which inhibits receptor tyrosine kinase signaling by VEGF , platelet-derived growth factor , and fibroblast growth factors [28] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438923",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an oral angiokinase inhibitor that targets receptors in three proangiogenic pathways: vascular endothelial growth factor (VEGF) receptors , platelet-derived growth factor receptors \u03b1/\u03b2 , and fibroblast growth factor receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438923",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Therefore , nintedanib that the target the VEGF pathway may enhance the prevention of ICI-induced pneumonitis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The strong antivascular effect seen with nintedanib may result from its potential to simultaneously inhibit multiple angiogenic and mitogenic signalling pathways (mediated by VEGFR , PDGFR , FGFR , RET and Flt3 [25]) , which may enable the drug to block compensatory angiogenic pathways that can be activated when anti-VEGF agents are used in isolation [3-12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "The incidences of AEs associated with VEGF inhibitors were comparable between the nintedanib and sunitinib groups: thromboembolic events and haemorrhage (Table 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In conclusion , the current trial suggests nintedanib may have similar efficacy to sorafenib in patients with advanced HCC , with a tolerable and different safety profile , but with higher VEGF-related toxicity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26552487",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "P-values , calculated using a Mann\u2013Whitney test , are indicated in the figure The decrease in CD309 expression could be due to different factors , ranging from the progression of the disease per se in untreated patients to the pharmacological effect of pirfenidone and nintedanib , which can decrease the expression of CD309/VEGF-R , altering the VEGF\u2013VEGFR axis [27] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26552487",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib has shown consistent anti-fibrotic and anti-inflammatory activities in bleomycin-induced pulmonary fibrosis in rodents [28 , 36] and in human fibroblasts isolated from the lungs of patients with IPF , and inhibits FGF-induced , PDGF-induced , VEGF-induced profibrotic effects in human lung fibroblasts from patients with IPF [36\u201339] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31282197",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Recently , 2 drugs , pirfenidone and nintedanib , have been approved for the treatment of idiopathic pulmonary fibrosis.71 Pirfenidone has antifibrotic and anti-inflammatory activities via multiple targets such as TGF-\u03b2 , TNF , IL-10 , while nintedanib is an angiokinase inhibitor via VEGF receptor (VEGFR) , fibroblast growth factor receptor (FGFR), and PDGF receptor (PDGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26257929",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Small molecules that inhibit the VEGF tyrosine kinase receptor more or less specifically are , vatalanib , cediranib , dovitinib , pazopanib , nintedanib and axitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is a multi-target receptor tyrosine kinase inhibitor that works on key angiogenesis pathways including fibroblast growth factor (FGF) , platelet-derived growth factor (PDGF) , and vascular endothelial growth factor (VEGF) (5-7) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30568123",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Through its inhibitory action against the VEGF receptor , nintedanib might be associated with the development of PH under conditions of chronic hypoxia .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27775259",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Another anti-angiogenic drug , nintedanib , is an oral triple angiokinase inhibitor of VEGF receptors 1-3 , fibroblast growth factor receptors 1-3 , and platelet-derived growth factor receptors \u03b1 and \u03b2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30142803",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Three groups of antiangiogenic agentswere investigated including the anti-VEGF group (bevacizumab) , VEGF-R tyrosine kinase inhibitor (TKI) group (cediranib , pazopanib , sorafenib , nintedanib , erlotinib) , and angiopoietin inhibitors group (trebananib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29245325",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an oral triple TKI targeting vascular endothelial growth factor (VEGF) , platelet-derived growth factor (PDGF) , and fibroblast growth factor receptors , which play critical roles in the pathogenesis of pulmonary fibrosis and several cancers.[2,6,7] In our cases , IPF progressed over 3 weeks after nintedanib discontinuation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29245325",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib is an oral triple TKI targeting vascular endothelial growth factor (VEGF) , platelet-derived growth factor (PDGF) , and fibroblast growth factor receptors , which play critical roles in the pathogenesis of pulmonary fibrosis and several cancers.[2,6,7] In our cases , IPF progressed over 3 weeks after nintedanib discontinuation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25678824",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "Nintedanib (BIBF 1120) was the first triple angiokinase inhibitor developed with the principle of impeding tumor angiogenesis at multiple levels through targeting VEGF , fibroblast growth factor (FGF) , and platelet-derived growth factor (PDGF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26578138",
    "tail": {
      "word": "VEGF",
      "id": "P15692"
    },
    "sentence": "In addition , nintedanib inhibits the activity of VEGF receptors .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31431179",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "In previous work we found that drugs such as nintedanib and pirfenidone , which have been used to treat IPF [62,63] , elevate Rnd3 expression and thereby decrease RhoA activity [57] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "Knockdown of Rnd3 decreases IPF fibroblast sensitivity to nintedanib and pirfenidone .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "These data suggest that modulation of Rnd3 levels is critical to the anti-fibrotic action of nintedanib and pirfenidone .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "LL29 cells were treated with pirfenidone (1 mM) and nintedanib (1 \u03bcM) for 24 h. (A) The LL29 cells were then lysed , and Rnd3 levels analyzed by Western blot. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "Furthermore , nintedanib and pirfenidone were no longer able to impact the IPF phenotype (FN , collagen levels) in the Rnd3 siRNA-treated cells (Figure 10D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "Control LL29 IPF cells showed prominent stress fibers , whereas LL29 cells treated with nintedanib or pirfenidone showed decreased cell spreading and decreased stress fiber formation (Figure 9H) , consistent with the phenotype observed on Rnd3 overexpression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "LL29 cells were transfected with control , Rnd3 #1 , or Rnd3 #2 siRNA for 72 h and treated with nintedanib (1 \u03bcM) or pirfenidone (1 mM) for the final 24 h where indicated. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "To test whether the elevation of Rnd3 levels induced by pirfenidone and nintedanib is responsible for the ability of these drugs to decrease the IPF phenotype , we used siRNA to deplete the expression of Rnd3 in LL29 IPF cells and examined their response following treatment with nintedanib and pirfenidone (Figure 10A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rnd3",
      "id": "P61587"
    },
    "sentence": "Our finding that nintedanib , a tyrosine kinase inhibitor , elevates Rnd3 expression and p190RhoGAP activity raises the possibility that this pathway may also be inhibited by other tyrosine kinases that elevate RhoA activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OATP1B1",
      "id": "Q9Y6L6"
    },
    "sentence": "In summary , in the clinical setting , nintedanib is unlikely to affect the pharmacokinetics of other drugs that are substrates of major drug-metabolising CYPs or uptake transporters , such as OATP1B1 , OATP1B3 , OAT1 , OAT3 or OCT2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "Fos",
      "id": "P01100"
    },
    "sentence": "reported that chronic treatment with nintedanib reduced pulmonary vascular remodeling in the Fos-related antigen-2 mouse model of systemic sclerosis [49] , which was supportive of our results .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "However , the efficacy of nintedanib to treat PAH by inhibiting PDGF and FGF signaling is still uncertain .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Based on this background information , we hypothesized that nintedanib is a novel and beneficial treatment for PAH by targeting vascular remodeling including neointimal lesion and medial wall thickening in PAs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "The expression of Twist1 protein , which is an EndMT-related transcription factor [11] , was evaluated by western blotting in lung tissues from Nx(5W) , SuHx(5W) , and SuHx(5W) + Nin groups to assess the contribution of EndMT in the vascular remodeling of PAs in rat PAH and to assess the anti-EndMT effect of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "This report assessed the beneficial effect of nintedanib for PAH both in vitro and in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Two-week treatment of PAH rats with nintedanib significantly ameliorated pulmonary hemodynamics accompanied with improved vascular remodeling of PAs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Based on this background , we hypothesized that nintedanib was a novel and tolerable treatment for PAH because of its anti-vascular remodeling via inhibition of PDGF and FGF signaling .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "These in vitro results suggest a beneficial , anti-remodeling effect of nintedanib in the intima and media of PAs in PAH .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "In the present study , we used SuHx-PAH rats , which have neointimal lesions similar to those in human PAH [42] , to evaluate the effect of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "The phosphorylation of PDGF and FGF receptors significantly increased in the proliferative neointimal lesions and medial walls in the PAH rat , indicating that these PAH-specific neointimal lesions could be a major therapeutic target of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "These findings indicate not only the contribution of EndMT in the development of proliferative occlusive neointimal lesions in PAH rats , but also the anti-EndMT effects of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "A recently published study demonstrated that nintedanib had no therapeutic effect on rat and human PAH [47] , which contradicted our results .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "The results of these recent studies of established animal and human PAH suggest that the therapeutic power of nintedanib may be limited at least in advanced stages of PAH .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Another recent study also showed that less dilatation , decreased fibrosis and hypertrophy of right ventricle after chronic treatment with nintedanib in Su/Hx-PAH rat by echocardiography and histological analysis [46] , suggesting no cardiac toxicity of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "In conclusion , we have shown the beneficial effects of nintedanib for PAH in vitro and in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Although the efficacy of nintedanib for mild to moderate PAH is still uncertain , the therapeutic benefit of nintedanib may rest with its ability to augment the effect of other vasodilators or to prevent the progression of PAH .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Fourth , higher concentrations or longer regimens of nintedanib treatment for PAH in the rat have not yet been evaluated .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "On the other hand , another more recent study showed that chronic treatment with nintedanib of established late-phase PAH , from 8 to 11 weeks , did not improved pulmonary hemodynamics and vascular remodeling in SuHx rats [46] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Chronic treatment with nintedanib reversed the elevated pulmonary arterial pressure in the PAH rat via anti-EndMT effects in HPMVECs and anti-proliferative effects in HPASMCs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Moreover , an expanded indication of nintedanib for the treatment of PAH would be advantageous , since nintedanib has been approved already for the treatment of other human diseases with good tolerability .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Although further investigations are necessary , the results of this study indicate that nintedanib may be a novel additional option for the treatment of human PAH , with an anti-vascular remodeling effect .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31339889",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "In fact , nintedanib treatment from 3 to 5 weeks significantly reduced the expression of those receptors and prevented the progression of neointimal lesions , resulting in improved pulmonary hemodynamics in the PAH rats .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29804068",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "The efficacy and safety of novel antifibrotic agents such as pirfenidone and nintedanib in patients with SSc\u2013IP are currently being evaluated in controlled clinical trials.1 However , with the emergence of evidence-based treatments , including a novel agent such as macitentan , and the focus on early detection of SSc\u2013PAH , there has been considerable improvement in patient survival .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Nintedanib has recently been shown to ameliorate histological features of pulmonary arterial hypertension (PAH) and pulmonary fibrosis in pre-clinical models of SSc , which has encouraging implications for ongoing phase III clinical trials of nintedanib in SSc-associated ILD [136] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29695053",
    "tail": {
      "word": "PAH",
      "id": "P00439"
    },
    "sentence": "Nintedanib has recently been shown to ameliorate histological features of pulmonary arterial hypertension (PAH) and pulmonary fibrosis in pre-clinical models of SSc , which has encouraging implications for ongoing phase III clinical trials of nintedanib in SSc-associated ILD [136] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31044096",
    "tail": {
      "word": "NNT",
      "id": "Q13423"
    },
    "sentence": "NNT values have not been presented previously on these particular therapies for IPF , and they show that a different clinical interpretation of the outcomes may lead to the conclusion that nintedanib has an advantage over pirfenidone .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "TGFBR1",
      "id": "P36897"
    },
    "sentence": "Indeed , nintedanib and pazopanib or sorafenib were active against TGFBR1 and TGFBR2 , respectively , within a similar concentration range as their IC50 on EMT progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "TGFBR1",
      "id": "P36897"
    },
    "sentence": "On the other hand , inhibitors reported to target TGFBR , such as SB-431542 , RepSox , SB-525334 and PP1 , together with the multi-kinase inhibitors PD-161570 , PD-166285 , nintedanib , pazopanib and sorafenib revealed a significant correlation between their efficacy in blocking EMT and their inhibition of TGFBR1 or 2 (Figure 5C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "TGFBR1",
      "id": "P36897"
    },
    "sentence": "Since nintedanib blocks EMT progression in NMuMG cells with an IC50 in the lower micromolar range and is able to block TGFBR1 activity in biochemical assays in the submicromolar range , it is plausible that TGFBR inhibition contributes to its beneficial effects in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "TGFBR1",
      "id": "P36897"
    },
    "sentence": "Similarly , in agreement with nintedanib's inhibitory effect on TGFBR1 activity as well as SMAD phosphorylation and EMT in our analyses , multiple studies report a lack of EMT induction after nintedanib treatment in cancer cell lines in vitro and in mouse models of cancer in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib also inhibits FMS-like tyrosine kinase-3 (Flt-3) with an IC50 of 26 nmol\u00b7L\u22121 [72] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (BIBF-1120) is an even-wider-spectrum angiokinase inhibitor targeting VEGFR1\u20133 , PDGF\u03b1/\u03b2 , and FGF receptors (FGFRs) 1\u20134 , as well as FLT-3 and SRC family kinases (Hilberg et al. .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib also blocks the activity of several non-RTKs (nRTKs) [17] , including FLT-3 (Fms-like tyrosine-protein kinase-3) , RET (ret proto-oncogene) and members of the Src-family , including Lck (lymphocyte-specific tyrosine-protein kinase) , Lyn (tyrosine-protein kinase lyn) and Src (proto-oncogene tyrosine-protein kinase src) kinases [14 , 15] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib also inhibits the proto-oncogene tyrosine-protein kinase Src (IC50=156 nmol/L) , lymphocyte-specific tyrosine-protein kinase Lck (IC50=16 nmol/L) , Lck/Yes novel tyrosine kinase Lyn (IC50=195 nmol/L) , and Fms-like tyrosine kinase 3 Flt-3 (IC50=26 nmol/L).51 Distinct functions that may impact the pathology of IPF have been described for specific tyrosine kinases .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "Fms-like tyrosine kinase 3",
      "id": "P36888"
    },
    "sentence": "Nintedanib also inhibits the proto-oncogene tyrosine-protein kinase Src (IC50=156 nmol/L) , lymphocyte-specific tyrosine-protein kinase Lck (IC50=16 nmol/L) , Lck/Yes novel tyrosine kinase Lyn (IC50=195 nmol/L) , and Fms-like tyrosine kinase 3 Flt-3 (IC50=26 nmol/L).51 Distinct functions that may impact the pathology of IPF have been described for specific tyrosine kinases .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30931251",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that targets fibroblast growth factor receptor (FGFR) 1 , 2 , and 3; platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2; vascular endothelial growth factor receptor (VEGFR) 1 , 2 , and 3; and Src family tyrosine kinases Lck , Lyn , and Flt-3 [8] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib also inhibits some non-receptor kinases such as Fms-like tyrosine protein kinase (Flt-3 , IC50 26 nmol/L) , proto-oncogene ret (Ret , IC50 35 nmol/L) , lymphocyte-specific tyrosine kinase (Lck , IC50 16 nmol/L) , tyrosine-protein kinase lyn (Lyn IC50 195 nmol/L) , and proto-oncogene tyrosine protein kinase src (Src , IC50 156 nmol/L)51,52 (Figure 1) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "Flt3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (BIBF 1120) is a potent , oral , and broadly active small-molecule tyrosine kinase inhibitor with median inhibitory concentrations in the low nanomolar range: 13\u201334 nmol/L for VEGF receptors 1\u20133; 59 nmol/L and 65 nmol/L for platelet-derived growth factor receptors \u03b1 and \u03b2 , respectively; 37\u2013108 nmol/L for fibroblast growth factor receptors 1\u20133; and 26 nmol/L for Flt3 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31523388",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "The most potent partners for CDK inhibitors in multiple myeloma are the HDAC inhibitors CUDC101 and CUDC907 , the MEK1/2 inhibitor trametinib , the NOTCH inhibitor PF-03084014 , the BCL2 inhibitors GX15-070 and ABT-263 , the IDH1/2 inhibitor AGI-5180 , the FLT3 and JAK2 inhibitor SB1317 and also the FGFR-targeting inhibitors XL999 and nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27029060",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "Currently , the most clinically advanced FGFR inhibitors are non-selective TKIs , such as nintedanib , lenvatinib , ponatinib , and dovitinib , with multiple targets , such as VEGFRs , PDGFRs KIT , and FLT3 [28\u201331] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "Flt3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (BIBF 1120) is a small molecule tyrosine kinase inhibitor that inhibits several angiokinases including VEGFR1/Flt1 , VEGFR2/Flk1/KDR and VEGFR3/Flt4 as well as FGFR1 , FGFR2 , FGFR3 , PDGFR-alpha , PDGFR-beta and Flt3 [5] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "In addition , nintedanib inhibits Src family tyrosine kinases (Src , Lck , Lyn) , Flt-3 and RET (Hilberg et al , 2008; Wollin et al , 2014; Awasthi and Schwarz , 2015) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28934120",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is a novel triple angiokinase inhibitor targeting VEGFR1\u20133 , platelet-derived growth factor receptor (PDGFR) \u03b1 and \u03b2 , fibroblast growth factor receptors (FGFR) 1\u20133 , and , in addition , is also an inhibitor of the Src family , RET , and FLT3 [46,47] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "Flt3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor that targets VEGFRs , platelet-derived growth factor receptors and fibroblast growth factor receptors (FGFRs) -the three key pathways involved in angiogenesis- , and to a lesser extent , RET , Flt3 and Src [28] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31443247",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "Nintedanib , PDGFR\u03b1-\u03b2 , FGFR1-3 , VEGFR1-3 , FLT3 , Lck kinase , Lyn kinase , and Src kinase .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29249039",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (BIBF1120) is a next generation , potent triple angiokinase inhibitor of VEGFR1/2/3 , FGFR1/2/3 and PDGFR\u03b1/\u03b2 , with lesser activity against RET , Flt-3 and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "Flt3",
      "id": "P36888"
    },
    "sentence": "In addition , nintedanib inhibits receptor kinases of RET , Flt3 , and the Src family [7] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26000013",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (BIBF1120) is an oral TKI of FGFR , VEGFR , PDGFR , FLT-3 , and lymphocyte-specific protein tyrosine kinase and significantly prolonged PFS in combination with docetaxel in patients with NSCLC [66] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is a TKI targeting VEGFR1\u20133 , platelet-derived growth factor receptor \u03b1 (alpha) and \u03b2 (beta) , and fibroblast growth factor receptors (FGFR) 1\u20133 and , in addition , it also inhibits the Src family , RET , and FLT3 (5 , 6) (Figure 2) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (Vargatef\u00ae; BIBF 1120) is a novel , potent , oral , triple angiokinase inhibitor that targets VEGF receptors 1 to 3 , PDGF receptors alpha and beta , and FGF receptors 1 to 3 (41\u201343) , as well as members of the Src family and FLT-3 (43) (Figure 1) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28168189",
    "tail": {
      "word": "fms-like tyrosine kinase 3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is an oral triple angiokinase inhibitor , hindering the vascular endothelial growth factor receptor (VEGFR1\u20133) , the FGFR1-3 , the platelet-derived growth factor receptors (PDGFR\u03b1/\u03b2) , fms-like tyrosine kinase 3 and members of the Src family (Src , Lyn , Lck) (63) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29270405",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "2014) EMA , but not FDA , approved the use of nintedanib , an oral multi-kinases inhibitor , targeting VEGFR1-3 , FRGFR1-3 , PDGFR\u03b1-\u03b2 , RET , FLT3 , and Src family kinases , combined with docetaxel for the second-line treatment of NSCLC (Lazzari et al. .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28943630",
    "tail": {
      "word": "Flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is a triple angiokinase inhibitor of VEGF , FGF and PDGF signaling , with lower levels of activity against RET , Flt-3 and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28396848",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "In the phase III LUME-lung 1 trial , nintedanib , an oral multiple TKI targeting FGFR1\u20133 , vascular endothelial growth factor receptor 1\u20133 , PDGFR \u03b1 and \u03b2 , RET , FLT3 , and Src family kinases , was investigated in combination with docetaxel after failure of first-line therapy versus placebo (37) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25538887",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (an inhibitor of VEGFR 1\u20133 , FGFR 1\u20134 , PDGFR , FLT-3 , and src) , is most advanced , with a positive randomized trial (LUME \u2013 Lung 1) in second line (docetaxel \u00b1 nintedanib) (21) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25538887",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib (an inhibitor of VEGFR 1\u20133 , FGFR 1\u20134 , PDGFR , FLT-3 , and src) , is most advanced , with a positive randomized trial (LUME \u2013 Lung 1) in second line (docetaxel \u00b1 nintedanib) (21) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "23936861",
    "tail": {
      "word": "flt-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib or BIBF 1120 (Boehringer Ingelheim; Ingelheim , Germany) is an oral small-molecule triple kinase inhibitor which inhibits VEGFR , PDGFR , and FGFRs and members of the Src family and flt-3 [83] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "Flt3",
      "id": "P36888"
    },
    "sentence": "The strong antivascular effect seen with nintedanib may result from its potential to simultaneously inhibit multiple angiogenic and mitogenic signalling pathways (mediated by VEGFR , PDGFR , FGFR , RET and Flt3 [25]) , which may enable the drug to block compensatory angiogenic pathways that can be activated when anti-VEGF agents are used in isolation [3-12] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "FLT-3",
      "id": "P36888"
    },
    "sentence": "Nintedanib is an orally available triple angiokinase inhibitor that specifically inhibits VEGFR-1-3 , PDGFR-\u03b1/\u03b2 and fibroblast growth factor receptor (FGFR)-1-3 , as well as FLT-3 , RET and members of the Src family (Hilberg et al , 2008; Reck et al , 2014) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28942086",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "As an example , MCEMP1 (mast cell-expressed membrane protein 1) one of the outcome predictive genes when overexpressed , encodes a transmembrane protein isolated from human mast cells38 , known to work in concert with fibroblasts to aggravate pulmonary fibrosis39 or FLT3 (Fms-related tyrosine kinase 3) a strong Nintedanib-responsive tyrosine kinase with unknown roles in pulmonary fibrosis .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29103264",
    "tail": {
      "word": "FLT3",
      "id": "P36888"
    },
    "sentence": "Sunitinib (SU11248) is an oral inhibitor of VEGFR-1 , -2 , -3 , PDG-FRs , KIT , FLT3 , RET , and CSF-1R [25] , while nintedanib (BIBF 1120) is an oral , triple angiokinase inhibitor , which acts simultaneously on 3 key receptor families involved in angiogenesis: VEGFRs , PDGFRs , and FGFRs [26] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24959299",
    "tail": {
      "word": "CD135",
      "id": "P36888"
    },
    "sentence": "Moreover; nintedanib has been observed to target proto-oncogene tyrosine-protein kinase (Src) and cluster of differentiation antigen 135 (CD135) 34 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31452723",
    "tail": {
      "word": "ABCC1",
      "id": "P33527"
    },
    "sentence": "Correlation analysis between ABC transporter expression levels and TKI response was based on the lowest concentrations of the TKI that induced significant cell count reduction (pazopanib: 1.25 \u00b5M , dovitinib: 6.25 \u00b5M , nintedanib: 6.25 \u00b5M) and the expression levels of ABCB1 , ABCC1 and ABCG2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OATP2B1",
      "id": "O94956"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29802256",
    "tail": {
      "word": "TCI",
      "id": "P20061"
    },
    "sentence": "Anti-fibrotic drugs Pirfenidone (P1871 , TCI America) and Nintedanib (S1010 , Selleckchem) were purchased from commercial suppliers .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OCT1",
      "id": "O15245"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29500603",
    "tail": {
      "word": "CYP3A4",
      "id": "P08684"
    },
    "sentence": "Only a minor extent of the biotransformation of nintedanib involves CYP pathways , with CYP3A4 being the predominant enzyme involved .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "CYP3A4",
      "id": "P08684"
    },
    "sentence": "In human liver microsomes , nintedanib was rapidly hydrolysed by esterases (major mechanism) and demethylated by CYP3A4 (minor mechanism) to form the metabolites BIBF 1202 and BIBF 1053 , respectively [33] .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29564136",
    "tail": {
      "word": "CYP3A4",
      "id": "P08684"
    },
    "sentence": "However , nintedanib is mainly a substrate of P\u2010glycoprotein (P\u2010gp) and only weakly interferes with CYP3A4 .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31151284",
    "tail": {
      "word": "CYP3A4",
      "id": "P08684"
    },
    "sentence": "The biotransformation of nintedanib affects CYP pathways in a very limited manner , CYP3A4 being the enzyme most closely involved .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27863518",
    "tail": {
      "word": "CYP3A4",
      "id": "P08684"
    },
    "sentence": "However , hepatic metabolism of pirfenidone primarily occurs through the CYP1A2 enzyme; whereas nintedanib is mainly a substrate of P-glycoprotein (P-gp) and only weakly interferes with CYP3A4 .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "Cyp3A4",
      "id": "P08684"
    },
    "sentence": "Both letrozole and nintedanib are metabolized by Cyp3A4 , and in line with our results , it appears that this interaction is clinically significant (Table 3; Fig .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "Cyp3A4",
      "id": "P08684"
    },
    "sentence": "Because exemestane [51] and anastrazole [52] are also metabolized by Cyp3A4 , it might be difficult to avoid nintedanib accumulation .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "PSA",
      "id": "P07288"
    },
    "sentence": "In another trial , the combination of nintedanib , docetaxel and prednisone led to a decrease from the baseline in prostate-specific antigen (PSA) levels and induced a partial response (16) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "prostate-specific antigen",
      "id": "P07288"
    },
    "sentence": "In another trial , the combination of nintedanib , docetaxel and prednisone led to a decrease from the baseline in prostate-specific antigen (PSA) levels and induced a partial response (16) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "PSA",
      "id": "P07288"
    },
    "sentence": "In a randomized Phase II trial , nintedanib combined with afatinib decreased PSA levels in ~50% of patients with castration-resistant Pca (15) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PSA",
      "id": "P07288"
    },
    "sentence": "However , nintedanib at 250 mg showed at least 50% PSA reduction in 5.6% patients and the rate of PSA increase in this group was significantly decelerated on treatment vs before treatment (P=0.002) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "PSA",
      "id": "P07288"
    },
    "sentence": "Two patients had a \u226550% decline in PSA , one each in the nintedanib and the Combi40 groups .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "PSA",
      "id": "P07288"
    },
    "sentence": "Moreover , 68.4% of Nintedanib treated patients showed decreased serum levels of prostate specific antigen (PSA) [30] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "PSA",
      "id": "P07288"
    },
    "sentence": "Only 5.6% of patients treated with nintedanib 250 mg obtained a prostate-specific antigen (PSA) decrease of at least 50% .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "prostate-specific antigen",
      "id": "P07288"
    },
    "sentence": "Only 5.6% of patients treated with nintedanib 250 mg obtained a prostate-specific antigen (PSA) decrease of at least 50% .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26346347",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "The antifibrotic effects of BIBF1000 \u2013 a compound similar to BIBF1120 \u2013 have been demonstrated in a BLM model in rats , and BIBF1000 weakly inhibited TGF-\u03b2 activity and subsequent \u03b1-SMA expression in lung fibroblasts in vitro.2 However , the kinase inhibitory profile of nintedanib suggests that PDGFR , FGFR , and VEGFR play important roles in lung fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26346347",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "Pirfenidone exerts its antifibrotic effect through regulation of lung IFN-\u03b3 , bFGF , and TGF-\u03b21 levels during the development of BLM-induced pulmonary fibrosis in mice.78 Nintedanib and pirfenidone have different mechanisms of action so combination therapy with these two drugs could be effective .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29690905",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "However , experiments with BLM-induced pulmonary fibrosis in vivo have been utilized for the development of currently widely used anti-fibrotic agents , including pirfenidone [43] and nintedanib [44] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "HPF; high-power fields We investigated whether nintedanib reduces the number of fibrocytes in a mouse model of BLM-induced pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "The percentage of fibrocytes (CXCR4+Col1+CD45+cells) among all lung cells in BLM-treated mice was elevated on day 7 , and nintedanib at 60 mg/kg was found to significantly reduce this percentage (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "Normal saline (NS) or BLM-treated mice with or without nintedanib (60 mg/kg/day) were killed on day 7 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "Consequently , when nintedanib was continuously administrated until day 21 , the number of fibrotic lesions in the lungs of BLM-treated mice was reduced (Additional file 2: Figure S3) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "Normal saline (NS) or BLM-treated mice with or without nintedanib (60 mg/kg/day) were killed on day 7 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "In all graphs: *P < 0.01 versus the group treated with BLM alone Nintedanib regulates the pool size of fibrocytes in bleomycin (BLM)-treated mouse lungs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "The administration of BLM significantly increased the number of fibrocytes per high-power field in the lungs of BLM-treated mice , while nintedanib at 60 mg/kg significantly reduced these numbers (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "In addition , treatment with nintedanib significantly reduced the accumulation of fibrocytes in the lungs of a BLM-induced pulmonary fibrosis model in mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "In all graphs: *P < 0.01 versus the group treated with BLM alone Nintedanib is a tyrosine kinase inhibitor that was recently approved for the treatment of patients with IPF in the major parts of the world .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "A quantitative histological analysis showed that the Ashcroft fibrotic score was significantly lower in mice treated with BLM and nintedanib at a dose of 60 mg/kg than in those treated with BLM alone (Additional file 2: Figure S4A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "The administration of nintedanib significantly reduced the number of fibrocytes in the lung tissues of mice treated with BLM to induce pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27307615",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "For example , in Table 10 , given Nintedanib , DrugE-Rank successfully identify the targets which interact with Nintedanib , such as Vascular endothelial growth factor receptor 3 , which was ranked out of top 50 by four component methods , k-NN , BLM-svc , BLM-svr and WNN-GIP .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28804709",
    "tail": {
      "word": "BLM",
      "id": "Q9K2N0"
    },
    "sentence": "Intriguingly , pirfenidone and nintedanib received approval to proceed to clinical trials based on preventive protocols or even therapeutic protocols targeting the inflammatory or the early-fibrotic phase of the BLM model (115\u2013117) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Nintedanib reduced TGF-\u03b2-stimulated collagen secretion and deposition by primary human lung fibroblasts from patients with IPF cultured for 48 h. Nintedanib also reduced secreted TIMP-2 levels [78] and induced the secretion of pro-matrix metalloproteinase (MMP)-2 [79] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Nintedanib also reduced secreted tissue inhibitor of metalloproteinase (TIMP)-2 levels.71 However , the enzymatic activity and secretion of MMP-2 were significantly reduced at lower concentrations (approximately 1 and 100 nmol/L , respectively).71 Additionally , nintedanib is expected to have indirect activity on ECM secretion and deposition by reducing the number of fibroblasts/myofibroblasts in fibrotic lungs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26715838",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Nintedanib also reduced secreted tissue inhibitor of metalloproteinase (TIMP)-2 levels.71 However , the enzymatic activity and secretion of MMP-2 were significantly reduced at lower concentrations (approximately 1 and 100 nmol/L , respectively).71 Additionally , nintedanib is expected to have indirect activity on ECM secretion and deposition by reducing the number of fibroblasts/myofibroblasts in fibrotic lungs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Effect of nintedanib on enzymatic activity (panel A-D) and secretion of matrix metalloproteinase (MMP)-2 (panel E , F) and tissue inhibitor of metalloproteinase (TIMP)-2 (panel G , H) by primary human lung IPF fibroblasts (A , C , E , G) and by non-fibrotic control cells (B , D , F , H) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Nintedanib treatment at 0.4 \u03bcM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 (ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) (g) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Nintedanib treatment at 0.4 \u03bcM (blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 (ADAM-17) , tissue inhibitor of metalloproteinase 1 (TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) (g) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "metalloproteinase",
      "id": "O43923"
    },
    "sentence": "Furthermore , nintedanib reverted significantly the effect of PDGF-AA on expression of the genes related with cell migration such as ADAM-17 (ADAM metallopeptidase domain 17) , TIMP-1 (tissue inhibitor of metalloproteinase 1) , and TIMP-2 (tissue inhibitor of metalloproteinase 2) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "Glut1",
      "id": "P11166"
    },
    "sentence": "To further assess the establishment of metabolic symbiosis in nintedanib therapy-resistant tumors , we assessed by immunofluorescence microscopy analysis the expression and localization of markers for hypoxia (pimonidazole) , glucose uptake (Glut1) , lactate export (MCT4) , mitochondrial biogenesis , and oxidative phosphorylation (PGC1\u03b1 and COX IV; LeBleu et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "Glut1",
      "id": "P11166"
    },
    "sentence": "Indeed , the expression of hypoxia-induced Glut1 correlated with the expression of hypoxia-induced MCT4 and with the hypoxia-marker pimonidazole in the hypoxic areas of nintedanib LT tumors (Figures 4C\u20134G , S4H , and S4I) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29297621",
    "tail": {
      "word": "Exo",
      "id": "P03697"
    },
    "sentence": "We found an overrepresentation of proteins in hAEC Exo that were involved in negatively regulating FGFR1 and FGFR2 , and PDGF\u2010mediated regulation of RAS through GAPs target pathways common to those targeted by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "TGFB1",
      "id": "P01137"
    },
    "sentence": "We observed that nintedanib at 0.4 \u03bcM reduced significantly the expression of COL1A1 (Collagen type I alpha 1 chain) , COL3A1 (collagen type III alpha 1 chain) , FN1 (Fibronectin 1) , CTGF (connective tissue growth factor) , PDGFA (platelet-derived growth factor A) , and TGFB1 (transforming growth factor beta 1) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Tgfb1",
      "id": "P01137"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Tgfb1",
      "id": "P01137"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "androgen receptor",
      "id": "P10275"
    },
    "sentence": "Therefore , in the subsequent experiments , only the 22RV1 (androgen receptor-positive) and DU145 (androgen receptor-negative) Pca cell lines were selected to further investigate the mechanism of entosis induced by nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29736460",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "However , the recent FDA approval of two drugs , pirfenidone and nintedanib , is believed to represent a watershed event in the medical management of IPF [12] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29736460",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib received FDA approval on October 15 , 2014 [18] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29736460",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Pirfenidone's New Drug Application (NDA) was first submitted to the FDA in November 2009 , whereas nintedanib's NDA was submitted to the FDA in May 2014 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27980445",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Because the results of these studies were considered acceptable , the FDA approved nintedanib for IPF treatment on the same date that pirfenidone was approved (October 2014) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27445644",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Plainly , the FDA has approved both pirfenidone and nintedanib regardless of disease severity , but the fact remains that patients with an FVC <50% have been excluded from the recent trials and it is unknown , at least for the time being , if the drugs are effective and safe in this group of patients .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26273193",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The improved efficacy of KBP-7018 over nintedanib , a drug approved by Food and Drug Administration (FDA) for the treatment of IPF , was even observed (unpublished data) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26273193",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "However , Richeldi and colleagues also failed to achieve the primary outcomes but only improvements in secondary outcome measures.19 Also encouraged by its well tolerance , nintedanib was just approved by FDA for its promising improvement in life quality of patients .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30611717",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The two currently FDA-approved drugs for fibrotic diseases , pirfenidone and nintedanib , are not curative .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30611717",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The two currently FDA-approved drugs for fibrotic diseases , pirfenidone and nintedanib , are not curative .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28761806",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In 2014 , the FDA provided fast-track approval of two anti-fibrotic drugs , pirfenidone and nintedanib , for the treatment of idiopathic pulmonary fibrosis based on the results of randomized clinical trials [23] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27382307",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Until now , three anti-VEGF agents , including bevacizumab , ramucirumab , and nintedanib , have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced NSCLC,6\u20139 and it is anticipated that the use of these agents in cancer patients would be increased in the near future .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29943133",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Only two drugs are currently licensed to treat IPF: pirfenidone (Esbriet , Roche) was approved by the European Medicines Agency (EMA) in 2011 and the US FDA in 2014 , and nintedanib (OFEV , Boehringer Ingelheim) was approved by the EMA in 2015 and the FDA in 2014 [5\u20137] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30443024",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Currently , two drugs approved by the FDA , such as pirfenidone and nintedanib , have been considered promising therapeutic agents for slowing down the progression of the disease , mainly by changing forced vital capacity (FVC)4,5 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27774992",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "However , current treatment options , including pirfenidone and nintedanib (BIBF 1120) , the only two drugs approved by the United States Food and Drug Administration (FDA) , are able to slow the progression of IPF but not reverse the established pulmonary fibrosis4 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27278104",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Although two new drugs , nintedanib and pirfenidone , were recently approved by the FDA to treat idiopathic pulmonary fibrosis , neither are recommended for patients with liver problems , and pirfenidone is not recommended for patients with end-stage kidney disease or for those who require dialysis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "There are currently two FDA approved drugs with inhibiting role against IPF; nintedanib and pirfenidone .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "After finding all repurposed drugs , we calculated their structural similarity with the FDA approved drugs for the disease , namely nintedanib and pirfenidone , using ChemBioServer (Supplementary Figures 1\u20134) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Except from the FDA approved drugs for IPF (nintedanib and pirfenidone) we searched the European Medicines Agency and recent bibliography for other potential inhibitors of IPF (Table 8) in order to compare their chemical structures to our repurposed drugs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "ERBB2 is also a target gene of the FDA approved drug Nintedanib , which inhibits it .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In the case of microRNAs , hsa-miR-25-3p and hsa-miR-208a-5p can inhibit genes that the FDA approved drug nintedanib targets .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27490795",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "While there are two FDA-approved drugs available to treat IPF (pirfenidone and nintedanib) , their costs are significant and improvement is limited to subsets of patients with mild to moderate functional impairment [38 , 39] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29176766",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Although pirfenidone and nintedanib , each approved by the Food and Drug Administration (FDA) in 2014 , may slow the rate of decline of lung function in some IPF patients , neither drug significantly alters the course of this lethal disease [2\u20134] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30481203",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "At present , the FDA approved drugs nintedanib (Ofev\u00ae) and pirfenidone (Esbriet\u00ae) are widely used for IPF therapy [5,21] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26317335",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Following clinical trials , two therapies (pirfenidone and nintedanib) were recently FDA approved [5 , 6]; however , these therapies only delay functional decline .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30189872",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Indeed , pirfenidone , one of the two currently US Food and Drug Administration (FDA) approved drugs (pirfenidone and nintedanib) for treatment of human IPF , exerts its anti-fibrotic property in part by suppressing TGF-\u03b2 expression relevant to macrophage M2 polarization and fibroblast activation [121] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29871641",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The FDA recently approved two new drugs , nintedanib and pirfenidone , to treat IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28292882",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Currently , only two drugs have FDA approval for the treatment of IPF , pirfenidone (an anti\u2010inflammatory , antifibrotic whose mechanism is unclear) and nintedanib (a tyrosine kinase inhibitor) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29952109",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The recent FDA approval of two new therapies for the treatment of IPF (pirfenidone and nintedanib) has resulted in guarded optimism , but there continues to be a desperate need for additional antifibrotic medications with increased efficacy and fewer side effects (Raghu et al .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30147727",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Currently , two drugs , pirfenidone and nintedanib , were approved by the FDA for clinical use as they were able to slow down the disease progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27001429",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Recently , the US FDA approved the first two drugs proven to slow progression of IPF: pirfenidone (Esbriet by Roche) and nintedanib (Ofev by Boehringer Ingelheim) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26173796",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib , a tyrosine kinase inhibitor , has since been approved for IPF by the FDA [7] and the EMA [8] (in 2014 and 2015 , respectively) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30042329",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Currently FDA-approved drugs (pirfenidone and nintedanib) act to slow the progression of the disease .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31248154",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Two FDA-approved anti-fibrotic drugs (Pirfenidone and Nintedanib) are known to hinder the disease progression by reducing the annual decline in forced vital capacity (FVC) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30404198",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib (BIBF1120) received FDA approval for treating patients with idiopathic pulmonary fibrosis , a rare disease but not for in applications in oncology .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29518028",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "While pirfenidone and nintedanib were both approved by the Food and Drug Administration (FDA) to treat IPF , they help to reduce clinical exacerbations that affect pulmonary function and do not represent curative approaches [12,13] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29518028",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Pirfenidone and nintedanib are both FDA approved for use in IPF with promising safety profiles [12,253,254,255] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27331812",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib has been approved by the Food and Drug Administration (FDA) for clinical applications of IPF [126,127,128] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28779751",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib was approved by the United States Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis in October 2014 following successful phase III clinical trials [18] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26231702",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Recently FDA approved drugs , pirfenidone and nintedanib , only slow the disease progression [5 , 6] and development of more effective therapies are hampered by an incomplete understanding of the factors involved in the disease pathogenesis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30866992",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In the same year , nintedanib combined with docetaxel therapy was approved for non-squamous non-small cell lung cancer (NSCLC) patients as a second-line treatment by the European Medicines Agency (EMA) but not by the FDA [62] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28035951",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In 2014 , the FDA approved two new drugs , pirfenidone (Esbriet , InterMune , Inc. , Brisbane , CA , USA) [44,45] and nintedanib (OFEV , Boehringer Ingelheim , Germany) [46] which will be described in greater detail later in this review .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30477216",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Over the past few years , two new anti-fibrotic therapies\u2014pirfenidone and nintedanib\u2014have been approved by the FDA for treatment of patients with IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29895744",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "By 2014 , Nintedanib (III , Ofev\u00ae , Figure 1) , an orally available isatin-based triple-angiokinase inhibitor , was approved by the FDA for the management of idiopathic pulmonary fibrosis [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30087305",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib (NDN) , previously known by its research code BIBF 1120 , is an intracellular inhibitor of tyrosine kinases (TKs) approved by the US Food and Drug Administration (FDA) , and was developed for the treatment of a number of cancer types such as those of the lung , kidney , and liver [10,11] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30897818",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Unfortunately , treatments for IPF were quite limited , and to date , only two small molecule drugs (Pirfenidone and Nintedanib) were approved by FDA for IPF treatment; nonetheless their treatment effect was not satisfactory [3,4] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29802256",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In proof of principle tests , we then document the utility of this system for multi-parameter , phenotypic analysis of the therapeutic efficacy of two FDA-approved anti-fibrosis drugs , Pirfenidone and Nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29802256",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Pirfenidone and Nintedanib were selected for proof-of-concept as they are the only anti-fibrosis drugs approved by FDA to treat IPF; both drugs were shown to reduce the decline in lung compliance in IPF patients30,31 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29057934",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "For example , nintedanib , a protein tyrosine kinase inhibitor approved by the FDA for idiopathic pulmonary fibrosis8 , has shown promising results in experimental models of SSc9 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31278260",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Currently , there are two FDA-approved drugs for treating IPF; pirfenidone , which is believed to act as a TGF\u03b21 inhibitor , and nintedanib , which is a multi-receptor tyrosine kinase inhibitor .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29249039",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In 2014 , FDA approved nintedanib for the treatment of idiopatic pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29378675",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "As an example , the recently FDA-approved drugs , nintedanib and pirfenidone , show anti-inflammatory and anti-fibrotic activity (Ahluwalia et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29378675",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "As an example , the recently FDA approved drugs nintedanib and pirfenidone can significantly reduce the progression of pulmonary fibrosis in patients although no full-remissions have been observed (Hunninghake , 2014; Karimi-Shah and Chowdhury , 2015; King et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25972814",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Despite some disappointments in the field of renal fibrosis , the FDA has recently approved two promising anti-fibrosis drugs , pirfenidone and nintedanib , for the treatment of idiopathic pulmonary fibrosis (IPF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29075197",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The efficacy of the FDA-approved treatment for IPF , nintedanib , is due to its inhibition of PDGF , FGF and vascular endothelial growth factor-signaling pathways (Fala , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29075197",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "However , two relatively recent FDA-approved therapies , pirfenidone , and nintedanib , reduce the rate of decline in lung function and increase survival , in some patients , albeit modestly (King et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28804709",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Numerous clinical trials have been completed based on preclinical studies in animals and have led to the FDA approval of two drugs , pirfenidone and nintedanib (15 , 16) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30013972",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib has been approved by the FDA in October 2014 and in Europe in early 2015 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29238708",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Four years ago FDA approved two novel anti-fibrotic compounds , pirfenidone and nintedanib , which are able to reduce disease progression in large multicenter clinical trials with IPF patients (9) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29270405",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "2014) EMA , but not FDA , approved the use of nintedanib , an oral multi-kinases inhibitor , targeting VEGFR1-3 , FRGFR1-3 , PDGFR\u03b1-\u03b2 , RET , FLT3 , and Src family kinases , combined with docetaxel for the second-line treatment of NSCLC (Lazzari et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26224133",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "A multi-kinase inhibitor (nintedanib) , which suppresses FGFR1\u20133 , was also recently FDA-approved for idiopathic pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29910813",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Recently , the FDA approved Ofev (nintedanib) and Esbriet (pirfenidone) for the treatment of IPF patients (5\u20137) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30459752",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "61 of the patients receiving SAP in this trial were also taking either pirfenidone or nintedanib , FDA-approved drugs that slow the decline in lung function in pulmonary fibrosis , while 16 other patients treated with SAP were not taking these drugs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31221221",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "However , nintedanib was not approved by the United States Food and Drug Administration (U.S. FDA) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27445819",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In October of 2015 , two drugs , Nintedanib and Pirfenidone , were approved by the United States Food and Drug Administration (FDA) for the treatment of IPF (George et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31481891",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Only nintedanib and pirfenidone have been approved by the Food and Drug Administration (FDA) (Mora et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29867501",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The efficacy of pirfenidone and nintedanib in reducing disease progression including better preservation of lung function , exercise tolerance and progression-free survival has led to concurrent FDA approval of the two drugs for IPF (King et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30618768",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Pirfenidone became the first European licensed therapy for IPF in 2011 (Annex , 2014) with the simultaneous FDA (Food and Drug Administration) approval of pirfenidone and nintedanib in 2014 (Raghu and Selman , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31164820",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "In the last few years , the European Medicines Agency and the Food and Drug Administration (FDA) approved the use of nintedanib and pirfenidone as new safe drugs for IPF treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26779535",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The US FDA has approved both pirfenidone and nintedanib with no prescription limitations and regardless of severity of lung function impairment , although clinical trials have limited enrollment to patients with mild-to-moderate IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30781901",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Among the latest Federal Drug Administration (FDA) approved LBF drugs are calcifediol [76] , nintedanib [77] , enzalutamide [78] , isotretinoin [79] and loratadine [80] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26732054",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The FDA recently approved pirfenidone and nintedanib for the treatment of IPF; how these therapies affect resource utilization and cost in a real-world setting is yet to be determined [9 , 10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30630460",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib and pirfenidone were both approved for use in the United States (US) by the Food and Drug Administration (FDA) in October 2014 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27871152",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Recently , FDA approved two novel drugs for IPF; pirfenidone and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26802230",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Other potential FDA approved drugs for counteracting interstitial fibrosis , pirfenidone and nintedanib , could be repurposed for EB-associated fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29200204",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The effects were comparable to those observed with oral administration of pirfenidone (100 mg/kg) or nintedanib (60 mg/kg) , the two drugs currently approved by the US FDA for the treatment of human IPF15 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29200204",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Lastly , aerosolized T3 showed comparable or superior effects on lung fibrosis or survival compared to the two US FDA-approved therapeutic compounds for the treatment of IPF , pirfenidone and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28433771",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "There are also FDA-approved drugs including ponatinib , nintedanib , pazopanib , and regorafenib , which are all multikinase inhibitors targeting FGFR1 with low specificity [19] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30587966",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib was successfully developed by Boehringer Ingelheim and then approved by the Food and Drug Administration (FDA) in 2014 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30587966",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Nintedanib soft capsules (reference dosage form) were successfully developed by Boehringer Ingelheim and then approved by the FDA in 2014 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "The US Food and Drug Administration (FDA) approved nintedanib as a new drug for IPF in 2014 based on these trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "FDA approved nintedanib for the treatment of IPF .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643263",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Of note , one of the few FDA-approved therapies for lung fibrosis , the small molecule receptor tyrosine kinase inhibitor nintedanib , blocks PDGF receptor signaling39 , and Pdgfra expressed by fibroblasts drives fibrosis in multiple organs in mice40\u201345 , including lung fibrosis induced by bleomycin treatment46 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29290631",
    "tail": {
      "word": "FDA",
      "id": "P0AB71"
    },
    "sentence": "Recently , the U.S. Food and Drug Administration (FDA) has recognized 2 medicines for IPF: pirfenidone , which inhibits TGF-\u03b2 and TGF-\u03b2-induced collagen production; and nintedanib , which inhibits tyrosine-kinase [5,6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "alkaline phosphatase",
      "id": "P00634"
    },
    "sentence": "For patients with AST and/or ALT elevations >3 \u00d7 ULN in conjunction with elevated bilirubin \u22652 \u00d7 ULN in the absence of elevated alkaline phosphatase levels (<2 \u00d7 ULN) , nintedanib treatment should be permanently discontinued unless an alternative cause of liver damage can be established .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30008572",
    "tail": {
      "word": "CYP1A2",
      "id": "P05177"
    },
    "sentence": "For example , clinically relevant drug interactions may potentially occur between pirfenidone and CYP1A2 inhibitors and inducers (concomitant use of fluvoxamine is contraindicated , and the use of tobacco is strongly discouraged) , and between nintedanib and P-glycoprotein inhibitors and inducers [26\u201328] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27863518",
    "tail": {
      "word": "CYP1A2",
      "id": "P05177"
    },
    "sentence": "However , hepatic metabolism of pirfenidone primarily occurs through the CYP1A2 enzyme; whereas nintedanib is mainly a substrate of P-glycoprotein (P-gp) and only weakly interferes with CYP3A4 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "LTF",
      "id": "P02788"
    },
    "sentence": "LTF is also known to stimulate cell migration and proliferation via VEGFA gene , whilst nintedanib targets the receptors for VEGFA , VEGFR1 and VEGFR2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28619847",
    "tail": {
      "word": "annexin V",
      "id": "P08758"
    },
    "sentence": "We , therefore , incubated freshly isolated CLL cells with 15 \u03bcM nintedanib and 8 \u03bcM MP07-66 at different times and monitored apoptosis by annexin V\u2013propidium iodide flow cytometry (Figure 7A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28619847",
    "tail": {
      "word": "annexin V",
      "id": "P08758"
    },
    "sentence": "A) Apoptosis of CLL cells from ten patients belonging to the various clinical and biological subtypes cultured in the absence and presence of 15 \u03bcM nintedanib , 8 \u03bcM MP07-66 or both over time analyzed by annexin V\u2013propidium iodide flow cytometry. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "Annexin V",
      "id": "P08758"
    },
    "sentence": "D. Apoptotic cell death induction was analyzed by Annexin V/PI-staining and FACS after 24 and 48 hours of 5\u03bcM nintedanib treatment of DMS114 and DMS114/NIN cells. * .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "Annexin V",
      "id": "P08758"
    },
    "sentence": "Also , apoptosis/cell death induction by nintedanib was significantly reduced in the subline as compared to the parental cell line , indicated by a lower percentage of cells with positive Annexin V/PI staining (Figure 1D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "Annexin V",
      "id": "P08758"
    },
    "sentence": "To determine apoptosis (Annexin V , BD Biosciences , Franklin Lakes , USA) and cell death (PI , Sigma , USA) induction , cells were treated with indicated concentrations of nintedanib for 24 and 48 hours .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28699195",
    "tail": {
      "word": "interferon gamma",
      "id": "P01579"
    },
    "sentence": "There were 8 trials with longitudinal \u0394%predicted FVC data , and the active treatments with longitudinal data were: etanercept , warfarin , interferon gamma , ambrisentan , nintedanib , N\u2010acetylcysteine , pirfenidone , and colchicine .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28699195",
    "tail": {
      "word": "interferon gamma",
      "id": "P01579"
    },
    "sentence": "Summary of treatments and clinical trials in the model\u2010based meta\u2010analysis dataset In the analysis dataset , the most commonly studied active treatments in the numbers of trials and subjects were interferon gamma , pirfenidone , and nintedanib , and the most common comparator was placebo with 2,035 subjects (Supplementary Figure S1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26913068",
    "tail": {
      "word": "FGR",
      "id": "P09769"
    },
    "sentence": "Nintedanib is a simultaneous inhibitor of VEGFR , PDGFR , and FGR , which shows antiangiogenic and antineoplasic inhibitory activity in lung cancer , impeding the growth of tumour cells [206] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "MCP-1",
      "id": "P13500"
    },
    "sentence": "Similar high values could be found after nintedanib treatment (eg , TNF\u03b1 , IL-6 , INF\u03b3 and MCP-1) , which confirms that rather M1 macrophages with their typical inflammatory mediators are the important subpopulation in our transplant model .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Vimentin",
      "id": "P08670"
    },
    "sentence": "c) Immunoflouresence staining for Vimentin (green) and E-cadherin (red) in DMSO control and 2.5 \u00b5M Nintedanib treated PC3 cells after 72 h of incubation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Vimentin",
      "id": "P08670"
    },
    "sentence": "c) Immunoflouresence staining for Vimentin (green) and E-cadherin (red) in DMSO control and 2.5 \u00b5M Nintedanib treated PC3 cells after 72 h of incubation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Vimentin",
      "id": "P08670"
    },
    "sentence": "Results indicated that Nintedanib treatment caused an increase in E-cadherin expression in PC3 cells without affecting Vimentin levels after 72 h of exposure (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Vimentin",
      "id": "P08670"
    },
    "sentence": "Importantly , to delineate whether the inhibitory effect of Nintedanib on the invasive potential of PC3 cells was mediated by its effect on mesenchymal to epithelial transition phase , Nintedanib (2.5 \u00b5M) treated PC3 cells were subjected to immunofluorescence staining for mesenchymal marker (Vimentin) and epithelial marker (E-cadherin) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "VIM",
      "id": "P08670"
    },
    "sentence": "The effects of E-cadherin induction seen in nintedanib in combination with siRNAs against CD99L2 , EMP3 , ITGA5 , VIM resulted from the BIBF1120 effect on the down-regulation of SYDE1 and ZEB1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "VIM",
      "id": "P08670"
    },
    "sentence": "The induction of SYDE1 or ZEB1 downstream of nintedanib might explain why silencing the mesenchymal genes such as CD99L2 , EMP3 , ITGA5 , and VIM alone did not lead to any significant up-regulation of E-cadherin .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "vimentin",
      "id": "P08670"
    },
    "sentence": "Epithelial marker E-cadherin expression was lower , and mesenchymal marker vimentin expression was higher in the 5 nintedanib-resistant cell lines (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "vimentin",
      "id": "P08670"
    },
    "sentence": "We observed that the increases in vimentin and ZEB1 expression and decrease in E-cadherin expression activated by TGF-\u03b21 were more reduced in A549 cells treated with nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31452723",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "A significant correlation (P=0.0138) was observed between the nintedanib response and ABCB1 expression level .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31452723",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Correlation analysis for TKI and ABC transporter expression shows a significant association (P=0.0138) between the nintedanib response and ABCB1 expression levels .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31452723",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Correlation analysis between ABC transporter expression levels and TKI response was based on the lowest concentrations of the TKI that induced significant cell count reduction (pazopanib: 1.25 \u00b5M , dovitinib: 6.25 \u00b5M , nintedanib: 6.25 \u00b5M) and the expression levels of ABCB1 , ABCC1 and ABCG2 .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "We have identified ATP-binding-cassette transporter B1 (ABCB1) overexpression as decisive mechanism for acquired nintedanib resistance in FGFR1-driven SCLC but not NSCLC cell models .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Additionally , we demonstrate that nintedanib is a substrate of ABCB1 and , hence , this resistance mechanism needs to be considered as a factor limiting therapy response .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Next , we investigated whether ABCB1 expression in response to nintedanib is a consequence of immediate stress response .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "E. Impact of short-term (24 and 48 hours) nintedanib exposure on ABCB1 expression in DMS114 and DMS114/NIN cells was analyzed by Western blot analysis .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "This suggests that ABCB1 activity negatively interferes with nintedanib cytotoxicity , possibly by direct efflux .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "F. Impact of removal of nintedanib selection pressure on ABCB1 expression levels in DMS114/NIN cells was analyzed by Western blot analysis over 40 days .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Next , we investigated whether pharmacological inhibition of ABCB1 restores sensitivity of DMS114/NIN cells towards nintedanib as well as known ABCB1 substrate drugs .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "However , exposure of the parental cell line to 1\u03bcM nintedanib up to 48 hours did not induce detectable levels of ABCB1 expression (Figure 3E) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "not detected; D. ABCB1 protein expression levels of DMS114 (SCLC) , NCI-H1703 and NCI-H520 (both NSCLC SCC) and its respective nintedanib-selected sublines were determined by Western blot .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "D. Impact of nintedanib on intracellular accumulation of the fluorescent ABCB1 substrate calcein .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Removal of nintedanib selection pressure for up to 40 days resulted in gradual loss of ABCB1 expression in DMS114/NIN cells (Figure 3F) , leading to a significant attenuation of resistance in the revertant cell line towards nintedanib and vincristine .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "To further elucidate whether ABCB1 upregulation upon nintedanib selection is restricted to SCLC , we tested our two additional FGFR1-driven NSCLC cell lines (NCI-H1703/NIN , NCI-H520/NIN) with acquired nintedanib resistance .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "E. Impact of nintedanib on the ABCB1 ATPase function was determined using ABCB1-enriched Sf9 cells .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Presence of the third generation ABCB1 inhibitor elacridar (10\u03bcM) , itself not influencing cell viability , almost completely abrogated acquired nintedanib resistance of DMS114/NIN cells (Figure 4A and Supplementary Figure S3A) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "A. Impact of the ABCB1 modulator elacridar on the anticancer activity of nintedanib in DMS114 and DMS114/NIN cells was measured by MTT assay after 72 hours drug exposure. ** .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Vera= verapamil , Elac= elacridar , Nin= nintedanib; Additionally , we tested whether nintedanib is an inhibitor of ABCB1 using the fluorescent dye Rh123 as substrate (Supplementary Figure S5A) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "In contrast , ABCB1-driven efflux of calcein AM was inhibited with similar potency by elacridar , verapamil and nintedanib , suggesting a preferential binding of nintedanib to the calcein AM binding site of ABCB1 (Figure 4D) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Moreover , nintedanib dose-dependently stimulated the ATPase activity of ABCB1 in Sf9 crude membrane extracts with a maximum effect at the highest tested dose (10\u03bcM) , where nintedanib exhibited a potency almost comparable with the positive control verapamil (Figure 4E) [18] .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "B. Impact of nintedanib on intracellular accumulation of the fluorescent ABCB1 substrate calcein was determined .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "In addition , inhibition of ABCB1 by elacridar resensitized KBC-1 and KB-V1 cells against high doses of nintedanib (Supplementary Figure S6B and S6C) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "B. The impact of the ABCB1 modulator elacridar on nintedanib-mediated inhibition of FGFR1 downstream target phosphorylation in DMS114 and DMS114/NIN cells was analyzed by Western blot .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Vera= verapamil , Elac= elacridar , Nin= nintedanib; Genetic amplification of the ABCB1 locus is frequently observed in MDR cell lines selected against cytotoxic anticancer drugs [20] .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "In line with these findings , partial PKC knockdown by siRNA resulted in decreased levels of ABCB1 , pNF\u03baB p65 and a significantly increased cytotoxicity of nintedanib in DMS114/NIN cells (Figure 8C and 8D , respectively) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Our subsequent analyses confirmed that massive overexpression of ABCB1 is underlying the MDR phenotype and nintedanib resistance of DMS114/NIN cells .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "In summary , this suggests that transcriptional upregulation of ABCB1 in DMS114/NIN cells upon selection for nintedanib resistance is induced at least in part by an ETAR-mediated activation of the PKC-NF\u03baB signaling pathway (summarized in Figure 8F) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Furthermore , we proved that nintedanib is a direct substrate of ABCB1 .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Interestingly , nintedanib-selected sublines of NCI-H1703 and NCI-H520 cells , both lacking ABCB1 overexpression , also exhibited low and unaltered ETAR and ET-1 expression levels as compared to their parental cell lines (Figure 7E and 7F) .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "It is of interest why the upregulation of ABCB1 expression in response to nintedanib treatment occurred exclusively in the SCLC and not in the two NSCLC cell lines .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Therefore , it will be interesting to elucidate whether ABCB1 overexpression during selection of DMS114 for acquired resistance reflects a SCLC cell type-specific response to nintedanib treatment .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "In the current study we demonstrate that high level expression of ABCB1 is underlying acquired nintedanib resistance of the FGFR1-driven SCLC cell line DMS114 but not of the two NSCLC cell lines NCI-H1703 and NCI-H520 .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Importantly , nintedanib was also able to restore sensitivity of DMS114/NIN cells , colchicine-selected KBC-1 [35] and vinblastine-selected KB-V1 cells towards other ABCB1 substrate compounds leading to synergistic effects in combination experiments especially in a FGFR-driven background .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "For instance , high intrinsic ABCB1 expression in clear cell renal carcinoma might render nintedanib treatment ineffective [44] .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Hence , antagonism of ETAR by tezosentan led to decreased levels of ABCB1 protein accompanied by decreased PKC and NF\u03baB phosphorylation and , importantly , to a significant re-sensitization of DMS114/NIN cells towards nintedanib .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "One might hypothesize that ETAR-mediated ABCB1 activation is a consequence of the specific nintedanib target profile including major players in endothelial cell physiology like FGFR and VEGFR .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Moreover , combination approaches with ETAR antagonists or a switch to non-ABCB1 substrate FGFR inhibitors represent innovative strategies to manage nintedanib resistance in lung cancer .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Concerning the clinics , the fact that nintedanib is an ABCB1 substrate might impair its efficacy as a single treatment not only in lung cancer , but also in other cancer types .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27367030",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "After 15 minutes preincubation with the selective ABCB1 inhibitor elacridar (10\u03bcM) , cells were incubated with 1\u03bcM nintedanib for 10 or 60 minutes at 37\u00b0C .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Alternatively , DMS114 cells were incubated for 1 h with 10 \u03bcM nintedanib in the presence or absence of 10 \u03bcM of the ABCB1 inhibitor elacridar [34] .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "Based on this unique characteristic , nintedanib transport by ABCB1 was exemplarily dissected and inactivation by lysosomal trapping was identified to represent a novel resistance mechanism limiting nintedanib activity in FGFR1 amplification-driven lung cancer .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "In line , ABCB1 blockade by the allosteric inhibitor elacridar completely restored nintedanib sensitivity (Fig .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "a Expression of ABCB1 in DMS114 cells and their isogenic nintedanib-resistant counterpart DMS114/NIN was analyzed by Western blot .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "However , coincubation with elacridar completely restored nintedanib fluorescence intensity in DMS114/NIN cells while having no significant effects in the parental cell line lacking ABCB1 expression (Fig .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "a Expression of ABCB1 in DMS114 cells and their isogenic nintedanib-resistant counterpart DMS114/NIN was analyzed by Western blot .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "b Impact of ABCB1 inhibition by elacridar on the cytotoxic activity of nintedanib in DMS114 cells and their resistant subline was analyzed by MTT assay 72 h after drug exposure. ** .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "This resistance phenotype is mediated by overexpression of the ATP-binding cassette drug efflux transporter B1 (ABCB1 , P-glycoprotein) , which actively pumps nintedanib out of the cell , thus minimizing its cytotoxic efficacy (Fig .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28882160",
    "tail": {
      "word": "ABCB1",
      "id": "P08183"
    },
    "sentence": "b Impact of ABCB1 inhibition by elacridar on the cytotoxic activity of nintedanib in DMS114 cells and their resistant subline was analyzed by MTT assay 72 h after drug exposure. ** .",
    "relation": "substrate"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Pdgfb",
      "id": "P01127"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Pdgfb",
      "id": "P01127"
    },
    "sentence": "Col1a1 , Col3a1 , Pdgfa , Pdgfb , Tgfb1 , and Adgre1 expression was reduced in all muscles analyzed from nintedanib-treated mdx mice compared with mdx mice .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31126332",
    "tail": {
      "word": "aromatase",
      "id": "P11511"
    },
    "sentence": "The combination of nintedanib (200 mg/bid) plus letrozole (2.5 mg/d) effectively inhibited both FGFR1 and aromatase in breast cancer patients , as evidenced by plasma FGF23 and 17-B-estradiol levels .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OCT2",
      "id": "P09086"
    },
    "sentence": "In summary , in the clinical setting , nintedanib is unlikely to affect the pharmacokinetics of other drugs that are substrates of major drug-metabolising CYPs or uptake transporters , such as OATP1B1 , OATP1B3 , OAT1 , OAT3 or OCT2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "multidrug resistance-associated protein 2",
      "id": "Q92887"
    },
    "sentence": "Studies using cell lines that express different drug transporters showed that nintedanib was not a substrate of organic anion-transporting polypeptide (OATP) 1B1 , OATP1B3 , OATP2B1 , organic cation transporter (OCT) 2 , multidrug resistance-associated protein 2 (MRP-2) or the efflux breast cancer resistance protein (BCRP) , but was a weak substrate for OCT1 [31] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "VEGF-B",
      "id": "P49765"
    },
    "sentence": "Based on the targets of nintedanib , FGF2 , PDGF-AA , PDGF-BB , VEGF-A , VEGF-B , VEGF-C , and TGF\u03b2-1 were examined in the different culture supernatants using ELISA .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "p53",
      "id": "P04637"
    },
    "sentence": "Accordingly , the expression of the gene PT53 (tumor protein p53) and the number of Ki-67+ cells , which are well known cell cycle markers , were significantly lower in nintedanib-treated cells than in control non-treated cells (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "serum albumin",
      "id": "P02768"
    },
    "sentence": "Nintedanib is ~ 98% plasma protein bound , with serum albumin considered to be the major binding protein [20] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "SDS",
      "id": "P20132"
    },
    "sentence": "PCa cells were treated with vehicle (DMSO) or Nintedanib (5.0 \u00b5M , 10 \u00b5M and 25 \u00b5M) for 72 h , collected and lysed in non-denaturing lysis buffer; approximately 50\u201380 \u03bcg of protein lysate from whole-cell extracts was denatured in 5X sample buffer and subjected to sodium dodecyl sulfate\u2013polyacrylamide gel electrophoresis (SDS-PAGE) on Tris\u2013glycine gel .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "SDS",
      "id": "P20132"
    },
    "sentence": "We also studied whether myotubes treated with nintedanib were more resistant to chemical damage using 0.25 mM sodium dodecyl sulfate (SDS) , and we did not see an effect of nintedanib on sarcolemma repair (Figure S3D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "FGFR-3",
      "id": "P22607"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "FGFR-3",
      "id": "P22607"
    },
    "sentence": "Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDFGR-\u03b1 and PDFGR-\u03b2 , FGFR-1 , FGFR-2 , FGFR-3 , VEGFR-1 , VEGFR-2 , VEGFR-3 , and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "FGFR3",
      "id": "P22607"
    },
    "sentence": "Nintedanib (BIBF 1120) is an orally available indolinone derivate that competitively binds to the ATP-binding sites within the kinase domains of VEGF receptor (VEGFR)1 , VEGFR2 , VEGFR3 , FGF receptor (FGFR)1 , FGFR3 , and PDGF receptor (PDGFR)\u03b1 and PDGFR\u03b2 [7] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "FGFR3",
      "id": "P22607"
    },
    "sentence": "Nintedanib (BIBF 1120) is a small molecule tyrosine kinase inhibitor that inhibits several angiokinases including VEGFR1/Flt1 , VEGFR2/Flk1/KDR and VEGFR3/Flt4 as well as FGFR1 , FGFR2 , FGFR3 , PDGFR-alpha , PDGFR-beta and Flt3 [5] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "FGFR-3",
      "id": "P22607"
    },
    "sentence": "Nintedanib treatment on the other hand caused a significant decrease in FGFR-3 levels in the TN16 and TN22 (8\u201312) (Fig .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "FGFR-3",
      "id": "P22607"
    },
    "sentence": "Indeed , Nintedanib was effective precisely at that time when its expression was increased , since the treatment significantly decreased FGFR-3 levels in 16-week-old TRAMP animals .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30285760",
    "tail": {
      "word": "FGFR3",
      "id": "P22607"
    },
    "sentence": "The gene-centric search result also provided information on three drugs (namely , AZD4547 , PD-173074 and nintedanib) that target both FGFR1 and FGFR3 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "VEGFR3",
      "id": "P35916"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "VEGFR-3",
      "id": "P35916"
    },
    "sentence": "Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDFGR-\u03b1 and PDFGR-\u03b2 , FGFR-1 , FGFR-2 , FGFR-3 , VEGFR-1 , VEGFR-2 , VEGFR-3 , and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGFR3",
      "id": "P35916"
    },
    "sentence": "Nintedanib (BIBF 1120) is an orally available indolinone derivate that competitively binds to the ATP-binding sites within the kinase domains of VEGF receptor (VEGFR)1 , VEGFR2 , VEGFR3 , FGF receptor (FGFR)1 , FGFR3 , and PDGF receptor (PDGFR)\u03b1 and PDGFR\u03b2 [7] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27307615",
    "tail": {
      "word": "Vascular endothelial growth factor receptor 3",
      "id": "P35916"
    },
    "sentence": "For example , in Table 10 , given Nintedanib , DrugE-Rank successfully identify the targets which interact with Nintedanib , such as Vascular endothelial growth factor receptor 3 , which was ranked out of top 50 by four component methods , k-NN , BLM-svc , BLM-svr and WNN-GIP .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31063131",
    "tail": {
      "word": "MELK",
      "id": "Q14680"
    },
    "sentence": "b) Ratio of protein synthesis rates between mitotic and G2 L1210 cells after 3 hr treatment with OTSSP167 , Defactinib (also known as PF-04554878) , PF-3758309 (also known as PF-309) or Nintedanib (also known as BIBF 1120) , all of which inhibit MELK kinase with sub-micromolar affinity (Klaeger et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "31063131",
    "tail": {
      "word": "MELK",
      "id": "Q14680"
    },
    "sentence": "b) Ratio of protein synthesis rates between mitotic and G2 L1210 cells after 3 hr treatment with OTSSP167 , Defactinib (also known as PF-04554878) , PF-3758309 (also known as PF-309) or Nintedanib (also known as BIBF 1120) , all of which inhibit MELK kinase with sub-micromolar affinity (Klaeger et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28949289",
    "tail": {
      "word": "transcriptase",
      "id": "P26676"
    },
    "sentence": "A) Quantitative reverse transcriptase (qRT)-PCR was used to detect the expression levels of Shh in 14Fp cell line after trichostatin A (TSA) and nintedanib (NIN) treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "cyclin",
      "id": "P12004"
    },
    "sentence": "The results showed that nintedanib inhibited the expression levels of activated STAT3 (p-STAT3) and its downstream pro-proliferative molecules Mcl-1 , cyclin D1 and survivin at the indicated doses (Figure 2a) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "Cyclin",
      "id": "P12004"
    },
    "sentence": "Cyclin D1 expression was also decreased due to nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Cyclin",
      "id": "P12004"
    },
    "sentence": "Significantly decreased levels of Cyclin A and E and CDKs 2 and 4 were also observed after treatment with all doses in LNCaP cells , besides significant decrease in Cyclin D1 after treatment with 25 \u00b5M dose of Nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Cyclin",
      "id": "P12004"
    },
    "sentence": "In case of PC3 cells , the levels of key molecules involved in cell cycle progression such as Cyclin A , D1 and E as well as CDKs 2 , 4 and 6 were significantly reduced dose-dependently after 72 h treatment with Nintedanib (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Cyclin",
      "id": "P12004"
    },
    "sentence": "Interestingly , a significant decrease in Cyclin D1 positive cells was observed in Nintedanib groups (from both studies) when compared to its respective control groups (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "Cyclin",
      "id": "P12004"
    },
    "sentence": "Nintedanib effect leading to cell cycle arrest was confirmed in vivo , as shown by decreased Cyclin D1 levels and proliferation rate of tumor cells in PC3 xenografts , which contributes to reduced tumor volume in animals that received the drug .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "cyclin",
      "id": "P12004"
    },
    "sentence": "Furthermore , Nintedanib exposure upregulated the cyclin-dependent kinase inhibitors such as CDKN1 and 2 that act like negative regulators of cell cycle progression alongside growth arrest and DNA damage-inducible 45 (GADD45) , a tumor suppressor known to play a role in mediating the anti-cancer activity of several chemotherapeutic drugs29,30 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28499383",
    "tail": {
      "word": "PCNA",
      "id": "P12004"
    },
    "sentence": "Animals treated with Nintedanib in tumor development grades (8 and 12 weeks of age) and sacrificed immediately , showed a decrease in PCNA immunolabeling in the TN12 and TN16 groups .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557253",
    "tail": {
      "word": "cyclin",
      "id": "P12004"
    },
    "sentence": "Nintedanib , that is , BIBF1120 was discovered as a side product from large screening assays targeting the cyclin-dependent kinase (CDK4) kinase (10 , 11) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27627050",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "There was no clear correlation between nintedanib exposure (AUC\u03c4,ss,norm) and AST or ALT levels (days 1\u201322 of cycle 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30249169",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Rise in ALT/AST > three times ULN was seen in 5.7% of patients receiving add-on therapy but not seen in the nintedanib-only group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Nintedanib plus docetaxel had a manageable safety profile as AEs more common in the combination group than in the docetaxel alone group included diarrhea (42.3% vs 21.8%) , increases in ALT (28.5% vs 8.4%) , increase in AST (22.5% vs 6.6%) , nausea (24.2% vs 18%) , and vomiting (16.9% vs 9.3%) (Table 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26677336",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most frequent (>5% of patients in any group) grade \u22653 AEs after nintedanib compared to sorafenib included diarrhea (10% vs 6%) , fatigue (7% vs 2%) , anemia (7% vs 6%) , increased AST (8% vs 13%) and ALT (6% vs 8%) , thrombocytopenia (5% vs 8%) , and skin reaction (1% vs 6%) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "We previously reported that 11 of 32 patients with IPF newly treated with nintedanib at a dose of 150 mg twice daily from September to December 2015 exhibited aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevation with the Common Terminology Criteria for Adverse Events (CTCAE) grade \u226526 , 7 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "First , a low BSA was associated with AST and/or ALT elevation with a CTCAE grade \u22652 when treated with nintedanib at a dose of 150 mg twice daily .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Second , 80% of the patients who resumed nintedanib at a reduced dose of 100 mg twice daily after treatment interruption due to hepatotoxicity did not again develop AST and/or ALT elevation with a CTCAE grade \u22652 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "However , the present study suggested that a low BSA predicts an AST and/or ALT elevation with a CTCAE grade \u22652 when treating with nintedanib at a dose of 150 mg twice daily .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "However , 6 of the 16 patients (37.5%) who needed a treatment interruption due to AST and/or ALT elevation with a CTCAE grade \u22652 could not resume nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "It is also noteworthy that 8 of 10 patients (80%) successfully resumed nintedanib at a reduced dose of 100 mg twice daily after treatment interruption due to AST and/or ALT elevation with a CTCAE grade \u22652 at a dose of 150 mg twice daily .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "In the present study , the median interval from nintedanib initiation to AST and/or ALT elevation with a CTCAE grade \u22652 was only 6 days , whereas the protocol of the INPULSIS trials specified that hepatic enzymes must be examined once every 2 weeks during the first 6 weeks .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28883482",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "When a patient developed AST and/or ALT elevation with CTCAE grade \u22652 , treatment interruption or dose reduction was needed in accordance with the guide for appropriate use of nintedanib (Ofev\u00ae)15 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Thirty-two patients (5.0 %) in the nintedanib group and 3 patients (0.7 %) in the placebo group had ALT and/or AST elevations \u22653x ULN .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "For ALT , AST and bilirubin , the proportion of patients who had normal values at baseline but maximum values above the ULN during treatment was higher in the nintedanib group than in the placebo group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26400368",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Nevertheless , a greater proportion of patients in the nintedanib group than in the placebo group had a last value on treatment above the ULN for ALT (4.4 % versus 3.4 %) and AST (5.0 % versus 1.7 %) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most common reasons for nintedanib dose reduction were increased alanine aminotransferase (ALT) levels , increased aspartate aminotransferase (AST) levels and diarrhea .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most frequent grade \u22653 AEs in the nintedanib group were liver-related AEs , mainly increased ALT (8%) and AST (8%) levels , and fatigue .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30010751",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most common of these in the nintedanib group was fatigue (n = 8) , followed by asthenia , decreased appetite , and malignant neoplasm progression (all n = 6); in the placebo group , the most common were increased blood bilirubin and increased AST levels (both n = 5) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "If a patient experienced DLTs other than CTCAE grade \u2265 3 AST and/or ALT increase , the starting dose was not considered to be appropriate , even if nintedanib could be administered at a reduced dose .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most common AEs leading to dose reduction of nintedanib were increased ALT and increased AST (30% each); the most common AE leading to dose reduction of docetaxel was decreased neutrophil count (40%) , followed by decreased WBC count and febrile neutropenia (20% each) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Patient 2 (who had experienced CTCAE grade 3 increased ALT and CTCAE grade 3 increased AST) was able to be retreated with a reduced nintedanib dose of 150 mg bid in combination with docetaxel 75 mg/m2 , and completed cycle 2 without further DLTs; they then went on to receive 6 cycles of combination therapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30073583",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Overall , the safety profile of the combination therapy was consistent with previous clinical trials with nintedanib and the known safety profile of docetaxel , with the most common drug-related AEs being myelotoxicity (neutropenia and leukopenia) , liver enzyme elevations (increased AST and ALT) , gastrointestinal AEs (diarrhea and nausea) , and alopecia .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30975118",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most common AE of nintedanib was AST / ALT elevation (63.3%) , followed by anorexia (46.7%) , diarrhea (46.7%) , and weight loss (20.0%) , whereas the most common CTCAE grade \u2265 2 AE was anorexia (36.7%) , followed by diarrhea (26.7%) and AST/ALT elevation (23.3%) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30975118",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Similarly , despite the relatively short observation period of the present study , the incidence and severity of nintedanib-induced AEs , such as AST/ALT elevation and anorexia , tended to be higher in this study than in the INPULSIS trials .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30975118",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "However , although the values of physique-related factors were significantly lower in the switch-group than in the pirfenidone-naive group in the present study , only nintedanib-induced anorexia was significantly more frequent and severer in the switch-group than in the pirfenidone-naive group , whereas no significant differences were observed in other AEs such as diarrhea and AST/ALT elevation .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Four of the 14 patients treated with once-daily nintedanib experienced an increase in ALT and/or AST \u2265 CTC grade 3 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "In contrast , there were no ALT/AST increases > CTC grade 2 in the 16 patients receiving twice-daily nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "25012508",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Summary of nintedanib-related toxicities Abbreviations: AE adverse event , ALT alanine aminotransferase , AST aspartate aminotransferase , CTC Common Toxicity Criteria , GGT gamma-glutamyl transpeptidase .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Dose reductions in the nintedanib group were indicated for patients with diarrhoea grade 2 for >7 days despite optimal management; vomiting grade \u2a7e2; elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels grade \u2a7e2 together with elevated bilirubin levels grade >1; or any other AE grade 3/4 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Adverse events occurring markedly more frequently in patients receiving nintedanib vs sunitinib were diarrhoea , and increases in gamma-glutamyltransferase (GGT) , AST (any grade: 9.4% vs 0%) and ALT(7.8% vs 0%) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26448178",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The rate of patients with AEs of increased GGT , ALT and AST liver enzymes was higher with nintedanib than with sunitinib , while AEs of increased lipases were higher with sunitinib than for nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26512876",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "In the event of treatment-related Grade \u2a7e3 aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) elevations or Grade \u2a7e2 elevation in conjunction with Grade \u2a7e1 bilirubin elevation , treatment with nintedanib was interrupted until recovery to baseline .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29563636",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Thus , an exploratory objective of this trial was to describe the effect of liver function assessed by AST/ALT plasma concentrations at study baseline (by allocation of patients to group I or II) and Child\u2013Pugh classification on the PK parameters of nintedanib and its metabolites .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The AEs that occurred with nintedanib plus docetaxel more frequently than with placebo plus docetaxel were gastrointestinal (GI) events (diarrhea , nausea and vomiting) and elevations in liver enzymes (increases in alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels) [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Table 6 provides an overview of the considerations for managing ALT/AST and bilirubin elevation associated with nintedanib therapy .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "Nintedanib treatment can be resumed at a reduced dose when AST/ALT enzyme values return to \u22642.5 \u00d7 ULN in conjunction with bilirubin to normal [6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "The most commonly reported liver enzyme elevations in patients of adenocarcinoma tumor histology receiving nintedanib in combination with docetaxel in LUME-Lung 1 were elevated AST (30.3%) and elevated ALT (37.8%) levels [7] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "It is recommended that nintedanib treatment be interrupted in patients with AST and/or ALT elevations >2.5 \u00d7 ULN in conjunction with total bilirubin elevations \u22651.5 \u00d7 ULN or AST and/or ALT elevations >5 \u00d7 ULN [6] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643547",
    "tail": {
      "word": "AST",
      "id": "P80357"
    },
    "sentence": "For patients with AST and/or ALT elevations >3 \u00d7 ULN in conjunction with elevated bilirubin \u22652 \u00d7 ULN in the absence of elevated alkaline phosphatase levels (<2 \u00d7 ULN) , nintedanib treatment should be permanently discontinued unless an alternative cause of liver damage can be established .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "Cdk5",
      "id": "Q00535"
    },
    "sentence": "Given the role of Cdk5 in MTC proliferation [16] and in angiogenesis [37] , Cdk5 inhibitors might be considered as therapeutic drugs to be used alone or in combination with a TKI such as Nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "MMP-9",
      "id": "P14780"
    },
    "sentence": "There is a possibility that by decreasing Endothelin levels , Nintedanib was also effective in decreasing MMP-9 expression , which could possibly lead to decreased tumor invasiveness and metastasis45,46 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30792658",
    "tail": {
      "word": "COX-2",
      "id": "P35354"
    },
    "sentence": "Two commercial anti-fibrotic drugs , nintedanib , and pirfenidone , were found to possess anti-inflammatory activity and COX-2 suppression effect (Choi et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "CD40L",
      "id": "P29965"
    },
    "sentence": "After nintedanib treatment only PDGF and PECAM-1 showed a significantly decreased expression compared to untreated allografts and CD40L was slightly but statistically not significantly reduced .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "CD40L",
      "id": "P29965"
    },
    "sentence": "Another link to reduced T-cell numbers can be seen in the lowered intragraft expression of CD40L in the nintedanib group , because binding of lymphocyte CD40L is an important costimulatory signal for T-cell activation.50 Additionally , reduced T-cell amounts could also derive from a direct effect of nintedanib on T cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27800477",
    "tail": {
      "word": "LZM",
      "id": "P61626"
    },
    "sentence": "In fact , the addition of Erlotinib-HCl and Nintedanib to BIOW2 cultures resulted in the 50% reduction of the CD73+CD90+ population (mean inhibition index: 54.2 \u00b1 7.7% , p < 0.05 , n = 6) at the primary cultures , producing suitable MPC products (>95% of purity) comparable to ones obtained applying LZM (Figure 5A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "Rho",
      "id": "P08100"
    },
    "sentence": "We treated LL29 IPF cells with pirfenidone or nintedanib and examined the Rho signaling pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "PTEN",
      "id": "P60484"
    },
    "sentence": "Various PTPs have been reported to regulate the STAT3 pathway , including SHP-1,31 , 32 SHP-233 and PTEN.34 However , as shown in Supplementary Figure 4 , nintedanib treatment had no obvious effect on either PTEN or SHP-2 but suppressed the phosphorylation of JAK2 (Tyr1007/1008) and Src (Tyr 416) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "PTEN",
      "id": "P60484"
    },
    "sentence": "Although PC3 is a Pca cell line with a deep PTEN deletion and Akt activation , treatment of PC3 cells with nintedanib still increased the expression of ROCK1/2 and E-cadherin (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29103264",
    "tail": {
      "word": "PKs",
      "id": "P10398"
    },
    "sentence": "It is probable that intracellular proliferation depends on PKs that are not influenced by non-EGFR TKs , as sunitinib and nintedanib are considered multi-targeted anti-angiogenic agents that act against VEGFRs , PDG-FRs and FGFRs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29319036",
    "tail": {
      "word": "TRT",
      "id": "O14746"
    },
    "sentence": "Preclinical studies have shown the efficacy of nintedanib in controlling ILD and decreasing the risk of RP.[12] A Phase II has recently been opened by Memorial Sloan Kettering Cancer Center (MSKCC) which assess the role of nintedanib in the development of RP after TRT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "JAK2",
      "id": "O60674"
    },
    "sentence": "Cell lysates treated with nintedanib were prepared and analyzed by western blot as previously reported.18 Antibodies targeting p-JAK2 (Tyr1007/1008) , JAK2 , p-SRC (Tyr416) , SRC , p-STAT3 (Tyr705) , STAT3 , survivin , poly (ADP-ribose) polymerase (PARP) and cleaved caspase 3 were purchased from Cell Signaling (Danvers , MA , USA) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "JAK2",
      "id": "O60674"
    },
    "sentence": "SHP-1 is known to directly bind to JAK2 kinase to induce its dephosphorylation and inhibition.35 It is possible that nintedanib decreased the p-JAK2 levels by increasing the SHP-1 activity .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "JAK2",
      "id": "O60674"
    },
    "sentence": "Various PTPs have been reported to regulate the STAT3 pathway , including SHP-1,31 , 32 SHP-233 and PTEN.34 However , as shown in Supplementary Figure 4 , nintedanib treatment had no obvious effect on either PTEN or SHP-2 but suppressed the phosphorylation of JAK2 (Tyr1007/1008) and Src (Tyr 416) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28798401",
    "tail": {
      "word": "JAK2",
      "id": "O60674"
    },
    "sentence": "Alternatively , nintedanib is a multitargeted angiokinase inhibitor against PDGFR , FGFR , VEGFR and non-receptor tyrosine kinases such as Src.15 Since PDGF\u03b2 has been reported to induce the JAK2\u2013STAT3 pathway by activating Src,36 nintedanib might inhibit JAK2 by directly inhibiting PDGF\u03b2 and Src .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31523388",
    "tail": {
      "word": "JAK2",
      "id": "O60674"
    },
    "sentence": "The most potent partners for CDK inhibitors in multiple myeloma are the HDAC inhibitors CUDC101 and CUDC907 , the MEK1/2 inhibitor trametinib , the NOTCH inhibitor PF-03084014 , the BCL2 inhibitors GX15-070 and ABT-263 , the IDH1/2 inhibitor AGI-5180 , the FLT3 and JAK2 inhibitor SB1317 and also the FGFR-targeting inhibitors XL999 and nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30082518",
    "tail": {
      "word": "prolyl endopeptidase",
      "id": "Q9X6R4"
    },
    "sentence": "It reduced pulmonary inflammation by decreasing prolyl endopeptidase activity and acetyl-proline-glycine-proline.[25] In a therapeutic protocol , the influence of using PDE-4 inhibitors to reduce lung fibrosis was almost same to nintedanib and pirfenidone .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "ROCK2",
      "id": "O75116"
    },
    "sentence": "Therefore , RhoA and ROCK1/2 expression was analyzed in Pca cells and it was observed that nintedanib treatment of 22RV1 and DU145 cells led to an increase in the expression of RhoA , ROCK1 and ROCK2 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "UGT1A1",
      "id": "P22309"
    },
    "sentence": "Further in vitro data indicated that nintedanib , at clinically relevant concentrations , did not inhibit glucuronidation by uridine 5\u2032-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase , UGT) 1A1 (UGT1A1) in human liver microsomes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "UGT1A1",
      "id": "P22309"
    },
    "sentence": "Nintedanib is rapidly metabolised , primarily via ester cleavage , resulting in the formation of the free acid moiety (BIBF 1202) that is subsequently glucuronidated by hepatic and intestinal uridine 5\u2032-diphospho-glucuronosyltransferase (UGT) 1A1 (UGT1A1) enzymes to form BIBF 1202 glucuronide and excreted in the feces (about 94% of the dose) [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29119292",
    "tail": {
      "word": "UGT1A1",
      "id": "P22309"
    },
    "sentence": "Despite limited data , there was also no substantial difference in nintedanib pharmacokinetics between Black patients (9 of the 1191 patients included) , alcohol consumption (11 patients included) or UGT1A1 polymorphism status .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28824643",
    "tail": {
      "word": "PDGFRA",
      "id": "P16234"
    },
    "sentence": "Considering then the target PDGFRA (overexpressed in Ip) , a drug compound of interest is lenvatinib (multiple kinase inhibitor) , then regorafenib (multikinase inhibitor targeting angiogenesis , stromal/microenvironment and oncogenesis) , and also nintedanib (small molecule tyrosine-kinase inhibitor , targeting VEGFR and FGFR) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30598078",
    "tail": {
      "word": "PDGFRA",
      "id": "P16234"
    },
    "sentence": "Using the Cancer Therapeutics Response Portal v2 , we found that the PDGFRA gene was targeted by six drugs , including axitinib , Ki8751 , lenvatinib , masitinib , nintedanib , and sunitinib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30643263",
    "tail": {
      "word": "Pdgfra",
      "id": "P16234"
    },
    "sentence": "Of note , one of the few FDA-approved therapies for lung fibrosis , the small molecule receptor tyrosine kinase inhibitor nintedanib , blocks PDGF receptor signaling39 , and Pdgfra expressed by fibroblasts drives fibrosis in multiple organs in mice40\u201345 , including lung fibrosis induced by bleomycin treatment46 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26346347",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "The development of nintedanib began with the identification of a lead compound from a group of six-substituted indolinones via assessment of tumor angiogenesis inhibition , and this compound was shown to inhibit VEGFR-2.54 Derivatives of the lead compound were screened for triple angiokinase (eg , VEGFR-2 , FGFR-1 , and PDGFR\u03b1) inhibitory activity .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "Structural modelling studies with recombinant VEGFR-2 kinase demonstrated that nintedanib binds to the ATP-binding site in the cleft between the NH2 and COOH terminal lobes of the kinase domain [14].Fig .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "In cell-based assays , inhibition of VEGFR-2 phosphorylation was sustained for at least 32 h in VEGFR-2-transfected NIH3T3 cells exposed to nintedanib for 1 h [14] , suggesting a sustained inhibitory effect .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27340254",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "This strategy is also supported by the results of ramucirumab (a monoclonal antibody directed against VEGFR2) , and nintedanib (a TKI inhibiting VEGFR , PDGFR and FGFR) in the second-line setting [Garon et al .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Although the expression of both PDGFR\u03b1 and PDGFR\u03b2 was clearly downregulated in nintedanib-treated grafts , the expression of FGFR1 , FGFR2 , and VEGFR2 was not influenced by nintedanib and interestingly the expression of the VEGFR1 was even elevated .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Suesskind-Schwendi et al44 used nintedanib in a rat lung transplantation model and also found receptor down-regulation (PDGFR\u03b1 and VEGFR2) , but interestingly did not reveal decreased fibrosis development after lung transplantation .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26893682",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "In addition , small molecule inhibitors of receptor tyrosine kinases , which work with VEGFR-2 , nintedanib , sunitinib , sorafenib , vandetanib and vatalanib , have been tested as potential anticancer therapies (25,26) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26622180",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Baseline and posttreatment levels of circulating CD117 (c-KIT)-positive bone-marrow-derived progenitor cell subsets as well as of plasma soluble VEGFR2 (sVEGFR2) were evaluated as potential biomarkers for the pharmacodynamics and dose\u2013response relation of nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDFGR-\u03b1 and PDFGR-\u03b2 , FGFR-1 , FGFR-2 , FGFR-3 , VEGFR-1 , VEGFR-2 , VEGFR-3 , and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28974751",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "LTF is also known to stimulate cell migration and proliferation via VEGFA gene , whilst nintedanib targets the receptors for VEGFA , VEGFR1 and VEGFR2 .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27716819",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "Although the mechanisms responsible for the decrease of circulating VEGF receptors upon small molecule inhibition are not fully understood , our results are entirely in line with previous observations made with nintedanib in solid tumors [31] and with other kinase inhibitors targeting VEGFR-2 such as cediranib [32] or AG-01736 [33] in AML .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25496490",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Nintedanib (BIBF 1120) is an orally available indolinone derivate that competitively binds to the ATP-binding sites within the kinase domains of VEGF receptor (VEGFR)1 , VEGFR2 , VEGFR3 , FGF receptor (FGFR)1 , FGFR3 , and PDGF receptor (PDGFR)\u03b1 and PDGFR\u03b2 [7] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26853940",
    "tail": {
      "word": "vascular endothelial growth factor receptor 2",
      "id": "P35968"
    },
    "sentence": "The crystal structure of nintedanib in complex with vascular endothelial growth factor receptor 2 (PDB: 3c7q) revealed that the compound wraps around the outside of the hinge region .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Consistent with its anti-angiogenic effects , Nintedanib therapy also reduced phosphorylation of RET , VEGFR2 , and ERK1/2 in MTC tumors (Figure 4D). .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Romidepsin had no effect on phosphorylation of RET , VEGFR2 , or ERK1/2 while Nintedanib alone or in combination with Romidepsin lowered these signals , consistent with the previous results (Figure 5D) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Furthermore , Nintedanib , which blocks VEGFR2 , RET , ERK1,2 and PI3K/AKT/FOXO1 like Vandetanib , also inhibits PI3K/AKT/mTOR , but may still have limited long-term anti-tumor effects on MTC due to the development of resistance .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29455659",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "VEGFR-2 blocking antibodies , such as ramucirumab , antibody-like decoy traps that bind both VEGF and placental growth factor , as aflibercept and several TKIs acting as specific inhibitors or pan-kinase inhibitors that also target VEGFR , namely sunitinib , sorafenib , pazopanib , axitinib , regorafenib , nintedanib , cabozantinib and vatalanib [41\u201343] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30635009",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "Sunitinib targets a broader spectrum of receptor tyrosine kinases [82] , compared to nintedanib [28] , and its potency for inhibiting VEGFR-2 function may be greater .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27618114",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "Nintedanib , which inhibits the VEGF receptor-2 (VEGFR-2) , was shown to specifically reverse VEGF-induced proliferation in human primary lung fibroblasts from IPF patients [23,24] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28066768",
    "tail": {
      "word": "VEGFR2",
      "id": "P35968"
    },
    "sentence": "Preclinical studies with nintedanib have shown sustained (>30 h) blockade of VEGFR2 in vitro and delay or arrest of tumor growth in xenograft models of human solid tumors , including lung cancer models (7) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28424759",
    "tail": {
      "word": "VEGFR-2",
      "id": "P35968"
    },
    "sentence": "These agents bind VEGFR-2 directly (e.g. , ramucirumab) , act as VEGF inhibitors (e.g. , aflibercept) , or block intracellular downstream signal transduction by the inhibition of the tyrosine kinases of VEGF receptors (e.g. , sorafenib and nintedanib) (6\u20138) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "Therefore , we hypothesized that nintedanib could induce entosis via the CDC42 pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "Consistent with the proliferation assay results , nintedanib treatment suppressed the expression of proteins downstream of PI3K , including CDC42 , phospho-Akt and phospho-ERK1/2 (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "In addition , nintedanib-associated entosis was significantly inhibited in cells overexpressing CDC42 compared with controls (P<0.05 , Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "IHC indicated that the expression of E-cadherin was increased in the nintedanib-treated tumors compared with in the controls , whereas CDC42 expression was markedly decreased in nintedanib-treated tumors (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "In the present study , the primers used reflect the total expression level of the two isoforms of CDC42 under nintedanib pressure .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "The results of the present study indicated that: i) Nintedanib is able to inhibit Pca cell proliferation and decrease the growth of xenografts; ii) resistance to nintedanib will develop during in vitro and vivo treatment; and iii) nintedanib induces Pca cell entosis via the upregulation of E-cadherin and ROCK1/2 through the PI3K/CDC42 signaling pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "The results of the present study indicated that: i) Nintedanib is able to inhibit Pca cell proliferation and decrease the growth of xenografts; ii) resistance to nintedanib will develop during in vitro and vivo treatment; and iii) nintedanib induces Pca cell entosis via the upregulation of E-cadherin and ROCK1/2 through the PI3K/CDC42 signaling pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "However , as the focus of the present study was on the resistance of Pca cells to the nintedanib and the entosis phenomenon , differences in the expression of the CDC42 isoforms were not investigated .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "Nintedanib could block FGFR and then inhibit the downstream PI3K/CDC42 signaling pathway to promote entosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "Nintedanib inhibits FGFR in Pca cells , and inhibits the activation of its downstream pathways , including PI3K. The data indicated that nintedanib inhibited CDC42 , Akt and ERK1/2 expression (downstream of PI3K) in 22RV1 and DU145 cells (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "Nintedanib inhibits FGFR in Pca cells , and inhibits the activation of its downstream pathways , including PI3K. The data indicated that nintedanib inhibited CDC42 , Akt and ERK1/2 expression (downstream of PI3K) in 22RV1 and DU145 cells (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30867745",
    "tail": {
      "word": "CDC42",
      "id": "P60953"
    },
    "sentence": "CDC42 is an important molecule in the PI3K downstream signaling pathway , and the results of the present study have demonstrated that treatment with nintedanib decreased the expression of CDC42 , and this effect was also observed in Pca cells treated with the PI3K inhibitor buparlisib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "CCNA2",
      "id": "P20248"
    },
    "sentence": "Moreover , the expression of genes associated with cell proliferation , such as CDK1 , CDK4 , CCNA2 , and PLK1 , was significantly diminished in the lung-resident fibroblasts of IPF patients treated with nintedanib as compared to vehicle (Figure 7D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "CCNA2",
      "id": "P20248"
    },
    "sentence": "D) Quantification of CDK1 , CDK4 , CCNA2 , and PLK1 gene transcripts by RT-PCR in the primary lung-resident fibroblasts isolated from human IPF lung cultures and treated with vehicle or nintedanib (1 \u03bcM) for 16 h (n = 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "However , the biological processes underlying both the positive therapeutic effects of nintedanib in ADC and the lack of such effects in SCC remain unknown .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In addition to lung ADC , nintedanib has been recently approved to treat patients with idiopathic pulmonary fibrosis (IPF) , based on its ability to slow the progression of this rare disease in clinical trials (Richeldi et al , 2014; Wollin et al , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Moreover we examined the potential inhibitory role of nintedanib on the tumour-promoting effects of activated TAFs in terms of growth and invasion in a panel of ADC and SCC cell lines .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "To test this hypothesis , we examined the inhibitory effects of nintedanib in lung TAFs from ADC and SCC patients as well as lung fibroblast from non-malignant tissue upon stimulation with either growth factors or TGF-\u03b21 in terms of growth and activation , respectively .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Therefore , given the known direct effects of nintedanib on lung fibroblasts and the distinct aberrant phenotypes of ADC-TAFs and SCC-TAFs , we hypothesised that the selective therapeutic effects of nintedanib on ADC may be due , at least in part , to a larger impact of this drug on ADC-TAFs compared to SCC-TAFs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "A panel of lung carcinoma cell lines derived from either ADC (H1437 , H522) or SCC (SK-MES-1 , H520) (ATCC) patients were used to examine the tumour-promoting effects of TAFs treated with nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "All carcinoma cell lines were wild-type EGFR and KRAS (Blanco et al , 2009) to mimic critical genetic aspects of lung ADC patients that may be treated with nintedanib in the clinic (Bronte et al , 2016) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "To examine this possibility , we first stimulated ADC-TAFs and SCC-TAFs with 10% FBS in the presence of increasing doses of nintedanib or DMSO vehicle .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "These experiments showed that the antiproliferative effects of nintedanib in TAFs were quantitatively similar in both ADC and SCC , eliciting comparable IC50 values to each other that were also close to that found in control fibroblasts (Table 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "The marked antiproliferative and antifibrotic responses to nintedanib observed in SCC-TAFs and ADC-TAFs in vitro raised the question of what of these effects might be more relevant in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "The selective therapeutic effects of nintedanib in ADC cells were even more dramatic when analysing invasion data .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Since IC50 values for both fibrillar collagens were very similar in ADC-TAFs and control fibroblasts (Table 1) , our data reveal for the first time that SCC-TAFs exhibit a poor antifibrotic response to nintedanib , whereas ADC-TAFs exhibit a normal antifibrotic response to this drug .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "These in vitro observations are in qualitative agreement with the selective anticancer effects of nintedanib observed in ADC patients in clinical trials (Reck et al , 2014; Novello et al , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "The CM was used to stimulate the growth and invasion of a panel of ADC and SCC cell lines that were selected based on their EGFR and KRAS wild-type status to mimic key genetic features of those patients that may be treated with nintedanib (Bronte et al , 2016) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Remarkably , such growth enhancement of carcinoma cells drop by \u223c30\u201340% when using CM from activated TAFs treated with 2 \u03bcM nintedanib in ADC cell lines only (Figure 5B) , whereas it remained virtually unaltered in SCC cells (Figure 5C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Finally , to assess the potential contribution of carcinoma cells themselves on the differential therapeutic effects of nintedanib on the carcinoma\u2013TAF cross-talk , we stimulated SCC cells with CM from ADC-TAFs and vice versa .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "CM of ADC-TAFs treated with nintedanib on SCC cells elicited negative therapeutic responses in terms of both growth and invasion (Figure 5F) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In contrast , the CM of SCC-TAFs treated with nintedanib on ADC cells elicited a negative response in terms of growth but a positive response in terms of invasion (Figure 5G) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Moreover , these results reveal for the first time that nintedanib in vitro induces a robust inhibition of both the growth and invasive advantages provided by soluble factors secreted by activated TAFs in ADC but not SCC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "We hypothesised that such selective effects could be due , at least in part , to a larger impact of nintedanib on ADC-TAFs compared to SCC-TAFs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In contrast , the observed increase in invasion was reduced by \u223c60\u201370% when using CM from activated TAFs treated with 2 \u03bcM nintedanib in ADC cell lines (Figure 5D) , whereas no reduction was observed in SCC (Figure 5E) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "These results support that there is a division of labour between TAFs and carcinoma cells in which both SCC-TAFs and carcinoma cells themselves (ADC and SCC) contribute to the observed differential therapeutic responses to nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Because TAFs are largely quiescent and activated in histologic sections , it is conceivable that the differential antifibrotic effects of nintedanib on ADC-TAFs and SCC-TAFs may be more therapeutically relevant than its antiproliferative function .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Nintedanib is a multi-kinase inhibitor initially designed as a next generation antiangiogenic drug (Hilberg et al , 2008) that has been recently approved to treat patients with advanced lung ADC , based on its selective therapeutic benefits on ADC patients (Reck et al , 2014; McCormack , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In agreement with our observations , a significant decrease in activated host fibroblasts was reported in tumour mouse xenografts with ADC cells upon nintedanib treatment , concomitantly with a reduction in tumour size and vessel density (Cenik et al , 2013) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Likewise an analysis of the potential differential expression of the corresponding receptors in ADC and SCC cells is warranted to shed light on the mechanisms underlying the cross-talk between TAFs and carcinoma cells in the selective therapeutic effects of nintedanib in ADC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Remarkably nintedanib downregulated the mRNA levels of the main fibrillar collagens in fibrosis to a larger extent in ADC-TAFs compared to SCC-TAFs .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In addition to the direct contribution of TAFs , our mixed CM experiments support that both ADC and SCC cells contribute themselves to the positive therapeutic effects of nintedanib in ADC but not in SCC , revealing a division of labour between TAFs and carcinoma cells in modulating the subtype-specific nintedanib responses .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In the present study we increased the list of subtype-specific aberrant features in TAFs by reporting differential antifibrotic responses to nintedanib , and revealed similar responses in ADC-TAFs and control fibroblasts .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Based on these findings , it is conceivable that part of the clinical benefits of the combination of nintedanib with docetaxel in ADC patients are due to the downregulation of fibrillar collagens elicited by nintedanib , for this downregulation may facilitate the delivery of docetaxel to carcinoma cells by removing interstitial barriers that hinder diffusion .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Likewise nintedanib elicited a larger downregulation of P4HA2 expression in ADC-TAFs than in SCC-TAFs , which is an essential enzyme for the intracellular stability of the procollagen triple helix that is required for its effective secretion (Chen and Raghunath , 2009; Schwarz , 2015) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Although the molecular underpinnings underlying all these subtype-specific alterations in TAFs remains to be elucidated , the differential antifibrotic responses to nintedanib strongly suggest that TAF activation in ADC and SCC elicited by TGF-\u03b21 may be regulated through distinct mechanisms .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Thus , even though the regulatory impact of nintedanib on the TGF-\u03b2 pathway remains incompletely defined (Rangarajan et al , 2016) , it is tempting to speculate that the differential antifibrotic effects of nintedanib in ADC-TAFs and SCC-TAFs could be associated with its ability to impact TGF-\u03b2 signalling at different regulatory levels in a subtype-specific fashion .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "However , although such antiproliferative effects appear to be relevant in IPF and other fibrotic disorders , we argue that the therapeutically relevant function of nintedanib against the desmoplastic tumour stroma in ADC is its antifibrotic rather than its antiproliferative effects , because TAFs are largely quiescent and activated in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "In summary , our preclinical study reveals that the selective therapeutic benefits of nintedanib combined with docetaxel in ADC are associated with at least two complementary processes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Yet , because our preclinical models of carcinoma\u2013TAF interactions captured the selective therapeutic effects of nintedanib in ADC (but not SCC) reported in clinical trials , we argue that these models may be useful in identifying the mechanisms underlying the poor antifibrotic response of SCC-TAFs to nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Our observed direct inhibitory effect of nintedanib on the activation and tumour-promoting effects of ADC-TAFs expand previous observations of a direct inhibitory effect of this drug on stromal cell types involved in angiogenesis (Hilberg et al , 2008) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "First , the direct antifibrotic effect of nintedanib on ADC-TAFs , which reduces the deposition of fibrillar collagens , thereby potentially reducing the physical barriers that may hinder the delivery of docetaxel to cancer cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "ADC",
      "id": "Q96A70"
    },
    "sentence": "Accordingly , the synergistic therapeutic effects of nintedanib combined with docetaxel reported in ADC patients illustrate an emerging strategy in cancer therapeutics based on combining drugs that target the aberrant tumour stroma with either cytotoxic drugs or targeted drugs against carcinoma cells (Mueller and Fusenig , 2004; Bremnes et al , 2011; Ohlund et al , 2014) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "24179413",
    "tail": {
      "word": "FGFR-2",
      "id": "P21802"
    },
    "sentence": "For nintedanib (BIBF 1120) , a potent small-molecule inhibitor of VEGFR1 , VEGFR2 , VEGFR3 , FGFR-1 , FGFR-2 , FGFR-3 , and PDGFR-\u03b1/\u03b2 , 2 phase III studies will be presented this year (LUME-Lung 1 and 2 studies) .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30046657",
    "tail": {
      "word": "FGFR2",
      "id": "P21802"
    },
    "sentence": "Although the expression of both PDGFR\u03b1 and PDGFR\u03b2 was clearly downregulated in nintedanib-treated grafts , the expression of FGFR1 , FGFR2 , and VEGFR2 was not influenced by nintedanib and interestingly the expression of the VEGFR1 was even elevated .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29297621",
    "tail": {
      "word": "FGFR2",
      "id": "P21802"
    },
    "sentence": "We found an overrepresentation of proteins in hAEC Exo that were involved in negatively regulating FGFR1 and FGFR2 , and PDGF\u2010mediated regulation of RAS through GAPs target pathways common to those targeted by nintedanib .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27824545",
    "tail": {
      "word": "FGFR-2",
      "id": "P21802"
    },
    "sentence": "Nintedanib leads to inhibition of several central molecules involved in fibroblast activation such as PDFGR-\u03b1 and PDFGR-\u03b2 , FGFR-1 , FGFR-2 , FGFR-3 , VEGFR-1 , VEGFR-2 , VEGFR-3 , and Src .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28915889",
    "tail": {
      "word": "FGFR2",
      "id": "P21802"
    },
    "sentence": "Second , The IC50 values of nintedanib for PDGFR\u03b1 and PDGFR\u03b2 have been reported to be in the range of 41\u201358 nM , whereas that for FGFR2 is 257 nM [7] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25015210",
    "tail": {
      "word": "FGFR2",
      "id": "P21802"
    },
    "sentence": "Nintedanib (BIBF 1120) is a small molecule tyrosine kinase inhibitor that inhibits several angiokinases including VEGFR1/Flt1 , VEGFR2/Flk1/KDR and VEGFR3/Flt4 as well as FGFR1 , FGFR2 , FGFR3 , PDGFR-alpha , PDGFR-beta and Flt3 [5] .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31242658",
    "tail": {
      "word": "FGFR2",
      "id": "P21802"
    },
    "sentence": "In human GC cell lines driven by an FGFR2 amplification , such as KatoIII , nintedanib is also confirmed to be highly effective .",
    "relation": "inhibitor"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "mTOR",
      "id": "P42345"
    },
    "sentence": "Nintedanib alone or in combination with Romidepsin inhibited mTOR signaling as evidenced by a decrease in the phosphorylation of mTOR downstream effectors , S6K and 4EBP-1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "mTOR",
      "id": "P42345"
    },
    "sentence": "It may also be important to determine if a Vandetanib/mTOR inhibitor combination or a Nintedanib monotherapy is the most beneficial through future patient-centered studies .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30701022",
    "tail": {
      "word": "mTOR",
      "id": "P42345"
    },
    "sentence": "Furthermore , Nintedanib , which blocks VEGFR2 , RET , ERK1,2 and PI3K/AKT/FOXO1 like Vandetanib , also inhibits PI3K/AKT/mTOR , but may still have limited long-term anti-tumor effects on MTC due to the development of resistance .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28186126",
    "tail": {
      "word": "mTOR",
      "id": "P42345"
    },
    "sentence": "Interestingly , targeted inhibition of mTOR (mTORC1/C2) correlated with nintedanib and regorafenib response profiles (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30231590",
    "tail": {
      "word": "mammalian target of rapamycin",
      "id": "P42345"
    },
    "sentence": "Clinical trials evaluating the role of pazopanib/nintedanib/dasatinib (tyrosine kinase inhibitors) , tamoxifen (AR inhibitor) , bicalutamide + triptorelin (AR inhibitor + GnRH agonist) and temsirolimus (mammalian target of rapamycin inhibitor) are also underway [10] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26846335",
    "tail": {
      "word": "BAL",
      "id": "P19835"
    },
    "sentence": "The aim of the present study was to evaluate the effects of pirfenidone and nintedanib on the ultrastructural and functional properties of stromal cells such as fibroblasts and myofibroblasts collected from BAL and lung tissue samples both from patients with IPF and from control lung .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27401332",
    "tail": {
      "word": "BAL",
      "id": "P19835"
    },
    "sentence": "In fact , the definition of AE-IPF used in recent clinical trials of nintedanib did not include the performance of endotracheal aspirate collection or BAL as essential components , and infection was excluded in accordance with routine clinical practice and microbiologic studies [37] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "BAL",
      "id": "P19835"
    },
    "sentence": "BAL = bronchoalveolar lavage; EBD = Evans blue dye; GAPDH = glyceraldehydes\u2010 phosphate dehydrogenase; MDA = malondialdehyde; N30 = 30 mg/kg nintedanib; N60 = 60 mg/kg nintedanib; N100 = 100 mg/kg nintedanib; TGF\u2010\u03b21 = transforming growth factor\u2010\u03b21 (TGF)\u2010\u03b21 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OAT3",
      "id": "Q8TCC7"
    },
    "sentence": "In summary , in the clinical setting , nintedanib is unlikely to affect the pharmacokinetics of other drugs that are substrates of major drug-metabolising CYPs or uptake transporters , such as OATP1B1 , OATP1B3 , OAT1 , OAT3 or OCT2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "GAPDH",
      "id": "Q8IKK7"
    },
    "sentence": "The relative quantification of gene expression between control and Nintedanib treated samples was achieved by normalization against endogenous GAPDH and \u03b2-Actin using the \u0394\u0394CT method of quantification and the data was analyzed using the software provided by the manufacturer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "GAPDH",
      "id": "Q8IKK7"
    },
    "sentence": "The relative quantification of gene expression between control and Nintedanib treated samples was achieved by normalization against endogenous GAPDH and \u03b2-Actin using the \u0394\u0394CT method of quantification and the data was analyzed using the software provided by the manufacturer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "GAPDH",
      "id": "Q8IKK7"
    },
    "sentence": "The relative quantification of gene expression between control and Nintedanib-treated samples was achieved by normalization against endogenous GAPDH and \u03b2-Actin using the \u2206\u2206CT method of quantification and the data was analyzed using the software provided by the manufacturer .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "GAPDH",
      "id": "Q8IKK7"
    },
    "sentence": "BAL = bronchoalveolar lavage; EBD = Evans blue dye; GAPDH = glyceraldehydes\u2010 phosphate dehydrogenase; MDA = malondialdehyde; N30 = 30 mg/kg nintedanib; N60 = 60 mg/kg nintedanib; N100 = 100 mg/kg nintedanib; TGF\u2010\u03b21 = transforming growth factor\u2010\u03b21 (TGF)\u2010\u03b21 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "Gapdh",
      "id": "Q8IKK7"
    },
    "sentence": "A) Immunoblot analysis of Bak , Bax , and Gapdh in fibrotic lung-resident myofibroblasts treated with vehicle or nintedanib (1 \u03bcM) for 72 h. For quantification , Bak and Bax were normalized to loading control Gapdh. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "Gapdh",
      "id": "Q8IKK7"
    },
    "sentence": "B) Immunoblot analysis of Bak , Bax , and Gapdh in fibrotic lung fibrocytes treated with vehicle or nintedanib (1 \u03bcM) for 72 h. For quantification , Bak and Bax were normalized to loading control Gapdh .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30636861",
    "tail": {
      "word": "glyceraldehyde-3-phosphate dehydrogenase",
      "id": "Q8IKK7"
    },
    "sentence": "B,C: HTFs were treated with TGF-\u03b21 (5 ng/ml) in the presence or absence of SB203580 or nintedanib (1 \u03bcM) for 24 h. The mRNA (B) and protein (C) expression of \u03b1-SMA were analyzed by quantitative reverse transcription polymerase chain reaction (RT-PCR) and western blot , respectively , and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30636861",
    "tail": {
      "word": "GAPDH",
      "id": "Q8IKK7"
    },
    "sentence": "B,C: HTFs were treated with TGF-\u03b21 (5 ng/ml) in the presence or absence of SB203580 or nintedanib (1 \u03bcM) for 24 h. The mRNA (B) and protein (C) expression of \u03b1-SMA were analyzed by quantitative reverse transcription polymerase chain reaction (RT-PCR) and western blot , respectively , and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30636861",
    "tail": {
      "word": "GAPDH",
      "id": "Q8IKK7"
    },
    "sentence": "B,C: Human Tenon\u2019s fibroblasts (HTFs) were treated with TGF-\u03b21 (5 ng/ml) in the presence or absence of SB203580 or nintedanib (1 \u03bcM) for 24 h. The mRNA (B) and protein (C) expressions of Snail were analyzed by quantitative reverse transcription polymerase chain reaction (RT-PCR) and western blot , respectively , and normalized to GAPDH expression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib at concentrations of \u2265300 nmol\u00b7L\u22121 did not change the morphology of primary alveolar type II epithelial cells derived from donors without IPF and showed no inhibitory activity on the TGF-\u03b2-induced (2 ng\u00b7mL\u22121) EMT (online supplementary material section B) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib was found to have no effect on EMT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "25745043",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib was found to have no effect on EMT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30881019",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nishijima et al showed that retention of the epithelial phenotype with high levels of miR-200 family ensured good sensitivity to nintedanib in NSCLC cells.12 In addition , induction of miR-200b and miR-141 showed reversal of EMT and increased sensitivity for nintedanib in naturally resistant A549 cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29934570",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Modification in cell structure leading to metastasis; epithelial to mesenchymal transition (EMT) , is characterized by loss of cell-cell adhesion and invasion of basement membranes; therefore , substances that promote E-cadherin expression , such as Nintedanib , are expected to prevent EMT33,34 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Two recent reports suggest an inhibition of EMT by Nintedanib in ovarian cancer cells along with increased E-cadherin levels [42 , 43] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Furthermore , we explored the functional contribution of these six mesenchymal genes in the presence of an EMT reversing agent , nintedanib (BIBF1120) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Collectively , these data indicate that E-cadherin gene induction follows a dose-dependent , linear function of the active concentration of nintedanib , and we can therefore conclude that EMT reversal and E-cadherin restoration caused by nintedanib were not due to random off-target effects .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We next asked whether the EMT reversing effect of nintedanib might be mediated by mesenchymal signature genes other than ZEB1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Here , we treated Intermediate Mesenchymal SKOV3 cells with nintedanib (BIBF1120) , another TKI that has phenotypic EMT reversing effects (Figure 4A) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Further silencing of SYDE1 and ZEB1 might sensitize the cells for nintedanib-induced EMT reversal .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We continued to explore the possible mechanism of nintedanib-mediated E-cadherin induction by examining changes in the expression of several known EMT players: CDH1 , ERBB3 , SNAI1 , and ZEB1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib-treated SKOV3-GFP cells showed a slightly lower EMT score as compared with those treated with saracatinib or both drugs in combination .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "However , we did observe that when treating the SKOV3 cells in vivo xenografts with saracatinib and nintedanib as single agents or in combination , the EMT scores of the xenografts were decreased , suggesting a reversal (Figure 6F) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "F. Plot of the EMT scores of SKOV3-luc-D3 xenografts treated with control , saracatinib (AZD0530) , nintedanib (BIBF1120) , or combined (AZD0530+BIBF1120) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "To test if the nintedanib effect in EMT reversal is exclusive for ovarian cancer , three additional cell lines A549 , T24 , and Mia-Paca2 representing lung , bladder , and pancreatic cancer were selected for testing .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Our data supported that nintedanib had a general EMT reversal effect on cancer cell lines with an intermediate EMT state in the in vitro system .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "C. Plot of the EMT scores (y-axis) of SKOV3-GFP cells treated with control (SKOV3_GFP) , saracatinib (SKOV3_AZD) , nintedanib (SKOV3_BIBF) , or combined (SKOV3_AZD+BIBF) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Down-regulating these two mesenchymal genes , SYDE1 and ZEB1 , further enhanced the effect of nintedanib in CDH1 induction , suggesting that nintedanib might act via SYDE1 and ZEB1 to mediate E-cadherin restoration and EMT reversal effects .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Furthermore , we show that reversing the EMT phenotype in SKOV3 cells with nintedanib was accompanied by an up-regulation of CDH1 , at both the gene expression level and at the promoter region , as well as a down-regulation of the mesenchymal genes , SYDE1 and ZEB1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "In our hands , SKOV3 xenografts have shown a significant induction of E-cadherin expression and decreased EMT scores following nintedanib treatment .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Intriguingly , nintedanib has been shown to exert no effect on either the EMT phenotype or E-cadherin expression in lung or pancreatic cancer xenograft models [23] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We also reported , for the first time , that a triple angiokinase inhibitor , nintedanib , exerts EMT reversal effects in both colony compaction and restoration of E-cadherin expression via the regulation of two mesenchymal genes , SYDE1 and ZEB1 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "This suggests that down-regulation of SYDE1 and ZEB1 might \u201cprime\u201d the cells towards the epithelial side of the spectrum to become more \u201cIntermediate Epithelial\u201d-like , and this , in turn , sensitizes the cell's response to nintedanib in terms of EMT reversal .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26061747",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Further depletion of either SYDE1 or ZEB1 significantly enhances the nintedanib-induced CDH1 up-regulation , suggesting that the restoration of E-cadherin expression or reversal of EMT can be achieved more efficiently by targeting the pivotal regulatory nodes .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Many multi receptor tyrosine kinase (RTK) inhibitors blocked EMT progression in the micromolar range , including nintedanib (BIBF-1120) [31] , sorafenib [32] and pazopanib [33] , while other anti-angiogenic drugs , such as vandetanib [34] and axitinib [35] , were toxic to the cells (Table 1 , Supplementary Table 1) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Indeed , nintedanib and pazopanib or sorafenib were active against TGFBR1 and TGFBR2 , respectively , within a similar concentration range as their IC50 on EMT progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "The effect of idoxuridine , PD-161570 , PD-166285 and nintedanib on EMT inhibition in Py2T cells could not be validated since they exhibited increased cytotoxicity in these cells (Figure 7B , Table 1). .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "On the other hand , inhibitors reported to target TGFBR , such as SB-431542 , RepSox , SB-525334 and PP1 , together with the multi-kinase inhibitors PD-161570 , PD-166285 , nintedanib , pazopanib and sorafenib revealed a significant correlation between their efficacy in blocking EMT and their inhibition of TGFBR1 or 2 (Figure 5C) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Additionally , in lung and pancreatic cancer models , nintedanib treatment has a potent anti-angiogenic effect but does not induce EMT , although tumor hypoxia , a well-described EMT inducer , is high [66] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Finally , unlike other anti-angiogenic treatments , there is currently no indication that nintedanib treatment would induce an EMT switch allowing cells to become more invasive and thus favoring the formation of metastasis [67] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Interestingly , other multi-kinase inhibitors , such as nintedanib , pazopanib and sorafenib , similarly inhibit EMT in accordance with a reduction in the biochemical activity of TGFBR and a decrease in SMAD3 phosphorylation in cells (Table 3 and Figure 6) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Since nintedanib blocks EMT progression in NMuMG cells with an IC50 in the lower micromolar range and is able to block TGFBR1 activity in biochemical assays in the submicromolar range , it is plausible that TGFBR inhibition contributes to its beneficial effects in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Similarly , in agreement with nintedanib's inhibitory effect on TGFBR1 activity as well as SMAD phosphorylation and EMT in our analyses , multiple studies report a lack of EMT induction after nintedanib treatment in cancer cell lines in vitro and in mouse models of cancer in vivo .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "29518028",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib is a tyrosine kinase inhibitor that blocks platelet-derived growth factor receptor , fibroblast growth factor receptor and Src (among others) , all of which have been shown to be important in EMT and fibroblast proliferation , migration and differentiation [255,260] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We suggested that , following bleomycin\u2010induced ALI , nintedanib therapy can ameliorate high tidal volume mechanical stretch\u2010augmented EMT and pulmonary fibrosis by suppressing the Src pathway .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Using mice pre\u2010treated with bleomycin as a VILI model to simulate the early fibroproliferative response in clinical ARDS , we first explored whether nintedanib could inhibit MV\u2010augmented bleomycin\u2010induced EMT and pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Moreover , we explored the effects of nintedanib treatment in attenuating EMT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "There was only partial inhibition of lung injury and fibrogenesis through Src knockout and pharmacologic inhibition with nintedanib suggested that there are other potential mechanisms , such as PDGFR , FGFR and VEGFR pathways contributing to MV\u2010induced EMT and pulmonary fibrosis (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Collectively , our results demonstrated that nintedanib therapy can suppress MV\u2010induced inflammatory responses and EMT in the lung by inhibiting the Src pathway (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "D) Schematic figure: bleomycin\u2010induced augmentation of mechanical stretch\u2010mediated cytokine production and EMT were attenuated by the administration of nintedanib and with Src heterozygous knockout .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Furthermore , we examined the effects of nintedanib on MV\u2010augmented bleomycin\u2010mediated Src activation , EMT and pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "However , the protective effects of nintedanib on VILI\u2010associated EMT and pulmonary fibrosis are not well defined .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Additionally , a previous A549 epithelial cell study showed that both the transcript and protein expressions of E\u2010cadherin substantially increased following nintedanib treatment , indicating that EMT reversal can be achieved by tyrosine kinase inhibition 36 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Compared with the control mice , partial inhibition of lung injury and fibrogenesis through Src knockout or pharmacologic inhibition with nintedanib suggested that Src signalling was only one of the many pathways contributing to MV\u2010induced EMT and pulmonary fibrosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Using an in vivo murine model of bleomycin\u2010induced VILI , we demonstrated that nintedanib attenuated high tidal volume MV\u2010induced lung inflammation\u2010associated EMT , pulmonary fibrosis and epithelial apoptosis through the inhibition of Src signalling pathway and TGF\u2010\u03b21 production .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28598023",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "In this study , we demonstrated that nintedanib , a multitargeted tyrosine kinase inhibitor , magnitude dependently suppressed high tidal volume MV\u2010induced Src phosphorylation and EMT (downregulation of an epithelial marker E\u2010cadherin and upregulation of a mesenchymal marker \u03b1\u2010SMA in the bronchiolar epithelium and peribronchiolar lung parenchyma) , mimicking the inhibitory effects provided by Src heterozygous knockout (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27455225",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "miR-200 family enhanced sensitivity to nintedanib by regulating EMT in NSCLC [104] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27551531",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "However , most of these kinase inhibitors have not been demonstrated to exhibit anti-EMT-related effects in the clinical settings except for nintedanib (BIBF1120) which has been shown to resolve idiopathic pulmonary fibrosis by inhibiting the TGF\u03b2 pathway.10 Therefore , there is a need to explore other classes of compounds .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26557253",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "NAC has been shown to regulate MUC5ac and epithelial EMT , phenomena that have not been investigated with either pirfenidone or nintedanib (49 , 50) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28293555",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Another recent study evaluating the co-treatment of nintedanib with small interfering RNAs against six specific genes involved in EMT has shown that this molecule is able to do a downregulation of SYDE1 and ZEB1 , and this sensitizes the cell\u2019s response to the drug in terms of EMT reversal (47) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26932377",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib works mainly by inhibiting angiogenesis so it may have implications for EMT-Type-III where angiogenesis is prominent and on the other hand Pirfenidone is more anti-fibrotic in action so may have implications for EMT-Type-II .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30042678",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We also undertook comparative assessment of the activity of nintedanib , pirfenidone and PF670462 on markers of EMT in A549 cells (Figure 5) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30042678",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Studies on the mechanism of PF670462 suggest suppression of EMT , in addition to regulatory effects on lung fibroblasts , presenting a pharmacological profile that is distinct to nintedanib , which reduces (myo)fibroblast activity , with limited effect on EMT (Wollin et al. .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We demonstrate that miR-200b and miR-141 associated with epithelial-mesenchymal transition (EMT) are predictive biomarkers and therapeutic targets of nintedanib in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Furthermore , we found that nintedanib inhibited EMT and reversed the resistance to EGFR-TKI with TGF-\u03b2-induced EMT through miR-200 family induction in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Therefore , we evaluated whether nintedanib overcomes EMT and the resistance to the EGFR-TKI gefitinib in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "In functional analysis in a recent report , nintedanib could reverse the EMT phenotype in lung cancer and pancreatic cancer cells (26) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "These results suggest that nintedanib combined with EGFR-TKI might be a novel therapeutic strategy for NSCLC cells with EMT phenotype .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Reversal of EMT by nintedanib might be attributed to inhibition of fibroblast function .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "In addition , induction of miR-200b and miR-141 showed reversal of EMT and increased sensitivity for nintedanib in both naturally resistant A549 and acquired resistant PC1-R cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Taken together with our results , the reversal of EMT might be mainly regulated by FGFR inhibition of nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "We also found that treatment with nintedanib caused reversal of TGF-\u03b21-induced EMT and resistance to gefitinib through upregulation of miR-200b and miR-141 in A549 lung cancer cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "These findings demonstrated a novel role of nintedanib as a potential therapeutic strategy for resistance to EGFR-TKI associated with TGF-\u03b21-induced EMT in NSCLC cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Further studies should be performed to clarify the effect of nintedanib on EMT and EGFR-TKI therapy in NSCLC .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "26783187",
    "tail": {
      "word": "EMT",
      "id": "O75751"
    },
    "sentence": "Nintedanib combined with EGFR-TKI might be a new therapeutic strategy for NSCLC patients with acquired resistance to EGFR-TKI by EMT .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28008744",
    "tail": {
      "word": "SQC",
      "id": "Q16769"
    },
    "sentence": "Agents targeted to FGFR1 , such as AZD4547 and nintedanib , have presented good safety and definite efficacy in this subtype of NSCLC.21 , 22 Along with developments in immunotherapy and targeted therapy for SQC , a great challenge faced is how to combine these two kinds of treatments to improve patient prognosis .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31275535",
    "tail": {
      "word": "CEA",
      "id": "P06731"
    },
    "sentence": "Furthermore , this CEA reached the same conclusion as the Evidence Review Group\u2019s alternative base case conducted for the NICE STA of nintedanib [46] , i.e. , the domination of pirfenidone over nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "27800477",
    "tail": {
      "word": "hGF",
      "id": "P14210"
    },
    "sentence": "Moreover , data presented here also provide interesting application for Erlotinib-HCl and Nintedanib in the production of MPC in autologous serum , where any possible source of variability , related to fluctuations in hGF serum concentration , could be mitigated by receptors inhibition .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31164944",
    "tail": {
      "word": "GHSR",
      "id": "Q92847"
    },
    "sentence": "For example , ropinirole [31] is used in the treatment of early Parkinson\u2019s disease , nintedanib is employed against pulmonary fibrosis [32] , tenidap [33] is a nonsteroidal anti-inflammatory drug (NSAID) , while indolidan [34] and adibendan [35] are potent long-acting cardiotonic agents and SM-130686 is a GHSR agonist [36] (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "CDK1",
      "id": "P06493"
    },
    "sentence": "Moreover , the expression of genes associated with cell proliferation , such as CDK1 , CDK4 , CCNA2 , and PLK1 , was significantly diminished in the lung-resident fibroblasts of IPF patients treated with nintedanib as compared to vehicle (Figure 7D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "CDK1",
      "id": "P06493"
    },
    "sentence": "D) Quantification of CDK1 , CDK4 , CCNA2 , and PLK1 gene transcripts by RT-PCR in the primary lung-resident fibroblasts isolated from human IPF lung cultures and treated with vehicle or nintedanib (1 \u03bcM) for 16 h (n = 4) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27134168",
    "tail": {
      "word": "MCT1",
      "id": "P53985"
    },
    "sentence": "Immunofluorescence staining for MCT1 and MCT4 demonstrated a diffuse baseline expression of MCT1 that remained unchanged during nintedanib treatment , whereas MCT4 was highly expressed in non-vascularized areas of LT nintedanib-treated tumors and to a lesser extent in ST-treated tumors (Figures 4A and S4B\u2013S4D) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31016670",
    "tail": {
      "word": "OAT1",
      "id": "Q4U2R8"
    },
    "sentence": "In summary , in the clinical setting , nintedanib is unlikely to affect the pharmacokinetics of other drugs that are substrates of major drug-metabolising CYPs or uptake transporters , such as OATP1B1 , OATP1B3 , OAT1 , OAT3 or OCT2 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26846335",
    "tail": {
      "word": "fibronectin",
      "id": "P02751"
    },
    "sentence": "Both pirfenidone and nintedanib reduced fibronectin labelling in both IPF samples while no major effect was visible on control cells (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "26846335",
    "tail": {
      "word": "fibronectin",
      "id": "P02751"
    },
    "sentence": "Chaudhary and co-authors administered BIBF1000 , a compound that resembles nintedanib , and demonstrated that the drug decreased the levels of fibrosis , TGF\u03b21 , procollagen type I , fibronectin and connective tissue growth factor (CTGF) in lung tissue .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "Fn1",
      "id": "P02751"
    },
    "sentence": "Nintedanib significantly downregulated mRNA levels of Fn1 and Col1a1 at 1 \u03bcM (\u2212 0.94 \u00b1 0.25 and \u2212 1.51 \u00b1 0.99 , respectively; log fold change compared to control) , while Pirfenidone significantly downregulated Col1a1 at 2.5 mM (\u2212 1.36 \u00b1 1.39 and \u2212 1.95 \u00b1 1.07 , respectively; log fold change compared to control) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "Fn1",
      "id": "P02751"
    },
    "sentence": "Fn1 was significantly downregulated by both Nintedanib and Pirfenidone in healthy and fibrotic pmATII cells as assessed by qPCR (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "Fn1",
      "id": "P02751"
    },
    "sentence": "The pmATII cells were cultured in the presence of Nintedanib (1 \u03bcM) and Pirfenidone (500 \u03bcM) for 48 h. a Gene expression analysis by qPCR of fibrotic marker Fn1 in pmATII cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30219058",
    "tail": {
      "word": "Fn1",
      "id": "P02751"
    },
    "sentence": "The pmATII cells were cultured in the presence of Nintedanib (1 \u03bcM) and Pirfenidone (500 \u03bcM) for 48 h. a Gene expression analysis by qPCR of fibrotic marker Fn1 in pmATII cells .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "FN1",
      "id": "P02751"
    },
    "sentence": "We observed that nintedanib at 0.4 \u03bcM reduced significantly the expression of COL1A1 (Collagen type I alpha 1 chain) , COL3A1 (collagen type III alpha 1 chain) , FN1 (Fibronectin 1) , CTGF (connective tissue growth factor) , PDGFA (platelet-derived growth factor A) , and TGFB1 (transforming growth factor beta 1) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29991677",
    "tail": {
      "word": "Fibronectin",
      "id": "P02751"
    },
    "sentence": "We observed that nintedanib at 0.4 \u03bcM reduced significantly the expression of COL1A1 (Collagen type I alpha 1 chain) , COL3A1 (collagen type III alpha 1 chain) , FN1 (Fibronectin 1) , CTGF (connective tissue growth factor) , PDGFA (platelet-derived growth factor A) , and TGFB1 (transforming growth factor beta 1) (Fig .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31156440",
    "tail": {
      "word": "Fn1",
      "id": "P02751"
    },
    "sentence": "D) Quantification of Col1\u03b1 and Fn1 gene transcripts by RT-PCR in the lungs of vehicle- or nintedanib-treated TGF\u03b1 mice (n = 4/group) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "30984775",
    "tail": {
      "word": "fibronectin",
      "id": "P02751"
    },
    "sentence": "Nintedanib and Pirfenidone have the potential to reduce the accumulation of collagens and fibronectin in isolated cells; however , such an effect has not been proven in patient samples [7 , 8 , 39 , 44] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31438928",
    "tail": {
      "word": "fibronectin",
      "id": "P02751"
    },
    "sentence": "This could be partly explained by the reduced fibronectin production of cardiac fibroblasts exposed to nintedanib [16] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "29995590",
    "tail": {
      "word": "fibronectin",
      "id": "P02751"
    },
    "sentence": "LL29 cells were plated onto fibronectin-coated coverslips for 24 h. In some experiments , cells were treated with pirfenidone (1 mM) or nintedanib 1 \u00b5M) for the final 16 h of plating before fixing/permeabilizing in 3.7% paraformaldehyde , then 0.02% Triton X-100 .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "Nintedanib",
      "id": "DB09079"
    },
    "pmid": "24124571",
    "tail": {
      "word": "FGFR4",
      "id": "P22455"
    },
    "sentence": "In this study , a panel of RMS cell lines as well as a Ba/F3 cell line engineered to overexpress FGFR4 were tested for sensitivity to five FGFR tyrosine kinase inhibitors , including AP24534 (ponatinib) , AZD2171 (Cediranib) , BIBF1120 (Nintedanib) , TKI258 (Dovitinib) , and PHA739358 (Danusertib) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "TAF",
      "id": "Q16270"
    },
    "sentence": "Finally , to assess the potential contribution of carcinoma cells themselves on the differential therapeutic effects of nintedanib on the carcinoma\u2013TAF cross-talk , we stimulated SCC cells with CM from ADC-TAFs and vice versa .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "TAF",
      "id": "Q16270"
    },
    "sentence": "Although the molecular underpinnings underlying all these subtype-specific alterations in TAFs remains to be elucidated , the differential antifibrotic responses to nintedanib strongly suggest that TAF activation in ADC and SCC elicited by TGF-\u03b21 may be regulated through distinct mechanisms .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28898237",
    "tail": {
      "word": "TAF",
      "id": "Q16270"
    },
    "sentence": "Yet , because our preclinical models of carcinoma\u2013TAF interactions captured the selective therapeutic effects of nintedanib in ADC (but not SCC) reported in clinical trials , we argue that these models may be useful in identifying the mechanisms underlying the poor antifibrotic response of SCC-TAFs to nintedanib .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "27036020",
    "tail": {
      "word": "TGFBR2",
      "id": "P37173"
    },
    "sentence": "Indeed , nintedanib and pazopanib or sorafenib were active against TGFBR1 and TGFBR2 , respectively , within a similar concentration range as their IC50 on EMT progression .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30890862",
    "tail": {
      "word": "PDC",
      "id": "P06672"
    },
    "sentence": "Overall mean adherence was similar in both medication groups , with a PDC of 84.2% in the nintedanib group and 83.4% in the pirfenidone group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30890862",
    "tail": {
      "word": "PDC",
      "id": "P06672"
    },
    "sentence": "For the full sample , PDC in the nintedanib group was 84.2% (SD = 17.0) , and 71.3% of patients were adherent with a PDC \u2a7e 80% .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30890862",
    "tail": {
      "word": "PDC",
      "id": "P06672"
    },
    "sentence": "In the nintedanib group , the sex variable was also significant in predicting adherence , with men (mean PDC = 87.9%) displaying significantly higher (P < .02) PDC than women (mean PDC = 82.6%) .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "30890862",
    "tail": {
      "word": "PDC",
      "id": "P06672"
    },
    "sentence": "Both populations contained most of the adherent patients , with 70.0% of patients exhibiting greater than 80% PDC in the nintedanib group and 71.3% of patients with greater than 80% PDC in the pirfenidone group .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "28462234",
    "tail": {
      "word": "CPI",
      "id": "P29166"
    },
    "sentence": "In subgroup analyses of pooled data from the INPULSIS trials , nintedanib slowed disease progression irrespective of CPI (Composite Physiologic Index) [53] or the level of gas exchange impairment at baseline [54] .",
    "relation": "NA"
  },
  {
    "head": {
      "word": "nintedanib",
      "id": "DB09079"
    },
    "pmid": "31488107",
    "tail": {
      "word": "CPI",
      "id": "P29166"
    },
    "sentence": "Age , gender , smoking history , dyspnea , comorbidities , lung function parameters and prognostic indices (GAP , CPI) were similar in patients with and without occupational exposure to dusts , both at diagnosis and after 12 month therapy with pirfenidone or nintedanib .",
    "relation": "NA"
  }
]